EUROPEAN COMMISSION

Brussels, 22.10.2021
C(2021) 7708 final

**PUBLIC VERSION**

In the published version of this decision, some information has been omitted pursuant to Article 17(2) of Council Regulation (EC) No 139/2004 concerning non-disclosure of business secrets and other confidential information. The omissions are shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a general description.

CVC Capital Partners SICAV-FIS S.A.
20 Avenue Monterey
L-2163 Luxembourg
Luxembourg

**Subject:** **Case M. 10247 – CVC/Cooper**
**Commission decision pursuant to Article 6(1)(b) of Council Regulation No 139/2004[1] and Article 57 of the Agreement on the European Economic Area[2]**

Dear Sir or Madam,

(1) On 17 September 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation , by which CVC Capital Partners SICAV-FIS S.A. ("CVC", Luxembourg or the "Notifying Party") acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Cooper Consumer Health S.A.S. and its subsidiaries ("Cooper", France or the "Target") (the "Transaction")[3], by way of purchase of securities. Together, CVC and Cooper are referred to as the "Parties".

1 OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'. The terminology of the TFEU will be used throughout this decision.

2 OJ L 1, 3.1.1994, p. 3 (the 'EEA Agreement').

3 Publication in the Official Journal of the European Union No C 392, 28.09.2021, p. 5.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.

## 1. THE PARTIES

(2) CVC and/or its subsidiaries manage investment funds and platforms. CVC controls a number of companies, including companies in the pharmaceutical sector, e.g., Recordati; Genetic; and Theramex, as well as in the private hospital and clinics (Hellenic health Care Group and Mehiläinen), nursing homes (Vitalia), provision of specialised medical equipment (Sebia), flexible packaging (AR Packaging) and packaging machinery (Syntegon) sectors.

(3) Cooper and its subsidiaries develop, produce, and market pharmaceuticals, which are typically sold over the counter ("OTC").

## 2. THE OPERATION AND THE CONCENTRATION

(4) Pursuant to a Put Option Agreement, dated 10 March 2021, and a Securities Purchase Agreement, dated 5 May 2021, CVC plans to acquire control over Cooper through a special purpose vehicle. Post-Transaction, CVC will hold [60-70]% of the Target's share capital. As a result, CVC will acquire sole control over Cooper. The Transaction constitutes a concentration under Article 3(1)(b) EUMR.

## 3. UNION DIMENSION

(5) The undertakings concerned have a combined aggregate world-wide turnover of more than EUR 5 000 million[4]. Each of them has a Union-wide turnover in excess of EUR 250 million, but they do not achieve more than two-thirds of their aggregate Union-wide turnover within one and the same Member State. The notified operation therefore has a Union dimension.

## 4. ASSESSMENT

### 4.1. Horizontal overlaps

(6) Both Parties are active in the development, manufacture, and commercialisation of finished dose pharmaceuticals ("FDPs"). FDPs are pharmaceutical products that have undergone all stages of production, including packaging in the final container and labelling.

#### *4.1.1. Market Definitions*

4.1.1.1. Product market definitions

(7) To define relevant product markets regarding FDPs, the Commission typically takes into account the Anatomical Therapeutic Classification ("ATC") of the European Pharmaceutical Marketing Research Association. In the context of this classification, at the ATC3 level,[5] FDPs are grouped by therapeutic indications. The Commission

4 Turnover calculated in accordance with Article 5 of the Merger Regulation.

5 ATC3 level classification is narrower than ATC1 and ATC2 level classifications. At ATC1, drugs are divided into 16 anatomical main groups. At ATC2, drugs are divided at pharmacological or therapeutic groups.

uses ATC3 as the starting point for relevant product market definition, since all products in the same ATC3 class generally have the same therapeutic indication and cannot be substituted by products from other ATC3 classes.[6] However, the Commission also recognised[7] that it may be appropriate to carry out analyses at the narrower classification level ATC4,[8] or possibly at the level of molecule. ATC classification concerns prescription-bound (Rx) and OTC-sold drugs. For OTC-sold drugs, IQVIA[9] also administers the Consumer Health Classification ("CHC"). With respect to OTC-sold drugs, the Commission typically uses CHC3 level[10] (the equivalent of ATC3) as a starting point for relevant product market definition but narrower delineations are also considered (e.g., at CHC4 level (the equivalent of ATC4) or by molecule).[11]

(8) For the purposes of the present Decision, it is not necessary to depart from the above approach, that is to define the markets for FDPs either at ATC3/CHC3, ATC4/CHC4 or molecule levels. The market investigation did not provide any indications that would require the Commission to depart from its previous decisional practice with respect to the product market definition for FDPs concerning the FDP categories in which the Parties overlap.

(A) Methodology for the identification and the assessment of affected markets

(9) To identify the affected markets that the Transaction gives rise to in relation to FDPs, the Notifying Party used IQVIA data (previously known as IMS). These are data on sales in value and volume of FDPs compiled by IQVIA, a third-party intelligence provider focusing on the healthcare sector.

(10) As will be further discussed further below in the present Decision (paragraphs (41) to (43), the Commission consistently defines relevant markets at national level.

(11) In line with Commission precedents in pharmaceutical mergers with a large number of affected markets (involving numerous product and geographic markets), the Commission has applied a system of filters aimed at determining the group of markets where concerns are most likely and on which it focuses its analysis. Based on the Commission's decisional practice in the pharmaceutical sector,[12] horizontally affected markets regarding FDPs can be grouped in the categories summarized in

6 Case M.9995 – Permira/Neuraxpharm, para. 7.

7 Case M.9995 – Permira/Neuraxpharm, para. 7.

8 ATC4 level classification is typically based on mode of action or mode of administration of the drugs.

9 IQVIA is an American multinational company serving the combined industries of health information technology and clinical research, formerly Quintiles and IMS Health, Inc.

10 Case COMP/M.8889 – *Teva/PGT OTC Assets*, para. 21

11 Case COMP/M.8889 – *Teva/PGT OTC Assets*, para. 21

12 Case M.9554 – Elanco Animal Health/Bayer Animal Health Division, para. 89; M.8889 - Teva/PGT OTC Assets, para. 35; M.7746 – Teva/Allergan Generics, para. 58; and M.9044 - CVC/Recordati, para. 25; M.7645 - Mylan/ Perrigo, para. 33; M.8974 – Procter & Gamble / Merck Consumer Health Business, para. 24.

**Table 1**:

| Table 1 – Market Categorization in FDPs | |
|---|---|
| **Group Category** | **Description** |
| Group 1 | Parties' combined share (in volume/value) exceeds 35% and the increment exceeds 1%. |
| Group 1+ | (i) Parties' combined share (in volume/value) <35% but only one competitor remains in the market or (ii) Parties' combined share >35% and the increment is <1% but the party with the smaller increment is a recent entrant. |
| Group 2 | Parties' combined share (in volume/value) >35% but the increment is <1%. |
| Group 3 | Parties' combined share (in volume/value) is 20%-35%. |

(12) The Commission has analysed all markets affected by the Transaction under all plausible market definitions ATC3/CHC3, ATC4/CHC4 or molecule. The transaction results in a total of 188 (national) overlap markets in FDPs, of which 28 are affected. **Table 2** presents a summary of those.

| Table 2: Overview of horizontally affected markets for FDPs | | | | | |
|---|---|---|---|---|---|
| **Market level** | **Overlap markets** | **Group 1 / 1+** | **Group 2** | **Group 3** | **Not affected** |
| ATC3/CHC3 | 98 | 2 | 0 | 7 | 89 |
| ATC4/CHC4 | 74 | 6 | 1 | 8 | 59 |
| Molecule | 16 | 1 | 1 | 2 | 12 |
| **Total** | **188** | **9** | **2** | **17** | **160** |

(13) On this basis, the markets are affected by the Transaction are presented in **Table 3**:

| Table 3 -- Overview of Horizontally Affected Markets (all groups) | | | | | |
|---|---|---|---|---|---|
| **Product category** | **Group** | **Country** | **Affected at ATC3/CHC3 level** | **Affected at ATC4/CHC4 level** | **Affected at molecule level** |
| Antihaemorrhoids<br>Topical antihaemorrhoidals<br>Antihaemorrhoids – ointments / creams | 1 / 1+ | IT | ✓ (10A1)<br>✓ (C5A) | ✓ (10A1O) | |
| Antihaemorrhoids – ointments / creams | 1 / 1+ | RO | | ✓ (10A1O) | |
| Antitussives Combination | 1 / 1+ | LUX | | ✓ (R5D2) | |
| Sore throat Remedies – aerosols / Sprays | 1 / 1+ | FR | | ✓ (01C1A) | |
| Mouth Pain Relief Liquids (topical) | 1 / 1+ | FR | | ✓ (02D1L) | |
| Ear Care – other Forms | 1 / 1+ | ES | | ✓ (08A1Z) | |
| Intestinal Anti-Infectives (Nifuroxazide) | 1 / 1+ | FR | | | ✓(A7A0) |
| Other forms of fibre laxatives | 2 | ES | | ✓(03C1Z) | |
| Beta-Alanine - products for menopause | 2 | FR | | | ✓(12D4) |
| Mineral supplements - calcium | 3 | LUX | ✓ (A12A) | | |
| Mouth pain relief | 3 | FR | ✓ (02D1) | | |
| Calming and sleeping products | 3 | IT | ✓ (13A9) | | |
| Antifungals for nails<br>Antifungals for nails – liquids topical | 3 | PT | ✓ (06G2) | ✓ (06G2L) | |
| Antihaemorrhoids<br>Antihaemorrhoids – ointments / creams | 3 | PT | ✓ (10A1) | ✓ (10A1O) | |
| Antihaemorrhoids | 3 | RO | ✓ (10A1) | | |
| Ear care | 3 | ES | ✓ (08A1) | | ✓ |
| Drugs for constipation - osmotic laxatives | 3 | IT | | ✓(A6A6) | |
| Mouth pain relief - ointments | 3 | FR | | ✓((02D1O) | |
| Mouth pain relief - other forms | 3 | FR | | ✓02D1Z) | |
| Antifungals - Skin – aerosols / sprays | 3 | IT | | ✓(06G3A)) | |
| Antinauseants caps/tabs | 3 | IT | | ✓(11A1C | |
| Liquids topical, | 3 | PT | | ✓(06G2L) | |
| Ear care - other forms | 3 | PT | | ✓(08A1Z) | |
| Vitamins - Ascorbic acid | 3 | FR | | | ✓ (A13A) |
| Mineral supplements - Calcium | 3 | LUX | | | ✓ (A12A) |

(B) Group 2 and Group 3 markets

(14) In line with previous decisions,[13] the product market definitions of Group 2 and Group 3 markets are not individually discussed in detail in this Section.

(C) Group 1 and Group 1+ markets

*(C.i) Antihaemorrhoids*

(15) CHC3 code 10A1 covers pharmaceuticals for the treatment of anal fissures and haemorrhoids, that being swollen or dilated veins of the rectum or anus. CHC4 code 10A1O covers ointments and creams used to treat haemorrhoids and anal fissures. ATC3 class C5A comprises agents for local use, such as suppositories, ointments,

13 See M.8974 – Procter & Gamble / Merck Consumer Health Business, para. 25.

etc. for the treatment of haemorrhoids and anal fissures.[14] Preparations used for treatment of perineal trauma are also classified here.

(16) The Commission has in the past left open the questions of either whether ATC3 class was the appropriate level to define the relevant product market for antihaemorrhoids (as opposed to the ATC4 class)[15], or whether prescription and non prescription-products should be seen as belonging to the same market. [16] The Commission has not assessed antihaemorrhoids in the past based on their CHC3 or CHC4 classification.

(17) As explained above,[17] the Commission consistently defines the market for FDPs looking at both the ATC3/CHC3 level and at ATC4/CHC4 level. Also in this case, both ATC3 class C5A, CHC3 code 10A1 and CHC4 code 10A1O constitute plausible relevant product markets.

(18) In the present case, the Notifying Party considers that the precise product market definition can be left open because the Transaction does not give rise to competition concerns under any plausible product market definition (including under the narrowest plausible market definition where the Parties' activities overlap, namely at CHC4 level – Antihaemorrhoids – Ointments / Creams).

(19) The Commission's market investigation did not provide conclusive evidence regarding the question whether the relevant product market should be defined at ATC3/CHC3 level (including all types of antihaemorrhoids) or at ATC4/CHC4 level (including only antihaemorrhoidal ointments and creams).[18] For the purposes of this decision, the product market definition for antihaemorrhoids can be left open, as the Transaction does not give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement even in the narrowest plausible market where the Parties' activities overlap (i.e., antihaemorrhoidal ointments and creams at CHC4 level).

*(C.ii) Sore throat remedies*

(20) In the past, [19] the Commission considered a relevant market for sore throat remedies at ATC3 level (R2A) but eventually left open the issue of product market definition. The Commission has not assessed sore throat remedies in the past based on their CHC3 or CHC4 classification.

(21) In the present case, the Notifying Party considers that the precise product market definition could be left open because the Transaction does not give rise to competition concerns under any plausible product market definition (including under the narrowest plausible market definition where the Parties' activities overlap, namely at CHC4 level – sore throat remedies in the form of aerosols and sprays).

---

14 Although the ATC3 class C5A (topical antihaemorrhoidals) is not fully identical to the CHC3 class 10A1 (antihaemorrhoids) since the ATC3 class only covers the topical drugs against haemorrhoids, both classes have essentially the same therapeutic indication: the treatment of haemorrhoids. Consequently, ATC3 class C5A includes some, but not all, products of the Parties falling under the CHC3 class 10A1 in Italy.

15 See M.4198 – Bayer / Schering, paragraph 12.

16 Commission decision, Case M.4314 – Johnson & Johnson / Pfizer Consumer Healthcare, paragraph 22.

17 See paragraph (7).

18 Replies to Questionnaire Q3 and to Questionnaire Q4.

19 M.7276 GSK / Novartis, paragraph 249.

(22) The Commission's market investigation did not provide conclusive evidence regarding the question whether the relevant product market should be defined at ATC3/CHC3 level (including all types of sore throat remedies) or at ATC4/CHC4 level (including only aerosols and sprays).[20] For the purposes of this decision, the product market definition for sore throat remedies can be left open, as the Transaction does not give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement even in the narrowest plausible market where the Parties' activities overlap (i.e., sore throat remedies in form of aerosols or sprays at CHC4 level).

*(C.iii) Mouth pain relief products*

(23) In the past, [21] the Commission considered that the there are two separate product markets for mouth pain relief products. Namely (i) a market for adult mouth pain relief products that covers products classified under ATC4 class A1A2 excluding mouthwashes (i.e. antiseptics and anti-infectives) and products classified under ATC4 class A1A3 (i.e. anti-inflammatories and analgesics), and (ii) a market for paediatric mouth pain relief products that covers products classified under ATC4 class A1A2 excluding mouthwashes (i.e. antiseptics and anti-infectives) and products classified under ATC4 class A1A3 (i.e. anti-inflammatories and analgesics).

(24) The Commission has not assessed mouth pain relief products in the past based on their CHC3 or CHC4 classification.

(25) The Notifying Party does not contest the Commission's general approach to the product market definition for FDPs. However, it submits that in markets where the Parties' activities overlap, the competition takes place at ATC3 level.[22]

(26) The Commission's market investigation did not provide any indication on whether the relevant product market should be defined at ATC3/CHC3 level (including all types of mouth pain relief products) or at ATC4/CHC4 level (including only liquids). For the purposes of this decision, the product market definition for mouth pain relief products can be left open, as the Transaction does not give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement even in the narrowest plausible market where the Parties' activities overlap (i.e., mouth pain relief in the form of liquids at CHC4 level).

*(C.iv) Ear care products*

(27) The Parties' ear care products that give rise to affected markets belong to the CHC3 code 08A1 – Ear Care and CHC4 code 08A1Z – Ear Care in other forms. The Commission has not previously considered the markets for ear care products belonging to these categories. As explained above,[23] the Commission consistently defines market for FDPs based on both the CHC3 level and at CHC4 level, and therefore both CHC3 code 08A1 and CHC4 code 08A1Z constitute plausible relevant product markets.

---

20 Replies to Questionnaire Q1, question 11.

21 Case M.5953 – *Reckitt Benckiser/SSL*, paragraph 27.

22 Form CO, paragraph 99.

23 See paragraph (7).

(28) The CHC4 code 08A1Z, however, is a catch-all category that includes any products that cannot be included in other CHC4 codes within the CHC3 code 08A1, instead of combining products with similar properties. With respect to other catch-all pharmaceutical classes, the Commission has previously considered that these do not form an appropriate basis for defining the relevant product markets.[24]

(29) The Notifying Party does not contest the Commission's general approach to the product market definition for FDPs. However, it submits that in markets where the Parties' activities overlap, the competition takes place at ATC3 level.[25] With respect to CHC4 code 08A1Z specifically, the Notifying Party notes that the category does not represent the actual market conditions given its catch-all nature.[26]

(30) The investigation did not provide any indication on whether CHC4 code 08A1Z – Ear Care in other forms could constitute a separate relevant product market.

(31) For the purposes of this decision, the exact product market definition for ear care products can be left open since the Transaction does not give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement even under the narrowest plausible market defined at the CHC4 code 08A1Z –Ear Care products in other forms.

*(C.v) Antitussives (in combination)*

(32) ATC4 class R5D2 includes antitussives (which relieve coughs by blocking the cough reflex, and are most effective at relieving dry coughs, also known as cough suppressants) in combinations with expectorants, antihistamines, ephedrine, herbal tinctures, etc. [27] ATC3 class R5D includes all antitussives.

(33) The Commission has not previously considered the markets for antitussives belonging to these categories. As explained above,[28] the Commission consistently defines market for FDPs based on both the ATC3 level and at ATC4 level, and therefore both ATC3 code R5D and ATC4 code R5D2 constitute plausible relevant product markets.

(34) The investigation did not provide any indication on whether the relevant product market could be defined either at ATC3 class R5D or ATC4 class R5D2.

(35) In the present case, the Notifying Party considers that the precise product market definition for antitussives could be left open because the Transaction does not give rise to competition concerns under any plausible product market definition (namely the narrowest plausible market definition where the Parties' activities overlap, ATC4 class R5D2).

---

24 Case M.5476 – *Pfizer/Wyeth,* paragraph 43.

25 Form CO, paragraph 99.

26 Form CO, paragraph 386.

27 Combinations with analgesics and antipyretics (ATC3 class R5A) and combinations with anti-infectives (ATC3 class R5B) are excluded.

28 See paragraph (7).

*(C.vi) Intestinal anti-infective anti-diarrhoeals*

(36) Intestinal anti-infective anti-diarrhoeals are used for disinfection and stabilisation of the intestinal microflora and for treatment of acute diarrhoeal diseases. They can be based on different molecules, including nifuroxazide, colistin, fidacomicin, and rifaximin.

(37) In *Sanofi-Aventis/Zentiva*, the Commission considered a relevant market for intestinal anti-infective anti-diarrhoeals at ATC3 level (A7A) but eventually left open the issue of relevant market definition.[29] The Commission has not assessed intestinal anti-infective anti-diarrhoeals at molecule level in the past.

(38) In the present case, the Notifying Party considers that the precise product market definition could be left open because the Transaction does not give rise to competition concerns under any plausible product market definition (including under the narrowest plausible market definition where the Parties' activities overlap, namely at molecule level – nifuroxazide-based intestinal anti-infective anti-diarrhoeals).

(39) The investigation did not provide any indication on whether the ATC3 class A7A could be considered a distinct product market.

(40) For the purposes of this decision, the product market definition for intestinal anti-infective anti-diarrhoeals can be left open, as the Transaction does not give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement even in the narrowest plausible market where the Parties' activities overlap (i.e., at molecule level for nifuroxazide-based products).

4.1.1.2. Geographic market definitions

(41) For FDPs, the Commission consistently defines relevant markets at national level.[30]

(42) The market investigation did not provide any indications that would require the Commission to depart from its previous decisional practice on the geographic scope of the different plausible markets for FDPs. [31]

(43) Therefore, for the purposes of this decision, the Commission considers the geographic scope of the different plausible markets for FDPs, including all of the Group1/1+ markets, Group 2 and Group 3 to be national in scope.

*4.1.2. Legal framework*

(44) Article 2 of the Merger Regulation requires the Commission to examine whether notified concentrations are compatible with the internal market, by assessing whether they would significantly impede effective competition in the internal market or in a substantial part of it, in particular as a result of the creation or strengthening of a dominant position.

---

29 Case M.5253 – *Sanofi-Aventis/Zentiva*, recitals 55ff.

30 Case M.9995 – *Permira/Neuraxpharm*, para. 11.

31 Replies to Questionnaires Q1 to Questionnaire Q6.

(45) A merger giving rise to a significant impediment of effective competition may do so as a result of the creation or strengthening of a dominant position in the relevant market(s). Moreover, mergers in oligopolistic markets involving the elimination of the important competitive constraints that the parties previously exerted on each other, together with a reduction of competitive pressure on the remaining competitors, may also result in a significant impediment to effective competition, even in the absence of dominance.

(46) The Commission Guidelines on the assessment of horizontal mergers under the Merger Regulation (the "Horizontal Merger Guidelines")[32] describe horizontal non-coordinated effects as follows: *"A merger may significantly impede effective competition in a market by removing important competitive constraints on one or more sellers who consequently have increased market power. The most direct effect of the merger will be the loss of competition between the merging firms. For example, if prior to the merger one of the merging firms had raised its price, it would have lost some sales to the other merging firm. The merger removes this particular constraint. Non-merging firms in the same market can also benefit from the reduction of competitive pressure that results from the merger, since the merging firms' price increase may switch some demand to the rival firms, which, in turn, may find it profitable to increase their prices. The reduction in these competitive constraints could lead to significant price increases in the relevant market."*[33]

(47) The Horizontal Merger Guidelines list a number of factors which may influence whether or not significant non-coordinated effects are likely to result from a merger, such as large market shares of the merging firms, the fact that the merging firms are close competitors, the limited possibilities for customers to switch suppliers, or the fact that the merger would eliminate an important competitive force.[34] That list of factors applies equally regardless of whether a merger would create or strengthen a dominant position, or would otherwise significantly impede effective competition due to non-coordinated effects. Furthermore, not all of these factors need to be present for significant non-coordinated effects to be likely. The list of factors, each of which is not necessarily decisive in its own right, is also not an exhaustive list.[35]

(48) Finally, the Horizontal Merger Guidelines describe a number of factors, which could counteract the harmful effects of the merger on competition, including the likelihood of buyer power, the entry of new competitors on the market, and efficiencies.

*4.1.3. Competitive assessment of group 2 and 3 markets*

(49) For all of the Group 2 and Group 3 markets, the market shares of the Parties are limited, and significant competitors that will likely sufficiently constrain the merged entity remain on the market post-Transaction and/or the Transaction brings about only a limited increment. In addition, the market investigation did not reveal any concerns in relation to any of the Group 2 and 3 markets.[36]

---

32 OJ C 31, 5.2.2004, p. 5.

33 Horizontal Merger Guidelines, paragraph 24.

34 Horizontal Merger Guidelines, paragraphs 27 and following.

35 Horizontal Merger Guidelines, paragraphs 24-38.

36 Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.

(50) The Commission assessed the competitive situation on these markets analysing the nature and the number of existing competitors and considered that the Transaction does not raise serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement as a result of a horizontal effects in any of those markets. Consequently, in line with previous decisions[37] Group 2 and Group 3 overlaps will not be assessed any further in the present Decision.

*4.1.4. Competitive assessment of group 1 and 1+ markets*

4.1.4.1. Antihaemorrhoids in Italy and in Romania

(51) At each of the ATC3 class C5A (topical antihaemorrhoidals) and CHC3 code 10A1 (antihaemorrhoids), the Parties activities result in a Group 1/1+ affected market in Italy, while in the CHC4 code 10A1O (antihaemorrhoids - ointments and creams) the Parties activities result in a Group 1/1+ affected market in Italy and Romania.

(A) ATC3 level C5A (topical antihaemorrhoidals) in Italy

(52) Recordati sells Proctolyn (based on fluocinolone acetonide and ketocaine), while Cooper sells Ruscoroid (based on ruscogenins and tetracaine) in Italy.

(53) The Notifying Party submits that the Transaction does not give rise to competition concerns in topical antihaemorrhoidals in Italy, because the Parties' products do not compete closely, given their different active ingredients and the combined entity would face vigorous competition in this market.

(54) Tables 4 below show the market shares of the Parties and their main rivals in the market for topical antihaemorrhoidals in Italy in the last three years, in value and in volume.

[37] See M.8974 – Procter & Gamble / Merck Consumer Health Business, para. 25.

| Table 4 - C5A (topical antihaemorrhoidals) in Italy<br>Market Shares in terms of value (2018-2020) | | | | | | |
|---|---|---|---|---|---|---|
| **Supplier** | **2018 Revenue (EUR 000)** | **2019 Revenue (EUR 000)** | **2020 Revenue (EUR 000)** | **2018 Share of Sales (%)** | **2019 Share of Sales (%)** | **2020 Share of Sales (%)** |
| **CVC (Recordati)** | [...] | [...] | [...] | [30-40]% | [30-40]% | [30-40]% |
| **Cooper** | [...] | [...] | [...] | [5-10]% | [5-10]% | [5-10]% |
| ***Combined*** | [...] | [...] | [...] | *[40-50]%* | *[40-50]%* | *[40-50]%* |
| Bayer | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| Neopharmed Gentili | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| Glaxosmithkline | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| Alfasigma | [...] | [...] | [...] | [5-10]% | [5-10]% | [10-20]% |
| **Others** | [...] | [...] | [...] | [5-10]% | [5-10]% | [0-5]% |
| **Total** | [...] | [...] | [...] | 100% | 100% | 100% |

*Source: IQVIA*

| Table 5 - C5A (topical antihaemorrhoidals) in Italy<br>Market Shares in terms of volume (2018-2020) | | | | | | |
|---|---|---|---|---|---|---|
| **Supplier** | **2018 (000 Units Sold)** | **2019 (000 Units Sold)** | **2020 (000 Units Sold)** | **2018 Share of Sales (%)** | **2019 Share of Sales (%)** | **2020 Share of Sales (%)** |
| **CVC (Recordati)** | [...] | [...] | [...] | [30-40]% | [30-40]% | [30-40]% |
| **Cooper** | [...] | [...] | [...] | [10-20]% | [5-10]% | [5-10]% |
| ***Combined*** | [...] | [...] | [...] | *[40-50]%* | *[40-50]%* | *[40-50]%* |
| Glaxosmithkline | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| Bayer | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| Neopharmed Gentili | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| Alfasigma | [...] | [...] | [...] | [5-10]% | [5-10]% | [10-20]% |
| **Others** | [...] | [...] | [...] | [5-10]% | [5-10]% | [0-5]% |
| **Total** | [...] | [...] | [...] | 100% | 100% | 100% |

*Source: IQVIA*

(55) In 2020, the combined share of the Parties in the market for topical antihaemorrhoidals in Italy was [40-50]% in value and [40-50]% in volume (with an increment of [5-10]% in value and [5-10]% in volume contributed by Cooper). There are four competitors with market shares in value and volume higher than the increment brought by the Transaction.

(56) In this market, the Transaction is unlikely to give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement for the following reasons:

(a) Post-Transaction, in the market for topical antihaemorrhoidals in Italy, the combined entity would face competitive constraints from several rivals. According to IQVIA, in 2020, there were around 12 competitors active in this market.[38] These rivals include Bayer, Neopharmed Gentili, Glaxosmithkline and Alfasigma, each holding shares at, or above 10% (both in value and in volume) in 2020. The results of the market investigation confirm this. All respondents (competitors and customers) replied that post-Transaction a sufficient number of suppliers will continue offering topical antihaemorrhoidals in Italy.[39]

(b) There is no evidence that the products of the Parties in this market compete closely with each other, since they are not close substitutes. Proctolyn and Ruscoroid are based on different active ingredients and Proctolyn contains corticosteroids, while Ruscoroid does not. Products with corticosteroids may lead to severe side effects, consequently, anti-haemorrhoidals with corticosteroids are preferably used to treat acute and severe haemorroids due to a strong anti-inflammatory action for a short period of no longer than seven days, while anti-haemorroidals without corticosteroids can be used for milder symptoms and possibly for a longer period as a maintenance therapy since they have a weaker anti-inflammatory action.[40] The results of the market investigation confirmed to a certain extent that Proctolyn and Ruscoroid are not each others' closest competitor. [41]

(c) Finally, the market investigation did not reveal any concerns in relation to topical antihaemorrhoidals in Italy.[42]

(57) In light of the above considerations, the Commission concludes that the Transaction does not raise serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement as a result of a horizontal effects in the market for topical antihaemorrhoidals in Italy.

38 See Form CO Annex 7.4-1.

39 Replies to Questionnaire Q3, question 12 - 14 and Questionnaire Q4, question 9 - 11.

40 Replies to Questionnaire Q3, question 10 and Questionnaire Q4, question7.

41 Replies to Questionnaire Q3, question 8 and Questionnaire Q4, question 6.

42 Replies to Questionnaire Q3, questions 15 & 16 and Questionnaire Q4, question 12. No customer raised competition concerns regarding the impact of the Transaction in topical antihaemorrhoidals in Italy. Only one competitor of the Parties considered that the Transaction could have a negative impact because of the increased capacity of the merged entity to invest. However, this customer does not foresee any impact on the price and availability of topical antihaemorrhoidals in Italy.

(B) CHC3 code 10A1 (antihaemorrhoids) and CHC4 code 10A1O (antihaemorrhoids - ointments and creams) in Italy

(58) Recordati sells Proctolyn in the forms of cream and suppositories, and Proctolyn Integra Plus, a food supplement sold in the form of sachets. Cooper sells Ruscoroid in the form of cream, Ruscoroid Forte, a food supplement in sachet form, Vasostar, which comes in the form of a cream and used to treat internal and external haemorrhoids and Micro H in the form of a gel or wipes, producing a calming effect that reduces haemorrhoidal problems.[43]

(59) While the products contain some of the same active substances, each product also contain further substances with different mechanisms of action to achieve the desired effect.[44]

(60) The Notifying Party submits that the Transaction does not give rise to competition concerns either in antihaemorrhoids, or in antihaemorrhoidal ointments and creams in Italy, because the Parties' products do not compete closely, given their different active ingredients and the combined entity would face vigorous competition in this market.

(61) Tables 6 and 7 below show the market shares of the Parties and their main rivals in the market for antihaemorrhoids in Italy in the last three years in value and in volume.

43 Micro H is exiting the market as a result of commercial decisions by Cooper. See Form CO, paragraph 281.

44 See Form CO, paragraph 289.

| Table 6 - 10A1 (antihaemorrhoids) in Italy<br><br>Market Shares in terms of Value (2018-2020) | | | | | | |
|---|---|---|---|---|---|---|
| **Supplier** | **2018 Revenue (EUR 000)** | **2019 Revenue (EUR 000)** | **2020 Revenue (EUR 000)** | **2018 Share of Sales (%)** | **2019 Share of Sales (%)** | **2020 Share of Sales (%)** |
| **CVC (Recordati)** | [...] | [...] | [...] | [20-30]% | [20-30]% | [20-30]% |
| **Cooper** | [...] | [...] | [...] | [0-5]% | [0-5]% | [0-5]% |
| **Combined** | [...] | [...] | [...] | [30-40]% | [20-30]% | [20-30]% |
| Bayer | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| Glaxosmithkline | [...] | [...] | [...] | [10-20]% | [5-10]% | [5-10]% |
| Alfasigma | [...] | [...] | [...] | [5-10]% | [5-10]% | [5-10]% |
| Aboca | [...] | [...] | [...] | [5-10]% | [5-10]% | [5-10]% |
| **Others**[45] | [...] | [...] | [...] | [60-70]% | [60-70]% | [60-70]% |
| **Total** | [...] | [...] | [...] | 100% | 100% | 100% |

*Source: IQVIA*

45 Including Pasquali, Urgo, Uniderm, etc.

| Table 7 - 10A1 (antihaemorrhoids) in Italy<br><br>Market Shares in terms of volume (2018-2020) | | | | | | |
|---|---|---|---|---|---|---|
| **Supplier** | **2018 (000 Units Sold)** | **2019 (000 Units Sold)** | **2020 (000 Units Sold)** | **2018 Share of Sales (%)** | **2019 Share of Sales (%)** | **2020 Share of Sales (%)** |
| **CVC (Recordati)** | [...] | [...] | [...] | [30-40]% | [30-40]% | [30-40]% |
| **Cooper** | [...] | [...] | [...] | [5-10]% | [5-10]% | [5-10]% |
| ***Combined*** | [...] | [...] | [...] | *[40-50]%* | *[40-50]%* | *[40-50]%* |
| Glaxosmithkline | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| Bayer | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| Alfasigma | [...] | [...] | [...] | [5-10]% | [5-10]% | [5-10]% |
| Aboca | [...] | [...] | [...] | [5-10]% | [0-5]% | [0-5]% |
| **Others**[46] | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| **Total** | [...] | [...] | [...] | 100% | 100% | 100% |

*Source: IQVIA*

(62) In 2020, the combined share of the Parties in the market for antihaemorrhoids in Italy was [20-30]% in value and [40-50]% in volume (with an increment of [0-5]% in value and [5-10]% in volume contributed by Cooper). On a value basis there are five[47] with market shares higher than the increment brought by the transaction. On a volume basis there are two competitors.

(63) Tables 8 and 9 below show the market shares of the Parties and their main rivals in the market for antihaemorrhoidal ointments and creams in Italy in the last three years in value and in volume.

46 Including Urgo, Pasquali, Omikron, etc.

47 Pasquali has a 5% market share.

| Table 8 - 10A1O (antihaemorrhoids - ointments and creams) in Italy<br><br>Market Shares in terms of value (2018-2020) | | | | | | |
|---|---|---|---|---|---|---|
| **Supplier** | **2018 Revenue (EUR 000)** | **2019 Revenue (EUR 000)** | **2020 Revenue (EUR 000)** | **2018 Share of Sales (%)** | **2019 Share of Sales (%)** | **2020 Share of Sales (%)** |
| **CVC (Recordati)** | [...] | [...] | [...] | [20-30]% | [20-30]% | [20-30]% |
| **Cooper** | [...] | [...] | [...] | [5-10]% | [5-10]% | [5-10]% |
| ***Combined*** | [...] | [...] | [...] | [30-40]% | [30-40]% | [30-40]% |
| Bayer | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| Glaxosmithkline | [...] | [...] | [...] | [10-20]% | [10-20]% | [5-10]% |
| Alfasigma | [...] | [...] | [...] | [5-10]% | [5-10]% | [5-10]% |
| Aboca | [...] | [...] | [...] | [5-10]% | [5-10]% | [5-10]% |
| **Others**[48] | [...] | [...] | [...] | [30-40]% | [30-40]% | [30-40]% |
| **Total** | [...] | [...] | [...] | 100% | 100% | 100% |

*Source: IQVIA*

48 Including Pasquali, Uniderm, THD, etc.

| Table 9 - 10A1O (antihaemorrhoids - ointments and creams) in Italy<br><br>Market Shares in terms of volume (2018-2020) | | | | | | |
|---|---|---|---|---|---|---|
| **Supplier** | **2018 (000 Units Sold)** | **2019 (000 Units Sold)** | **2020 (000 Units Sold)** | **2018 Share of Sales (%)** | **2019 Share of Sales (%)** | **2020 Share of Sales (%)** |
| **CVC (Recordati)** | [...] | [...] | [...] | [40-50]% | [40-50]% | [40-50]% |
| **Cooper** | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| ***Combined*** | [...] | [...] | [...] | *[50-60]%* | *[50-60]%* | *[40-50]%* |
| Glaxosmithkline | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| Bayer | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| Alfasigma | [...] | [...] | [...] | [5-10]% | [5-10]% | [10-20]% |
| Karo Pharma | [...] | [...] | [...] | [0-5]% | [0-5]% | [0-5]% |
| **Others**[49] | [...] | [...] | [...] | [5-10]% | [10-20]% | [10-20]% |
| **Total** | [...] | [...] | [...] | 100% | 100% | 100% |

*Source: IQVIA*

(64) In 2020, the combined share of the Parties in the market for antihaemorrhoidal ointments and creams in Italy was [30-40]% in value and [40-50]% in volume (with an increment of [5-10]% in value and [10-20]% in volume contributed by Cooper). On a value basis, there are four competitors with market shares higher than the increment brought by the transaction. On a volume basis there are two.

(65) In this market, the Transaction is unlikely to give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement for the following reasons:

(a) Post-Transaction, in both of the market for antihaemorrhoids and for the market for antihaemorrhoidal creams and ointments in Italy, the combined entity would face competitive constraints from several rivals. According to IQVIA, in 2020, there were more than 100 competitors active in each of these markets. These rivals include Glaxosmithkline, Bayer Alfasigma and Aboca, each holding shares in volume at, or above 10% in 2020. The results of the market investigation confirm this. All respondents (competitors and customers) replied that post-Transaction a sufficient number of suppliers will continue offering antihaemorrhoids and antihaemorrhoidal creams and ointments in Italy.[50]

(b) There is no evidence that the products of the Parties in the market for antihaemorrhoids in Italy compete closely with each other, since they are not close substitutes, given their different active ingredients and the fact that they

49 Including Urgo, Servier, Desma Pharma, etc.

50 Replies to Questionnaire Q3, question 12 - 14 and Questionnaire Q4, question 9 - 11.

exist in different forms, cream (Proctolyn, Vasostar and Ruscoroid), food supplements in the form of a sachet (Proctolyn Integra Plus and Ruscoroid Fort) and single-dose gel and a single-dose wipe (Micro H). The results of the market investigation confirmed to a certain extent that the Parties' products are not each others' closest competitor. [51]

(c) Finally, the market investigation did not reveal any concerns in relation to antihaemorrhoids and antihaemorrhoidal creams and ointments in Italy.[52]

(66) In light of the above considerations, the Commission concludes that the Transaction does not raise serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement as a result of a horizontal effects in the markets for antihaemorrhoids and in the market for antihaemorrhoidal creams and ointments in Italy.

(C) CHC4 level 10A1O (antihaemorrhoids - ointments and creams) in Romania[53]

(67) Recordati sells Procto Glyvenol in the form of an ointment. Cooper has sold its Micro H (in form of a gel) in an one-off sale.[54]

(68) The Notifying Party submits that the Transaction does not give rise to competition concerns in antihaemorrhoidal ointments and creams in Romania, because the Parties' products do not compete closely, given their different active ingredients and the combined entity would face vigorous competition in this market.

(69) Tables 10 and 11 below show the market shares of the Parties and their main rivals in the market for antihaemorrhoids - ointments and creams in Romania in the last three years, in value and in volume.

51 Replies to Questionnaire Q3, question 8 and Questionnaire Q4, question 6.

52 Replies to Questionnaire Q3, questions 15 & 16 and Questionnaire Q4, question 12. No customer raised competition concerns regarding the impact of the Transaction in topical antihaemorrhoidals in Italy. Only one competitor of the Parties considered that the Transaction could have a negative impact because of the increased capacity of the merged entity to invest. However this customer does not foresee any impact on the price and availability of topical antihaemorrhoidals in Italy.

53 At ATC3/CHC3 level (10A1), the Parties' market shares result in a Group 3 affected market in Romania.

54 The Notifying Party submits that this was truly marginal in absolute terms ([…]). See Form CO, paragraph 318. Moreover, the Notifying Party recalls that Micro H is exiting the market, see footnote 43.

| Table 10 - 10A1O (antihaemorrhoids - ointments and creams) in Romania<br><br>Market Shares in terms of value (2018-2020) | | | | | | |
|---|---|---|---|---|---|---|
| **Supplier** | **2018 Revenue (EUR 000)** | **2019 Revenue (EUR 000)** | **2020 Revenue (EUR 000)** | **2018 Share of Sales (%)** | **2019 Share of Sales (%)** | **2020 Share of Sales (%)** |
| **CVC (Recordati)** | [...] | [...] | [...] | [30-40]% | [30-40]% | [30-40]% |
| **Cooper** | [...] | [...] | [...] | - | - | [0-5]% |
| ***Combined*** | [...] | [...] | [...] | [30-40]% | [30-40]% | [30-40]% |
| H.I.P. Health Innov | [...] | [...] | [...] | [30-40]% | [20-30]% | [20-30]% |
| ZDROVIT | [...] | [...] | [...] | [0-5]% | [10-20]% | [10-20]% |
| Global Treat | [...] | [...] | [...] | [10-20]% | [10-20]% | [5-10]% |
| MBA Pharma | [...] | [...] | [...] | - | [0-5]% | [0-5]% |
| **Others**[55] | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| **Total** | [...] | [...] | [...] | 100% | 100% | 100% |

*Source: IQVIA*

55 Including Aboca, Fiterman, Biofarm, etc.

| Table 11 - 10A1O (antihaemorrhoids - ointments and creams) in Romania<br><br>Market Shares in terms of volume (2018-2020) | | | | | | |
|---|---|---|---|---|---|---|
| **Supplier** | **2018 (000 Units Sold)** | **2019 (000 Units Sold)** | **2020 (000 Units Sold)** | **2018 Share of Sales (%)** | **2019 Share of Sales (%)** | **2020 Share of Sales (%)** |
| **CVC (Recordati)** | [...] | [...] | [...] | [40-50]% | [30-40]% | [30-40]% |
| **Cooper** | [...] | [...] | [...] | | | [0-5]% |
| ***Combined*** | [...] | [...] | [...] | [40-50]% | [30-40]% | [30-40]% |
| ZDROVIT | [...] | [...] | [...] | [0-5]% | [20-30]% | [20-30]% |
| H.I.P. Health Innov | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| Biofarm | [...] | [...] | [...] | [5-10]% | [5-10]% | [5-10]% |
| Aboca | [...] | [...] | [...] | [0-5]% | [0-5]% | [5-10]% |
| **Others**[56] | [...] | [...] | [...] | [20-30]% | [10-20]% | [10-20]% |
| **Total** | [...] | [...] | [...] | 100% | 100% | 100% |

*Source: IQVIA*

(70) In 2020, the combined share of the Parties in the market for antihaemorrhoidal ointments and creams in Romania was [30-40]% in value and [30-40]% in volume (with an increment of [0-5]% both in value and in volume contributed by Cooper). On a value basis, there are at least eight competitors with market shares higher than the increment brought by the Transaction.[57] On a volume basis there are at least seven.[58]

(71) The Commission takes note that the overlap in antihaemorrhoidal creams and ointments in Romania only exists because of an exceptional one off sale (of an insignificant value) of Micro H. Moreover, Micro H is discontinued as a product.

(72) In light of the above considerations, the Commission concludes that the Transaction does not raise serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement as a result of a horizontal effects in the markets for antihaemorrhoids and in the market for antihaemorrhoidal creams and ointments in Romania.

56 Including Fiterman, MBA Pharma, etc.

57 Aboca, Fiterman, Biofarm and Naturpharma have shares between 3% and at least 1 %.

58 Fiterman, MBA Pharma, and Global Treat have shares between 4% and 3%.

4.1.4.2. Sore throat remedies in France[59]

(73) Cooper markets two sore throat remedies in France: Colludol[60] and Clariver. Recordati markets Hexaspray. The Parties' activities in this product category in France give rise to a horizontally affected market only at CHC4 level (01C1A - Sore throat Remedies – Aerosols/Sprays).[61]

(74) The Notifying Party submits that the Transaction does not give rise to competition concerns in sore throat remedies in France (in the form of aerosols and sprays) because the Parties' products do not compete closely and the combined entity would face vigorous competition in this market.

(75) Table 12 below shows the market shares of the Parties and their main rivals in the market for sore throat remedies in the form of aerosols/sprays in France in the last three years.

**Table 12 - 01C1A - Sore throat Remedies – Aerosols/Sprays in France**

**Market Shares in terms of Value (2018-2020)**

| Supplier | 2018 Revenue (EUR 000) | 2019 Revenue (EUR 000) | 2020 Revenue (EUR 000) | 2018 Share of Sales (%) | 2019 Share of Sales (%) | 2020 Share of Sales (%) |
|---|---|---|---|---|---|---|
| CVC (Recordati) | [...] | [...] | [...] | [20-30]% | [20-30]% | [20-30]% |
| Cooper | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| ***Combined*** | [...] | [...] | [...] | [30-40]% | [30-40]% | [40-50]% |
| Procter & Gamble | [...] | [...] | [...] | [10-20]% | [10-20]% | [10-20]% |
| Urgo | [...] | [...] | [...] | [5-10]% | [5-10]% | [5-10]% |
| Pfizer | [...] | [...] | [...] | [5-10]% | [5-10]% | [5-10]% |
| Others[62] | [...] | [...] | [...] | [30-40]% | [30-40]% | [30-40]% |
| Total | [...] | [...] | [...] | 100% | 100% | 100% |

*Source: IQVIA*

(76) Post-Transaction, the combined share of the Parties in the market for sore throat remedies in the form of aerosols/sprays in France would be (in value) [40-50]%

59 The Parties' activities in sore throat remedies also overlap in Luxembourg and Italy but the Transaction does not give rise to affected markets in these countries (under any plausible relevant product market delineation).

60 In 2020, Colludol represented [90-100]% of Cooper's sales in this market.

61 At ATC3 or CHC3 level, the Parties' combined share does not result in an affected market. The Parties' products do not overlap at molecule level.

62 Including Reckitt Benckiser; Pierre Fabre; Pranarom; Perrigo; Pediact; Sanofi; and Aboca.

(with an increment of [10-20]% contributed by Cooper).[63] In this market, the Transaction is unlikely to give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement for the following reasons:

(a) Post-Transaction, in the market for sore throat remedies in the form of aerosols/sprays in France, the combined entity would face competitive constraints from several rivals. According to IQVIA, in 2020, there were more than 60 competitors active in this market. These rivals include Procter & Gamble; Urgo; and Pfizer, each holding shares above 5% in 2020. The results of the market investigation confirm this. All respondents (competitors and customers) replied that post-Transaction a sufficient number of suppliers will continue offering sore throat remedies in the form of aerosols and sprays in France.[64]

(b) There is no evidence that the products of the Parties in this market compete closely with each other. Colludol and Hexaspray have different therapeutic effects.[65] Hexaspray has antibacterial and antiseptic action. Colludol has antiseptic action but also includes lidocaine and thus works as an anaesthetic for the sore throat. Colludol competes more closely with Procter & Gamble's and Urgo's products (which contain lidocaine and have anaesthetic action) than with Hexaspray.

The results of the market investigation confirm this. None of the respondents (competitors and customers) identified Hexaspray as the closest competing product for Colludol.[66] The vast majority of the respondents did not identify Hexaspray among the three closest competitors to Colludol nor Colludol among the three closest competitors to Hexaspray.[67]

[…].[68] […].[69] […].[70]

(c) Sore throat remedies are also available in forms other than aerosols/sprays, e.g., as lozenges or syrups. While lozenges and syrups are not part of the relevant market which is affected by the concentration (01C1A – Sore throat Remedies – Aerosols/Sprays), they could still exert competitive constraints over the combined entity post-Transaction.

The results of the market investigation confirm this. The majority of competitors stated that consumers consider substitutable (at least to some

63 By volume, Cooper held a share of [0-5]% and CVC held a share of [0-5]%. This discrepancy between value- and volume-based market shares exists because IQVIA does not properly convert "actual units" of competitor products to "standard units" (which it does for the Parties' products).

64 Replies to Questionnaire Q1, question 12 and Questionnaire Q2, question 10.

65 Clariver and Hexaspray also do not compete closely. Clariver is based on natural ingredients while Hexaspray includes active pharmaceutical ingredients. In the market investigation, none of the respondents identified Clariver as a product competing closely with Hexaspray (Replies to Questionnaire Q1, question 8 and Replies to Questionnaire Q2, question 6).

66 Replies to Questionnaire Q1, question 8 and Questionnaire Q2, question 6.

67 Replies to Questionnaire Q1, question 8 and Questionnaire Q2, question 6.

68 Form CO, Annex 7.4-XI – Target's Document (Part 1) on Colludol_Hexaspray, page 30.

69 Form CO, Annex 7.4-XI – Target's Document (Part 1) on Colludol_Hexaspray, page 30.

70 Form CO, footnote 161.

extent) sore throat remedies in aerosols/sprays and sore throat remedies in other forms.[71]

In its internal documents, Recordati […]".[72]

(d) The market investigation did not reveal any substantiated concerns in relation to sore throat remedies in the form of aerosols/sprays in France.[73]

(77) In light of the above considerations, the Commission concludes that the Transaction does not raise serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement as a result of a horizontal effects in the market for sore throat remedies in the form of aerosols/sprays in France.

4.1.4.3. Mouth pain relief liquids in France

(78) The Parties' activities in this product category in France give rise to a Group 1/1+ horizontally affected market only at CHC4 level (02D1L – Mouth Pain Relief – Liquids (Topical)).[74]

(79) Cooper markets products under the brand names Hyalugel and Dentobaume. Hyalugel is a mouthwash based on hyaluronic acid used to treat irritant conditions of the gums (e.g. inflammation of the gums, bleeding, receding gums) or traumatic conditions of the gums (e.g. due to cleaning, abrasion, extraction of teeth). As such, Hyalugel is recommended by dentists and practitioners as part of healing treatments. Dentobaume is a local anaesthetic indicated for the treatment of acute gingivodental pain. The product is liquid is and applied by a soaked pad directly on the painful gum or tooth. In 2020, Dentobaume represented [60-70]% of Cooper's sales in this market.

(80) Recordati markets Aphtavea, a mouthwash based on hyaluronic acid and aloe vera to treat mouth ulcers and mouth injury. Aphtavea provides a protective mechanical barrier over aphthous ulcers or oral lesions, isolating it from potential external influences, such as food particles or hot liquids.

(81) The Notifying Party submits that the Transaction does not give rise to competition concerns in mouth pain relief products in the form of liquids because the Parties' products are not close competitors, the Parties will continually consider their competitors and there is vibrant competition with recent entrants.[75]

---

71 Replies to Questionnaire Q1, question 11.

72 Form CO, Annex 7.4-XV-1 – Recordati's additional ordinary course documents prepared in 2019 and 2020, page 2.

73 Replies to Questionnaire Q1, question 13 and Questionnaire Q2, question 11. No customer raised competition concerns regarding the impact of the Transaction in sore throat remedies in the form of aerosols/sprays in France. Only one competitor of the Parties considered that the Transaction could have a negative impact on the market (leading to higher prices). However, this competitor did not substantiate its concerns. Instead, this same competitor identified "*16 other sore throat sprays brands*" that would compete with the combined entity and admitted that the Parties' products do not compete closely with each other (see Replies to Questionnaire Q1, questions 8, 12.1, and 13).

74 At ATC3/CHC3 level (02D1 – Mouth Pain Relief), the Parties' market shares result in a Group 3 affected market. The Parties' products do not overlap at molecule level.

75 Form CO, paragraphs 379 ff.

(82) Table 13 below shows the market shares of the Parties and their main competitors in the market for mouth pain relief products in the form of liquids in France in the last three years, in value.

**Table 13 – 02D1L Mouth Pain Relief Liquids in France**
**Market Shares in terms of Value (2018-2020)**

| Supplier | 2018 Revenue (EUR 000) | 2019 Revenue (EUR 000) | 2020 Revenue (EUR 000) | 2018 Share of Sales (%) | 2019 Share of Sales (%) | 2020 Share of Sales (%) |
|---|---|---|---|---|---|---|
| CVC (Recordati) | [...] | [...] | [...] | [5-10]% | [5-10]% | [0-5]% |
| Cooper | [...] | [...] | [...] | [50-60]% | [50-60]% | [50-60]% |
| *Combined* | [...] | [...] | [...] | ***[60-70]%*** | ***[60-70]%*** | ***[50-60]%*** |
| Bausch Health | [...] | [...] | [...] | [20-30]% | [20-30]% | [20-30]% |
| Urgo | [...] | [...] | [...] | [0-5]% | [0-5]% | [5-10]% |
| Groupe Batteur | [...] | [...] | [...] | [10-20]% | [5-10]% | [5-10]% |
| Aboca | [...] | [...] | [...] | [0-5]% | [0-5]% | [0-5]% |
| Others[76] | [...] | [...] | [...] | [0-5]% | [0-5]% | [0-5]% |
| Total | [...] | [...] | [...] | **100%** | **100%** | **100%** |

*Source: IQVIA*

(83) In 2020, the combined share of the Parties in the market for mouth pain relief products in the form of liquids in France was [50-60]% (in value), with an increment of [0-5]% contributed by CVC Recordati).[77]

(84) In this market, the Transaction is unlikely to give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement for the following reasons:

(a) There is no evidence that the products of the Parties compete closely in this market, given their different active ingredients, therapeutic indications, and different modes of action. Dentobaume is a local anaesthetic in the form of a liquid, indicated for the treatment of acute gingivodental pain. Since it is applied by a soaked pad directly on the painful gum or tooth, it is not a mouthwash like Hyalugel and Aphtavea. On the other hand, both Hyalugel and Aphtavea are mouthwashes based on hyaluronic acid, with Aphtavea indicated generally for mouth sores and Hyalugel indicated specifically as part of healing treatments.

76 Including Church & Dwight, Bi Pharma, Biopharme, and H2 Pharma.

77 By volume, Cooper held a share of [20-30]% and CVC held a share of [5-10]%. This discrepancy between value- and volume-based market shares exists because IQVIA does not properly convert "actual units" of Recordati's products to "standard units" (which it does for Cooper's and competitors' products).

The fact that Aphtavea is not a close competitor to Hyalugel (which represents more than [60-70]% of Coopers' sales by value),[78] is reflected in a response of a competitor to the market investigation, which indicates that the closest substitutes to Hyalugel are Bioxaphte (a product marketed by Bausch Health), and Urgo Dentilia and Mercurochrome (marketed by Urgo) and not Aphtavea [79] since *"The two brands selected are we believe as strong as Hyalugel. A pharmacist could easily recommend one or another."* Consequently, the bulk of the Cooper's sales are for a product which is not seen as a close competitor of CVC Recordati.

The share increment contributed by CVC Recordati is limited to [0-5]% in value, so the Transaction will not significantly affect the competitive landscape in this market. The Parties would continue facing competitive constraints from several competitors with shares higher or equal to that of CVC Recordati. These include Bausch Health ([20-30]% value share in 2020), Urgo ([5-10]%), Groupe Batteur ([5-10]%), and Aboca ([0-5]%).

The results of the market investigation confirm that post-Transaction a sufficient number of suppliers will offer mouth pain relief liquids in France.[80] The same competitor states: *"Mouth pain relief products exist in different formats. The liquid form is popular but gels are also very common. Plus some mouthwashes can also be used to treat mouth pain relief (eg. Eludril). Therefore plenty of products exist on the market."*[81]

(b) There is some evidence of new entrants into this market, suggesting that barriers to entry are not high. Urgo and Aboca entered the market only in 2020 and already have market shares comparable or higher to that of Cooper.

(c) The market investigation did not reveal any concerns in relation to mouth pain relief products in the form of liquids in France.[82]

(85) In light of the above considerations, the Commission concludes that the Transaction does not raise serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement as a result of horizontal effects in the market for mouth pain relief products in the form of liquids in France.

4.1.4.4. Ear care products in Spain

(86) The Parties' activities in this product category in Spain give rise to a Group 1/1+ horizontally affected market only at CHC4 level (08A1Z – Ear Care – Other Forms).[83]

78 Form CO Table 11

79 Reply to Questionnaire Q5, question 7. "The two brands selected [ are we believe as strong as Hyalugel. A pharmacist could easily recommend one or another."

80 Reply to Questionnaire Q5, question 9.

81 Reply to Questionnaire Q5, question 9.

82 Replies to Questionnaire Q5, questions 12-13, as well as replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14.

(87) CHC4 code 08A1Z is a catch-all category that includes ear care products in forms other than those included in other CHC4 codes within CHC3 codes 08A1. In Spain, Cooper markets two ear care products that belong to the CHC4 code 08AIZ: Audispray[84] and Audilyse (both in the form of an ear spray). Recordati markets Elebiotic (a food supplement in the form of a sachet).

(88) The Notifying Party submits that the Transaction does not give rise to competition concerns in ear care products in other forms in Spain because the Parties' products are not close competitors and are not substitutable from a demand perspective and the combined entity would face vigorous competition in this market.[85]

(89) Tables 14 and 15 below show the market shares of the Parties and their main competitors in the market for ear care in other forms in Spain in the last three years, in value and in volume.

**Table 14 – 08A1Z - Ear Care – Other forms in Spain**
**Market Shares in terms of Value (2018-2020)**

| Supplier | 2018 Revenue (EUR 000) | 2019 Revenue (EUR 000) | 2020 Revenue (EUR 000) | 2018 Share of Sales (%) | 2019 Share of Sales (%) | 2020 Share of Sales (%) |
|---|---|---|---|---|---|---|
| CVC (Recordati) | […] | […] | […] | [0-5]% | [0-5]% | [0-5]% |
| Cooper | […] | […] | […] | [30-40]% | [30-40]% | [30-40]% |
| *Combined* | […] | […] | […] | [30-40]% | [30-40]% | [30-40]% |
| Faes Farma | […] | […] | […] | [20-30]% | [20-30]% | [20-30]% |
| Perrigo | […] | […] | […] | [10-20]% | [10-20]% | [10-20]% |
| M4 Pharma | […] | […] | […] | [10-20]% | [10-20]% | [10-20]% |
| Normon | […] | […] | […] | [0-5]% | [0-5]% | [0-5]% |
| Others[86] | […] | […] | […] | [10-20]% | [10-20]% | [10-20]% |
| Total | […] | […] | […] | **100%** | **100%** | **100%** |

*Source: IQVIA*

83 At ATC3/CHC3 level (08A1 – Ear Care), the Parties' shares result in a Group 3 affected market. The Parties' products do not overlap at molecule level.

84 In 2020, Audispray represented more than [90-100]% of Cooper's sales in this market.

85 Form CO, paragraphs 390 and 391.

86 Including Hulka, Salvat, Reig Jofre, Quies, Cofares, Walgreens Boots Al, Ordesa, Ysana, Fitodis, Sodeinn, Otosan, Inebios, Vaza Lab, Deca, Fleming, Cantabria, Dermoestetica Sur and Urgo.

| Table 15 – 08A1Z- Ear Care – Other forms in Spain<br>Market Shares in terms of Volume (2018-2020) | | | | | | |
|---|---|---|---|---|---|---|
| **Supplier** | **2018 (000 Units Sold)** | **2019 (000 Units Sold)** | **2020 (000 Units Sold)** | **2018 Share of Sales (%)** | **2019 Share of Sales (%)** | **2020 Share of Sales (%)** |
| CVC (Recordati) | […] | […] | […] | [0-5]% | [0-5]% | [0-5]% |
| Cooper | […] | […] | […] | [30-40]% | [30-40]% | [30-40]% |
| ***Combined*** | […] | […] | […] | [30-40]% | [30-40]% | [30-40]% |
| Faes Farma | […] | […] | […] | [10-20]% | [10-20]% | [10-20]% |
| Perrigo | […] | […] | […] | [20-30]% | [20-30]% | [10-20]% |
| M4 Pharma | […] | […] | […] | [5-10]% | [5-10]% | [5-10]% |
| Reig Jofre | […] | […] | […] | [5-10]% | [5-10]% | [5-10]% |
| Others[87] | […] | […] | […] | [10-20]% | [10-20]% | [10-20]% |
| Total | […] | […] | […] | **100%** | **100%** | **100%** |

*Source: IQVIA*

(90) In 2020, the combined share of the Parties in the market for ear care in other forms in Spain was [30-40]% in value and [30-40]% in volume (with an increment of [0-5]% in value and [0-5]% in volume contributed by CVC Recordati).

(91) In this market, the Transaction is unlikely to give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement for the following reasons:

(a) The Parties' products do not compete and are not substitutable from the demand side. Instead, the overlap appears only due to the catch-all nature of CHC4 code 081AZ. Cooper's products Audispray and Audilyse both come in a form of an ear spray. Audilyse helps soften and dissolve earwax and contributes to eliminating the feeling of clogged ears.[88] Audispray is a cleaning solution, which works by gradually thinning and dissolving earwax. It removes excess earwax, dust and dirt, and prevents blockages. Recordati's product Elebiotic, on the other hand, is a food supplement in a form of a sachet marketed for the benefit of the ear health of children. The Parties' products therefore have different modes of application, different ingredients and different therapeutic uses.

(b) Even if the Parties were to compete in this market, the share increment contributed by CVC Recordati is limited to [0-5]% in value and [0-5]% in volume. Thus, the Transaction is unlikely to cause significant change in the competitive landscape in this plausible market.

87 Others include Normon, Hulka, Salvat, Quies, Cofares, Walgreens Boots Al, Ordesa, Ysana, Fitodis, Sodeinn, Otosan, Inebios, Vaza Lab, Deca, Fleming, Cantabria, Dermoestetica Sur and Urgo.

88 It is formulated on the basis of an aqueous complex with quick-impact cerumenolytic effect.

(c) Again, even if the Parties were to compete in this market, Post-Transaction, the combined entity would continue facing competitive constraints from several competitors with shares higher than that of CVC Recordati. These include Faes Farma ([20-30]% in value and [10-20]% in volume in 2020), Perrigo ([10-20]% in value and [10-20]% in volume) and M4 Pharma ([10-20]% in value and [5-10]% in volume).

(d) The market investigation did not reveal any concerns in relation to ear care products in other forms in Spain.[89]

(92) In light of the above considerations, the Commission concludes that the Transaction does not raise serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement as a result of a horizontal effects in the market for ear care products in other forms in Spain.

4.1.4.5. Antitussives (in combination) in Luxembourg

(93) Antitussives[90] (also known as cough suppressants), relieve coughs by blocking the cough reflex, and are most effective at relieving dry coughs. The ATC4 class R5D2, the only class where the Parties' activities in antitussives give rise to an affected market, includes antitussives in combinations with expectorants, antihistamines, ephedrine, herbal tinctures, etc.[91]

(94) Coopers' Pholco Mereprine is an OTC medicine used for antitussive effect. It is a syrup intended to suppress dry coughs and irritable coughs. Recordati's Neo-Codion is a cough suppressant, i.e. used as a treatment that stops the cough reflex. It is used to treat dry coughs for adults and children. It is sold both in Rx and OTC variants.

(95) Tables 16 and 17 below show the market shares of the Parties and their main rivals in the market for antitussives in Luxembourg in the last three years, in value and in volume.

89 Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.

90 ATC3 class R5D.

91 Combinations with analgesics and antipyretics (R5A) and combinations with anti-infectives (R5B) are excluded, see https://www.ephmra.org/media/4973/atc-guidelines-2021-final.pdf, page 133.

| Table 16 – R5D2 (Antitussives, in combination)<br>Market Shares in terms of value (2018-2020) | | | | | | |
|---|---|---|---|---|---|---|
| **Supplier** | **2018 Revenue (EUR 000)** | **2019 Revenue (EUR 000)** | **2020 Revenue (EUR 000)** | **2018 Share of Sales (%)** | **2019 Share of Sales (%)** | **2020 Share of Sales (%)** |
| **CVC (Recordati)** | [...] | [...] | [...] | [10-20]% | [20-30]% | [30-40]% |
| **Cooper** | [...] | [...] | [...] | [30-40]% | [40-50]% | [50-60]% |
| ***Combined*** | [...] | [...] | [...] | *[50-60]%* | *[60-70]%* | *[90-100]%* |
| **ACP (Belgium)** | [...] | [...] | [...] | [0-5]% | [0-5]% | [0-5]% |
| **Boiron** | [...] | [...] | [...] | [0-5]% | [0-5]% | [0-5]% |
| **Qualiphar** | [...] | [...] | [...] | [5-10]% | [5-10]% | [0-5]% |
| **Klosterfrau** | [...] | [...] | [...] | [30-40]% | [20-30]% | - |
| **Wolfs** | [...] | [...] | [...] | [0-5]% | [0-5]% | |
| **Total** | [...] | [...] | [...] | 100% | 100% | 100% |

*Source: IQVIA*

| Table 17 – R5D2 (Antitussives, in combination)<br>Market Shares in terms of volume (2018-2020) | | | | | | |
|---|---|---|---|---|---|---|
| **Supplier** | **2018 (000 Units Sold)** | **2019 (000 Units Sold)** | **2020 (000 Units Sold)** | **2018 Share of Sales (%)** | **2019 Share of Sales (%)** | **2020 Share of Sales (%)** |
| **CVC (Recordati)** | [...] | [...] | [...] | [30-40]% | [30-40]% | [50-60]% |
| **Cooper** | [...] | [...] | [...] | [20-30]% | [20-30]% | [30-40]% |
| ***Combined*** | [...] | [...] | [...] | *[50-60]%* | *[60-70]%* | *[90-100]%* |
| **ACP (Belgium)** | [...] | [...] | [...] | [5-10]% | [5-10]% | [5-10]% |
| **Boiron** | [...] | [...] | [...] | [0-5]% | [0-5]% | [0-5]% |
| **Qualiphar** | [...] | [...] | [...] | [0-5]% | [0-5]% | [0-5]% |
| **Klosterfrau** | [...] | [...] | [...] | [30-40]% | [20-30]% | |
| **Wolfs** | [...] | [...] | [...] | [0-5]% | [0-5]% | |
| **Total** | [...] | [...] | [...] | 100% | 100% | 100% |

*Source: IQVIA*

(96) In 2020, the combined share of the Parties in the market for antitussives in combination in Luxembourg was [90-100]% in value and [90-100]% in volume (with an increment of [0-5]% both in value and in volume contributed by Cooper).

(97) The Notifying Party submits that these combined shares do not appear to reflect the current competitive dynamics within the market segment R5D2, because regulatory changes stemming from the Belgian legislation[92] which are expected to be followed by Luxembourg, ban the combination syrups as of January 2020. As a result, during 2020, Pholco-Mereprine has been withdrawn from the market and is no longer marketed in the EEA. Its replacement, Pholco Mereprine Mono is not part of the ATC4 class R5D2, but of R5D1. Thus, the overlap in the ATC4 class R5D2 is only historical and will not persist in the future.[93] Additionally, one of the largest market participants, Klosterfrau, is no longer included in the IQVIA data set in the R5D2 class for 2020, while it had market shares of more than approximately [20-30]% in the previous years. [94] Finally, the Notifying Party notes that the overall sales in this market decreased by around [70-80]%, further proof that other players also had fewer sales.

(98) Moreover, the Notifying Party underlines that the two do not contain the same molecules[95] and can also be distinguished based on the different forms in which they are marketed and used. Vemedia's Pholco Mereprine is sold in the form of a syrup, while Recordati's Neo-Codion is sold either in the form of a tablet or in the form of a syrup.[96]

(99) The Commission takes note that the regulatory changes discussed above, make that the Parties no longer overlap in ATC4 class R5D2. Vermedia has replaced Pholco Mereprine by Pholco Mereprine Mono, based on the molecule pholcodine (which is not contained in Recordati's Neo-Codion). Therefore, there is no overlap at the molecule level.

(100) The Commission also notes that in ATC3 class R5D (including both Neo-Codion's R5D2 and Pholco Mereprine's Mono R5D1), combined market shares would be below [20-30]%.

(101) Finally, the market investigation did not reveal any concerns in relation to antitussives, in combination in Luxembourg.[97]

---

92 Decision of the Federal Agency for Medicines and Health Products ("FAMHP") of Belgium of January 2020.

93 See Form CO paragraph 340 and Annex 7.4-VII

94 According to the Notifying Party, Klosterfrau was active on the Luxemburg market with a combined product named "Toplexil", but this product was withdrawn on 1 Jan 2020 and has not been replaced by an alternative, see Form CO, footnote 156.

95 Vemedia's Pholco Mereprine has been a combined syrup based (until May 2020), on the following ingredients benzoic acid, doxylamine, pholcodine and sulfogaiacol. On the other hand, Recordati's Neo-Codion, is based on ascorbic acid, bromoform, codeine, benzoic acid, bromine, adiantum capillus veneris, drosera rotundifolia, grindelia robusta, papaver rhoeas, polygala senega, senna, sulfogaiacol and thymus serpyllum. Therefore the Parties' products are considered antitussives in combinations (R5D2) rather than plain antitussives (R5D1) have only two molecules in common (sulfogaiacol, an expectorant, and benzoic acid, a preservative). See Form CO paragraph 339.

96 See Form CO paragraph 341 and footnote 148.

97 Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.

(102) In light of the above considerations, the Commission concludes that the Transaction does not raise serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement as a result of a horizontal effects in the market for antitussives, in combination in Luxembourg.

4.1.4.6. Nifuroxazide-based intestinal anti-infective anti-diarrhoeals in France

(103) Cooper marketed one intestinal anti-infective anti-diarrhoeal in France, Diafuryl. Recordati marketed Panfurex and Panfuryl. Diafuryl, Panfurex, and Panfuryl were all based on nifuroxazide. The Parties' activities in this product category in France give rise to a horizontally affected market only at molecule level (i.e., nifuroxazide-based intestinal anti-infective antidiarrhoeals).[98]

(104) The Notifying Party submits that the Transaction does not give rise to competition concerns in nifuroxazide-based intestinal anti-infective anti-diarrhoeals in France because the Parties have discontinued the sales of Diafuryl, Panfurex, and Panfuryl in France.

(105) Tables 18 and 19 below show the market shares (in value and volume) of the Parties and their main competitors in the relevant market for nifuroxazide-based intestinal anti-infective anti-diarrhoeals in France in the last three years.

**Table 18 - A7A0 - Nifuroxazide-based Intestinal Anti-infective anti-diarrhoeals in France Market Shares in terms of Value (2018-2020)**

| Supplier | 2018 Revenue (EUR 000) | 2019 Revenue (EUR 000) | 2020 Revenue (EUR 000) | 2018 Share of Sales (%) | 2019 Share of Sales (%) | 2020 Share of Sales (%) |
|---|---|---|---|---|---|---|
| CVC (Recordati) | […] | […] | […] | [10-20]% | [10-20]% | [20-30]% |
| Cooper | […] | […] | […] | [5-10]% | [5-10]% | [10-20]% |
| *Combined* | […] | […] | […] | [10-20]% | [10-20]% | [40-50]% |
| Sanofi | […] | […] | […] | [40-50]% | [40-50]% | [30-40]% |
| Servier | […] | […] | […] | [20-30]% | [20-30]% | [10-20]% |
| Viatris | […] | […] | […] | [10-20]% | [5-10]% | [0-5]% |
| Teva | […] | […] | […] | [5-10]% | [5-10]% | [0-5]% |
| Others[99] | […] | […] | […] | [5-10]% | [5-10]% | [0-5]% |
| Total | […] | […] | […] | 100% | 100% | 100% |

*Source: IQVIA*

98 At ATC3 level (A7A), the Parties' combined share does not result in an affected market.

99 Others include Qualifar and Aurobindo.

| Table 19 - A7A0 - Nifuroxazide-based Intestinal Anti-infective Anti-diarrhoeals in France Market Shares in terms of Volume (2018-2020) | | | | | | |
|---|---|---|---|---|---|---|
| **Supplier** | **2018 (000 Units Sold)** | **2019 (000 Units Sold)** | **2020 (000 Units Sold)** | **2018 Share of Sales (%)** | **2019 Share of Sales (%)** | **2020 Share of Sales (%)** |
| CVC (Recordati) | […] | […] | […] | [10-20]% | [10-20]% | [30-40]% |
| Cooper | […] | […] | […] | [0-5]% | [0-5]% | [10-20]% |
| *Combined* | […] | […] | […] | [10-20]% | [10-20]% | [40-50]% |
| Sanofi | […] | […] | […] | [20-30]% | [20-30]% | [20-30]% |
| Servier | […] | […] | […] | [20-30]% | [30-40]% | [20-30]% |
| Viatris | […] | […] | […] | [10-20]% | [5-10]% | [5-10]% |
| Teva | […] | […] | […] | [10-20]% | [5-10]% | [0-5]% |
| Others[100] | […] | […] | […] | [5-10]% | [5-10]% | [5-10]% |
| Total | […] | […] | […] | 100% | 100% | 100% |

(106) In 2020, the combined share of the Parties in the market for nifuroxazide-based intestinal anti-infective anti-diarrhoeals in France was [40-50]% in value and [40-50]% in volume (with an increment of [10-20]% in value and [10-20]% in volume contributed by Cooper). In this market, the Transaction is unlikely to give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement for the following reasons:

(a) In July 2019, the Agence nationale de sécurité du médicament et des produits de santé ("ANSM") changed the status of nifuroxazide-based products to prescription-only and limited the use of these products to adults only. As a result, several suppliers exited the market, including Cooper and Recordati. As the Notifying Party submitted, Diafuryl, Panfurex, and Panfuryl have already been discontinued.[101] The overlap between the activities of the Parties in this market in France is thus, historical.

(b) The market for nifuroxazide-based intestinal anti-infective anti-diarrhoeals in France becomes an affected (Group 1) market only on the basis of 2020 share figures. However, the 2020 market shares are not representative of the actual competitive landscape in the relevant market, because they are based on sales of remaining stock of the Parties and their rivals. Based on 2018 and 2019 market shares (in value and in volume), the relevant market would not be affected.

100 Others include Qualifar and Aurobindo.

101 See for Diafuryl, https://m.base-donnees-publique.medicaments.gouv.fr/#!info-62845364; for Panfurex, https://m.base-donnees-publique.medicaments.gouv.fr/#!info-60558682 and https://m.base-donnees-publique.medicaments.gouv fr/#!info-61972227; and for Panfuryl, https://m.base-donnees-publique.medicaments.gouv fr/#!info-65232039. Neither Party has plans to restart marketing nifuroxazide-based intestinal anti-infective anti-diarrhoeals in France now or in the future (Form CO, paragraph 402).

(c) The market investigation did not reveal any concerns in relation to nifuroxazide-based intestinal anti-infective anti-diarrhoeals in France.[102]

(107) In light of the above considerations, the Commission concludes that the Transaction does not raise serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement as a result of a horizontal effects in the market for nifuroxazide-based intestinal anti-infective anti-diarrhoeals in France.

*4.1.5. Overall conclusion on horizontal effects*

(108) In light of the considerations discussed in paragraphs (49) to (107), the Commission concludes that the Transaction does not raise serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement as a result of horizontal effects in the Group 1 / Group 1+, Group 2 and Group 3 markets presented in paragraph (13).

## 4.2. Vertical relationships

*4.2.1. Summary of the vertical overlaps*

(109) There are also numerous (actual and potential) vertical links between the activities of the Parties. The Transaction gives rise to affected markets for 3,452 of these vertical links. The vertically affected markets are summarised in **Table 20** below.

**Table 20 -- Overview of Vertically Affected Markets**

| Upstream Market | Party Active | Downstream Market | Party Active | Number of Vertical Links |
|---|---|---|---|---|
| Flexible Packaging for Pharmaceuticals (EEA) | CVC | FDPs (National) | Target | 12 |
| Packaging Machines for Pharmaceuticals (EEA) | CVC | FDPs (National) | Target | 12 |
| Excipients (EEA) | CVC | FDPs (National)<br>CDMO services (EEA) | Target | 14 |
| Active Pharmaceutical Ingredients (EEA) | CVC | FDPs (National) | Target | 15 |
| Excipients (EEA) | Target | FDPs (National) | CVC | 723 |
| Active Pharmaceutical Ingredients (EEA) | Target | FDPs (National) | CVC | 252 |
| CDMO services (EEA) | Target | FDPs (National) | CVC | 2,422 |
| FDPs (EEA) | Target | Private Hospital Services (National) | CVC | 2 |

*4.2.2. Market Definitions*

4.2.2.1. FDPs

(A) Product market definition

(110) As explained above,[103] the Commission consistently considers plausible product market for FDPs based on the IQVIA datasets, at ATC3/CHC3 level; at ATC4/CHC4 level; or at molecule level.

[102] Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.

(111) The market investigation did not provide any indications that would require the Commission to depart from its previous decisional practice with respect to the product market definition for FDPs that are vertically affected.

(112) The precise delineation of the FDP market(s) that are vertically affected by the Transaction can be left open because no competition concerns arise under any plausible relevant market definition.

(B) Geographic market definition

(113) As explained above,[104] the Commission consistently defines the different plausible markets for FDPs as national in scope.

(114) The market investigation did not provide any indications that would require the Commission to depart from its previous decisional practice on the geographic scope of the different plausible markets for FDPs that are vertically affected.

(115) Therefore, for the purposes of this decision, the Commission considers the geographic scope of the different plausible markets for FDPs to be national in scope.

4.2.2.2. Flexible packaging for pharmaceuticals

(A) Product market definition

(116) Previously the Commission described the production of flexible packaging as the manufacture, supply and conversion of plastic and cellulose films, aluminium foils and papers into reels of packaging.[105]

(117) The Commission previously considered that flexible packaging could be segmented by distinguishing the end-use of the packaging. That is, distinct product markets exist for flexible packaging for: (i) food, (ii) medical supplies, (iii) pharmaceuticals, (iv) household products, and (v) other non-food.[106]

(118) With respect to flexible packaging for pharmaceuticals, the Commission has previously considered a narrower segmentation into (a) laminated sachets, (b) coldform blister bases, (c) plastic-based blister bases and (d) blister lidding, but ultimately left the product market definition open.[107]

(119) The Notifying Party submits that there is a high degree of supply-side substitutability within all types of flexible packaging,[108] but does not contest the Commission's decisional practice.

(120) The Commission's investigation did not provide any indications that it would be appropriate for the Commission to depart from its previous decisional practice to consider a distinct market for flexible packaging for pharmaceuticals.

---

103 See Section 4.1.2.

104 See Section 4.1.2.

105 Case M.9094 – Amcor/Bemis, paragraph 13.

106 Case M.9094 – Amcor/Bemis, paragraph 14; Case M.5599 – Amcor/Alcan, paragraph 15; Case M.3225 – Alcan/Pechiney, paragraphs 128 and 131.

107 Case M.8107 – CVC/AR Packaging, paragraph 12; Case M.5599 – Amcor/Alcan, paragraph 13.

108 Form CO, paragraph 94.

(121) In this case, the question of whether the market for flexible packaging for pharmaceuticals should be further segmented in line with the four segments listed at paragraph (118) above, can be left open since the Transaction does not give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement under any of these narrower plausible market definitions.

(B) Geographic market definition

(122) The Commission has previously considered the geographic scope of markets for flexible packaging for pharmaceuticals as EEA-wide or wider.[109]

(123) The Notifying Party agrees with the previous Commission decisions that the geographic market for flexible packaging is EEA-wide or wider.[110]

(124) The Commission's investigation did not provide any indications that would require the Commission to depart from its previous decisional practice that the geographic market for flexible packaging for pharmaceuticals is at least EEA-wide.

(125) Therefore, for the purposes of this decision, the Commission considers the geographic scope for flexible packaging for pharmaceuticals to be at least EEA-wide.

4.2.2.3. Packaging machinery for the pharmaceutical sector

(A) Product market definition

(126) The Commission has not considered the market for packaging machinery in its previous Decisions.

(127) The Notifying Party explains that there is typically competitive interaction between the different formats, types of machines and/or technologies, as customers would typically purchase a range of packaging machines and technologies that could be applied to different categories/sectors, as opposed to a single type of packaging machinery or technology for a specific type of product.[111] However, the Notifying Party submits that, on the narrowest plausible basis, the market for packaging machinery could be defined by reference to end-use (e.g. packaging machinery for the pharmaceutical sector, medical sector etc.).[112]

(128) The Commission's investigation did not provide any indications as to the appropriate level for defining the market for packaging machinery. The question of whether the relevant product market includes all packaging machinery, or packaging machinery for the pharmaceutical sector only, can be left open since the Transaction does not give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement under any plausible product market definition.

[109] Case M.8107 – CVC/AR Packaging, paragraph 14; Case M.5599 – Amcor/Alcan, paragraph 48.
[110] Form CO, paragraph 121.
[111] Form CO, paragraph 109.
[112] Form CO, paragraph 109.

(B) Geographic market definition

(129) The Commission has not previously considered the geographic scope of markets for packaging machinery.

(130) The Notifying Party submits that the geographic market for packaging machinery (including for packaging machinery for the pharmaceutical sector) is EEA-wide or wider.[113]

(131) The Commission's investigation did not provide any indications as to the appropriate geographic scope of the market for packaging machinery (or packaging machinery for the pharmaceutical sector).

(132) Therefore, for the purposes of this decision, the Commission considers the geographic scope for packaging machinery for pharmaceuticals to be at least EEA-wide.

4.2.2.4. APIs

(A) Product market definition

(133) Active pharmaceutical ingredients ("APIs") are the molecules (under patent or expired) that are used to manufacture FDPs.[114]

(134) Per the Commission's decisional practice, in principle, each API belongs to a separate product market but substitutability between APIs, either in general, or for certain applications must also be considered.[115]

(135) The Notifying Party agrees with the decisional practice of the Commission regarding the product market definition in APIs.[116]

(136) The Commission's investigation did not provide any indications that it would be appropriate for the Commission to depart from its previous decisional practice for APIs.

(137) In this case, the exact product market definition for APIs can be left open since the Transaction does not give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement under any plausible market definition.

(B) Geographic market definition

(138) The Commission has previously considered the geographic scope for APIs is at least EEA-wide.[117]

(139) The Notifying Party did not depart from the decisional practice of the Commission regarding the geographic market definition in APIs. [118]

---

113 Form CO, paragraph 122.
114 Case M.6278 – Takeda/Nycomed, para. 16.
115 Case M. 7746 – *Teva/Allergan Generics*, paras. 644, 645.
116 Form CO, paragraph 81.
117 Case M. 7746 – *Teva/Allergan Generics*, paras. 646, 647.

(140) The Commission's investigation did not provide any indications that it would be appropriate for the Commission to depart from its previous decisional practice for APIs.

(141) In this case, the exact geographic market definition for APIs can be left open since the Transaction does not give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement under any plausible market definition.

4.2.2.5. Excipients

(A) Product market definition

(142) (Pharmaceutical) excipients are inert substances with which the API is combined to form an FDP.

(143) In *Ashland/International Specialty Products*, the Commission considered pharmaceutical excipients belong to separate relevant markets based on the substance from which each excipient was made (e.g., lactose, starch, cellulose) and considered plausible markets for binders, coatings and plausible narrower segments.[119] In *Friesland Foods/Campina*, the Commission defined even narrower markets for lactose excipients, namely separate markets for (i) wet granulation lactose and (ii) direct compression lactose.[120]

(144) The Notifying Party did not depart from the decisional practice of the Commission regarding product market definition in pharmaceutical excipients.

(145) The Commission's investigation did not provide any indications that would require the Commission to depart from its previous decisional practice to consider separate markets for excipients based on their substance ingredients and to sub-segment the market for lactose into (i) wet granulation lactose and (ii) direct compression lactose.

(B) Geographic market definition

(146) In *Ashland/International Specialty Products* and in *Friesland Foods/Campina*, the Commission found that the scope of the relevant markets for excipients is at least EEA-wide.[121]

(147) The Notifying Party did not depart from the decisional practice of the Commission regarding geographic market definition in pharmaceutical excipients.

(148) The Commission's investigation did not provide any indications that would require the Commission to depart from its previous decisional practice to consider at least EEA-wide markets for excipients based on their substance ingredients and to sub-segment the market for lactose into (i) wet granulation lactose and (ii) direct compression lactose.

---

118 Form CO, paragraph 113.

119 Case M.6313 – *Ashland/International Speciality Products*, para. 12.

120 Case M.5046 – *Friesland Foods/Campina*, paras. 1622 and 1652, 1656

121 Case M.6313 – *Ashland/International Speciality Products*, para. 26.

4.2.2.6. CDMO services to pharmaceutical companies

(A) Product market definition

(149) Contract development and manufacturing organisations ("CDMOs") provide manufacturing services for FDPs and APIs to third-party pharmaceutical companies.

(150) In the past, the Commission distinguished (i) a CDMO market for FDPs and (ii) a CDMO market for APIs.[122] As regards the CDMO market for FDPs, further segmentation was considered based on (i) the pharmaceutical form manufactured (e.g., solids, semi-solids, injectables); (ii) the conditions of manufacture (e.g., toxicity, sterile environment); (iii) the type of API used for its production and the delivery mechanism used (e.g., swallowing, intravenous, injection, etc.).[123] The Commission also examined whether there is a separate market for contract manufacturing organization ("CMO") services but eventually left the question open.[124]

(151) The Notifying Party submits that irrespective of the precise market definition and even based on the narrowest plausible market segment, the Transaction would not lead to competitive concerns.[125]

(152) The Commission's investigation did not provide any indications that it would be appropriate for the Commission to depart from its previous decisional practice for CDMOs.

(153) In this case, the exact product market definition for CDMOs can be left open since the Transaction does not give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement under any plausible market definition.

(B) Geographic market definition

(154) The Commission added that the geographic scope of all plausible CDMO services markets is at least EEA-wide.[126]

(155) The Notifying Party did not depart from the decisional practice of the Commission regarding the geographic market definition for CDMOs. [127]

(156) The Commission's investigation did not provide any indications that it would be appropriate for the Commission to depart from its previous decisional practice for CDMOs.

(157) In this case, the exact geographic market definition for CDMOs can be left open since the Transaction does not give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement under any plausible geographic market definition for CDMOs.

---

122 Case M.9315 – *CHR. Hansen/Lonza/JV*, para. 17.
123 Case M.9315 – *CHR. Hansen/Lonza/JV*, para. 22.
124 Case M.9315 – *CHR. Hansen/Lonza/JV*, para. 19.
125 Form C0, paragraph 105.
126 Case M.9315 – *CHR. Hansen/Lonza/JV*, para. 24.
127 Form C0, paragraph 116.

4.2.2.7. Private hospital services

(A) Product market definition

(158) In *CVC/Recordati*, the Commission considered a relevant product market for private hospital services which would be separate from public hospital services, depending on the specificities of the case and the national market in question.[128]

(159) The Notifying Party acknowledges the past decisional practice of the Commission and submits that the issue can be left open, since the Transaction would not lead to competitive concerns even if a product market for private hospital services were to be considered.[129]

(160) The Commission's investigation did not provide any indications that it would be appropriate for the Commission to depart from its previous decisional practice for private hospital services.

(161) In this case, the product market definition for hospital services can be left open since the Transaction does not give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement even under the narrowest plausible product market definition of private hospital services.

(B) Geographic market definition

(162) The Commission found that the geographic scope of this market is national or narrower.[130]

(163) The Notifying Party did not depart from the decisional practice of the Commission regarding market definition in private hospital services.

(164) The Commission's investigation did not provide any indications that it would be appropriate for the Commission to depart from its previous decisional practice for private hospital services.

(165) In this case, the exact geographic market definition for private hospital services can be left open since the Transaction does not give rise to serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement under any plausible product market definition of private hospital services.

*4.2.3. Legal framework*

(166) A concentration can also entail vertical and/or conglomerate effects. The Commission Guidelines on the assessment of non-horizontal mergers under the Merger Regulation[131] (the "Non-Horizontal Merger Guidelines") distinguish between two main ways in which non-horizontal mergers may significantly impede effective competition: (a) when they give rise to input and/or customer foreclosure (non-coordinated effects); and (b) when the merger changes the nature of

[128] Case M.9044 – *CVC/Recordati*, paras. 21 and 145.

[129] See Form CO, paragraph 184 (c) (i)

[130] Case M.9044 – *CVC/Recordati*, para. 22.

[131] Commission Guidelines on the assessment of non-horizontal mergers under the Merger Regulation (OJ C 265, 18.10.2008, p. 6).

competition in such a way that firms that previously were not coordinating their behaviour, are now more likely to coordinate to raise prices or otherwise harm effective competition (coordinated effects).[132] The Non-Horizontal Merger Guidelines distinguish two types of foreclosure: (a) where the merger is likely to raise the costs of downstream rivals by restricting their access to an important input (input foreclosure) and (b) where the merger is likely to foreclose upstream rivals by restricting their access to a sufficient customer base (customer foreclosure)[133].

(167) In assessing the likelihood of an anticompetitive input foreclosure strategy, the Commission has to examine whether (i) the merged entity would have the ability to substantially foreclose access to inputs; (ii) whether it would have the incentive to do so; and (iii) whether a foreclosure strategy would have a significant detrimental effect on competition downstream.[134] In assessing the likelihood of an anticompetitive customer foreclosure strategy, the Commission has to examine whether (i) the merged entity would have the ability to foreclose access to downstream markets by reducing its purchases from upstream rivals; (ii) whether it would have the incentive to do so; and (iii) whether a foreclosure strategy would have a significant detrimental effect on consumers in the downstream market.[135] According to the Non-Horizontal Merger Guidelines, the Commission is unlikely to find concern in non-horizontal mergers, where the market share post-merger of the new entity in each of the markets concerned is below 30%.[136]

(168) The Non-Horizontal Merger Guidelines define conglomerate mergers as mergers between firms that are in a relationship which is neither horizontal (as competitors in the same relevant market) nor vertical (as suppliers or customers).[137]

*4.2.4. Competitive assessment*

4.2.4.1. Flexible Packaging for Pharmaceuticals – CVC (Upstream) / FDPs – Target (Downstream)

(169) One of the CVC portfolio companies, Syntegon, is active in the upstream market for flexible packaging for pharmaceuticals in the EEA. Flexible packaging is an input for several FDPs of the Target (downstream). The vertically linked upstream and downstream markets and the Parties' shares are identified in Appendix 1. As shown in this Appendix, CVC Syntegon's share in all upstream markets (that is in flexible packaging for the pharmaceutical sector and narrower plausible segments for laminated sachets, coldform blister bases, plastic-based blister bases and blister lidding) is 10% or less while Cooper's share is 30% or more in all the downstream markets.

(170) The combined entity is unlikely to have the ability to engage in input foreclosure because it would not have market power in any of the upstream markets for flexible packaging for pharmaceuticals (under any plausible market delineation) in the EEA, where it is active. CVC Syntegon holds a share of 10% or less in the upstream

132 Non-horizontal Merger Guidelines, paragraphs 17-19.
133 Non-horizontal Merger Guidelines, paragraph 30.
134 Non-horizontal Merger Guidelines, paragraph 32.
135 Non-horizontal Merger Guidelines, paragraph 59.
136 Non-horizontal Merger Guidelines, paragraph 25.
137 Non-horizontal Merger Guidelines, paragraph 5.

markets for flexible packaging for pharmaceuticals (under any plausible market delineation) in the EEA and it would face competition from several players, including Amcor, Wipak, Constantia Flexibles and others. Post-Transaction, the Target's downstream rivals could turn to any of CVC's rivals (at least CVC's rivals in the EEA or possibly to an even wider set of rivals if the geographic upstream market is defined as wider than the EEA) to source flexible packaging, even if the combined entity decided to discontinue supply of its upstream inputs.

(171) The combined entity is unlikely to have the ability to engage in customer foreclosure because it would not constitute an important customer for flexible packaging of pharmaceuticals (or any plausible market delineation) in the EEA. Rather, Cooper's demand for any flexible packaging of pharmaceuticals in the upstream markets does not exceed 10% of the total EEA-wide demand.[138] That is because flexible packaging used for individual FDPs of Cooper is used for a variety of other use cases, including for example other FDPs where Cooper's market share is limited. In case the combined entity decided to source flexible packaging that CVC Syntegon offers today only in-house, CVC's rivals (both its rivals in the EEA or in a wider market) would continue to have access to a significant customer base to sell their products.

(172) Given that the combined entity would not have the ability to foreclose its downstream rivals in FDPs or its upstream rivals in the provision of flexible packaging for pharmaceuticals in the EEA (or wider), it would also not have an incentive to attempt a foreclosure as it would not be able to gain anything from such a strategy. In the absence of the ability to foreclose, any foreclosure strategy by the combined entity would have no impact on the national markets for FDP and the market for flexible packaging for pharmaceuticals in the EEA (or wider). In any event, no respondent to the market investigation raised concerns regarding the impact of the proposed Transaction on these vertically linked markets. [139]

4.2.4.2. Packaging Machinery for Pharmaceuticals – CVC (Upstream) / FDPs – Target (Downstream)

(173) One of the CVC portfolio companies, AR Packaging, is active in the plausible upstream market for packaging machines (for pharmaceuticals) in the EEA. Such machines are used to manufacture several FDPs of the Target (downstream). The vertically linked upstream and downstream markets and the Parties' shares are identified in Appendix 2. As shown in this Appendix, CVC AR Packaging's share in all plausible upstream markets (that is in packaging machinery or packaging machinery for pharmaceuticals) is 10% or less while the Target's share is 30% or more in all the downstream markets.

---

138 Cooper's share of 30% or more are based on markets defined at ATC3/CHC3, ATC4/CHC4, or molecule level (or in case of anti-lice products on GERS data). Cooper's high market shares in a few countries concerning a small number of FDPs (and often under narrow market delineations) do not give the combined entity sufficient market power to foreclose upstream rivals (see Case M.9995 – Permira/Neuraxpharm, para. 36; Case M.7975 – Mylan/Meda, para. 598; and Case M.5253 – Sanofi-Aventis/Zentiva, para. 533.)

139 Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.

(174) The combined entity is unlikely to have the ability to engage in input foreclosure because it would not have market power in any of the upstream markets (for packaging machinery or packaging machinery for pharmaceuticals) in the EEA, where it is active. CVC AR Packaging holds a share of 10% or less in the upstream markets for packaging machinery (under any plausible market delineation) in the EEA and it would face competition from several players, including IMA Group, Bausch & Ströbel, Optima and others. Post-Transaction, the Target's downstream rivals could turn to any of CVC's rivals (at least CVC's rivals in the EEA or possibly to an even wider set of rivals if the geographic upstream market is defined as wider than the EEA) to source packaging machines, even if the combined entity decided to discontinue supply of its upstream inputs.

(175) The combined entity is unlikely to have the ability to engage in customer foreclosure because it would not constitute an important customer for packaging machines for pharmaceuticals (or any narrower plausible market) in the EEA. Rather, the Target's demand for any packaging machines for pharmaceuticals in the upstream markets does not exceed 10% of the total EEA-wide demand.[140] That is because the packaging machinery used for FDPs by Cooper is also used for a variety of other packaging purposes, and because, according to the Parties, Cooper only procures packaging machinery in case of an expansion or to replace obsolete packaging machinery.[141] In case the combined entity decided to source packaging machine that CVC AR Packaging offers today only in-house, CVC's rivals (both its rivals in the EEA or in a wider market) would continue to have access to a significant customer base to sell their products.

(176) Given that the combined entity would not have the ability to foreclose its downstream rivals in national markets for FDPs or its upstream rivals in the provision of packaging machines for pharmaceuticals in the EEA (or wider), it would also not have an incentive to attempt a foreclosure as it would not be able to gain anything from such a strategy. In the absence of the ability to foreclose, any foreclosure strategy by the combined entity would have no impact on the national markets for FDP and the market for packaging machines for pharmaceuticals in the EEA (or wider). In any event, no respondent to the market investigation raised concerns regarding the impact of the proposed Transaction on these vertically linked markets. [142]

4.2.4.3. APIs – CVC's Recordati (Upstream) / FDPs – Cooper (Downstream)

(177) CVC is active in the upstream API markets for (i) diphenhydramine hydrochloride in the EEA and (ii) dimenhydrinate in the EEA. These APIs are inputs to 15 FDPs marketed by Cooper downstream. The vertically linked upstream and downstream markets and the Parties' shares are identified in Appendix 4.

---

140 Cooper's share of 30% or more are based on markets defined at ATC3/CHC3, ATC4/CHC4, or molecule level (or in case of anti-lice products on GERS data). Cooper's high market shares in a few countries concerning a small number of FDPs (and often under narrow market delineations) do not give the combined entity sufficient market power to foreclose upstream rivals (see Case M.9995 – Permira/Neuraxpharm, para. 36; Case M.7975 – Mylan/Meda, para. 598; and Case M.5253 – Sanofi-Aventis/Zentiva, para. 533.)

141 Form CO, paragraph 251.

142 Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.

(178) In 2020, the Target sourced diphenhydramine hydrochloride from CVC worth approximately EUR […] (or [5-10]% of CVC's total sales in the EEA for this API). [143] The Target has not sourced dimenhydrinate since 2018 due to sufficient material in stock. [144]

(179) The combined entity is unlikely to have the ability to engage in input foreclosure for either of these products. Firstly, for diphenhydramine hydrochloride, since it is a product which can be manufactured easily and which is sold by a number of companies globally and in Europe, e.g. by Caesar & Loretz GmbH, Tiefenbacher API + Ingredients, LGC Limited, Wanbury Limited and Kongo Chemical Co. Limited. All these suppliers would be able to supply Cooper's downstream rivals. Given Cooper's low market shares in the downstream markets (overall sales values of less than EUR 1m), Recordati would have to forego all or the vast majority of its sales for diphenhydramine hydrochloride in the EEA. Regarding dimenhydrinate the fact that for the last three years the Target has not sourced it demonstrates the low importance of the product and therefore the lack of any ability to foreclose.

(180) The combined entity is unlikely to have the ability to engage in customer foreclosure because it would not constitute an important customer for diphenhydramine hydrochloride or dimenhydrinate in the EEA or wider. In 2020 Cooper's purchases of diphenhydramine hydrochloride amounted to approximately EUR […] ([5-10]% of the total of Recordati's total EEA sales for that year).[145]

(181) Given that the combined entity would not have the ability to foreclose its downstream rivals in the national markets for FDPs or its upstream rivals in APIs in the EEA or wider, it would also not have an incentive to attempt a foreclosure as it would not be able to gain anything from such a strategy. In the absence of the ability to foreclose, any foreclosure strategy by the combined entity would have no impact on the national markets for FDPs and the market for APIs in the EEA or wider. In any event, no respondent to the market investigation raised concerns regarding the impact of the proposed Transaction on these vertically linked markets. [146]

4.2.4.4. APIs – Target (Upstream) / FDPs – CVC (Downstream)

(182) The Target is active in different upstream markets for APIs in the EEA. These APIs can be an input for a number of FDPs of CVC's Recordati and Genetic (downstream). The vertically linked ((at the ATC3/CHC3, ATC4/CHC4 and molecule levels)) upstream and downstream markets and the Parties' shares are identified in Appendix 6 (under all plausible market definitions). As shown in this Appendix, Cooper's share in all upstream markets is 10% or less while CVC's Recordati and Genetic's share is 30% or more in all the downstream markets.

(183) The combined entity is unlikely to have the ability to engage in input foreclosure because it would not have market power in any of the upstream markets for APIs in the EEA, where it is active. Under all plausible market definitions, the Target holds a

[143] Form CO, footnote 88.

[144] Form CO, footnote 106

[145] See Form CO, footnote 88.

[146] Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.

share of 10% or less in the upstream markets for APIs in the EEA[147] and it would face competition from several players, Brenntag, Univar, Helm, IMCD and others.[148] Post-Transaction, Recordati's and Genetic's downstream rivals could turn to any of Cooper's rivals (at least Cooper's rivals in the EEA or possibly to an even wider set of rivals if the geographic upstream market is defined as wider than the EEA) to source APIs, even if the combined entity decided to discontinue supply of its upstream inputs.

(184) The combined entity is unlikely to have the ability to engage in customer foreclosure because it would not constitute an important customer for APIs in the EEA or wider market. Rather, Recordati's and Genetic's demand for any APIs in the upstream markets does not exceed 10% of the total EEA-wide demand. In case the combined entity decided post-Transaction to source the APIs that Cooper offers today only in-house, Cooper's rivals would continue to have access to a significant customer base to sell their products.

(185) Given that the combined entity would not have the ability to foreclose its downstream rivals in the national markets for FDPs or its upstream rivals in APIs, it would also not have an incentive to attempt a foreclosure as it would not be able to gain anything from such a strategy. In the absence of the ability to foreclose, any foreclosure strategy by the combined entity would have no impact on the national markets for FDPs and the market for APIs. In any event, no respondent to the market investigation raised concerns regarding the impact of the proposed Transaction on these vertically linked markets. [149]

4.2.4.5. Excipients – Cooper (Upstream) / FDPs – CVC's Recordati and Genetic (Downstream)

(186) The Target is active in different upstream markets for pharmaceutical excipients in the EEA. These excipients can be an input for several FDPs of CVC's Recordati and Genetic (downstream). The vertically linked upstream and downstream markets and the Parties' shares are identified in Appendix 5. As shown in this Appendix, Cooper's share in all upstream markets (even under the narrowest plausible markets defined at the level of individual excipients) is 10% or less while CVC's Recordati and Genetic's share is 30% or more in all the downstream markets.

(187) The combined entity is unlikely to have the ability to engage in input foreclosure because it would not have market power in any of the upstream markets for excipients in the EEA, where it is active. Under all plausible market definitions, Cooper holds a share of 10% or less in the upstream markets for excipients in the EEA[150] and it would face competition from several players, including Brenntag, Safic Alcan, Quimdis, and others. Post-Transaction, Recordati's and Genetic's downstream rivals could turn to any of Cooper's rivals (at least Cooper's rivals in the EEA or possibly to an even wider set of rivals if the geographic upstream market is defined as wider than the EEA) to source excipients, even if the combined entity decided to discontinue supply of its upstream inputs.

147 See Form CO, Annex 6.4 – Overview of vertical relationships (affected markets).

148 See Form CO, footnote 117.

149 Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.

150 See Form CO, Annex 6.4 – Overview of vertical relationships (affected markets).

(188) The combined entity is unlikely to have the ability to engage in customer foreclosure because it would not constitute an important customer for excipients in the EEA. Rather, Recordati's and Genetic's demand for any excipients in the upstream markets does not exceed 10% of the total EEA-wide demand.[151] In case the combined entity decided to source the excipients that Cooper offers today only in-house, Cooper's rivals (both its rivals in the EEA or in a wider market) would continue to have access to a significant customer base to sell their products.

(189) Given that the combined entity would not have the ability to foreclose its downstream rivals in the national markets for FDP and or its upstream rivals in excipients in the EEA (or wider), it would also not have an incentive to attempt a foreclosure as it would not be able to gain anything from such a strategy. In the absence of the ability to foreclose, any foreclosure strategy by the combined entity would have no impact on the national markets for FDPs and the market for excipients in the EEA (or wider). In any event, no respondent to the market investigation raised concerns regarding the impact of the proposed Transaction on these vertically linked markets.[152]

4.2.4.6. Excipients (Wet granulation lactose and direct compression lactose) – CVC's DFE Pharma (Upstream) / FDPs and CDMO services – Cooper (Downstream)

(190) DFE Pharma (a portfolio company controlled by CVC) is active in the upstream markets for wet granulation lactose and direct compression lactose in the EEA. These excipients are used as inputs for FDPs of Cooper in 12 downstream markets and for CDMO services that Cooper offers to third parties. The vertically linked upstream and downstream markets and the Parties' shares are identified in Appendix 3. As shown in this Appendix, DFE Pharma's share in the upstream markets is slightly above 30% while Cooper's share is less than 30% in all the downstream markets.

(191) The combined entity is unlikely to have the ability to engage in input foreclosure because it would not have market power in the upstream markets. In 2020, DFE Pharma held shares of [30-40]% in wet granulation lactose and [30-40]% in direct compression lactose in the EEA but it faced competition from major international rivals in the EEA[153], e.g., Meggle ([10-20]% in wet granulation lactose and [30-40]% in direct compression lactose) and Kerry ([10-20]% in wet granulation lactose and [5-10]% in direct compression lactose). Post-Transaction, Cooper's downstream rivals could turn to any of DFE Pharma's competitors (at least rivals in the EEA or possibly to an even wider set of rivals if the geographic upstream market is defined as wider than the EEA) to source wet granulation lactose and direct compression lactose, even if the combined entity decided to discontinue supply of its upstream inputs. e.g., Meggle, Kerry, and Armor

(192) The combined entity is unlikely to have the ability to engage in customer foreclosure because it would not constitute an important customer for the upstream inputs in the EEA. In 2020, Cooper purchased wet granulation lactose worth EUR […] (which represents [0-5]% of the total demand for this product) and direct compression

151 See footnote 74 above.

152 Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.

153 See Form CO Tables 6 & 8.

lactose worth EUR […] (which represents [0-5]% of the total demand for this product). In case the combined entity decided to source wet granulation lactose and direct compression lactose only in-house, DFE Pharma's rivals (both its rivals in the EEA or in a wider market) would continue to have access to a significant customer base to sell their products.

(193) Given that the combined entity would not have the ability to foreclose its downstream rivals in the national markets for FDPs and the market for CDMO services in the EEA (or wider), or its upstream rivals in the provision of in wet granulation and direct granulation lactose in the EEA (or wider), it would also not have an incentive to attempt a foreclosure as it would not be able to gain anything from such a strategy. In the absence of the ability to foreclose, any foreclosure strategy by the combined entity would have no impact on the national markets for FDPs, the market for CDMO services in the EEA (or wider) and the market for in wet granulation and direct granulation lactose in the EEA (or wider). In any event, no respondent to the market investigation raised concerns regarding the impact of the proposed Transaction on these vertically linked markets. [154]

4.2.4.7. CDMO Services – Target (Upstream) / FDPs – CVC (Downstream)

(194) The Target is active in the upstream markets for CDMO services in the EEA. These CDMO services can be an input for several FDPs of CVC (downstream). For some of these FDPs, CVC has a share >30% at national level.

(195) The Target is active in different upstream markets for the provision of CDMO services in the EEA. These CDMO servicescan be an input for a number of FDPs of CVC's Recordati and Theramex (downstream). The vertically linked ((at the ATC3/CHC3, ATC4/CHC4 and molecule levels)) upstream and downstream markets and the Parties' shares are identified in Appendixes 7i and 7ii (under all plausible market definitions). As shown in this Appendix, Cooper's share in all upstream markets is 10% or less while CVC's Recordati and Theramex's share is 30% or more in all the downstream markets.

(196) The combined entity is unlikely to have the ability to engage in input foreclosure because it would not have market power in any of the upstream markets for CDMO services in the EEA, where it is active. Under all plausible market definitions, The Target holds a share of 10% or less in the upstream markets for CDMO services in the EEA[155] and it would face competition from several players, including Lonza, Catalent, Pantheon, Recipharm and others. Post-Transaction, Recordati's and Theramex's downstream rivals could turn to any of Cooper's rivals (at least Cooper's rivals in the EEA or possibly to an even wider set of rivals if the geographic upstream market is defined as wider than the EEA) to source CDMO services, even if the combined entity decided to discontinue supply of its upstream inputs.

(197) The combined entity is unlikely to have the ability to engage in customer foreclosure because it would not constitute an important customer for CDMO services in the EEA. Rather, Recordati's and Genetic's demand for any CDMO services in the

[154] Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.

[155] See Form CO, Annex 6.4 – Overview of vertical relationships (affected markets).

upstream markets does not exceed 10% of the total EEA-wide demand. In case the combined entity decided post-Transaction to source the CDMO services that Cooper offers today only in-house, Cooper's rivals (both in the EEA or wider) would continue to have access to a significant customer base to sell their products.

(198) Given that the combined entity would not have the ability to foreclose its downstream rivals the national markets for FDPs, or its upstream rivals in CDMO services in the EEA (or wider), it would also not have an incentive to attempt a foreclosure as it would not be able to gain anything from such a strategy. In the absence of the ability to foreclose, any foreclosure strategy by the combined entity would have no impact on the national markets for FDPs and the market for CDMO services in the EEA (or wider). In any event, no respondent to the market investigation raised concerns regarding the impact of the proposed Transaction on these vertically linked markets. [156]

4.2.4.8. FDPs – Target (Upstream) / Private Hospital Services – CVC (Downstream)

(199) CVC is active in the downstream market for private hospital services in Greece.[157] Cooper offers FDPs in Greece[158] that could be an upstream input for the operation of private hospitals downstream. The vertically linked (at the ATC3/CHC3 level) upstream and downstream markets and the Parties' shares are identified in Appendix 8.

(200) The combined entity is unlikely to have the ability to engage in input foreclosure because it would not have market power in any of the upstream markets for FDPs in Greece. Cooper holds a share of 30% or less in all of the upstream markets for FDPs in Greece. Moreover, already now, Cooper does not supply any hospitals in Greece, which therefore do not rely on Cooper for the supply of FDPs. Post-Transaction, CVC's downstream rivals could simply keep purchasing the FDPs from their current suppliers, even if the combined entity decided to not supply FDPs to its downstream rivals.

(201) The combined entity is unlikely to have the ability to engage in customer foreclosure because it would not constitute an important customer for the upstream FDP markets in Greece. In a plausible downstream market including all private hospitals in Greece, CVC's hospitals held a share of [30-40]% in 2020. However, FDPs are used by a far wider set of customers other than hospitals, including for example wholesalers, drugstores and pharmacies. In case the combined entity decided to source FDPs that Cooper offers today only in-house, CVC's rivals would continue to have access to a significant customer base to sell their products, including both private hospitals as well as other types of customers.

---

[156] Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.

[157] Through the Hellenic Healthcare Group ("HHG"), which is the largest private hospital group in Greece, consisting of six hospitals: Metropolitan Hospital; Metropolitan General; Hygeia Hospital; Mitera; Leto; and Creta Interclinic. HHG provides all major procedures and treats approximately 100,000 inpatients and 1 million outpatients annually.

[158] These are FDPs in ATC3 class N5B – Hypnotics and Sedatives and in CHC3 class 13A2 – Calming Products.

(202) Given that the combined entity would not have the ability to foreclose its downstream rivals in the provision of hospital services in Greece its upstream rivals in FDPs in Greece, it would also not have an incentive to attempt a foreclosure as it would not be able to gain anything from such a strategy. In the absence of the ability to foreclose, any foreclosure strategy by the combined entity would have no impact on the market for hospital services in Greece and the market for FDPs in Greece. In any event, no respondent to the market investigation raised concerns regarding the impact of the proposed Transaction on these vertically linked markets. [159]

4.2.4.9. Overall conclusion on vertical effects

(203) In light of the considerations discussed in paragraphs (169) to (202), the Commission concludes that the Transaction does not raise serious doubts as to its compatibility with the internal market or the functioning of the EEA agreement in terms of its competition impact on the vertical relationships identified in paragraph (109).

## 5. CONCLUSION

(204) For the above reasons, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement.

*For the Commission*

*(Signed)*
*Margrethe VESTAGER*
*Executive Vice-President*

[159] Replies to Questionnaire Q1, questions 15-16 ; to Questionnaire Q2, questions 12-13; to Questionnaire Q3, questions 17-18 ; to Questionnaire Q4, questions 13-14 ; and to Questionnaire Q5, questions 12-13.

| (Potential) Vertical Links Giving Rise to Affected Markets Involving CVC's Activities in Flexible Packaging (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (AR Packaging)** | | | **Downstream FDP Market (Target)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market** | **Share (2020)** |
| Flexible packaging (Any plausible product market delineation) | At least EEA-wide | <10% | France | FDPs: Anti-lice products | [40-50]% (GERS data) |
| | | | France | (CHC4): 03C2S SUPPOSITORIES | [30-40]% by value / [40-50]% by volume |
| | | | France | (ATC4): A6A9 OTH DRUGS FOR CONSTIPAT | [10-20]% by value / [30-40]% by volume |
| | | | Italy | (CHC4): 13A9C CAPS/TABS | [30-40]% by value / [30-40]% by volume |
| | | | Italy | (ATC4): N5B5 HERB HYPNOTICS/SEDATIVES | [50-60]% by value / [70-80]% by volume |
| | | | France | (Molecule level): 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> LIDOCAINE!ZINC | [90-100]% by value / [90-100]% by volume |
| | | | France | (Molecule level): A1A STOMATOLOGICALS --> A1A3 MOUTH A-INFLAM+TOP.ANALG --> LIDOCAINE!ZINC | [90-100]% by value / [90-100]% by volume |
| | | | France | (Molecule level): 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2S SUPPOSITORIES --> GLYCEROL | [40-50]% by value / [40-50]% by volume |
| | | | France | (Molecule level): A6A DRUGS FOR CONSTIPATION --> A6A9 OTH DRUGS FOR CONSTIPAT --> GLYCEROL | [40-50]% by value / [40-50]% by volume |
| | | | France | (Molecule level): 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ACONITUM NAPELLUS!BORIC ACID!CODEINE!MENTHOL!TETRACAINE | [90-100]% by value / [90-100]% by volume |
| | | | France | (Molecule level): R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> ACONITUM NAPELLUS!BORIC ACID!CODEINE!MENTHOL!TETRACAINE | [90-100]% by value / [90-100]% by volume |
| | | | Italy | (Molecule level): 13A9 CALMING&SLEEPING PRODUCTS --> 13A9C CAPS/TABS --> VALERIANA | [70-80]% by value / [60-70]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving CVC's Activities in Flexible Packaging (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (AR Packaging)** | | | **Downstream FDP Market (Target)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market** | **Share (2020)** |
| | | | | OFFICINALIS | |
| | | | Italy | (Molecule level): N5B HYPNOTICS & SEDATIVES --> N5B5 HERB HYPNOTICS/SEDATIVES --> VALERIANA OFFICINALIS | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving CVC's Activities in Packaging Machines (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Syntegon)** | | | **Downstream FDP Market (Target)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market** | **Share (2020)** |
| Packaging Machines (Any plausible product market delineation) | At least EEA-wide | <10% | France | Anti-lice products | [40-50]% (GERS data) |
| | | | France | (CHC4): 03C2S SUPPOSITORIES | [30-40]% by value / [40-50]% by volume |
| | | | France | (ATC4): A6A9 OTH DRUGS FOR CONSTIPAT | [10-20]% by value / [30-40]% by volume |
| | | | Italy | (CHC4): 13A9C CAPS/TABS | [30-40]% by value / [30-40]% by volume |
| | | | Italy | (ATC4): N5B5 HERB HYPNOTICS/SEDATIVES | [50-60]% by value / [70-80]% by volume |
| | | | France | (Molecule level): 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> LIDOCAINE!ZINC | [90-100]% by value / [90-100]% by volume |
| | | | France | (Molecule level): A1A STOMATOLOGICALS --> A1A3 MOUTH A-INFLAM+TOP.ANALG --> LIDOCAINE!ZINC | [90-100]% by value / [90-100]% by volume |
| | | | France | (Molecule level): 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2S SUPPOSITORIES --> GLYCEROL | [40-50]% by value / [40-50]% by volume |
| | | | France | (Molecule level): A6A DRUGS FOR CONSTIPATION --> A6A9 OTH DRUGS FOR CONSTIPAT --> GLYCEROL | [40-50]% by value / [40-50]% by volume |
| | | | France | (Molecule level): 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ACONITUM NAPELLUS!BORIC ACID!CODEINE!MENTHOL!TETRACAINE | [90-100]% by value / [90-100]% by volume |
| | | | France | (Molecule level): R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> ACONITUM NAPELLUS!BORIC ACID!CODEINE!MENTHOL!TETRACAINE | [90-100]% by value / [90-100]% by volume |
| | | | Italy | (Molecule level): 13A9 CALMING&SLEEPING PRODUCTS --> 13A9C CAPS/TABS --> VALERIANA OFFICINALIS | [70-80]% by value / [60-70]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving CVC's Activities in Packaging Machines (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Syntegon)** | | | **Downstream FDP Market (Target)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market** | **Share (2020)** |
| | | | Italy | (Molecule level): N5B HYPNOTICS & SEDATIVES --> N5B5 HERB HYPNOTICS/SEDATIVES --> VALERIANA OFFICINALIS | [90-100]% by value / [90-100]% by volume |

## Appendix 3

| (Potential) Vertical Links Giving Rise to Affected Markets Involving CVC's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (DFE Pharma)** | | | **Downstream Market (Target)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market** | **Share (2020)** |
| Wet granulation lactose | At least EEA-wide | [30-40]% by value / [30-40]% by volume | Netherlands | (ATC3): N2B NON-NARCOTIC ANALGESICS | <[30-40]%[1] |
| | | | Netherlands | (CHC3): 02A1 GENER.PAIN RELIEF ADULTS | |
| | | | Netherlands | (ATC3): R5D ANTITUSSIVES | |
| | | | Netherlands | (CHC3): 01A3 DRY COUGH PRODUCTS | |
| | | | At least EEA-wide | CDMO services | <[10-20]% |
| Direct compression lactose | At least EEA-wide | [30-40]% by value / [30-40]% by volume | Belgium | (ATC3): N5B HYPNOTICS & SEDATIVES | <[30-40]%[2] |
| | | | Luxembourg | (ATC3): N5B HYPNOTICS & SEDATIVES | <[30-40]%[3] |
| | | | Belgium | (CHC3): 13A3 SLEEPING PRODUCTS | <[30-40]%[4] |
| | | | Belgium | (ATC3): D4A TOPICAL ANTIPRURITICS | <[30-40]%[5] |
| | | | Belgium | (ATC3): R6A ANTIHISTAMINES SYSTEMIC | <[30-40]%[6] |
| | | | Belgium | (CHC3): 01E1 RESPIR & GENER ANTIALLERG | <[30-40]%[7] |
| | | | Belgium | (CHC3): 06C1 TOPICAL ANTIHISTAMINES | <[30-40]%[8] |
| | | | Belgium | (CHC3): 11A1 ANTINAUSEANTS | <[30-40]%[9] |
| | | | At least EEA-wide | CDMO services | <[10-20] |

1 Also at ATC4/CHC4 and at molecule level.
2 Also at ATC4/CHC4 and at molecule level.
3 Also at ATC4/CHC4 and at molecule level.
4 Also at ATC4/CHC4 and at molecule level.
5 Also at ATC4/CHC4 and at molecule level.
6 Also at ATC4/CHC4 and at molecule level.
7 Also at ATC4/CHC4 and at molecule level.
8 Also at ATC4/CHC4 and at molecule level.
9 Also at ATC4/CHC4 and at molecule level.

## Appendix 4

| (Actual) Vertical Links Giving Rise to Affected Markets Involving CVC's Activities in APIs (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Recordati)** | | | **Downstream FDP Market (Target)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (ATC3/CHC3)** | **Share (2020)[1]** |
| Diphenhydramine hydrochloride | At least EEA-wide | Potentially >30% | Luxembourg | N5B Hypnotics & Sedatives | <30% (by value or by volume) |
| | | | Belgium | N5B Hypnotics & Sedatives | |
| | | | | 13A3 Sleeping Products | |
| | | | | D4A Topical Antipruritics | |
| | | | | R6A Antihistamines Systemic | |
| | | | | 01E1 Respir & Gener Antiallerg | |
| | | | | 06C1 Topical Antihistamines | |
| | | | | 11A1 Antinauseants | |
| | | | France | A4A Antiemetics+Antinauseants | |
| | | | | 11A1 Antinauseants | |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving CVC's Activities in APIs (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Recordati)** | | | **Downstream FDP Market (Target)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (ATC3/CHC3)** | **Share (2020)[2]** |
| Dimenhydrinate | At least EEA-wide | Potentially >30% | Belgium | D4A Topical Antipruritics | <30% (by value or by volume) |
| | | | | R6A Antihistamines Systemic | |
| | | | | 01E1 Respir & Gener Antiallerg | |
| | | | | 06C1 Topical Antihistamines | |
| | | | | 11A1 Antinauseants | |

1 Same market share also at ATC4/CHC4 and molecule level for the Target's products.
2 Same market share also at ATC4/CHC4 and molecule level for the Target's products.

# Appendix 5

| (Actual) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule)** | **Share (2020)** |
| Citric acid monhydrate granular | At least EEA-wide | [0-5]% or less | France | R2A Throat Preparations - Biclotymol!Enoxolone!Lysozyme | [90-100]% by value / [90-100]% by volume |
| | | | France | 01C1 Sore Throat Remedies - Biclotymol!Enoxolone!Lysozyme | [90-100]% by value / [90-100]% by volume |
| Sodium edetate | | | France | R2A Throat Preparations - Biclotymol | [90-100]% by value / [20-30]% by volume |
| | | | Luxembourg | R2A Throat Preparations - Biclotymol | [90-100]% by value / [90-100]% by volume |
| | | | France | 01C1 Sore Throat Remedies - Biclotymol | [90-100]% by value / [90-100]% by volume |
| Sodium lauryl sulfate | | | Czech Republic | G4C BPH Products - Silodosin | [90-100]% by value / [90-100]% by volume |
| | | | France | G4C BPH Products - Silodosin | [30-40]% by value / [20-30]% by volume |
| | | | Poland | G4C BPH Products - Silodosin | [90-100]% by value / [90-100]% by volume |
| | | | Portugal | G4C BPH Products - Silodosin | [50-60]% by value / [40-50]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (ATC3/CHC3)** | **Share (2020)** |
| Acide Citrique Gran H2o | At least EEA-wide | <[10-20]% | Italy | 10A1 Antihaemorrhoids | [20-30]% by value / [30-40]% by volume |
| | | | | C5A Topical Antihaemorrhoidl | [30-40]% by value / [30-40]% by volume |
| Acide Sorbique | | | France | N7F Drugs Used In Opioid Dep | [30-40]% by value / [40-50]% by volume |
| Acide Stearique | | | Cyprus | C5A Topical Anti-Haemorrhoidals | [70-80]% by value / [80-90]% by volume |
| | | | Latvia | 10A1 Antihaemorrhoids | [30-40]% |
| | | | | C5A Topical Antihaemorrhoidl | [30-40]% by value / [20-30]% by volume |
| | | | Poland | 10A1 Antihaemorrhoids | [30-40]% by value / [30-40]% by volume |
| | | | | C5A Topical Antihaemorrhoidl | [30-40]% by value / [30-40]% by volume |
| | | | Romania | 10A1 ANTIHAEMORRHOIDS | [20-30]% by value / [30-40]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (ATC3/CHC3)** | **Share (2020)** |
| | | | | C5A Topical Antihaemorrhoidl | [50-60]% by value / [40-50]% by volume |
| | | | Slovakia | C5A Topical Antihaemorrhoidl | [20-30]% by value / [30-40]% by volume |
| Aerosil 200 | | | France | N7F Drugs Used In Opioid Dep | [30-40]% by value / [40-50]% by volume |
| | | | Spain | 03D3 Antidiarr Electrol | [70-80]% |
| | | | | A7G Oral Electrol. Replacer | [80-90]% by value / [90-100]% by volume |
| Cellulose Microcristalline | | | Luxembourg | C8A Calcium Antagonist Plain | [40-50]% by value / [20-30]% by volume |
| Lactose H2o Exp | | | France | N7F Drugs Used In Opioid Dep | [30-40]% by value / [40-50]% by volume |
| | | | Luxembourg | C8A Calcium Antagonist Plain | [40-50]% by value / [20-30]% by volume |
| Magnesium Stearate | | | France | N7F Drugs Used In Opioid Dep | [30-40]% by value / [40-50]% by volume |
| | | | Luxembourg | C8A Calcium Antagonist Plain | [40-50]% by value / [20-30]% by volume |
| Menthol Levo Crist Cosm | | | Italy | 10A1 Antihaemorrhoids | [20-30]% by value / [30-40]% by volume |
| | | | | C5A Topical Antihaemorrhoidl | [30-40]% by value / [30-40]% by volume |
| Parahydroxybenz Meth | | | Cyprus | C5A Topical Anti-Haemorrhoidals | [70-80]% by value / [80-90]% by volume |
| | | | Czech Republic | D5A Top Antipsoriasis Prds | [10-20]% by value / [80-90]% by volume |
| | | | Italy | 10A1 Antihaemorrhoids | [20-30]% by value / [30-40]% by volume |
| | | | | C5A Topical Antihaemorrhoidl | [30-40]% by value / [30-40]% by volume |
| | | | Latvia | 10A1 Antihaemorrhoids | [30-40]% |
| | | | | C5A Topical Antihaemorrhoidl | [30-40]% by value / [20-30]% by volume |
| | | | Poland | 10A1 Antihaemorrhoids | [30-40]% by value / [30-40]% by volume |
| | | | | C5A Topical Antihaemorrhoidl | [30-40]% by value / [30-40]% by volume |
| | | | Romania | 10A1 Antihaemorrhoids | [20-30]% by value / [30-40]% by volume |
| | | | | C5A Topical Antihaemorrhoidl | [50-60]% by value / [40-50]% by volume |
| | | | Slovakia | C5A Topical Antihaemorrhoidl | [20-30]% by value / [30-40]% by volume |
| Parahydroxybenz Prop | | | Cyprus | C5A Topical Anti-Haemorrhoidals | [70-80]% by value / [80-90]% by volume |
| | | | Czech Republic | D5A Top Antipsoriasis Prds | [10-20]% by value / [80-90]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (ATC3/CHC3)** | **Share (2020)** |
| | | | Italy | 10A1 Antihaemorrhoids | [20-30]% by value / [30-40]% by volume |
| | | | | C5A Topical Antihaemorrhoidl | [30-40]% by value / [30-40]% by volume |
| | | | Latvia | 10A1 Antihaemorrhoids | [30-40]% |
| | | | | C5A Topical Antihaemorrhoidl | [30-40]% by value / [20-30]% by volume |
| | | | Poland | 10A1 Antihaemorrhoids | [30-40]% by value / [30-40]% by volume |
| | | | | C5A Topical Antihaemorrhoidl | [30-40]% by value / [30-40]% by volume |
| | | | Romania | 10A1 Antihaemorrhoids | [20-30]% by value / [30-40]% by volume |
| | | | | C5A Topical Antihaemorrhoidl | [50-60]% by value / [40-50]% by volume |
| | | | Slovakia | C5A Topical Antihaemorrhoidl | [20-30]% by value / [30-40]% by volume |
| Potassium Bicarbonate | | | Spain | A6B Bowel Cleansers | [50-60]% by value / [40-50]% by volume |
| Propylene Glycol | | | Greece | G1B Gynaecolog Antifungals | [60-70]% by value / [40-50]% by volume |
| | | | Hungary | G1B Gynaecolog Antifungals | [20-30]% by value / [60-70]% by volume |
| | | | Italy | 10A1 Antihaemorrhoids | [20-30]% by value / [30-40]% by volume |
| | | | | C5A Topical Antihaemorrhoidl | [30-40]% by value / [30-40]% by volume |
| | | | Poland | 12D2 Gynaecological Antifungal | [80-90]% by value / [30-40]% by volume |
| | | | | G1B Gynaecolog Antifungals | [50-60]% by value / [20-30]% by volume |
| | | | Romania | G1B Gynaecolog Antifungals | [10-20]% by value / [30-40]% by volume |
| Saccharine Sodique | | | Spain | 03D3 Antidiarr Electrol | [70-80]% |
| | | | | A6B Bowel Cleansers | [50-60]% by value / [40-50]% by volume |
| | | | | A7G Oral Electrol. Replacer | [80-90]% by value / [90-100]% by volume |
| Saccharose Crist | | | France | N7F Drugs Used In Opioid Dep | [30-40]% by value / [40-50]% by volume |
| Sodium Benzoate | | | Spain | A6B Bowel Cleansers | [50-60]% by value / [40-50]% by volume |
| Sodium Citrate Trisod Gran | | | Spain | 03D3 Antidiarr Electrol | [70-80]% |
| | | | | A7G Oral Electrol. Replacer | [80-90]% by value / [90-100]% by volume |
| Sodium Edetate | | | Belgium | 03C4 Saline Laxatives | [70-80]% by value / [30-40]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (ATC3/CHC3)** | **Share (2020)** |
| | | | Greece | G1B Gynaecolog Antifungals | [60-70]% by value / [40-50]% by volume |
| | | | Hungary | G1B Gynaecolog Antifungals | [20-30]% by value / [60-70]% by volume |
| | | | Poland | 12D2 Gynaecological Antifungal | [80-90]% by value / [30-40]% by volume |
| | | | | G1B Gynaecolog Antifungals | [50-60]% by value / [20-30]% by volume |
| | | | Romania | G1B Gynaecolog Antifungals | [10-20]% by value / [30-40]% by volume |
| | | | Spain | 03C4 Saline Laxatives | [90-100]% |
| Sodium Hydroxyde Past. Tech | | | Spain | A6B Bowel Cleansers | [50-60]% by value / [40-50]% by volume |
| Sodium Sulfate Anh | | | Spain | 03D3 Antidiarr Electrol | [70-80]% |
| | | | | A6B Bowel Cleansers | [50-60]% by value / [40-50]% by volume |
| Xylitol Exp | | | France | N7F Drugs Used In Opioid Dep | [30-40]% by value / [40-50]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (ATC4/CHC4)** | **Share (2020)** |
| Acide Citrique Gran H2o Vr.K | At least EEA-wide | <[10-20]% | Czech Republic | 06F3O OINTMENTS/CREAMS | [20-30]% by value / [30-40]% by volume |
| Acide Citrique Gran H2o Vr.K | | | Italy | 10A1O OINTMENTS/CREAMS | [20-30]% by value / [40-50]% by volume |
| Acide Citrique Gran H2o Vr.K | | | Italy | C5A1 A-HAEMORRHOIDL+CORTICOID | [50-60]% by value / [60-70]% by volume |
| Acide Stearique Vr.K | | | Latvia | 10A1O OINTMENTS/CREAMS | [40-50]% by value / [30-40]% by volume |
| Acide Stearique Vr.K | | | Latvia | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| Acide Stearique Vr.K | | | Latvia | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| Acide Stearique Vr.K | | | Lithuania | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| Acide Stearique Vr.K | | | Poland | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |
| Acide Stearique Vr.K | | | Poland | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| Acide Stearique Vr.K | | | Poland | C5A2 A-HAEMORRHOID W/O CORTIC | [40-50]% by value / [30-40]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (ATC4/CHC4)** | **Share (2020)** |
| Acide Stearique Vr.K | | | Romania | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |
| Acide Stearique Vr.K | | | Romania | C5A2 A-HAEMORRHOID W/O CORTIC | [60-70]% by value / [50-60]% by volume |
| Acide Stearique Vr.K | | | Slovakia | 10A1S SUPPOSITORIES | [30-40]% by value / [30-40]% by volume |
| Acide Stearique Vr.K | | | Slovakia | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| Aerosil 200 Vr.K | | | Czech Republic | 06C4L LIQUIDS&LOTIONS (TOPICAL) | [20-30]% by value / [30-40]% by volume |
| Aerosil 200 Vr.K | | | Spain | 03D3P POWDER | [80-90]% by value / [80-90]% by volume |
| Amidon Mais Vr.K | | | Germany | 01B2C CAPS/TABS | [30-40]% by value / [10-20]% by volume |
| Amidon Mais Vr.K | | | Slovakia | G4C2 BPH ALPH-ADREN ANTAG PLN | [30-40]% by value / [10-20]% by volume |
| Carbopol 980 Excipient Nf Vr.K | | | Czech Republic | 97A9O OINTMENTS/CREAMS | [40-50]% by value / [90-100]% by volume |
| Cellulose Microcristalline Vr.K | | | Spain | C9B3 ACE INH COMB+CALC ANTAG | [30-40]% by value / [40-50]% by volume |
| Lactose H2o Exp Vr.K | | | Germany | 01B2C CAPS/TABS | [30-40]% by value / [10-20]% by volume |
| Lactose H2o Exp Vr.K | | | Spain | C9B3 ACE INH COMB+CALC ANTAG | [30-40]% by value / [40-50]% by volume |
| Magnesium Stearate Vr.K | | | Germany | 01B2C CAPS/TABS | [30-40]% by value / [10-20]% by volume |
| Magnesium Stearate Vr.K | | | Slovakia | G4C2 BPH ALPH-ADREN ANTAG PLN | [30-40]% by value / [10-20]% by volume |
| Magnesium Stearate Vr.K | | | Spain | C9B3 ACE INH COMB+CALC ANTAG | [30-40]% by value / [40-50]% by volume |
| Menthol Levo Crist Cosm Vr.K | | | Italy | 10A1O OINTMENTS/CREAMS | [20-30]% by value / [40-50]% by volume |
| Menthol Levo Crist Cosm Vr.K | | | Italy | C5A1 A-HAEMORRHOIDL+CORTICOID | [50-60]% by value / [60-70]% by volume |
| Parahydroxybenz Meth Vr.K | | | Italy | 10A1O OINTMENTS/CREAMS | [20-30]% by value / [40-50]% by volume |
| Parahydroxybenz Meth Vr.K | | | Italy | C5A1 A-HAEMORRHOIDL+CORTICOID | [50-60]% by value / [60-70]% by volume |
| Parahydroxybenz Meth Vr.K | | | Latvia | 10A1O OINTMENTS/CREAMS | [40-50]% by value / [30-40]% by volume |
| Parahydroxybenz Meth Vr.K | | | Latvia | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| Parahydroxybenz Meth Vr.K | | | Latvia | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (ATC4/CHC4)** | **Share (2020)** |
| Parahydroxybenz Meth Vr.K | | | Lithuania | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| Parahydroxybenz Meth Vr.K | | | Poland | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |
| Parahydroxybenz Meth Vr.K | | | Poland | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| Parahydroxybenz Meth Vr.K | | | Poland | C5A2 A-HAEMORRHOID W/O CORTIC | [40-50]% by value / [30-40]% by volume |
| Parahydroxybenz Meth Vr.K | | | Romania | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |
| Parahydroxybenz Meth Vr.K | | | Romania | C5A2 A-HAEMORRHOID W/O CORTIC | [60-70]% by value / [50-60]% by volume |
| Parahydroxybenz Meth Vr.K | | | Slovakia | 10A1S SUPPOSITORIES | [30-40]% by value / [30-40]% by volume |
| Parahydroxybenz Meth Vr.K | | | Slovakia | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| Parahydroxybenz Prop Vr.K | | | Italy | 10A1O OINTMENTS/CREAMS | [20-30]% by value / [40-50]% by volume |
| Parahydroxybenz Prop Vr.K | | | Italy | C5A1 A-HAEMORRHOIDL+CORTICOID | [50-60]% by value / [60-70]% by volume |
| Parahydroxybenz Prop Vr.K | | | Latvia | 10A1O OINTMENTS/CREAMS | [40-50]% by value / [30-40]% by volume |
| Parahydroxybenz Prop Vr.K | | | Latvia | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| Parahydroxybenz Prop Vr.K | | | Latvia | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| Parahydroxybenz Prop Vr.K | | | Lithuania | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| Parahydroxybenz Prop Vr.K | | | Poland | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |
| Parahydroxybenz Prop Vr.K | | | Poland | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| Parahydroxybenz Prop Vr.K | | | Poland | C5A2 A-HAEMORRHOID W/O CORTIC | [40-50]% by value / [30-40]% by volume |
| Parahydroxybenz Prop Vr.K | | | Romania | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |
| Parahydroxybenz Prop Vr.K | | | Romania | C5A2 A-HAEMORRHOID W/O CORTIC | [60-70]% by value / [50-60]% by volume |
| Parahydroxybenz Prop Vr.K | | | Slovakia | 10A1S SUPPOSITORIES | [30-40]% by value / [30-40]% by volume |
| Parahydroxybenz Prop Vr.K | | | Slovakia | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| Potassium | | | France | A6B1 OSMOTIC | [40-50]% by value / |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (ATC4/CHC4)** | **Share (2020)** |
| Bicarbonate Vrac K | | | | BOWEL CLEANSERS | [5-10]% by volume |
| Potassium Bicarbonate Vrac K | | | Germany | 03C5P POWDERS | [50-60]% by value / [10-20]% by volume |
| Potassium Bicarbonate Vrac K | | | Germany | A6B1 OSMOTIC BOWEL CLEANSERS | [30-40]% by value / [30-40]% by volume |
| Potassium Bicarbonate Vrac K | | | Ireland | 03C4Q ENEMAS | [90-100]% by value / [90-100]% by volume |
| Potassium Bicarbonate Vrac K | | | Italy | A6B1 OSMOTIC BOWEL CLEANSERS | [70-80]% by value / [70-80]% by volume |
| Potassium Bicarbonate Vrac K | | | Poland | A6B1 OSMOTIC BOWEL CLEANSERS | [70-80]% by value / [10-20]% by volume |
| Potassium Bicarbonate Vrac K | | | Portugal | A6B1 OSMOTIC BOWEL CLEANSERS | [80-90]% by value / [80-90]% by volume |
| Potassium Bicarbonate Vrac K | | | Spain | A6B1 OSMOTIC BOWEL CLEANSERS | [90-100]% by value / [90-100]% by volume |
| Potassium Bicarbonate Vrac K | | | Sweden | A6B1 OSMOTIC BOWEL CLEANSERS | [40-50]% by value / [20-30]% by volume |
| Potassium Sorbate Vr.K | | | Spain | 03C1Z OTHER FORMS | [60-70]% by value / [40-50]% by volume |
| Propylene Glycol Vr.K | | | Czech Republic | 06C4L LIQUIDS&LOTIONS (TOPICAL) | [20-30]% by value / [30-40]% by volume |
| Propylene Glycol Vr.K | | | Czech Republic | 97A9O OINTMENTS/CREAMS | [40-50]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | Italy | 10A1O OINTMENTS/CREAMS | [20-30]% by value / [40-50]% by volume |
| Propylene Glycol Vr.K | | | Italy | C5A1 A-HAEMORRHOIDL+CORTICOID | [50-60]% by value / [60-70]% by volume |
| Propylene Glycol Vr.K | | | Poland | 12D2S SUPPOSITORIES | [90-100]% by value / [70-80]% by volume |
| Saccharine Sodique Vr.K | | | France | A6B1 OSMOTIC BOWEL CLEANSERS | [40-50]% by value / [5-10]% by volume |
| Saccharine Sodique Vr.K | | | Germany | 03C5P POWDERS | [50-60]% by value / [10-20]% by volume |
| Saccharine Sodique Vr.K | | | Germany | A6B1 OSMOTIC BOWEL CLEANSERS | [30-40]% by value / [30-40]% by volume |
| Saccharine Sodique Vr.K | | | Ireland | 03C4Q ENEMAS | [90-100]% by value / [90-100]% by volume |
| Saccharine Sodique Vr.K | | | Italy | A6B1 OSMOTIC BOWEL CLEANSERS | [70-80]% by value / [70-80]% by volume |
| Saccharine Sodique Vr.K | | | Poland | A6B1 OSMOTIC BOWEL CLEANSERS | [70-80]% by value / [10-20]% by volume |
| Saccharine | | | Portugal | A6B1 OSMOTIC | [80-90]% by value / |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (ATC4/CHC4)** | **Share (2020)** |
| Sodique Vr.K | | | | BOWEL CLEANSERS | [80-90]% by volume |
| Saccharine Sodique Vr.K | | | Spain | 03D3P POWDER | [80-90]% by value / [80-90]% by volume |
| Saccharine Sodique Vr.K | | | Spain | A6B1 OSMOTIC BOWEL CLEANSERS | [90-100]% by value / [90-100]% by volume |
| Saccharine Sodique Vr.K | | | Sweden | A6B1 OSMOTIC BOWEL CLEANSERS | [40-50]% by value / [20-30]% by volume |
| Sodium Benzoate Vr.K | | | France | A6B1 OSMOTIC BOWEL CLEANSERS | [40-50]% by value / [5-10]% by volume |
| Sodium Benzoate Vr.K | | | Germany | A6B1 OSMOTIC BOWEL CLEANSERS | [30-40]% by value / [30-40]% by volume |
| Sodium Benzoate Vr.K | | | Portugal | A6B1 OSMOTIC BOWEL CLEANSERS | [80-90]% by value / [80-90]% by volume |
| Sodium Benzoate Vr.K | | | Spain | 03C1Z OTHER FORMS | [60-70]% by value / [40-50]% by volume |
| Sodium Benzoate Vr.K | | | Spain | A6B1 OSMOTIC BOWEL CLEANSERS | [90-100]% by value / [90-100]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | Spain | 03C1Z OTHER FORMS | [60-70]% by value / [40-50]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | Spain | 03D3P POWDER | [80-90]% by value / [80-90]% by volume |
| Sodium Edetate Vr.K | | | Belgium | 03C4M MIXTURES (ORAL) | [40-50]% by value / [10-20]% by volume |
| Sodium Edetate Vr.K | | | Belgium | 03C4Q ENEMAS | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | Poland | 12D2S SUPPOSITORIES | [90-100]% by value / [70-80]% by volume |
| Sodium Edetate Vr.K | | | Spain | 03C4Q ENEMAS | [90-100]% by value / [90-100]% by volume |
| Sodium Hydroxyde Past. Tech Vr.K | | | Spain | A6B1 OSMOTIC BOWEL CLEANSERS | [90-100]% by value / [90-100]% by volume |
| Sodium Laurylsulfate Pulv Vr.K | | | Slovakia | G4C2 BPH ALPH-ADREN ANTAG PLN | [30-40]% by value / [10-20]% by volume |
| Sodium Sulfate Anh Vr.K | | | Spain | 03D3P POWDER | [80-90]% by value / [80-90]% by volume |
| Talc Officinal Vr.K | | | Czech Republic | 06C4L LIQUIDS&LOTIONS (TOPICAL) | [20-30]% by value / [30-40]% by volume |
| Zinc Oxyde Grade Excipient Vr.K | | | Czech Republic | 06C4L LIQUIDS&LOTIONS (TOPICAL) | [20-30]% by value / [30-40]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Acetone Technique Na 5l | At least EEA-wide | <[10-20]% | ITALY | 03A4 PRS FOR IBS&DIGEST SPASMS --> 03A4C CAPS/TABS --> ATROPA BELLADONNA!PAPA VERINE | [90-100]% by value / [90-100]% by volume |
| Acetone Technique Na 5l | | | ITALY | A3A ANTISPASM+ANTICH OL PLAIN --> A3A0 ANTISPASM+ANTICH OL PLAIN --> ATROPA BELLADONNA!PAPA VERINE | [90-100]% by value / [90-100]% by volume |
| Acide Citrique Gran H2o Vr.K | | | CZECH REPUBLIC | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL!IRON METAL | [90-100]% by value / [90-100]% by volume |
| Acide Citrique Gran H2o Vr.K | | | CZECH REPUBLIC | 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> PLANTAGO LANCEOLATA | [90-100]% by value / [90-100]% by volume |
| Acide Citrique Gran H2o Vr.K | | | CZECH REPUBLIC | 06P1 SKIN PROTECTOR+EMOLLI ENTS --> 06P1O OINTMENTS/CREAMS --> AGRIMONIA EUPATORIA | [30-40]% by value / [30-40]% by volume |
| Acide Citrique Gran H2o Vr.K | | | FRANCE | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> BICLOTYMOL!ENOX OLONE!LYSOZYME | [90-100]% by value / [90-100]% by volume |
| Acide Citrique Gran H2o Vr.K | | | FRANCE | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> BICLOTYMOL!ENOX OLONE!LYSOZYME | [90-100]% by value / [90-100]% by volume |
| Acide Citrique Gran H2o Vr.K | | | ITALY | 10A1 ANTIHAEMORRHOID S --> 10A1O OINTMENTS/CREAMS --> FLUOCINOLONE ACETONIDE!KETOCA INE | [90-100]% by value / [90-100]% by volume |
| Acide Citrique Gran H2o Vr.K | | | ITALY | 10A1 ANTIHAEMORRHOID S --> 10A1S SUPPOSITORIES --> | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | FLUOCINOLONE ACETONIDE!KETOCAINE | |
| Acide Citrique Gran H2o Vr.K | | | ITALY | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A1 A-HAEMORRHOIDL+CORTICOID --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| Acide Citrique Gran H2o Vr.K | | | ITALY | R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> CLONAZOLINE!FLUOCINOLONE ACETONIDE | [90-100]% by value / [90-100]% by volume |
| Acide Citrique Gran H2o Vr.K | | | ITALY | R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> FLUNISOLIDE | [40-50]% by value / [60-70]% by volume |
| Acide Citrique Gran H2o Vr.K | | | ITALY | R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> FLUOCINOLONE ACETONIDE | [90-100]% by value / [90-100]% by volume |
| Acide Citrique Gran H2o Vr.K | | | SLOVAKIA | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL + IRON METAL | [90-100]% by value / [90-100]% by volume |
| Acide Citrique Gran H2o Vr.K | | | SLOVAKIA | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> COMPOSITION UNKNOWN | [80-90]% by value / [90-100]% by volume |
| Acide Citrique Gran H2o Vr.K | | | SLOVAKIA | 06P1 SKIN PROTECTOR+EMOLLIENTS --> 06P1O OINTMENTS/CREAMS --> AGRIMONIA EUPATORIA | [90-100]% by value / [90-100]% by volume |
| Acide Sorbique Vr.K | | | FRANCE | N7F DRUGS USED IN OPIOID DEP --> N7F0 DRUGS USED IN OPIOID DEP --> METHADONE | [90-100]% by value / [90-100]% by volume |
| Acide Stearique | | | CZECH | 10A1 | [90-100]% by value / |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Vr.K | | | REPUBLIC | ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by volume |
| Acide Stearique Vr.K | | | CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Acide Stearique Vr.K | | | CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| Acide Stearique Vr.K | | | CZECH REPUBLIC | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Acide Stearique Vr.K | | | ITALY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> NAPROXEN | [40-50]% by value / [40-50]% by volume |
| Acide Stearique Vr.K | | | ITALY | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> NAPROXEN | [50-60]% by value / [40-50]% by volume |
| Acide Stearique Vr.K | | | ITALY | N3A ANTI-EPILEPTICS --> N3A0 ANTI-EPILEPTICS --> PHENYTOIN | [60-70]% by value / [90-100]% by volume |
| Acide Stearique Vr.K | | | LATVIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Acide Stearique Vr.K | | | LATVIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Acide Stearique | | | LATVIA | C5A TOPICAL | [90-100]% by value / |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Vr.K | | | | ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by volume |
| Acide Stearique Vr.K | | | LITHUANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Acide Stearique Vr.K | | | LITHUANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Acide Stearique Vr.K | | | LITHUANIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Acide Stearique Vr.K | | | POLAND | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [50-60]% by value / [60-70]% by volume |
| Acide Stearique Vr.K | | | POLAND | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Acide Stearique Vr.K | | | POLAND | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [70-80]% by value / [60-70]% by volume |
| Acide Stearique Vr.K | | | PORTUGAL | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Acide Stearique | | | PORTUGA | C5A TOPICAL | [90-100]% by value / |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Vr.K | | | L | ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by volume |
| Acide Stearique Vr.K | | | ROMANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Acide Stearique Vr.K | | | ROMANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Acide Stearique Vr.K | | | ROMANIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Acide Stearique Vr.K | | | SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Acide Stearique Vr.K | | | SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Acide Stearique Vr.K | | | SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| Acide Stearique Vr.K | | | SLOVAKIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Aerosil 200 Vr.K | | | CZECH REPUBLIC | 06C4 OTHER SKIN IRRITATION --> 06C4L LIQUIDS&LOTIONS | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | (TOPICAL) --> GLYCEROL!MENTHOL!TALC!ZINC | |
| Aerosil 200 Vr.K | | | CZECH REPUBLIC | 06C4 OTHER SKIN IRRITATION --> 06C4L LIQUIDS&LOTIONS (TOPICAL) --> GLYCEROL!TALC!ZINC | [90-100]% by value / [90-100]% by volume |
| Aerosil 200 Vr.K | | | FRANCE | N7F DRUGS USED IN OPIOID DEP --> N7F0 DRUGS USED IN OPIOID DEP --> METHADONE | [90-100]% by value / [90-100]% by volume |
| Aerosil 200 Vr.K | | | GREECE | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [90-100]% by value / [90-100]% by volume |
| Aerosil 200 Vr.K | | | ITALY | N3A ANTI-EPILEPTICS --> N3A0 ANTI-EPILEPTICS --> PHENYTOIN | [60-70]% by value / [90-100]% by volume |
| Aerosil 200 Vr.K | | | SPAIN | 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CITRIC ACID!GLUCOSE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| Aerosil 200 Vr.K | | | SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> CITRIC ACID!GLUCOSE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| Aerosil 200 Vr.K | | | SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| Aerosil 200 Vr.K | | | SPAIN | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [80-90]% by value / [80-90]% by volume |
| Aerosil 200 Vr.K | | | SPAIN | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Alcool | | | FRANCE | 01C1 SORE THROAT | [90-100]% by value / |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Benzylique 11 | | | | REMS. --> 01C1A AEROSOLS/SPRAYS --> BICLOTYMOL | [90-100]% by volume |
| Alcool Benzylique 11 | | | FRANCE | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> BICLOTYMOL | [90-100]% by value / [20-30]% by volume |
| Amidon Mais Vr.K | | | AUSTRIA | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| Amidon Mais Vr.K | | | CZECH REPUBLIC | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| Amidon Mais Vr.K | | | FRANCE | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [30-40]% by value / [20-30]% by volume |
| Amidon Mais Vr.K | | | FRANCE | H3B ANTI-THYROID PREPARATION --> H3B0 ANTI-THYROID PREPARATION --> BENZYLTHIOURACIL | [90-100]% by value / [90-100]% by volume |
| Amidon Mais Vr.K | | | GERMANY | 01B2 NASAL DECONGESTANTS --> 01B2C CAPS/TABS --> PSEUDOEPHEDRINE! TRIPROLIDINE | [90-100]% by value / [90-100]% by volume |
| Amidon Mais Vr.K | | | GERMANY | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [60-70]% by value / [60-70]% by volume |
| Amidon Mais Vr.K | | | GERMANY | R1B SYSTEMIC NASAL PREPS --> R1B0 SYSTEMIC NASAL PREPS --> PSEUDOEPHEDRINE! TRIPROLIDINE | [90-100]% by value / [90-100]% by volume |
| Amidon Mais Vr.K | | | GREECE | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| Amidon Mais Vr.K | | | IRELAND | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| Amidon Mais Vr.K | | | ITALY | 03A4 PRS FOR IBS&DIGEST SPASMS --> 03A4C CAPS/TABS --> ATROPA BELLADONNA!PAPA | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | VERINE | |
| Amidon Mais Vr.K | | | ITALY | A3A ANTISPASM+ANTICHOL PLAIN --> A3A0 ANTISPASM+ANTICHOL PLAIN --> ATROPA BELLADONNA!PAPAVERINE | [90-100]% by value / [90-100]% by volume |
| Amidon Mais Vr.K | | | ITALY | C10A CHOLEST&TRIGLY.REGULATOR --> C10A1 STATINS (HMG-COA RED) --> LOVASTATIN | [70-80]% by value / [70-80]% by volume |
| Amidon Mais Vr.K | | | ITALY | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [60-70]% by value / [60-70]% by volume |
| Amidon Mais Vr.K | | | ITALY | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> ASCORBIC ACID!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| Amidon Mais Vr.K | | | ITALY | N3A ANTI-EPILEPTICS --> N3A0 ANTI-EPILEPTICS --> METHYLPHENOBARBITAL!PHENYTOIN | [90-100]% by value / [90-100]% by volume |
| Amidon Mais Vr.K | | | ITALY | N3A ANTI-EPILEPTICS --> N3A0 ANTI-EPILEPTICS --> PHENYTOIN | [60-70]% by value / [90-100]% by volume |
| Amidon Mais Vr.K | | | POLAND | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| Amidon Mais Vr.K | | | PORTUGAL | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [50-60]% by value / [40-50]% by volume |
| Amidon Mais Vr.K | | | ROMANIA | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| Amidon Mais Vr.K | | | SLOVAKIA | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [80-90]% by volume |
| Amidon Mais Vr.K | | | SPAIN | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN -- | [40-50]% by value / [40-50]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | > SILODOSIN | |
| Bleu Patente V Excipient Vr.K | | | FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BENZOIC ACID!BROMINE!CODEINE | [90-100]% by value / [90-100]% by volume |
| Bleu Patente V Excipient Vr.K | | | FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BROMOFORM!CODEINE | [90-100]% by value / [90-100]% by volume |
| Bleu Patente V Excipient Vr.K | | | FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL | [90-100]% by value / [90-100]% by volume |
| Carbopol 980 Excipient Nf Vr.K | | | CZECH REPUBLIC | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL!IRON METAL | [90-100]% by value / [90-100]% by volume |
| Carbopol 980 Excipient Nf Vr.K | | | CZECH REPUBLIC | 97A9 ALL OTH MISC PRODS --> 97A9O OINTMENTS/CREAMS --> CREAMS (BASIS) | [90-100]% by value / [90-100]% by volume |
| Carbopol 980 Excipient Nf Vr.K | | | SLOVAKIA | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL + IRON METAL | [90-100]% by value / [90-100]% by volume |
| Cellulose Microcristalline Vr.K | | | BELGIUM | C8A CALCIUM ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [40-50]% by value / [40-50]% by volume |
| Cellulose Microcristalline Vr.K | | | FINLAND | C8A CALCIUM ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [70-80]% by value / [70-80]% by volume |
| Cellulose Microcristalline Vr.K | | | FRANCE | 01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS --> BICLOTYMOL | [90-100]% by value / [90-100]% by volume |
| Cellulose Microcristalline | | | FRANCE | C9B ACE INHIBITORS COMBINAT --> C9B3 | [40-50]% by value / [40-50]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Vr.K | | | | ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | |
| Cellulose Microcristalline Vr.K | | | FRANCE | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Cellulose Microcristalline Vr.K | | | FRANCE | H3B ANTI-THYROID PREPARATION --> H3B0 ANTI-THYROID PREPARATION --> BENZYLTHIOURACIL | [90-100]% by value / [90-100]% by volume |
| Cellulose Microcristalline Vr.K | | | FRANCE | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> BICLOTYMOL | [90-100]% by value / [20-30]% by volume |
| Cellulose Microcristalline Vr.K | | | GERMANY | C8A CALCIUM ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [70-80]% by value / [90-100]% by volume |
| Cellulose Microcristalline Vr.K | | | GERMANY | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [60-70]% by value / [60-70]% by volume |
| Cellulose Microcristalline Vr.K | | | GERMANY | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Cellulose Microcristalline Vr.K | | | GREECE | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [90-100]% by value / [90-100]% by volume |
| Cellulose Microcristalline Vr.K | | | GREECE | C8A CALCIUM ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [50-60]% by value / [50-60]% by volume |
| Cellulose Microcristalline Vr.K | | | GREECE | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANI | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | DIPINE | |
| Cellulose Microcristalline Vr.K | | | IRELAND | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [90-100]% by value / [80-90]% by volume |
| Cellulose Microcristalline Vr.K | | | IRELAND | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Cellulose Microcristalline Vr.K | | | ITALY | C10A CHOLEST&TRIGLY.REGULATOR --> C10A1 STATINS (HMG-COA RED) --> LOVASTATIN | [70-80]% by value / [70-80]% by volume |
| Cellulose Microcristalline Vr.K | | | ITALY | C8A CALCIUM ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [60-70]% by value / [50-60]% by volume |
| Cellulose Microcristalline Vr.K | | | ITALY | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [60-70]% by value / [50-60]% by volume |
| Cellulose Microcristalline Vr.K | | | ITALY | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Cellulose Microcristalline Vr.K | | | ITALY | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> ASCORBIC ACID!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| Cellulose Microcristalline Vr.K | | | ITALY | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> KETOROLAC | [80-90]% by value / [80-90]% by volume |
| Cellulose Microcristalline Vr.K | | | ITALY | N3A ANTI-EPILEPTICS --> N3A0 ANTI-EPILEPTICS --> PHENYTOIN | [60-70]% by value / [90-100]% by volume |
| Cellulose | | | LUXEMBO | C8A CALCIUM | [90-100]% by value / |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Microcristalline Vr.K | | | URG | ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [90-100]% by volume |
| Cellulose Microcristalline Vr.K | | | NETHERLANDS | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Cellulose Microcristalline Vr.K | | | POLAND | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [90-100]% by value / [90-100]% by volume |
| Cellulose Microcristalline Vr.K | | | PORTUGAL | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [40-50]% by value / [30-40]% by volume |
| Cellulose Microcristalline Vr.K | | | PORTUGAL | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Cellulose Microcristalline Vr.K | | | SPAIN | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [80-90]% by value / [80-90]% by volume |
| Cellulose Microcristalline Vr.K | | | SPAIN | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [80-90]% by value / [80-90]% by volume |
| Cellulose Microcristalline Vr.K | | | SPAIN | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Color Jaune Orange S Vr.K | | | FRANCE | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> BICLOTYMOL!ENOXOLONE!LYSOZYME | [90-100]% by value / [90-100]% by volume |
| Color Jaune Orange S Vr.K | | | FRANCE | R2A THROAT PREPARATIONS --> R2A0 THROAT | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | PREPARATIONS --> BICLOTYMOL!ENOXOLONE!LYSOZYME | |
| Color Jaune Orange S Vr.K | | | FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BENZOIC ACID!BROMINE!CODEINE | [90-100]% by value / [90-100]% by volume |
| Color Jaune Orange S Vr.K | | | FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BROMOFORM!CODEINE | [90-100]% by value / [90-100]% by volume |
| Color Jaune Orange S Vr.K | | | FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL | [90-100]% by value / [90-100]% by volume |
| Gelatine Poudre Vr.Kg | | | FRANCE | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Gelatine Poudre Vr.Kg | | | IRELAND | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Gelatine Poudre Vr.Kg | | | NETHERLANDS | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Gelatine Poudre Vr.Kg | | | PORTUGAL | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Gomme Arabique Pdre Vr.K | | | FRANCE | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> BICLOTYMOL!ENOXOLONE!LYSOZYME | [90-100]% by value / [90-100]% by volume |
| Gomme Arabique Pdre Vr.K | | | FRANCE | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Gomme Arabique Pdre Vr.K | | | FRANCE | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> BICLOTYMOL!ENOXOLONE!LYSOZYME | [90-100]% by value / [90-100]% by volume |
| Gomme Arabique Pdre Vr.K | | | IRELAND | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Gomme Arabique Pdre Vr.K | | | ITALY | 03A4 PRS FOR IBS&DIGEST SPASMS --> 03A4C CAPS/TABS --> ATROPA BELLADONNA!PAPAVERINE | [90-100]% by value / [90-100]% by volume |
| Gomme Arabique Pdre Vr.K | | | ITALY | A3A ANTISPASM+ANTICHOL PLAIN --> A3A0 ANTISPASM+ANTICHOL PLAIN --> ATROPA BELLADONNA!PAPAVERINE | [90-100]% by value / [90-100]% by volume |
| Gomme Arabique Pdre Vr.K | | | NETHERLANDS | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Gomme Arabique Pdre Vr.K | | | PORTUGAL | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Lactose H2o Exp Vr.K | | | BELGIUM | C8A CALCIUM ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [40-50]% by value / [40-50]% by volume |
| Lactose H2o Exp Vr.K | | | FINLAND | C8A CALCIUM ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [70-80]% by value / [70-80]% by volume |
| Lactose H2o Exp Vr.K | | | FRANCE | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [40-50]% by value / [40-50]% by volume |
| Lactose H2o Exp Vr.K | | | FRANCE | G4D URINARY INCONTINENCE PRD - | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | -> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | |
| Lactose H2o Exp Vr.K | | | FRANCE | H3B ANTI-THYROID PREPARATION --> H3B0 ANTI-THYROID PREPARATION --> BENZYLTHIOURACIL | [90-100]% by value / [90-100]% by volume |
| Lactose H2o Exp Vr.K | | | FRANCE | N7F DRUGS USED IN OPIOID DEP --> N7F0 DRUGS USED IN OPIOID DEP --> METHADONE | [90-100]% by value / [90-100]% by volume |
| Lactose H2o Exp Vr.K | | | GERMANY | 01B2 NASAL DECONGESTANTS --> 01B2C CAPS/TABS --> PSEUDOEPHEDRINE!TRIPROLIDINE | [90-100]% by value / [90-100]% by volume |
| Lactose H2o Exp Vr.K | | | GERMANY | C8A CALCIUM ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [70-80]% by value / [90-100]% by volume |
| Lactose H2o Exp Vr.K | | | GERMANY | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [60-70]% by value / [60-70]% by volume |
| Lactose H2o Exp Vr.K | | | GERMANY | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Lactose H2o Exp Vr.K | | | GERMANY | R1B SYSTEMIC NASAL PREPS --> R1B0 SYSTEMIC NASAL PREPS --> PSEUDOEPHEDRINE!TRIPROLIDINE | [90-100]% by value / [90-100]% by volume |
| Lactose H2o Exp Vr.K | | | GREECE | C8A CALCIUM ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [50-60]% by value / [50-60]% by volume |
| Lactose H2o Exp Vr.K | | | GREECE | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Lactose H2o Exp Vr.K | | | IRELAND | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [90-100]% by value / [80-90]% by volume |
| Lactose H2o Exp Vr.K | | | IRELAND | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Lactose H2o Exp Vr.K | | | ITALY | 03A4 PRS FOR IBS&DIGEST SPASMS --> 03A4C CAPS/TABS --> ATROPA BELLADONNA!PAPAVERINE | [90-100]% by value / [90-100]% by volume |
| Lactose H2o Exp Vr.K | | | ITALY | A3A ANTISPASM+ANTICHOL PLAIN --> A3A0 ANTISPASM+ANTICHOL PLAIN --> ATROPA BELLADONNA!PAPAVERINE | [90-100]% by value / [90-100]% by volume |
| Lactose H2o Exp Vr.K | | | ITALY | C10A CHOLEST&TRIGLY.REGULATOR --> C10A1 STATINS (HMG-COA RED) --> LOVASTATIN | [70-80]% by value / [70-80]% by volume |
| Lactose H2o Exp Vr.K | | | ITALY | C8A CALCIUM ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [60-70]% by value / [50-60]% by volume |
| Lactose H2o Exp Vr.K | | | ITALY | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [60-70]% by value / [50-60]% by volume |
| Lactose H2o Exp Vr.K | | | ITALY | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Lactose H2o Exp Vr.K | | | ITALY | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> KETOROLAC | [80-90]% by value / [80-90]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Lactose H2o Exp Vr.K | | | LUXEMBOURG | C8A CALCIUM ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [90-100]% by value / [90-100]% by volume |
| Lactose H2o Exp Vr.K | | | NETHERLANDS | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Lactose H2o Exp Vr.K | | | POLAND | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [90-100]% by value / [90-100]% by volume |
| Lactose H2o Exp Vr.K | | | PORTUGAL | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [40-50]% by value / [30-40]% by volume |
| Lactose H2o Exp Vr.K | | | PORTUGAL | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Lactose H2o Exp Vr.K | | | SPAIN | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [80-90]% by value / [80-90]% by volume |
| Lactose H2o Exp Vr.K | | | SPAIN | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | AUSTRIA | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | BELGIUM | C8A CALCIUM ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [40-50]% by value / [40-50]% by volume |
| Magnesium Stearate Vr.K | | | CZECH REPUBLIC | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN -- | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | > SILODOSIN | |
| Magnesium Stearate Vr.K | | | FINLAND | C8A CALCIUM ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [70-80]% by value / [70-80]% by volume |
| Magnesium Stearate Vr.K | | | FRANCE | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> BICLOTYMOL!ENOXOLONE!LYSOZYME | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | FRANCE | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [40-50]% by value / [40-50]% by volume |
| Magnesium Stearate Vr.K | | | FRANCE | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [30-40]% by value / [20-30]% by volume |
| Magnesium Stearate Vr.K | | | FRANCE | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | FRANCE | H3B ANTI-THYROID PREPARATION --> H3B0 ANTI-THYROID PREPARATION --> BENZYLTHIOURACIL | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | FRANCE | N7F DRUGS USED IN OPIOID DEP --> N7F0 DRUGS USED IN OPIOID DEP --> METHADONE | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | FRANCE | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> BICLOTYMOL!ENOXOLONE!LYSOZYME | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | GERMANY | 01B2 NASAL DECONGESTANTS --> 01B2C CAPS/TABS --> PSEUDOEPHEDRINE!TRIPROLIDINE | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | GERMANY | C8A CALCIUM ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [70-80]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Magnesium Stearate Vr.K | | | GERMANY | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [60-70]% by value / [60-70]% by volume |
| Magnesium Stearate Vr.K | | | GERMANY | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [60-70]% by value / [60-70]% by volume |
| Magnesium Stearate Vr.K | | | GERMANY | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | GERMANY | R1B SYSTEMIC NASAL PREPS --> R1B0 SYSTEMIC NASAL PREPS --> PSEUDOEPHEDRINE!TRIPROLIDINE | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | GREECE | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | GREECE | C8A CALCIUM ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [50-60]% by value / [50-60]% by volume |
| Magnesium Stearate Vr.K | | | GREECE | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | GREECE | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | IRELAND | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [90-100]% by value / [80-90]% by volume |
| Magnesium Stearate Vr.K | | | IRELAND | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN -- | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | > SILODOSIN | |
| Magnesium Stearate Vr.K | | | IRELAND | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | ITALY | 03A4 PRS FOR IBS&DIGEST SPASMS --> 03A4C CAPS/TABS --> ATROPA BELLADONNA!PAPA VERINE | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | ITALY | A3A ANTISPASM+ANTICH OL PLAIN --> A3A0 ANTISPASM+ANTICH OL PLAIN --> ATROPA BELLADONNA!PAPA VERINE | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | ITALY | C10A CHOLEST&TRIGLY.R EGULATOR --> C10A1 STATINS (HMG-COA RED) --> LOVASTATIN | [70-80]% by value / [70-80]% by volume |
| Magnesium Stearate Vr.K | | | ITALY | C8A CALCIUM ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [60-70]% by value / [50-60]% by volume |
| Magnesium Stearate Vr.K | | | ITALY | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANI DIPINE | [60-70]% by value / [50-60]% by volume |
| Magnesium Stearate Vr.K | | | ITALY | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [60-70]% by value / [60-70]% by volume |
| Magnesium Stearate Vr.K | | | ITALY | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | ITALY | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> ASCORBIC ACID!PARACETAMO L!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Magnesium Stearate Vr.K | | | ITALY | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> KETOROLAC | [80-90]% by value / [80-90]% by volume |
| Magnesium Stearate Vr.K | | | ITALY | N3A ANTI-EPILEPTICS --> N3A0 ANTI-EPILEPTICS --> METHYLPHENOBARBITAL!PHENYTOIN | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | LUXEMBOURG | C8A CALCIUM ANTAGONIST PLAIN --> C8A0 CALCIUM ANTAGONIST PLAIN --> LERCANIDIPINE | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | NETHERLANDS | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | POLAND | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | POLAND | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | PORTUGAL | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [40-50]% by value / [30-40]% by volume |
| Magnesium Stearate Vr.K | | | PORTUGAL | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [50-60]% by value / [40-50]% by volume |
| Magnesium Stearate Vr.K | | | PORTUGAL | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | ROMANIA | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| Magnesium Stearate Vr.K | | | SLOVAKIA | G4C BPH PRODUCTS --> G4C2 BPH ALPH- | [90-100]% by value / [80-90]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | ADREN ANTAG PLN --> SILODOSIN | |
| Magnesium Stearate Vr.K | | | SPAIN | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [80-90]% by value / [80-90]% by volume |
| Magnesium Stearate Vr.K | | | SPAIN | C9B ACE INHIBITORS COMBINAT --> C9B3 ACE INH COMB+CALC ANTAG --> ENALAPRIL!LERCANIDIPINE | [80-90]% by value / [80-90]% by volume |
| Magnesium Stearate Vr.K | | | SPAIN | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [40-50]% by value / [40-50]% by volume |
| Magnesium Stearate Vr.K | | | SPAIN | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Menthol Levo Crist Cosm Vr.K | | | ITALY | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| Menthol Levo Crist Cosm Vr.K | | | ITALY | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| Menthol Levo Crist Cosm Vr.K | | | ITALY | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A1 A-HAEMORRHOIDL+CORTICOID --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| Menthol Levo Crist Cosm Vr.K | | | SPAIN | 10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> ALLANTOIN!AMINOACRIDINE!HYDROCORTISONE!LIDOCAINE | [90-100]% by value / [90-100]% by volume |
| Menthol Levo | | | SPAIN | C5A TOPICAL | [90-100]% by value / |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Crist Cosm Vr.K | | | | ANTIHAEMORRHOIDL --> C5A1 A-HAEMORRHOIDL+CORTICOID --> ALLANTOIN!AMINOACRIDINE!HYDROCORTISONE!LIDOCAINE | [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | CZECH REPUBLIC | 06P1 SKIN PROTECTOR+EMOLLIENTS --> 06P1O OINTMENTS/CREAMS --> GERANIUM ROBERTIANUM!HELIANTHUS ANNUUS!RICINUS COMMUNIS!SKIN LOTION!SODIUM!WHITE BEESWAX | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | CZECH REPUBLIC | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | FRANCE | 01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS --> BICLOTYMOL | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | FRANCE | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> BICLOTYMOL | [90-100]% by value / [20-30]% by volume |
| Parahydroxybe | | | FRANCE | R5D ANTITUSSIVES -- | [90-100]% by value / |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| nz Meth Vr.K | | | | > R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BENZOIC ACID!BROMINE!CODEINE | [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BROMOFORM!CODEINE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | ITALY | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | ITALY | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | ITALY | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A1 A-HAEMORRHOIDL+CORTICOID --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | ITALY | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> KETOROLAC | [80-90]% by value / [80-90]% by volume |
| Parahydroxybenz Meth Vr.K | | | LATVIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Parahydroxybenz Meth Vr.K | | | LATVIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | LATVIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | LITHUANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | LITHUANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | LITHUANIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | POLAND | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [50-60]% by value / [60-70]% by volume |
| Parahydroxybenz Meth Vr.K | | | POLAND | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | POLAND | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [70-80]% by value / [60-70]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Parahydroxybenz Meth Vr.K | | | PORTUGAL | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | PORTUGAL | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | ROMANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | ROMANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | ROMANIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Meth Vr.K | | | SLOVAKIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A- | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | |
| Parahydroxybenz Prop Vr.K | | | CZECH REPUBLIC | 06P1 SKIN PROTECTOR+EMOLLIENTS --> 06P1O OINTMENTS/CREAMS --> GERANIUM ROBERTIANUM!HELIANTHUS ANNUUS!RICINUS COMMUNIS!SKIN LOTION!SODIUM!WHITE BEESWAX | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | CZECH REPUBLIC | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BENZOIC ACID!BROMINE!CODEINE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BROMOFORM!CODEINE | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Parahydroxybenz Prop Vr.K | | | FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | ITALY | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | ITALY | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | ITALY | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A1 A-HAEMORRHOIDL+CORTICOID --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | ITALY | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> KETOROLAC | [80-90]% by value / [80-90]% by volume |
| Parahydroxybenz Prop Vr.K | | | LATVIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | LATVIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | LATVIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENO | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | SIDE | |
| Parahydroxybenz Prop Vr.K | | | LITHUANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | LITHUANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | LITHUANIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | POLAND | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [50-60]% by value / [60-70]% by volume |
| Parahydroxybenz Prop Vr.K | | | POLAND | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | POLAND | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [70-80]% by value / [60-70]% by volume |
| Parahydroxybenz Prop Vr.K | | | PORTUGAL | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | PORTUGAL | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENO | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | SIDE | |
| Parahydroxybenz Prop Vr.K | | | ROMANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | ROMANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | ROMANIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Vr.K | | | SLOVAKIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| Potassium Bicarbonate Vrac K | | | FRANCE | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID!MAGNESIUM!PICOSULFURIC ACID | [60-70]% by value / [60-70]% by volume |
| Potassium | | | GERMANY | 03C5 CONTACT | [50-60]% by value / |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Bicarbonate Vrac K | | | | LAXATIVES --> 03C5P POWDERS --> CITRIC ACID!MAGNESIUM!PICOSULFURIC ACID | [50-60]% by volume |
| Potassium Bicarbonate Vrac K | | | GERMANY | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID!MAGNESIUM!PICOSULFURIC ACID | [40-50]% by value / [40-50]% by volume |
| Potassium Bicarbonate Vrac K | | | IRELAND | 03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| Potassium Bicarbonate Vrac K | | | IRELAND | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| Potassium Bicarbonate Vrac K | | | ITALY | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID!MAGNESIUM!PICOSULFURIC ACID | [70-80]% by value / [70-80]% by volume |
| Potassium Bicarbonate Vrac K | | | POLAND | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID!MAGNESIUM!PICOSULFURIC ACID | [80-90]% by value / [80-90]% by volume |
| Potassium Bicarbonate Vrac K | | | PORTUGAL | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID!MAGNESIUM!PICOSULFURIC ACID | [90-100]% by value / [90-100]% by volume |
| Potassium Bicarbonate Vrac K | | | SPAIN | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID!MAGNESIUM!PICOSULFURIC ACID | [90-100]% by value / [90-100]% by volume |
| Potassium Bicarbonate Vrac K | | | SWEDEN | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC | [40-50]% by value / [40-50]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | ACID!MAGNESIUM!PICOSULFURIC ACID | |
| Potassium Sorbate Vr.K | | | GERMANY | 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2M MIXTURES (ORAL) --> MACROGOL(S) | [30-40]% by value / [10-20]% by volume |
| Potassium Sorbate Vr.K | | | GERMANY | 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2P POWDERS --> MACROGOL(S) | [30-40]% by value / [20-30]% by volume |
| Potassium Sorbate Vr.K | | | GERMANY | A6A DRUGS FOR CONSTIPATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [30-40]% by value / [20-30]% by volume |
| Potassium Sorbate Vr.K | | | ITALY | A6A DRUGS FOR CONSTIPATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [40-50]% by value / [30-40]% by volume |
| Potassium Sorbate Vr.K | | | PORTUGAL | 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2P POWDERS --> MACROGOL(S) | [30-40]% by value / [30-40]% by volume |
| Potassium Sorbate Vr.K | | | PORTUGAL | A6A DRUGS FOR CONSTIPATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [70-80]% by value / [70-80]% by volume |
| Potassium Sorbate Vr.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE | [90-100]% by value / [90-100]% by volume |
| Potassium Sorbate Vr.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| Potassium Sorbate Vr.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE | [90-100]% by value / [90-100]% by volume |
| Potassium Sorbate Vr.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> | [70-80]% by value / [0-5]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | VEGETABLE FIBRE | |
| Potassium Sorbate Vr.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| Potassium Sorbate Vr.K | | | SPAIN | A6A DRUGS FOR CONSTIPATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | BULGARIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | CZECH REPUBLIC | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL!IRON METAL | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | CZECH REPUBLIC | 06C4 OTHER SKIN IRRITATION --> 06C4L LIQUIDS&LOTIONS (TOPICAL) --> GLYCEROL!MENTHOL!TALC!ZINC | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | CZECH REPUBLIC | 06C4 OTHER SKIN IRRITATION --> 06C4L LIQUIDS&LOTIONS (TOPICAL) --> GLYCEROL!TALC!ZINC | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | CZECH REPUBLIC | 97A9 ALL OTH MISC PRODS --> 97A9O OINTMENTS/CREAMS --> CREAMS (BASIS) | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | CZECH REPUBLIC | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | GREECE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | GREECE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | --> FENTICONAZOLE | |
| Propylene Glycol Vr.K | | | GREECE | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | GREECE | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | HUNGARY | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [80-90]% by value / [80-90]% by volume |
| Propylene Glycol Vr.K | | | ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | ITALY | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | ITALY | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | ITALY | 12D2 GYNAECOLOGICAL | [50-60]% by value / [60-70]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | ANTIFUNGAL --> 12D2S SUPPOSITORIES --> FENTICONAZOLE | |
| Propylene Glycol Vr.K | | | ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | ITALY | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A1 A-HAEMORRHOIDL+CORTICOID --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | ITALY | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | ITALY | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [60-70]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | ITALY | R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> CLONAZOLINE!FLUOCINOLONE ACETONIDE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | ITALY | R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> FLUNISOLIDE | [40-50]% by value / [60-70]% by volume |
| Propylene Glycol Vr.K | | | ITALY | R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> FLUOCINOLONE ACETONIDE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | LITHUANIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | POLAND | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | 12D2O OINTMENTS/CREAMS --> FENTICONAZOLE | |
| Propylene Glycol Vr.K | | | POLAND | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | POLAND | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | ROMANIA | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | ROMANIA | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | ROMANIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Propylene Glycol Vr.K | | | SLOVAKIA | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL + IRON METAL | [90-100]% by value / [90-100]% by volume |
| Saccharine Sodique Vr.K | | | FRANCE | 01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS --> BICLOTYMOL | [90-100]% by value / [90-100]% by volume |
| Saccharine Sodique Vr.K | | | FRANCE | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID!MAGNESIUM!PI COSULFURIC ACID | [60-70]% by value / [60-70]% by volume |
| Saccharine Sodique Vr.K | | | FRANCE | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [50-60]% by value / [40-50]% by volume |
| Saccharine Sodique Vr.K | | | FRANCE | R2A THROAT PREPARATIONS --> | [90-100]% by value / [20-30]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | R2A0 THROAT PREPARATIONS --> BICLOTYMOL | |
| Saccharine Sodique Vr.K | | | GERMANY | 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2M MIXTURES (ORAL) --> MACROGOL(S) | [30-40]% by value / [10-20]% by volume |
| Saccharine Sodique Vr.K | | | GERMANY | 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2P POWDERS --> MACROGOL(S) | [30-40]% by value / [20-30]% by volume |
| Saccharine Sodique Vr.K | | | GERMANY | 03C4 SALINE LAXATIVES --> 03C4M MIXTURES (ORAL) --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| Saccharine Sodique Vr.K | | | GERMANY | 03C5 CONTACT LAXATIVES --> 03C5P POWDERS --> CITRIC ACID!MAGNESIUM!PICOSULFURIC ACID | [50-60]% by value / [50-60]% by volume |
| Saccharine Sodique Vr.K | | | GERMANY | A6A DRUGS FOR CONSTIPATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [30-40]% by value / [20-30]% by volume |
| Saccharine Sodique Vr.K | | | GERMANY | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID!MAGNESIUM!PICOSULFURIC ACID | [40-50]% by value / [40-50]% by volume |
| Saccharine Sodique Vr.K | | | GERMANY | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| Saccharine Sodique Vr.K | | | IRELAND | 03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| Saccharine Sodique Vr.K | | | IRELAND | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| Saccharine Sodique Vr.K | | | ITALY | A6A DRUGS FOR CONSTIPATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [40-50]% by value / [30-40]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Saccharine Sodique Vr.K | | | ITALY | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID!MAGNESIUM!PICOSULFURIC ACID | [70-80]% by value / [70-80]% by volume |
| Saccharine Sodique Vr.K | | | NORWAY | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| Saccharine Sodique Vr.K | | | POLAND | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID!MAGNESIUM!PICOSULFURIC ACID | [80-90]% by value / [80-90]% by volume |
| Saccharine Sodique Vr.K | | | PORTUGAL | 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2P POWDERS --> MACROGOL(S) | [30-40]% by value / [30-40]% by volume |
| Saccharine Sodique Vr.K | | | PORTUGAL | A6A DRUGS FOR CONSTIPATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [70-80]% by value / [70-80]% by volume |
| Saccharine Sodique Vr.K | | | PORTUGAL | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID!MAGNESIUM!PICOSULFURIC ACID | [90-100]% by value / [90-100]% by volume |
| Saccharine Sodique Vr.K | | | PORTUGAL | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [70-80]% by value / [70-80]% by volume |
| Saccharine Sodique Vr.K | | | SPAIN | 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CITRIC ACID!GLUCOSE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| Saccharine Sodique Vr.K | | | SPAIN | A6A DRUGS FOR CONSTIPATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [90-100]% by value / [90-100]% by volume |
| Saccharine Sodique Vr.K | | | SPAIN | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | CLEANSERS --> CITRIC ACID!MAGNESIUM!PICOSULFURIC ACID | |
| Saccharine Sodique Vr.K | | | SPAIN | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [50-60]% by value / [50-60]% by volume |
| Saccharine Sodique Vr.K | | | SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> CITRIC ACID!GLUCOSE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| Saccharine Sodique Vr.K | | | SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| Saccharine Sodique Vr.K | | | SWEDEN | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID!MAGNESIUM!PICOSULFURIC ACID | [40-50]% by value / [40-50]% by volume |
| Saccharose Crist Vr.K | | | FRANCE | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> BICLOTYMOL!ENOXOLONE!LYSOZYME | [90-100]% by value / [90-100]% by volume |
| Saccharose Crist Vr.K | | | FRANCE | N7F DRUGS USED IN OPIOID DEP --> N7F0 DRUGS USED IN OPIOID DEP --> METHADONE | [90-100]% by value / [90-100]% by volume |
| Saccharose Crist Vr.K | | | FRANCE | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> BICLOTYMOL!ENOXOLONE!LYSOZYME | [90-100]% by value / [90-100]% by volume |
| Sodium Benzoate Vr.K | | | FRANCE | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [50-60]% by value / [40-50]% by volume |
| Sodium Benzoate Vr.K | | | GERMANY | 03C2 OSMOTIC LAXAT(EXC SALINE) | [30-40]% by value / [10-20]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | --> 03C2M MIXTURES (ORAL) --> MACROGOL(S) | |
| Sodium Benzoate Vr.K | | | GERMANY | 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2P POWDERS --> MACROGOL(S) | [30-40]% by value / [20-30]% by volume |
| Sodium Benzoate Vr.K | | | GERMANY | 03C4 SALINE LAXATIVES --> 03C4M MIXTURES (ORAL) --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| Sodium Benzoate Vr.K | | | GERMANY | A6A DRUGS FOR CONSTIPATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [30-40]% by value / [20-30]% by volume |
| Sodium Benzoate Vr.K | | | GERMANY | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| Sodium Benzoate Vr.K | | | ITALY | A6A DRUGS FOR CONSTIPATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [40-50]% by value / [30-40]% by volume |
| Sodium Benzoate Vr.K | | | NORWAY | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| Sodium Benzoate Vr.K | | | PORTUGAL | 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2P POWDERS --> MACROGOL(S) | [30-40]% by value / [30-40]% by volume |
| Sodium Benzoate Vr.K | | | PORTUGAL | A6A DRUGS FOR CONSTIPATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [70-80]% by value / [70-80]% by volume |
| Sodium Benzoate Vr.K | | | PORTUGAL | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [70-80]% by value / [70-80]% by volume |
| Sodium Benzoate Vr.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Sodium Benzoate Vr.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| Sodium Benzoate Vr.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE | [90-100]% by value / [90-100]% by volume |
| Sodium Benzoate Vr.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> VEGETABLE FIBRE | [70-80]% by value / [0-5]% by volume |
| Sodium Benzoate Vr.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| Sodium Benzoate Vr.K | | | SPAIN | A6A DRUGS FOR CONSTIPATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [90-100]% by value / [90-100]% by volume |
| Sodium Benzoate Vr.K | | | SPAIN | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [50-60]% by value / [50-60]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | GERMANY | 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2M MIXTURES (ORAL) --> MACROGOL(S) | [30-40]% by value / [10-20]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | GERMANY | 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2P POWDERS --> MACROGOL(S) | [30-40]% by value / [20-30]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | GERMANY | A6A DRUGS FOR CONSTIPATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [30-40]% by value / [20-30]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | ITALY | A6A DRUGS FOR CONSTIPATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [40-50]% by value / [30-40]% by volume |
| Sodium Citrate | | | ITALY | R1A TOPICAL NASAL | [40-50]% by value / |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Trisod Gran Vr.K | | | | PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> FLUNISOLIDE | [60-70]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | PORTUGAL | 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2P POWDERS --> MACROGOL(S) | [30-40]% by value / [30-40]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | PORTUGAL | A6A DRUGS FOR CONSTIPATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [70-80]% by value / [70-80]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | SLOVAKIA | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> COMPOSITION UNKNOWN | [80-90]% by value / [90-100]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE | [90-100]% by value / [90-100]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE | [90-100]% by value / [90-100]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> VEGETABLE FIBRE | [70-80]% by value / [0-5]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | SPAIN | 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CHLORINE!POTASSIU | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | M!SODIUM | |
| Sodium Citrate Trisod Gran Vr.K | | | SPAIN | 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CITRIC ACID!GLUCOSE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | SPAIN | 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> GLUCOSE!POTASSIUM!SODIUM!SUCROSE | [90-100]% by value / [90-100]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | SPAIN | A6A DRUGS FOR CONSTIPATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [90-100]% by value / [90-100]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> CITRIC ACID!GLUCOSE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| Sodium Citrate Trisod Gran Vr.K | | | SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM!SUCROSE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | BELGIUM | 03C4 SALINE LAXATIVES --> 03C4M MIXTURES (ORAL) --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | BELGIUM | 03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | BELGIUM | A6A DRUGS FOR CONSTIPATION --> A6A4 LAXATIVE ENEMAS --> PHOSPHORIC ACID | [70-80]% by value / [40-50]% by volume |
| Sodium Edetate Vr.K | | | BELGIUM | A6A DRUGS FOR CONSTIPATION --> | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | A6A6 OSMOTIC LAXATIVES --> PHOSPHORIC ACID | |
| Sodium Edetate Vr.K | | | BULGARIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | CZECH REPUBLIC | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | FRANCE | 01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS --> BICLOTYMOL | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | FRANCE | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> BICLOTYMOL | [90-100]% by value / [20-30]% by volume |
| Sodium Edetate Vr.K | | | GREECE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | GREECE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | GREECE | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | GREECE | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | HUNGARY | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate | | | ITALY | 06G3 ANTIFUNGALS | [80-90]% by value / |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Vr.K | | | | SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [80-90]% by volume |
| Sodium Edetate Vr.K | | | ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> FENTICONAZOLE | [50-60]% by value / [60-70]% by volume |
| Sodium Edetate Vr.K | | | ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | ITALY | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | ITALY | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [60-70]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | ITALY | R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> FLUNISOLIDE | [40-50]% by value / [60-70]% by volume |
| Sodium Edetate Vr.K | | | LITHUANIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | POLAND | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate | | | POLAND | 12D2 | [90-100]% by value / |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Vr.K | | | | GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> FENTICONAZOLE | [90-100]% by volume |
| Sodium Edetate Vr.K | | | POLAND | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | ROMANIA | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | ROMANIA | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | ROMANIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| Sodium Edetate Vr.K | | | SPAIN | 03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> COMPOSITION UNKNOWN | [90-100]% by value / [90-100]% by volume |
| Sodium Hydroxyde Past. Tech Vr.K | | | CZECH REPUBLIC | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL!IRON METAL | [90-100]% by value / [90-100]% by volume |
| Sodium Hydroxyde Past. Tech Vr.K | | | SLOVAKIA | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL + IRON METAL | [90-100]% by value / [90-100]% by volume |
| Sodium Hydroxyde Past. Tech Vr.K | | | SPAIN | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [50-60]% by value / [50-60]% by volume |
| Sodium Laurylsulfate Pulv Vr.K | | | AUSTRIA | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| Sodium Laurylsulfate | | | CZECH REPUBLIC | G4C BPH PRODUCTS --> G4C2 BPH ALPH- | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Pulv Vr.K | | | | ADREN ANTAG PLN --> SILODOSIN | |
| Sodium Laurylsulfate Pulv Vr.K | | | FRANCE | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [30-40]% by value / [20-30]% by volume |
| Sodium Laurylsulfate Pulv Vr.K | | | GERMANY | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [60-70]% by value / [60-70]% by volume |
| Sodium Laurylsulfate Pulv Vr.K | | | GREECE | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| Sodium Laurylsulfate Pulv Vr.K | | | IRELAND | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| Sodium Laurylsulfate Pulv Vr.K | | | ITALY | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [60-70]% by value / [60-70]% by volume |
| Sodium Laurylsulfate Pulv Vr.K | | | POLAND | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| Sodium Laurylsulfate Pulv Vr.K | | | PORTUGAL | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [50-60]% by value / [40-50]% by volume |
| Sodium Laurylsulfate Pulv Vr.K | | | ROMANIA | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| Sodium Laurylsulfate Pulv Vr.K | | | SLOVAKIA | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [80-90]% by volume |
| Sodium Laurylsulfate Pulv Vr.K | | | SPAIN | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [40-50]% by value / [40-50]% by volume |
| Sodium Sulfate Anh Vr.K | | | SPAIN | 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CHLORINE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| Sodium Sulfate Anh Vr.K | | | SPAIN | 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CITRIC ACID!GLUCOSE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| Sodium Sulfate | | | SPAIN | A6B BOWEL | [90-100]% by value / |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Anh Vr.K | | | | CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> MACROGOL(S)!PHOSPHORIC ACID!POTASSIUM!SODIUM | [90-100]% by volume |
| Sodium Sulfate Anh Vr.K | | | SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> CITRIC ACID!GLUCOSE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| Sodium Sulfate Anh Vr.K | | | SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| Talc Officinal Vr.K | | | CZECH REPUBLIC | 06C4 OTHER SKIN IRRITATION --> 06C4L LIQUIDS&LOTIONS (TOPICAL) --> GLYCEROL!MENTHOL!TALC!ZINC | [90-100]% by value / [90-100]% by volume |
| Talc Officinal Vr.K | | | CZECH REPUBLIC | 06C4 OTHER SKIN IRRITATION --> 06C4L LIQUIDS&LOTIONS (TOPICAL) --> GLYCEROL!TALC!ZINC | [90-100]% by value / [90-100]% by volume |
| Talc Officinal Vr.K | | | FRANCE | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Talc Officinal Vr.K | | | FRANCE | H3B ANTI-THYROID PREPARATION --> H3B0 ANTI-THYROID PREPARATION --> BENZYLTHIOURACIL | [90-100]% by value / [90-100]% by volume |
| Talc Officinal Vr.K | | | GERMANY | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Talc Officinal Vr.K | | | IRELAND | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| Talc Officinal Vr.K | | | ITALY | 03A4 PRS FOR IBS&DIGEST SPASMS --> 03A4C CAPS/TABS --> ATROPA BELLADONNA!PAPA VERINE | [90-100]% by value / [90-100]% by volume |
| Talc Officinal Vr.K | | | ITALY | A3A ANTISPASM+ANTICH OL PLAIN --> A3A0 ANTISPASM+ANTICH OL PLAIN --> ATROPA BELLADONNA!PAPA VERINE | [90-100]% by value / [90-100]% by volume |
| Talc Officinal Vr.K | | | ITALY | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Talc Officinal Vr.K | | | ITALY | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> ASCORBIC ACID!PARACETAMO L!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| Talc Officinal Vr.K | | | ITALY | N3A ANTI-EPILEPTICS --> N3A0 ANTI-EPILEPTICS --> METHYLPHENOBARB ITAL!PHENYTOIN | [90-100]% by value / [90-100]% by volume |
| Talc Officinal Vr.K | | | ITALY | N3A ANTI-EPILEPTICS --> N3A0 ANTI-EPILEPTICS --> PHENYTOIN | [60-70]% by value / [90-100]% by volume |
| Talc Officinal Vr.K | | | NETHERLA NDS | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Talc Officinal Vr.K | | | PORTUGA L | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Talc Officinal Vr.K | | | SPAIN | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| Xylitol Exp Vr.K | | | FRANCE | N7F DRUGS USED IN OPIOID DEP --> N7F0 DRUGS USED IN OPIOID DEP --> | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market** | **Geography** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (Molecule Level)** | **Share (2020)** |
| | | | | METHADONE | |
| Zinc Oxyde Grade Excipient Vr.K | | | CZECH REPUBLIC | 06C4 OTHER SKIN IRRITATION --> 06C4L LIQUIDS&LOTIONS (TOPICAL) --> GLYCEROL!MENTHOL!TALC!ZINC | [90-100]% by value / [90-100]% by volume |
| Zinc Oxyde Grade Excipient Vr.K | | | CZECH REPUBLIC | 06C4 OTHER SKIN IRRITATION --> 06C4L LIQUIDS&LOTIONS (TOPICAL) --> GLYCEROL!TALC!ZINC | [90-100]% by value / [90-100]% by volume |
| Zinc Oxyde Grade Excipient Vr.K | | | CZECH REPUBLIC | 06P1 SKIN PROTECTOR+EMOLLIENTS --> 06P1L LIQUIDS (TOPICAL) --> ZINC | [90-100]% by value / [90-100]% by volume |
| Zinc Oxyde Grade Excipient Vr.K | | | CZECH REPUBLIC | 06P1 SKIN PROTECTOR+EMOLLIENTS --> 06P1O OINTMENTS/CREAMS --> PARAFFIN OIL!ZINC | [90-100]% by value / [90-100]% by volume |
| Zinc Oxyde Grade Excipient Vr.K | | | CZECH REPUBLIC | 88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES NAPPY RASH --> COD LIVER OIL!PANTHENOL!PRUNUS AMYGDALUS (DULCIS)!VITAMIN E!ZINC | [90-100]% by value / [90-100]% by volume |
| Zinc Oxyde Grade Excipient Vr.K | | | CZECH REPUBLIC | 88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES NAPPY RASH --> COD LIVER OIL!PARAFFIN OIL!WHITE BEESWAX!ZINC | [90-100]% by value / [90-100]% by volume |
| Zinc Oxyde Grade Excipient Vr.K | | | SLOVAKIA | 06P1 SKIN PROTECTOR+EMOLLIENTS --> 06P1O OINTMENTS/CREAMS --> PARAFFIN OIL!ZINC | [90-100]% by value / [90-100]% by volume |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Genetic)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (ATC4/CHC4 or Molecule Level)** | **Share (2020)** |
| Acide Citrique Gran H2o Vr.K | At least EEA-wide | <[10-20]% | Italy | 01A4A AER/SPR | [50-60]% by value / [10-20]% by volume |
| Parahydroxybenz Meth Sode Vr.K | | | Italy | 01A4A AER/SPR | [50-60]% by value / [10-20]% by volume |
| Parahydroxybenz Prop Sode Vr.K | | | Italy | 01A4A AER/SPR | [50-60]% by value / [10-20]% by volume |
| Acide Citrique Gran H2o Vr.K | At least EEA-wide | <[10-20]% | Italy | 01A4 Chesty Cough Products --> 01A4A Aer/Spr --> Ambroxol | [90-100]% by value / [90-100]% by volume |
| Comp Chlorure Sodium 0,50g Vrk Nf | | | Italy | R3D Corticoids --> R3D1 Corticoids Inhalants --> Budesonide | [5-10]% by value / [0-5]% by volume (CVC share [60-70]% by value / [60-70]% by volume) |
| Lactose H2o Exp Vr.K | | | Italy | M5B Bone Calcium Regulators --> M5B3 Bisphosph Osteoporosis --> Risedronic Acid | [0-5]% by value / [0-5]% by volume (CVC share [40-50]% by value / [20-30]% by volume) |
| Parahydroxybenz Meth Sode Vr.K | | | Italy | 01A4 Chesty Cough Products --> 01a4a Aer/Spr --> Ambroxol | [90-100]% by value / [90-100]% by volume |
| Parahydroxybenz Prop Sode Vr.K | | | Italy | 01A4 Chesty Cough Products --> 01A4A Aer/Spr --> Ambroxol | [90-100]% by value / [90-100]% by volume |
| Polysorbate 80 Bd 25 L | | | Italy | R3D Corticoids --> R3D1 Corticoids Inhalants --> Budesonide | [5-10]% by value / [0-5]% by volume (CVC share [60-70]% by value / [60-70]% by volume) |
| | | | | R1A Topical Nasal Preps --> R1A1 Nasal Cortic W/O Antiinf --> Budesonide | [5-10]% by value / [5-10]% by volume (CVC share [70-80]% by value / [70-80]% by volume) |
| Potassium Sorbate Vr.K | | | Italy | R1A Topical Nasal Preps --> R1A1 Nasal Cortic W/O Antiinf --> Budesonide | [5-10]% by value / [5-10]% by volume (CVC share [70-80]% by value / [70-80]% by volume) |
| Sodium Citrate Trisod Gran Vr.K | | | Italy | R3D Corticoids --> R3D1 Corticoids Inhalants --> Budesonide | [5-10]% by value / [0-5]% by volume (CVC share [60-70]% by value / [60-70]% by volume) |
| Sodium Edetate Vr.K | | | Italy | R3D Corticoids --> R3D1 Corticoids Inhalants --> Budesonide | [5-10]% by value / [0-5]% by volume (CVC share [60-70]% by value / [60-70]% by volume) |
| | | | Italy | R1A Topical Nasal Preps | [5-10]% by value / [5- |

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in Excipients (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Genetic)** | | |
| **Product Market** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (ATC4/CHC4 or Molecule Level)** | **Share (2020)** |
| | | | | --> R1A1 Nasal Cortic W/O Antiinf --> Budesonide | 10]% by volume (CVC share [70-80]% by value / [70-80]% by volume) |

**Appendix 6**

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in APIs (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market (Target)** | **Geographic Market** | **Share (2020, EEA)** | **Geographic Market** | **Product Market (ATC3/CHC3)** | **Recordati share in 2020** |
| ACIDE CITRIQUE ANH PDRE VR.K | At least EEA-wide | <10% | SPA N | 03D3 ANT DIARR ELECTROL | [70-80]% |
| | | | | A6B BOWEL CLEANSERS | [50-60]% by value / [40-50]% by volume |
| | | | | A7G ORAL ELECTROL. REPLACER | [80-90]% by value / [90-100]% by volume |
| ACIDE PHOSPHORIQUE 85% VR.L | | | BELGIUM | 03C4 SALINE LAXATIVES | [70-80]% by value / [30-40]% by volume |
| | | | SPA N | A6B BOWEL CLEANSERS | [50-60]% by value / [40-50]% by volume |
| GLUCOSE ANH VR.K | | | SPA N | 03D3 ANT DIARR ELECTROL | [70-80]% |
| | | | | A7G ORAL ELECTROL. REPLACER | [80-90]% by value / [90-100]% by volume |
| GLYCERINE CONTAINER 1000 L | | | FRANCE | N7F DRUGS USED IN OPIOID DEP | [30-40]% by value / [40-50]% by volume |
| | | | SPA N | A6B BOWEL CLEANSERS | [50-60]% by value / [40-50]% by volume |
| ICHTHYOLAMMONIUM VR.K | | | CZECH REPUBLIC | 06V1 OTHER SKIN PRODUCTS | [30-40]% by value / [50-60]% by volume |
| | | | | D5A TOP ANTIPSORIASIS PRDS | [10-20]% by value / [80-90]% by volume |
| LIDOCAINE CHLTE VR.K | | | CYPRUS | C5A TOPICAL ANTI-HAEMORRHO DALS | [70-80]% by value / [80-90]% by volume |
| | | | LATVIA | 10A1 ANTIHAEMORRHO DS | [30-40]% |
| | | | | C5A TOPICAL ANTIHAEMORRHO DL | [30-40]% by value / [20-30]% by volume |
| | | | POLAND | 10A1 ANTIHAEMORRHO DS | [30-40]% by value / [30-40]% by volume |
| | | | | C5A TOPICAL ANTIHAEMORRHO DL | [30-40]% by value / [30-40]% by volume |
| | | | ROMANIA | 10A1 ANTIHAEMORRHO DS | [20-30]% by value / [30-40]% by volume |
| | | | | C5A TOPICAL ANTIHAEMORRHO DL | [50-60]% by value / [40-50]% by volume |
| | | | SLOVAKIA | C5A TOPICAL ANTIHAEMORRHO DL | [20-30]% by value / [30-40]% by volume |
| POTASSIUM CHLORURE VR.K | | | SPA N | 03D3 ANT DIARR ELECTROL | [70-80]% |
| | | | | A6B BOWEL CLEANSERS | [50-60]% by value / [40-50]% by volume |
| | | | | A7G ORAL ELECTROL. REPLACER | [80-90]% by value / [90-100]% by volume |
| SODIUM BICARBONATE VR.K | | | SPA N | A6B BOWEL CLEANSERS | [50-60]% by value / [40-50]% by volume |
| SODIUM CHLORURE VR.K | | | SPA N | 03C4 SALINE LAXATIVES | [90-100]% |
| | | | | 03D3 ANT DIARR ELECTROL | [70-80]% |
| | | | | A6B BOWEL CLEANSERS | [50-60]% by value / [40-50]% by volume |
| | | | | A7G ORAL ELECTROL. REPLACER | [80-90]% by value / 90% by volume |
| SODIUM PHOSPHATE MONO PUR CRIST VK | | | SPA N | A6B BOWEL CLEANSERS | [50-60]% by value / [40-50]% by volume |
| SORBITOL VR.K | | | CYPRUS | C5A TOPICAL ANTI-HAEMORRHO DALS | [70-80]% by value / [80-90]% by volume |
| | | | LATVIA | 10A1 ANTIHAEMORRHO DS | [30-40]% |
| | | | | C5A TOPICAL ANTIHAEMORRHO DL | [30-40]% by value / [20-30]% by volume |
| | | | POLAND | 10A1 ANTIHAEMORRHO DS | [30-40]% by value / [30-40]% by volume |
| | | | | C5A TOPICAL ANTIHAEMORRHO DL | [30-40]% by value / [30-40]% by volume |

| | | | | | |
|---|---|---|---|---|---|
| | | | ROMANIA | 10A1 ANTIHAEMORRHO DS | [20-30]% by value / [30-40]% by volume |
| | | | | C5A TOPICAL ANTIHAEMORRHO DL | [50-60]% by value / [40-50]% by volume |
| | | | SLOVAKIA | C5A TOPICAL ANTIHAEMORRHO DL | [20-30]% by value / [30-40]% by volume |

**Appendix 6**

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in APIs (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream FDP Market (Recordati)** | | |
| **Product Market (Target)** | **Geographic Marke** | **Share (2020, EEA)** | **Geographic Marke** | **Product Market (ATC4/CHC4)** | **Recordati share in 2020** |
| ACIDE CITRIQUE ANH PDRE VR.K | | | FRANCE | A6B1 OSMOTIC BOWEL CLEANSERS | [40-50]% by value / [5-10]% by volume |
| ACIDE CITRIQUE ANH PDRE VR.K | | | GERMANY | 03C5P POWDERS | [50-60]% by value / [10-20]% by volume |
| ACIDE CITRIQUE ANH PDRE VR.K | | | GERMANY | A6B1 OSMOTIC BOWEL CLEANSERS | [30-40]% by value / [30-40]% by volume |
| ACIDE CITRIQUE ANH PDRE VR.K | | | IRELAND | 03C4Q ENEMAS | [90-100]% by value / [90-100]% by volume |
| ACIDE CITRIQUE ANH PDRE VR.K | | | ITALY | A6B1 OSMOTIC BOWEL CLEANSERS | [70-80]% by value / [70-80]% by volume |
| ACIDE CITRIQUE ANH PDRE VR.K | | | POLAND | A6B1 OSMOTIC BOWEL CLEANSERS | [70-80]% by value / [10-20]% by volume |
| ACIDE CITRIQUE ANH PDRE VR.K | | | PORTUGAL | A6B1 OSMOTIC BOWEL CLEANSERS | [80-90]% by value / [80-90]% by volume |
| ACIDE CITRIQUE ANH PDRE VR.K | | | SPAIN | 03C1Z OTHER FORMS | [60-70]% by value / [40-50]% by volume |
| ACIDE CITRIQUE ANH PDRE VR.K | | | SPAIN | 03D3P POWDER | [80-90]% by value / [80-90]% by volume |
| ACIDE CITRIQUE ANH PDRE VR.K | | | SPAIN | A6B1 OSMOTIC BOWEL CLEANSERS | [90-100]% by value / [90-100]% by volume |
| ACIDE CITRIQUE ANH PDRE VR.K | | | SWEDEN | A6B1 OSMOTIC BOWEL CLEANSERS | [40-50]% by value / [20-30]% by volume |
| ACIDE PHOSPHORIQUE 85% VR.L | | | BELGIUM | 03C4M MIXTURES (ORAL) | [40-50]% by value / [10-20]% by volume |
| ACIDE PHOSPHORIQUE 85% VR.L | | | BELGIUM | 03C4Q ENEMAS | [90-100]% by value / [90-100]% by volume |
| ACIDE PHOSPHORIQUE 85% VR.L | | | FRANCE | A6B1 OSMOTIC BOWEL CLEANSERS | [40-50]% by value / [5-10]% by volume |
| ACIDE PHOSPHORIQUE 85% VR.L | | | GERMANY | A6B1 OSMOTIC BOWEL CLEANSERS | [30-40]% by value / [30-40]% by volume |
| ACIDE PHOSPHORIQUE 85% VR.L | | | PORTUGAL | 03C4Q ENEMAS | [90-100]% by value / [90-100]% by volume |
| ACIDE PHOSPHORIQUE 85% VR.L | | | PORTUGAL | A6A4 LAXATIVE ENEMAS | [70-80]% by value / [60-70]% by volume |
| ACIDE PHOSPHORIQUE 85% VR.L | | | PORTUGAL | A6B1 OSMOTIC BOWEL CLEANSERS | [80-90]% by value / [80-90]% by volume |
| ACIDE PHOSPHORIQUE 85% VR.L | | | SPAIN | A6A4 LAXATIVE ENEMAS | [30-40]% by value / [10-20]% by volume |
| ACIDE PHOSPHORIQUE 85% VR.L | | | SPAIN | A6B1 OSMOTIC BOWEL CLEANSERS | [90-100]% by value / [90-100]% by volume |
| GLUCOSE ANH VR.K | | | SPAIN | 03D3P POWDER | [80-90]% by value / [80-90]% by volume |
| GLYCERINE CONTAINER 1000 L | | | CZECH REPUBLIC | 06C4L LIQUIDS&LOTIONS (TOPICAL) | [20-30]% by value / [30-40]% by volume |
| GLYCERINE CONTAINER 1000 L | | | CZECH REPUBLIC | 06F3O OINTMENTS/CREAMS | [20-30]% by value / [30-40]% by volume |
| GLYCERINE CONTAINER 1000 L | | | FRANCE | A6B1 OSMOTIC BOWEL CLEANSERS | [40-50]% by value / [5-10]% by volume |

| | | | | | |
|---|---|---|---|---|---|
| GLYCERINE CONTAINER 1000 L | At least EEA-wide | <10% | GERMANY | A6B1 OSMOTIC BOWEL CLEANSERS | [30-40]% by value / [30-40]% by volume |
| GLYCERINE CONTAINER 1000 L | | | PORTUGAL | A6B1 OSMOTIC BOWEL CLEANSERS | [80-90]% by value / [80-90]% by volume |
| GLYCERINE CONTAINER 1000 L | | | SLOVAKIA | 06F3O OINTMENTS/CREAMS | [20-30]% by value / [40-50]% by volume |
| GLYCERINE CONTAINER 1000 L | | | SPAIN | A6A4 LAXATIVE ENEMAS | [30-40]% by value / [10-20]% by volume |
| GLYCERINE CONTAINER 1000 L | | | SPAIN | A6B1 OSMOTIC BOWEL CLEANSERS | [90-100]% by value / [90-100]% by volume |
| ICHTHYOLAMMONIUM VR.K | | | CZECH REPUBLIC | 06V1O OINTMENTS/CREAMS | [40-50]% by value / [50-60]% by volume |
| LIDOCAINE CHLTE VR.K | | | LATVIA | 10A1O OINTMENTS/CREAMS | [40-50]% by value / [30-40]% by volume |
| LIDOCAINE CHLTE VR.K | | | LATVIA | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| LIDOCAINE CHLTE VR.K | | | LATVIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| LIDOCAINE CHLTE VR.K | | | LITHUANIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| LIDOCAINE CHLTE VR.K | | | POLAND | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |
| LIDOCAINE CHLTE VR.K | | | POLAND | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| LIDOCAINE CHLTE VR.K | | | POLAND | C5A2 A-HAEMORRHOID W/O CORTIC | [40-50]% by value / [30-40]% by volume |
| LIDOCAINE CHLTE VR.K | | | ROMANIA | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |
| LIDOCAINE CHLTE VR.K | | | ROMANIA | C5A2 A-HAEMORRHOID W/O CORTIC | [60-70]% by value / [50-60]% by volume |
| LIDOCAINE CHLTE VR.K | | | SLOVAKIA | 10A1S SUPPOSITORIES | [30-40]% by value / [30-40]% by volume |
| LIDOCAINE CHLTE VR.K | | | SLOVAKIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| MANNITOL VR.K | | | SLOVAKIA | G4C2 BPH ALPH-ADREN ANTAG PLN | [30-40]% by value / [10-20]% by volume |
| POTASSIUM CHLORURE VR.K | | | SPAIN | 03D3P POWDER | [80-90]% by value / [80-90]% by volume |
| SODIUM CHLORURE VR.K | | | SPAIN | 03C4Q ENEMAS | [90-100]% by value / [90-100]% by volume |
| SODIUM CHLORURE VR.K | | | SPAIN | 03D3P POWDER | [80-90]% by value / [80-90]% by volume |
| SORBITOL VR.K | | | LATVIA | 10A1O OINTMENTS/CREAMS | [40-50]% by value / [30-40]% by volume |
| SORBITOL VR.K | | | LATVIA | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| SORBITOL VR.K | | | LATVIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| SORBITOL VR.K | | | LITHUANIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| SORBITOL VR.K | | | POLAND | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |
| SORBITOL VR.K | | | POLAND | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |

| | | | | | |
|---|---|---|---|---|---|
| SORBITOL VR.K | | | POLAND | C5A2 A-HAEMORRHOID W/O CORTIC | [40-50]% by value / [30-40]% by volume |
| SORBITOL VR.K | | | ROMANIA | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |
| SORBITOL VR.K | | | ROMANIA | C5A2 A-HAEMORRHOID W/O CORTIC | [60-70]% by value / [50-60]% by volume |
| SORBITOL VR.K | | | SLOVAKIA | 10A1S SUPPOSITORIES | [30-40]% by value / [30-40]% by volume |
| SORBITOL VR.K | | | SLOVAKIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |

**Appendix 6**

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in APIs (Upstream) | | | | | |
|---|---|---|---|---|---|
| Upstream Market (Target) | | | Downstream FDP Market (Recordati) | | |
| Product Market (Target) | Geographic Market | Share (2020, EEA) | Geographic Market | Product Market (Molecule) | Recordati share in 2020 |
| AC DE ASCORBIQUE GRAN F N VR.K | | | FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID BENZOIC AC D!BROMINE!CODEINE | [90-100]% by value / [90-100]% by volume |
| AC DE ASCORBIQUE GRAN F N VR.K | | | FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID BROMOFORM!CODEINE | [90-100]% by value / [90-100]% by volume |
| AC DE ASCORBIQUE GRAN F N VR.K | | | FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL | [90-100]% by value / [90-100]% by volume |
| AC DE ASCORBIQUE GRAN F N VR.K | | | ITALY | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> ASCORBIC ACID PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | FRANCE | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID | [60-70]% by value / [60-70]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | GERMANY | 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2M MIXTURES (ORAL) --> MACROGOL(S) | [30-40]% by value / [10-20]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | GERMANY | 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2P POWDERS --> MACROGOL(S) | [30-40]% by value / [20-30]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | GERMANY | 03C5 CONTACT LAXATIVES --> 03C5P POWDERS --> CITRIC AC D MAGNESIUM PICOSULFURIC AC D | [50-60]% by value / [50-60]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | GERMANY | A6A DRUGS FOR CONST PATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [30-40]% by value / [20-30]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | GERMANY | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID | [40-50]% by value / [40-50]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | IRELAND | 03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | IRELAND | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | ITALY | A6A DRUGS FOR CONST PATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [40-50]% by value / [30-40]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | ITALY | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID | [70-80]% by value / [70-80]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | ITALY | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> KETOROLAC | [80-90]% by value / [80-90]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | POLAND | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID | [80-90]% by value / [80-90]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | PORTUGAL | 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2P POWDERS --> MACROGOL(S) | [30-40]% by value / [30-40]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | PORTUGAL | A6A DRUGS FOR CONST PATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [70-80]% by value / [70-80]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | PORTUGAL | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID | [90-100]% by value / [90-100]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE | [90-100]% by value / [90-100]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE | [90-100]% by value / [90-100]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> VEGETABLE F BRE | [70-80]% by value / [0-5]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | SPAIN | 03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> FRUCTOOLIGSACCHAR DES + MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | SPAIN | 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CITRIC ACID!GLUCOSE POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | SPAIN | A6A DRUGS FOR CONST PATION --> A6A6 OSMOTIC LAXATIVES --> MACROGOL(S) | [90-100]% by value / [90-100]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | SPAIN | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID | [90-100]% by value / [90-100]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> CITRIC ACID!GLUCOSE POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| AC DE CITRIQUE ANH PDRE VR.K | | | SWEDEN | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> CITRIC ACID MAGNESIUM PICOSULFURIC ACID | [40-50]% by value / [40-50]% by volume |
| AC DE PHOSPHORIQUE [80-90]% VR.L | | | BELGIUM | 03C4 SALINE LAXATIVES --> 03C4M MIXTURES (ORAL) --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| AC DE PHOSPHORIQUE [80-90]% VR.L | | | BELGIUM | 03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| AC DE PHOSPHORIQUE [80-90]% VR.L | | | BELGIUM | A6A DRUGS FOR CONST PATION --> A6A4 LAXATIVE ENEMAS --> PHOSPHORIC ACID | [70-80]% by value / [40-50]% by volume |

| | |
|---|---|
| AC DE PHOSPHORIQUE [80-90]% VR.L | |
| AC DE PHOSPHORIQUE [80-90]% VR.L | |
| AC DE PHOSPHORIQUE [80-90]% VR.L | |
| AC DE PHOSPHORIQUE [80-90]% VR.L | |
| AC DE PHOSPHORIQUE [80-90]% VR.L | |
| AC DE PHOSPHORIQUE [80-90]% VR.L | |
| AC DE PHOSPHORIQUE [80-90]% VR.L | |
| AC DE PHOSPHORIQUE [80-90]% VR.L | |
| AC DE PHOSPHORIQUE [80-90]% VR.L | |
| AC DE PHOSPHORIQUE [80-90]% VR.L | |
| AC DE PHOSPHORIQUE [80-90]% VR.L | |
| AC DE PHOSPHORIQUE [80-90]% VR.L | |
| AC DE PHOSPHORIQUE [80-90]% VR.L | |
| GLUCOSE ANH VR.K | |
| GLUCOSE ANH VR.K | |
| GLUCOSE ANH VR.K | |
| GLUCOSE ANH VR.K | |
| GLUCOSE ANH VR.K | |
| GLUCOSE ANH VR.K | |
| GLYCERINE CONTA NER 1000 L | |
| GLYCERINE CONTA NER 1000 L | |
| GLYCERINE CONTA NER 1000 L | |
| GLYCERINE CONTA NER 1000 L | |
| GLYCERINE CONTA NER 1000 L | |
| GLYCERINE CONTA NER 1000 L | |
| GLYCERINE CONTA NER 1000 L | |
| GLYCERINE CONTA NER 1000 L | |
| GLYCERINE CONTA NER 1000 L | |
| GLYCERINE CONTA NER 1000 L | |
| GLYCERINE CONTA NER 1000 L | |
| GLYCERINE CONTA NER 1000 L | |
| GLYCERINE CONTA NER 1000 L | |
| GLYCERINE CONTA NER 1000 L | |
| GLYCERINE CONTA NER 1000 L | |

| | | |
|---|---|---|
| BELGIUM | A6A DRUGS FOR CONST PATION --> A6A6 OSMOTIC LAXATIVES --> PHOSPHORIC AC D | [90-100]% by value / [90-100]% by volume |
| FRANCE | A12A CALCIUM --> A12A0 CALCIUM --> MAGNESIUM | [50-60]% by value / [30-40]% by volume |
| FRANCE | A12A CALCIUM --> A12A0 CALCIUM --> PHOSPHORIC AC D | [50-60]% by value / [30-40]% by volume |
| FRANCE | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [50-60]% by value / [40-50]% by volume |
| GERMANY | 03C4 SALINE LAXATIVES --> 03C4M MIXTURES (ORAL) --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| GERMANY | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| ITALY | 03C2 OSMOTIC LAXAT(EXC SALINE) --> 03C2Q ENEMAS --> PHOSPHORIC ACID | [30-40]% by value / [30-40]% by volume |
| ITALY | A6A DRUGS FOR CONST PATION --> A6A4 LAXATIVE ENEMAS --> PHOSPHORIC ACID | [40-50]% by value / [10-20]% by volume |
| NORWAY | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A6A DRUGS FOR CONST PATION --> A6A4 LAXATIVE ENEMAS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [70-80]% by value / [70-80]% by volume |
| SPAIN | A6A DRUGS FOR CONST PATION --> A6A4 LAXATIVE ENEMAS --> PHOSPHORIC ACID | [80-90]% by value / [80-90]% by volume |
| SPAIN | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [50-60]% by value / [50-60]% by volume |
| SPAIN | 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CHLOR NE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CITRIC ACID!GLUCOSE POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> GLUCOSE POTASSIUM!SODIUM!SUCROSE | [90-100]% by value / [90-100]% by volume |
| SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> CITRIC ACID!GLUCOSE POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM!SUCROSE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 02E1 MUSC. PAIN REL EF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL!IRON METAL | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 06C4 OTHER SK N IRRITATION --> 06C4L LIQUIDS&LOTIONS (TOPICAL) --> GLYCEROL MENTHOL!TALC!ZINC | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 06C4 OTHER SK N IRRITATION --> 06C4L LIQUIDS&LOTIONS (TOPICAL) --> GLYCEROL!TALC!ZINC | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 06F3 WOUND HEAL NG PROD --> 06F3O OINTMENTS/CREAMS --> PANTOTHENIC ACID | [30-40]% by value / [30-40]% by volume |
| CZECH REPUBLIC | 06F3 WOUND HEAL NG PROD --> 06F3O OINTMENTS/CREAMS --> PLANTAGO LANCEOLATA | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 06P1 SK N PROTECTOR+EMOLLIENTS --> 06P1O O NTMENTS/CREAMS --> AGRIMONIA EUPATORIA | [30-40]% by value / [30-40]% by volume |
| FRANCE | 01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS --> BICLOTYMOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [50-60]% by value / [40-50]% by volume |
| FRANCE | N7F DRUGS USED N OPIOID DEP --> N7F0 DRUGS USED N OPIOID DEP --> METHADONE | [90-100]% by value / [90-100]% by volume |
| FRANCE | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> BICLOTYMOL | [90-100]% by value / [20-30]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID BENZOIC AC D!BROMINE!CODEINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID BROMOFORM!CODEINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL | [90-100]% by value / [90-100]% by volume |
| GERMANY | 03C4 SALINE LAXATIVES --> 03C4M MIXTURES (ORAL) --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| GERMANY | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |
| NORWAY | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [90-100]% by value / [90-100]% by volume |

| | | | | | |
|---|---|---|---|---|---|
| GLYCERINE CONTA NER 1000 L | At least EEA-wide | <10% | PORTUGAL | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [70-80]% by value / [70-80]% by volume |
| GLYCERINE CONTA NER 1000 L | | | SLOVAKIA | 02E1 MUSC. PAIN REL EF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL + IRON METAL | [90-100]% by value / [90-100]% by volume |
| GLYCERINE CONTA NER 1000 L | | | SLOVAKIA | 02E1 MUSC. PAIN REL EF (TOP) --> 02E1O OINTMENTS/CREAMS --> COMPOSITION UNKNOWN | [80-90]% by value / [90-100]% by volume |
| GLYCERINE CONTA NER 1000 L | | | SLOVAKIA | 06F3 WOUND HEAL NG PROD --> 06F3O OINTMENTS/CREAMS --> PANTOTHENIC ACID | [50-60]% by value / [50-60]% by volume |
| GLYCERINE CONTA NER 1000 L | | | SLOVAKIA | 06P1 SK N PROTECTOR+EMOLLIENTS --> 06P1O O NTMENTS/CREAMS --> AGRIMONIA EUPATORIA | [90-100]% by value / [90-100]% by volume |
| GLYCERINE CONTA NER 1000 L | | | SPAIN | A6B BOWEL CLEANSERS --> A6B1 OSMOTIC BOWEL CLEANSERS --> PHOSPHORIC ACID | [50-60]% by value / [50-60]% by volume |
| ICHTHYOLAMMONIUM VR.K | | | CZECH REPUBLIC | 06V1 OTHER SK N PRODUCTS --> 06V1O O NTMENTS/CREAMS --> ALUMINIUM!CALCIUM!ICHTYOLAMMONIUM!PERBORIC ACI | [90-100]% by value / [90-100]% by volume |
| ICHTHYOLAMMONIUM VR.K | | | CZECH REPUBLIC | D5A TOP ANT PSORIASIS PRDS --> D5A0 TOP ANTIPSORIASIS PRDS --> ALUMINIUM!CALCIUM!ICHTYOLAMMONIUM!PERBORIC ACI | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | CZECH REPUBLIC | 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | CZECH REPUBLIC | 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | CZECH REPUBLIC | 10A1 ANT HAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | CZECH REPUBLIC | C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | ITALY | 02E1 MUSC. PAIN REL EF (TOP) --> 02E1O OINTMENTS/CREAMS --> NAPROXEN | [40-50]% by value / [40-50]% by volume |
| LIDOCAINE CHLTE VR.K | | | ITALY | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> NAPROXEN | [50-60]% by value / [40-50]% by volume |
| LIDOCAINE CHLTE VR.K | | | LATVIA | 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | LATVIA | 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | LATVIA | C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | LITHUANIA | 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | LITHUANIA | 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | LITHUANIA | C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | POLAND | 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE | [50-60]% by value / [60-70]% by volume |
| LIDOCAINE CHLTE VR.K | | | POLAND | 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | POLAND | C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE | [70-80]% by value / [60-70]% by volume |
| LIDOCAINE CHLTE VR.K | | | PORTUGAL | 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE + TR BENOSIDE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | PORTUGAL | C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | ROMANIA | 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE + TR BENOSIDE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | ROMANIA | 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE + TRIBENOS DE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | ROMANIA | C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | SLOVAKIA | 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | SLOVAKIA | 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | SLOVAKIA | 10A1 ANT HAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | SLOVAKIA | C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | SPAIN | 10A1 ANT HAEMORRHOIDS --> 10A1Z OTHER FORMS --> ALLANTOIN!AMINOACR DINE HYDROCORTISONE LIDOCA NE | [90-100]% by value / [90-100]% by volume |
| LIDOCAINE CHLTE VR.K | | | SPAIN | C5A TOPICAL ANT HAEMORRHOIDL --> C5A1 A-HAEMORRHO DL+CORTICOID --> ALLANTOIN!AMINOACR DINE!HYDROCORTISONE L DOCA NI | [90-100]% by value / [90-100]% by volume |
| MANNITOL VR.K | | | AUSTRIA | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| MANNITOL VR.K | | | CZECH REPUBLIC | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |

| |
|---|
| MANNITOL VR.K |
| MANNITOL VR.K |
| MANNITOL VR.K |
| MANNITOL VR.K |
| MANNITOL VR.K |
| MANNITOL VR.K |
| MANNITOL VR.K |
| MANNITOL VR.K |
| MANNITOL VR.K |
| MANNITOL VR.K |
| POTASSIUM CHLORURE VR.K |
| POTASSIUM CHLORURE VR.K |
| POTASSIUM CHLORURE VR.K |
| POTASSIUM CHLORURE VR.K |
| POTASSIUM CHLORURE VR.K |
| POTASSIUM CHLORURE VR.K |
| POTASSIUM CHLORURE VR.K |
| SODIUM BICARBONATE VR.K |
| SODIUM CHLORURE VR.K |
| SODIUM CHLORURE VR.K |
| SODIUM CHLORURE VR.K |
| SODIUM CHLORURE VR.K |
| SODIUM CHLORURE VR.K |
| SODIUM CHLORURE VR.K |
| SODIUM CHLORURE VR.K |
| SODIUM CHLORURE VR.K |
| SODIUM PHOSPHATE MONO PUR CRIST VK |
| SODIUM PHOSPHATE MONO PUR CRIST VK |
| SORBITOL VR K |
| SORBITOL VR K |
| SORBITOL VR K |
| SORBITOL VR K |
| SORBITOL VR K |
| SORBITOL VR K |

| | | |
|---|---|---|
| FRANCE | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [30-40]% by value / [20-30]% by volume |
| GERMANY | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [60-70]% by value / [60-70]% by volume |
| GREECE | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| IRELAND | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| ITALY | 04C3 PLAIN VITAMIN B --> 04C3M MIXTURES (ORAL) --> COBAMAMIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [60-70]% by value / [60-70]% by volume |
| POLAND | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [50-60]% by value / [40-50]% by volume |
| ROMANIA | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [90-100]% by value / [80-90]% by volume |
| SPAIN | G4C BPH PRODUCTS --> G4C2 BPH ALPH-ADREN ANTAG PLN --> SILODOSIN | [40-50]% by value / [40-50]% by volume |
| SPAIN | 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CHLOR NE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CITRIC ACID!GLUCOSE POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> GLUCOSE POTASSIUM!SODIUM!SUCROSE | [90-100]% by value / [90-100]% by volume |
| SPAIN | A6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> MACROGOL(S)!PHOSPHORIC ACID POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> CITRIC ACID!GLUCOSE POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM!SUCROSE | [90-100]% by value / [90-100]% by volume |
| SPAIN | A6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> MACROGOL(S)!PHOSPHORIC ACID POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| ITALY | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> KETOROLAC | [80-90]% by value / [80-90]% by volume |
| ITALY | R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> FLUOCINOLONE ACETON DE | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> COMPOSITION UNKNOWN | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> CITRIC ACID!GLUCOSE POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03D3 ANTIDIARR ELECTROL --> 03D3P POWDER --> GLUCOSE POTASSIUM!SODIUM!SUCROSE | [90-100]% by value / [90-100]% by volume |
| SPAIN | A6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> MACROGOL(S)!PHOSPHORIC ACID POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> CITRIC ACID!GLUCOSE POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| SPAIN | A7G ORAL ELECTROL. REPLACER --> A7G0 ORAL ELECTROL. REPLACER --> GLUCOSE!POTASSIUM!SODIUM!SUCROSE | [90-100]% by value / [90-100]% by volume |
| ITALY | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> KETOROLAC | [80-90]% by value / [80-90]% by volume |
| SPAIN | A6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> MACROGOL(S)!PHOSPHORIC ACID POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 10A1 ANT HAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| ITALY | 02E1 MUSC. PAIN REL EF (TOP) --> 02E1O OINTMENTS/CREAMS --> NAPROXEN | [40-50]% by value / [40-50]% by volume |
| ITALY | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> NAPROXEN | [50-60]% by value / [40-50]% by volume |

| | | | | | |
|---|---|---|---|---|---|
| SORBITOL VR K | | | ITALY | R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> FLUNISOL DE | [40-50]% by value / [60-70]% by volume |
| SORBITOL VR K | | | LATVIA | 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| SORBITOL VR K | | | LATVIA | 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE | [90-100]% by value / [90-100]% by volume |
| SORBITOL VR K | | | LATVIA | C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| SORBITOL VR K | | | LITHUANIA | 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| SORBITOL VR K | | | LITHUANIA | 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE | [90-100]% by value / [90-100]% by volume |
| SORBITOL VR K | | | LITHUANIA | C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| SORBITOL VR K | | | POLAND | 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE | [50-60]% by value / [60-70]% by volume |
| SORBITOL VR K | | | POLAND | 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE | [90-100]% by value / [90-100]% by volume |
| SORBITOL VR K | | | POLAND | C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE | [70-80]% by value / [60-70]% by volume |
| SORBITOL VR K | | | PORTUGAL | 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE + TR BENOSIDE | [90-100]% by value / [90-100]% by volume |
| SORBITOL VR K | | | PORTUGAL | C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| SORBITOL VR K | | | ROMANIA | 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE + TR BENOSIDE | [90-100]% by value / [90-100]% by volume |
| SORBITOL VR K | | | ROMANIA | 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE + TRIBENOS DE | [90-100]% by value / [90-100]% by volume |
| SORBITOL VR K | | | ROMANIA | C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| SORBITOL VR K | | | SLOVAKIA | 10A1 ANT HAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> L DOCA NE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |
| SORBITOL VR K | | | SLOVAKIA | 10A1 ANT HAEMORRHOIDS --> 10A1S SUPPOSITORIES --> L DOCAINE!TRIBENOS DE | [90-100]% by value / [90-100]% by volume |
| SORBITOL VR K | | | SLOVAKIA | 10A1 ANT HAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| SORBITOL VR K | | | SLOVAKIA | C5A TOPICAL ANT HAEMORRHOIDL --> C5A2 A-HAEMORRHO D W/O CORTIC --> L DOCAINE!TR BENOS DE | [90-100]% by value / [90-100]% by volume |

**Appendix 7.1**

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream) | | | | | | |
|---|---|---|---|---|---|---|
| Upstream Market (Target) | | | | Downstream FDP Market (Recordati) | | |
| Upstream Hypothetical Market Segment (CDMO) | Upstream Hypothetical Market Sub-Segment (CDMO) | Geographic Market | Share (2020, EEA) | Geographic Market | Product Market (ATC3/CHC3) | Share (2020) |
| CDMO services for FDPs | - | | | BELGIUM | A16A OTHER METABOLIC PRODUCTS | <[0-5]% by value / [40-50]% by volume |
| | | | | | S1X OTHER OPHTHALMOLOGICALS | [80-90]% by value / [10-20]% by volume |
| | | | | DENMARK | S1X OTHER OPHTHALMOLOGICALS | Potentially up to [70-80]% |
| | | | | ESTONIA | H1C HYPOTHALAMIC HORMONES | [40-50]% by value / [40-50]% by volume |
| | | | | FRANCE | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [90-100]% by volume |
| | | | | GREECE | A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS | [70-80]% by value / [70-80]% by volume |
| | | | | | H1C HYPOTHALAMIC HORMONES | [30-40]% by value / [30-40]% by volume |
| | | | | | S1X OTHER OPHTHALMOLOGICALS | [50-60]% by value / [50-60]% by volume |
| | | | | HUNGARY | B6X OTHER HAEMATOLOGICAL AGENTS | [90-100]% by value / [90-100]% by volume |
| | | | | ITALY | S1X OTHER OPHTHALMOLOGICALS | [40-50]% by value / [0-5]% by volume |
| | | | | NETHERLANDS | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [90-100]% by volume |
| | | | | NORWAY | B6X OTHER HAEMATOLOGICAL AGENTS | [90-100]% by value / [90-100]% by volume |
| | | | | | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [30-40]% by volume |
| | | | | PORTUGAL | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [70-80]% by volume |
| | | | | SPAIN | B6X OTHER HAEMATOLOGICAL AGENTS | [40-50]% by value / <[0-5]% by volume |
| | | | | SWEDEN | B6X OTHER HAEMATOLOGICAL AGENTS | [70-80]% by value / [90-100]% by volume |
| | | | | | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [90-100]% by volume |
| | | | | BELGIUM | A16A OTHER METABOLIC PRODUCTS | <[0-5]% by value / [40-50]% by volume |
| | | | | | C8B CALCIUM ANTAGONIST COMBS | [90-100]% by value / [90-100]% by volume |
| | | | | CYPRUS | C7A BETA-BLOCKING AGENTS, PLAIN | [30-40]% by value / [20-30]% by volume |
| | | | | CZECH REPUBLIC | A13A TONICS | [70-80]% by value / [70-80]% by volume |
| | | | | | S1K DRY EYE PRODUCTS | [30-40]% by value / [30-40]% by volume |

| | | | | | | |
|---|---|---|---|---|---|---|
| | solid and powder pharmaceuticals | | | ESTONIA | C7A B-BLOCKING AGENTS,PLAIN | [40-50]% by value / [30-40]% by volume |
| | | | | | H1C HYPOTHALAMIC HORMONES | [40-50]% by value / [40-50]% by volume |
| | | | | FINLAND | C8B CALCIUM ANTAGONIST COMBS | [90-100]% by value / [90-100]% by volume |
| | | | | FRANCE | 83E1 LEG CARE PRODUCTS | [50-60]% by value / [50-60]% by volume |
| | | | | | C8B CALCIUM ANTAGONIST COMBS | [70-80]% by value / [50-60]% by volume |
| | | | | GERMANY | M3B MUSCLE RELAXANTS,CENTRAL | [40-50]% by value / [20-30]% by volume |
| | | | | GREECE | A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS | [70-80]% by value / [70-80]% by volume |
| | | | | | C8B CALCIUM ANTAGONIST COMBS | [70-80]% by value / [70-80]% by volume |
| | | | | | H1C HYPOTHALAMIC HORMONES | [30-40]% by value / [30-40]% by volume |
| | | | | HUNGARY | C8B CALCIUM ANTAGONIST COMBS | [40-50]% by value / [20-30]% by volume |
| | | | | ICELAND | C7A BETA-BLOCKING AGENTS, PLAIN | [30-40]% by value / [20-30]% by volume |
| | | | | LITHUANIA | C7A B-BLOCKING AGENTS,PLAIN | [30-40]% by value / [30-40]% by volume |
| | | | | PORTUGAL | 05A1 TONICS | [70-80]% |
| | | | | | A5B HEPATIC PROCT LIPOTROPIC | [70-80]% by value / [50-60]% by volume |
| | | | | SLOVAKIA | A13A TONICS | [90-100]% by value / [90-100]% by volume |
| | | | | SPAIN | C8B CALCIUM ANTAGONIST COMBS | [90-100]% by value / [90-100]% by volume |
| | | | | SWEDEN | C8B CALCIUM ANTAGONISTS, COMBINATIONS | [40-50]% by value / [40-50]% by volume |
| | | | | CYPRUS | C5A TOPICAL ANTI-HAEMORRHOIDALS | [70-80]% by value / [80-90]% by volume |
| | | | | CZECH REPUBLIC | S1K DRY EYE PRODUCTS | [30-40]% by value / [30-40]% by volume |
| | | | | FRANCE | 83E1 LEG CARE PRODUCTS | [50-60]% by value / [50-60]% by volume |
| | | | | GREECE | G1B GYNAECOLOG ANTIFUNGALS | [60-70]% by value / [40-50]% by volume |
| | | | | HUNGARY | G1B GYNAECOLOG ANTIFUNGALS | [20-30]% by value / [60-70]% by volume |
| | | | | ITALY | 02D1 MOUTH PAIN RELIEF | [30-40]% |
| | | | | | 09C1 MOUTH INFECTION TREATMENT | [10-20]% by value / [40-50]% by volume |
| | | | | | 10A1 ANTIHAEMORRHOIDS | [20-30]% by value / [30-40]% by volume |
| | | | | | C5A TOPICAL ANTIHAEMORRHOIDL | [30-40]% by value / [30-40]% by volume |

| | | | | | | |
|---|---|---|---|---|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals | | | | G4X ALL OTH UROLOGICAL PRODS | [20-30]% by value / [40-50]% by volume |
| | | | | | S2A ANTI-INFECTIVES - EAR | [40-50]% by value / [10-20]% by volume |
| | | | | | S2C STEROID/ANTI-INFECT-EAR | [20-30]% by value / [30-40]% by volume |
| | | | | LATVIA | 10A1 ANTIHAEMORRHOIDS | [30-40]% |
| | | | | | C5A TOPICAL ANTIHAEMORRHOIDL | [30-40]% by value / [20-30]% by volume |
| | | | | POLAND | 10A1 ANTIHAEMORRHOIDS | [30-40]% by value / [30-40]% by volume |
| | | | | | 12D2 GYNAECOLOGICAL ANTIFUNGAL | [80-90]% by value / [30-40]% by volume |
| | | | | | C5A TOPICAL ANTIHAEMORRHOIDL | [30-40]% by value / [30-40]% by volume |
| | | | | | G1B GYNAECOLOG ANTIFUNGALS | [50-60]% by value / [20-30]% by volume |
| | | | | ROMANIA | 10A1 ANTIHAEMORRHOIDS | [20-30]% by value / [30-40]% by volume |
| | | | | | C5A TOPICAL ANTIHAEMORRHOIDL | [50-60]% by value / [40-50]% by volume |
| | | | | | G1B GYNAECOLOG ANTIFUNGALS | [10-20]% by value / [30-40]% by volume |
| | | | | SLOVAKIA | C5A TOPICAL ANTIHAEMORRHOIDL | [20-30]% by value / [30-40]% by volume |
| | | | | SPAIN | 03D3 ANTIDIARR ELECTROL | [70-80]% |
| | | | | | A7G ORAL ELECTROL. REPLACER | [80-90]% by value / [90-100]% by volume |
| | sterile liquid pharmaceuticals | | | BELGIUM | S1X OTHER OPHTHALMOLOGICALS | [80-90]% by value / [10-20]% by volume |
| | | | | DENMARK | S1X OTHER OPHTHALMOLOGICALS | Potentially up to [70-80]% |
| | | | | ESTONIA | C7A B-BLOCKING AGENTS,PLAIN | [40-50]% by value / [30-40]% by volume |
| | | | | FRANCE | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [90-100]% by volume |
| | | | | GERMANY | M3B MUSCLE RELAXANTS,CENTRAL | [40-50]% by value / [20-30]% by volume |
| | | | | GREECE | S1X OTHER OPHTHALMOLOGICALS | [50-60]% by value / [50-60]% by volume |
| | | | | HUNGARY | B6X OTHER HAEMATOLOGICAL AGENTS | [90-100]% by value / [90-100]% by volume |
| | | | | ICELAND | C7A BETA-BLOCKING AGENTS, PLAIN | [30-40]% by value / [20-30]% by volume |
| | | | | ITALY | S1X OTHER OPHTHALMOLOGICALS | [40-50]% by value / [0-5]% by volume |
| | | | | LITHUANIA | C7A B-BLOCKING AGENTS,PLAIN | [30-40]% by value / [30-40]% by volume |
| | | | | NETHERLANDS | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [90-100]% by volume |

| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | NORWAY | B6X OTHER HAEMATOLOGICAL AGENTS | [90-100]% by value / [90-100]% by volume |
| | | | | | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [30-40]% by volume |
| | | | | PORTUGAL | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [70-80]% by volume |
| | | | | SPAIN | B6X OTHER HAEMATOLOGICAL AGENTS | [40-50]% by value / <[0-5]% by volume |
| | | | | SWEDEN | B6X OTHER HAEMATOLOGICAL AGENTS | [70-80]% by value / [90-100]% by volume |
| | | | | | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment | | | BELGIUM | S1X OTHER OPHTHALMOLOGICALS | [80-90]% by value / [10-20]% by volume |
| | | | | DENMARK | S1X OTHER OPHTHALMOLOGICALS | Potentially up to [70-80]% |
| | | | | ESTONIA | C7A B-BLOCKING AGENTS,PLAIN | [40-50]% by value / [30-40]% by volume |
| | | | | FRANCE | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [90-100]% by volume |
| | | | | GERMANY | M3B MUSCLE RELAXANTS,CENTRAL | [40-50]% by value / [20-30]% by volume |
| | | | | GREECE | S1X OTHER OPHTHALMOLOGICALS | [50-60]% by value / [50-60]% by volume |
| | | | | HUNGARY | B6X OTHER HAEMATOLOGICAL AGENTS | [90-100]% by value / [90-100]% by volume |
| | | | | ICELAND | C7A BETA-BLOCKING AGENTS, PLAIN | [30-40]% by value / [20-30]% by volume |
| | | | | ITALY | S1X OTHER OPHTHALMOLOGICALS | [40-50]% by value / [0-5]% by volume |
| | | | | LITHUANIA | C7A B-BLOCKING AGENTS,PLAIN | [30-40]% by value / [30-40]% by volume |
| | | | | NETHERLANDS | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [90-100]% by volume |
| | | | | NORWAY | B6X OTHER HAEMATOLOGICAL AGENTS | [90-100]% by value / [90-100]% by volume |
| | | | | | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [30-40]% by volume |
| | | | | PORTUGAL | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [70-80]% by volume |
| | | | | SPAIN | B6X OTHER HAEMATOLOGICAL AGENTS | [40-50]% by value / <[0-5]% by volume |
| | | | | SWEDEN | B6X OTHER HAEMATOLOGICAL AGENTS | [70-80]% by value / [90-100]% by volume |
| | | | | | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [90-100]% by volume |
| | | | | BELGIUM | C8B CALCIUM ANTAGONIST COMBS | [90-100]% by value / [90-100]% by volume |
| | | | | CYPRUS | C7A BETA-BLOCKING AGENTS, PLAIN | [30-40]% by value / [20-30]% by volume |
| | | | | ESTONIA | C7A B-BLOCKING AGENTS,PLAIN | [40-50]% by value / [30-40]% by volume |

| | | | | | | |
|---|---|---|---|---|---|---|
| | nature of the technology/know-how needed to produce the FDP | | | FINLAND | C8B CALCIUM ANTAGONIST COMBS | [90-100]% by value / [90-100]% by volume |
| | | | | FRANCE | C8B CALCIUM ANTAGONIST COMBS | [70-80]% by value / [50-60]% by volume |
| | | | | GREECE | C8B CALCIUM ANTAGONIST COMBS | [70-80]% by value / [70-80]% by volume |
| | | | | | G1B GYNAECOLOG ANTIFUNGALS | [60-70]% by value / [40-50]% by volume |
| | | | | HUNGARY | C8B CALCIUM ANTAGONIST COMBS | [40-50]% by value / [20-30]% by volume |
| | | | | | G1B GYNAECOLOG ANTIFUNGALS | [20-30]% by value / [60-70]% by volume |
| | | | | ICELAND | C7A BETA-BLOCKING AGENTS, PLAIN | [30-40]% by value / [20-30]% by volume |
| | | | | ITALY | G4X ALL OTH UROLOGICAL PRODS | [20-30]% by value / [40-50]% by volume |
| | | | | LITHUANIA | C7A B-BLOCKING AGENTS,PLAIN | [30-40]% by value / [30-40]% by volume |
| | | | | POLAND | 12D2 GYNAECOLOGICAL ANTIFUNGAL | [80-90]% by value / [30-40]% by volume |
| | | | | | G1B GYNAECOLOG ANTIFUNGALS | [50-60]% by value / [20-30]% by volume |
| | | | | ROMANIA | G1B GYNAECOLOG ANTIFUNGALS | [10-20]% by value / [30-40]% by volume |
| | | | | SPAIN | C8B CALCIUM ANTAGONIST COMBS | [90-100]% by value / [90-100]% by volume |
| | | | | SWEDEN | C8B CALCIUM ANTAGONISTS, COMBINATIONS | [40-50]% by value / [40-50]% by volume |
| | | | | BELGIUM | A16A OTHER METABOLIC PRODUCTS | <[0-5]% by value / [40-50]% by volume |
| | | | | | C8B CALCIUM ANTAGONIST COMBS | [90-100]% by value / [90-100]% by volume |
| | | | | | S1X OTHER OPHTHALMOLOGICALS | [80-90]% by value / [10-20]% by volume |
| | | | | CYPRUS | C5A TOPICAL ANTI-HAEMORRHOIDALS | [70-80]% by value / [80-90]% by volume |
| | | | | | C7A BETA-BLOCKING AGENTS, PLAIN | [30-40]% by value / [20-30]% by volume |
| | | | | CZECH REPUBLIC | A13A TONICS | [70-80]% by value / [70-80]% by volume |
| | | | | | S1K DRY EYE PRODUCTS | [30-40]% by value / [30-40]% by volume |
| | | | | DENMARK | S1X OTHER OPHTHALMOLOGICALS | Potentially up to [70-80]% |
| | | | | ESTONIA | C7A B-BLOCKING AGENTS,PLAIN | [40-50]% by value / [30-40]% by volume |
| | | | | | H1C HYPOTHALAMIC HORMONES | [40-50]% by value / [40-50]% by volume |
| | | | | FINLAND | C8B CALCIUM ANTAGONIST COMBS | [90-100]% by value / [90-100]% by volume |
| | | | | FRANCE | C8B CALCIUM ANTAGONIST COMBS | [70-80]% by value / [50-60]% by volume |

| | | | | | | |
|---|---|---|---|---|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs | At least EEA-wide | <[10-20]% | FRANCE | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [90-100]% by volume |
| | | | | GERMANY | M3B MUSCLE RELAXANTS,CENTRAL | [40-50]% by value / [20-30]% by volume |
| | | | | GREECE | A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS | [70-80]% by value / [70-80]% by volume |
| | | | | | C8B CALCIUM ANTAGONIST COMBS | [70-80]% by value / [70-80]% by volume |
| | | | | | G1B GYNAECOLOG ANTIFUNGALS | [60-70]% by value / [40-50]% by volume |
| | | | | | H1C HYPOTHALAMIC HORMONES | [30-40]% by value / [30-40]% by volume |
| | | | | | S1X OTHER OPHTHALMOLOGICALS | [50-60]% by value / [50-60]% by volume |
| | | | | HUNGARY | C8B CALCIUM ANTAGONIST COMBS | [40-50]% by value / [20-30]% by volume |
| | | | | | G1B GYNAECOLOG ANTIFUNGALS | [20-30]% by value / [60-70]% by volume |
| | | | | ICELAND | C7A BETA-BLOCKING AGENTS, PLAIN | [30-40]% by value / [20-30]% by volume |
| | | | | ITALY | 02D1 MOUTH PAIN RELIEF | [30-40]% |
| | | | | | 09C1 MOUTH INFECTION TREATMENT | [10-20]% by value / [40-50]% by volume |
| | | | | | 10A1 ANTIHAEMORRHOIDS | [20-30]% by value / [30-40]% by volume |
| | | | | | C5A TOPICAL ANTIHAEMORRHOIDL | [30-40]% by value / [30-40]% by volume |
| | | | | | G4X ALL OTH UROLOGICAL PRODS | [20-30]% by value / [40-50]% by volume |
| | | | | | S1X OTHER OPHTHALMOLOGICALS | [40-50]% by value / [0-5]% by volume |
| | | | | | S2A ANTI-INFECTIVES - EAR | [40-50]% by value / [10-20]% by volume |
| | | | | | S2C STEROID/ANTI-INFECT-EAR | [20-30]% by value / [30-40]% by volume |
| | | | | LATVIA | 10A1 ANTIHAEMORRHOIDS | [30-40]% |
| | | | | | C5A TOPICAL ANTIHAEMORRHOIDL | [30-40]% by value / [20-30]% by volume |
| | | | | LITHUANIA | C7A B-BLOCKING AGENTS,PLAIN | [30-40]% by value / [30-40]% by volume |
| | | | | NETHERLANDS | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [90-100]% by volume |
| | | | | NORWAY | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [30-40]% by volume |
| | | | | POLAND | 10A1 ANTIHAEMORRHOIDS | [30-40]% by value / [30-40]% by volume |
| | | | | | 12D2 GYNAECOLOGICAL ANTIFUNGAL | [80-90]% by value / [30-40]% by volume |
| | | | | | C5A TOPICAL ANTIHAEMORRHOIDL | [30-40]% by value / [30-40]% by volume |

| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | | G1B GYNAECOLOG ANTIFUNGALS | [50-60]% by value / [20-30]% by volume |
| | | | | PORTUGAL | 05A1 TONICS | [70-80]% |
| | | | | | A5B HEPATIC PROCT LIPOTROPIC | [70-80]% by value / [50-60]% by volume |
| | | | | | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [70-80]% by volume |
| | | | | ROMANIA | 10A1 ANTIHAEMORRHOIDS | [20-30]% by value / [30-40]% by volume |
| | | | | | C5A TOPICAL ANTIHAEMORRHOIDL | [50-60]% by value / [40-50]% by volume |
| | | | | | G1B GYNAECOLOG ANTIFUNGALS | [10-20]% by value / [30-40]% by volume |
| | | | | SLOVAKIA | A13A TONICS | [90-100]% by value / [90-100]% by volume |
| | | | | | C5A TOPICAL ANTIHAEMORRHOIDL | [20-30]% by value / [30-40]% by volume |
| | | | | SPAIN | C8B CALCIUM ANTAGONIST COMBS | [90-100]% by value / [90-100]% by volume |
| | | | | SWEDEN | C8B CALCIUM ANTAGONISTS, COMBINATIONS | [40-50]% by value / [40-50]% by volume |
| | | | | | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [90-100]% by volume |
| | biopharmaceutical APIs | | | FRANCE | 83E1 LEG CARE PRODUCTS | [50-60]% by value / [50-60]% by volume |
| | | | | HUNGARY | B6X OTHER HAEMATOLOGICAL AGENTS | [90-100]% by value / [90-100]% by volume |
| | | | | NORWAY | B6X OTHER HAEMATOLOGICAL AGENTS | [90-100]% by value / [90-100]% by volume |
| | | | | SPAIN | 03D3 ANTIDIARR ELECTROL | [70-80]% |
| | | | | | A7G ORAL ELECTROL. REPLACER | [80-90]% by value / [90-100]% by volume |
| | | | | | B6X OTHER HAEMATOLOGICAL AGENTS | [40-50]% by value / <[0-5]% by volume |
| | | | | SWEDEN | B6X OTHER HAEMATOLOGICAL AGENTS | [70-80]% by value / [90-100]% by volume |
| | | | | BELGIUM | A16A OTHER METABOLIC PRODUCTS | <[0-5]% by value / [40-50]% by volume |
| | | | | | C8B CALCIUM ANTAGONIST COMBS | [90-100]% by value / [90-100]% by volume |
| | | | | CYPRUS | C7A BETA-BLOCKING AGENTS, PLAIN | [30-40]% by value / [20-30]% by volume |
| | | | | CZECH REPUBLIC | A13A TONICS | [70-80]% by value / [70-80]% by volume |
| | | | | | S1K DRY EYE PRODUCTS | [30-40]% by value / [30-40]% by volume |
| | | | | ESTONIA | C7A B-BLOCKING AGENTS,PLAIN | [40-50]% by value / [30-40]% by volume |
| | | | | FINLAND | C8B CALCIUM ANTAGONIST COMBS | [90-100]% by value / [90-100]% by volume |

| | | | | | | |
|---|---|---|---|---|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i e. | swallowing | | | FRANCE | 83E1 LEG CARE PRODUCTS | [50-60]% by value / [50-60]% by volume |
| | | | | | C8B CALCIUM ANTAGONIST COMBS | [70-80]% by value / [50-60]% by volume |
| | | | | GERMANY | M3B MUSCLE RELAXANTS,CENTRAL | [40-50]% by value / [20-30]% by volume |
| | | | | GREECE | A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS | [70-80]% by value / [70-80]% by volume |
| | | | | | C8B CALCIUM ANTAGONIST COMBS | [70-80]% by value / [70-80]% by volume |
| | | | | HUNGARY | C8B CALCIUM ANTAGONIST COMBS | [40-50]% by value / [20-30]% by volume |
| | | | | ICELAND | C7A BETA-BLOCKING AGENTS, PLAIN | [30-40]% by value / [20-30]% by volume |
| | | | | ITALY | 09C1 MOUTH INFECTION TREATMENT | [10-20]% by value / [40-50]% by volume |
| | | | | LITHUANIA | C7A B-BLOCKING AGENTS,PLAIN | [30-40]% by value / [30-40]% by volume |
| | | | | PORTUGAL | 05A1 TONICS | [70-80]% |
| | | | | | A5B HEPATIC PROCT LIPOTROPIC | [70-80]% by value / [50-60]% by volume |
| | | | | SLOVAKIA | A13A TONICS | [90-100]% by value / [90-100]% by volume |
| | | | | SPAIN | 03D3 ANTIDIARR ELECTROL | [70-80]% |
| | | | | | A7G ORAL ELECTROL. REPLACER | [80-90]% by value / [90-100]% by volume |
| | | | | | C8B CALCIUM ANTAGONIST COMBS | [90-100]% by value / [90-100]% by volume |
| | | | | SWEDEN | C8B CALCIUM ANTAGONISTS, COMBINATIONS | [40-50]% by value / [40-50]% by volume |
| | absorption through the skin | | | CYPRUS | C5A TOPICAL ANTI-HAEMORRHOIDALS | [70-80]% by value / [80-90]% by volume |
| | | | | FRANCE | 83E1 LEG CARE PRODUCTS | [50-60]% by value / [50-60]% by volume |
| | | | | GREECE | G1B GYNAECOLOG ANTIFUNGALS | [60-70]% by value / [40-50]% by volume |
| | | | | ITALY | 02D1 MOUTH PAIN RELIEF | [30-40]% |
| | | | | | G4X ALL OTH UROLOGICAL PRODS | [20-30]% by value / [40-50]% by volume |
| | | | | LATVIA | 10A1 ANTIHAEMORRHOIDS | [30-40]% |
| | | | | | C5A TOPICAL ANTIHAEMORRHOIDL | [30-40]% by value / [20-30]% by volume |
| | | | | POLAND | 10A1 ANTIHAEMORRHOIDS | [30-40]% by value / [30-40]% by volume |
| | | | | | C5A TOPICAL ANTIHAEMORRHOIDL | [30-40]% by value / [30-40]% by volume |
| | | | | | 10A1 ANTIHAEMORRHOIDS | [20-30]% by value / [30-40]% by volume |

| | | |
|---|---|---|
| ROMANIA | C5A TOPICAL ANTIHAEMORRHOIDL | [50-60]% by value / [40-50]% by volume |
| | G1B GYNAECOLOG ANTIFUNGALS | [10-20]% by value / [30-40]% by volume |
| SLOVAKIA | C5A TOPICAL ANTIHAEMORRHOIDL | [20-30]% by value / [30-40]% by volume |
| BELGIUM | C8B CALCIUM ANTAGONIST COMBS | [90-100]% by value / [90-100]% by volume |
| | S1X OTHER OPHTHALMOLOGICALS | [80-90]% by value / [10-20]% by volume |
| CYPRUS | C5A TOPICAL ANTI-HAEMORRHOIDALS | [70-80]% by value / [80-90]% by volume |
| | C7A BETA-BLOCKING AGENTS, PLAIN | [30-40]% by value / [20-30]% by volume |
| CZECH REPUBLIC | A13A TONICS | [70-80]% by value / [70-80]% by volume |
| | S1K DRY EYE PRODUCTS | [30-40]% by value / [30-40]% by volume |
| DENMARK | S1X OTHER OPHTHALMOLOGICALS | Potentially up to [70-80]% |
| ESTONIA | C7A B-BLOCKING AGENTS,PLAIN | [40-50]% by value / [30-40]% by volume |
| FINLAND | C8B CALCIUM ANTAGONIST COMBS | [90-100]% by value / [90-100]% by volume |
| FRANCE | 83E1 LEG CARE PRODUCTS | [50-60]% by value / [50-60]% by volume |
| | C8B CALCIUM ANTAGONIST COMBS | [70-80]% by value / [50-60]% by volume |
| | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [90-100]% by volume |
| GERMANY | M3B MUSCLE RELAXANTS,CENTRAL | [40-50]% by value / [20-30]% by volume |
| GREECE | C8B CALCIUM ANTAGONIST COMBS | [70-80]% by value / [70-80]% by volume |
| | G1B GYNAECOLOG ANTIFUNGALS | [60-70]% by value / [40-50]% by volume |
| | S1X OTHER OPHTHALMOLOGICALS | [50-60]% by value / [50-60]% by volume |
| HUNGARY | B6X OTHER HAEMATOLOGICAL AGENTS | [90-100]% by value / [90-100]% by volume |
| | C8B CALCIUM ANTAGONIST COMBS | [40-50]% by value / [20-30]% by volume |
| | G1B GYNAECOLOG ANTIFUNGALS | [20-30]% by value / [60-70]% by volume |
| ICELAND | C7A BETA-BLOCKING AGENTS, PLAIN | [30-40]% by value / [20-30]% by volume |
| | 02D1 MOUTH PAIN RELIEF | [30-40]% |
| | 09C1 MOUTH INFECTION TREATMENT | [10-20]% by value / [40-50]% by volume |
| | 10A1 ANTIHAEMORRHOIDS | [20-30]% by value / [30-40]% by volume |

| | | | | | | |
|---|---|---|---|---|---|---|
| CMO services (excluding CDO services) | - | | | ITALY | C5A TOPICAL ANTIHAEMORRHOIDL | [30-40]% by value / [30-40]% by volume |
| | | | | | G4X ALL OTH UROLOGICAL PRODS | [20-30]% by value / [40-50]% by volume |
| | | | | | S1X OTHER OPHTHALMOLOGICALS | [40-50]% by value / [0-5]% by volume |
| | | | | | S2A ANTI-INFECTIVES - EAR | [40-50]% by value / [10-20]% by volume |
| | | | | | S2C STEROID/ANTI-INFECT-EAR | [20-30]% by value / [30-40]% by volume |
| | | | | LATVIA | 10A1 ANTIHAEMORRHOIDS | [30-40]% |
| | | | | | C5A TOPICAL ANTIHAEMORRHOIDL | [30-40]% by value / [20-30]% by volume |
| | | | | LITHUANIA | C7A B-BLOCKING AGENTS,PLAIN | [30-40]% by value / [30-40]% by volume |
| | | | | NETHERLANDS | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [90-100]% by volume |
| | | | | NORWAY | B6X OTHER HAEMATOLOGICAL AGENTS | [90-100]% by value / [90-100]% by volume |
| | | | | | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [30-40]% by volume |
| | | | | POLAND | 10A1 ANTIHAEMORRHOIDS | [30-40]% by value / [30-40]% by volume |
| | | | | | 12D2 GYNAECOLOGICAL ANTIFUNGAL | [80-90]% by value / [30-40]% by volume |
| | | | | | C5A TOPICAL ANTIHAEMORRHOIDL | [30-40]% by value / [30-40]% by volume |
| | | | | | G1B GYNAECOLOG ANTIFUNGALS | [50-60]% by value / [20-30]% by volume |
| | | | | PORTUGAL | 05A1 TONICS | [70-80]% |
| | | | | | A5B HEPATIC PROCT LIPOTROPIC | [70-80]% by value / [50-60]% by volume |
| | | | | | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [70-80]% by volume |
| | | | | ROMANIA | 10A1 ANTIHAEMORRHOIDS | [20-30]% by value / [30-40]% by volume |
| | | | | | C5A TOPICAL ANTIHAEMORRHOIDL | [50-60]% by value / [40-50]% by volume |
| | | | | | G1B GYNAECOLOG ANTIFUNGALS | [10-20]% by value / [30-40]% by volume |
| | | | | SLOVAKIA | A13A TONICS | [90-100]% by value / [90-100]% by volume |
| | | | | | C5A TOPICAL ANTIHAEMORRHOIDL | [20-30]% by value / [30-40]% by volume |
| | | | | SPAIN | 03D3 ANTIDIARR ELECTROL | [70-80]% |
| | | | | | A7G ORAL ELECTROL. REPLACER | [80-90]% by value / [90-100]% by volume |
| | | | | | B6X OTHER HAEMATOLOGICAL AGENTS | [40-50]% by value / <[0-5]% by volume |

| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | | C8B CALCIUM ANTAGONIST COMBS | [90-100]% by value / [90-100]% by volume |
| | | | | SWEDEN | B6X OTHER HAEMATOLOGICAL AGENTS | [70-80]% by value / [90-100]% by volume |
| | | | | | C8B CALCIUM ANTAGONISTS, COMBINATIONS | [40-50]% by value / [40-50]% by volume |
| | | | | | S1X OTHER OPHTHALMOLOGICALS | [90-100]% by value / [90-100]% by volume |

**Appendix 7.1**

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream) | | | | | | |
|---|---|---|---|---|---|---|
| Upstream Market (Target) | | | | Downstream FDP Market (Recordati) | | |
| Upstream Hypothetical Market Segment (CDMO) | Upstream Hypothetical Market Sub-Segment (CDMO) | Geographic Market | Share (2020, EEA | Geographic Market | Product Market (ATC4/CHC4) | Share (2020) |
| CDMO services for FDPs | - | At leat EEA-wide | <1[0-5]% | AUSTRIA | A11X3 VITAMIN E PLAIN | [70-80]% by value / [0-5]% by volume |
| CDMO services for FDPs | - | | | BELGIUM | S1X2 OTH OPHTHALM TOPICAL | [80-90]% by value / [10-20]% by volume |
| CDMO services for FDPs | - | | | FRANCE | A11X3 VITAMIN E PLAIN | [30-40]% by value / <[0-5]% by volume |
| CDMO services for FDPs | - | | | FRANCE | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs | - | | | ITALY | 30C1Z OTHER MODULES | [40-50]% by value / [20-30]% by volume |
| CDMO services for FDPs | - | | | ITALY | S1X2 OTH OPHTHALM TOPICAL | [40-50]% by value / [0-5]% by volume |
| CDMO services for FDPs | - | | | NETHERLANDS | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs | - | | | NORWAY | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [30-40]% by volume |
| CDMO services for FDPs | - | | | PORTUGAL | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [70-80]% by volume |
| CDMO services for FDPs | - | | | SWEDEN | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | solid and powder pharmaceuticals | | | BELGIUM | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | solid and powder pharmaceuticals | | | FINLAND | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | solid and powder pharmaceuticals | | | FRANCE | 01A4E EFFERVESCENT | [20-30]% by value / [30-40]% by volume |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | solid and powder pharmaceuticals | | | FRANCE | 01A4P POWDERS | [30-40]% by value / [40-50]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| FRANCE | 83E1 LEG CARE PRODUCTS | [50-60]% by value / [50-60]% by volume |
| FRANCE | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [80-90]% by volume |
| GREECE | C8B2 CALC ANTAG/B BLOCKR COMB | [70-80]% by value / [70-80]% by volume |
| HUNGARY | C8B2 CALC ANTAG/B BLOCKR COMB | [50-60]% by value / [40-50]% by volume |
| ITALY | A7E9 INFLAM BOWEL DIS PRD OTH | <[0-5]% by value / [90-100]% by volume |
| PORTUGAL | 03C4Q ENEMAS | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1M MIXTURES (ORAL) | [50-60]% by value / [40-50]% by volume |
| PORTUGAL | 05A1Z OTHER FORMS | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A2B9 ALL OTHER ANTIULCERANTS | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | A6A4 LAXATIVE ENEMAS | [70-80]% by value / [60-70]% by volume |
| ROMANIA | 03C1Z OTHER FORMS | [30-40]% by value / [20-30]% by volume |
| SPAIN | 03C1Z OTHER FORMS | [60-70]% by value / [40-50]% by volume |
| SPAIN | 03F1M MIXTURES (ORAL) | [40-50]% by value / [30-40]% by volume |
| SPAIN | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | A11X3 VITAMIN E PLAIN | [70-80]% by value / [0-5]% by volume |
| BELGIUM | S1X2 OTH OPHTHALM TOPICAL | [80-90]% by value / [10-20]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| FRANCE | 01A9Z OTHER FORMS | [90-100]% by value / [90-100]% by volume |
| FRANCE | 83E1 LEG CARE PRODUCTS | [50-60]% by value / [50-60]% by volume |
| FRANCE | A11X3 VITAMIN E PLAIN | [30-40]% by value / <[0-5]% by volume |
| FRANCE | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |
| ITALY | 02D1O OINTMENTS/CREAMS | [50-60]% by value / [40-50]% by volume |
| ITALY | 02D1Z OTHER FORMS | [40-50]% by value / [40-50]% by volume |
| ITALY | 02E1L LIQUIDS (TOPICAL) | [60-70]% by value / [10-20]% by volume |
| ITALY | 09C1G RINSES/GARGLES | [10-20]% by value / [40-50]% by volume |
| ITALY | 10A1O OINTMENTS/CREAMS | [20-30]% by value / [40-50]% by volume |
| ITALY | 30C1Z OTHER MODULES | [40-50]% by value / [20-30]% by volume |
| ITALY | C5A1 A-HAEMORRHOIDL+CORTICOID | [50-60]% by value / [60-70]% by volume |
| ITALY | S1X2 OTH OPHTHALM TOPICAL | [40-50]% by value / [0-5]% by volume |
| LATVIA | 10A1O OINTMENTS/CREAMS | [40-50]% by value / [30-40]% by volume |
| LATVIA | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| LATVIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| LITHUANIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| NETHERLANDS | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |
| NORWAY | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [30-40]% by volume |
| POLAND | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |
| POLAND | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| POLAND | 12D2S SUPPOSITORIES | [90-100]% by value / [70-80]% by volume |
| POLAND | C5A2 A-HAEMORRHOID W/O CORTIC | [40-50]% by value / [30-40]% by volume |
| PORTUGAL | 02D1O OINTMENTS/CREAMS | [30-40]% by value / [10-20]% by volume |
| PORTUGAL | 03F1M MIXTURES (ORAL) | [50-60]% by value / [40-50]% by volume |
| PORTUGAL | A2B9 ALL OTHER ANTIULCERANTS | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | G4E9 ERECTILE DYSFUNC PRD OTH | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [70-80]% by volume |
| ROMANIA | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |
| ROMANIA | C5A2 A-HAEMORRHOID W/O CORTIC | [60-70]% by value / [50-60]% by volume |
| SLOVAKIA | 10A1S SUPPOSITORIES | [30-40]% by value / [30-40]% by volume |
| SLOVAKIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| SPAIN | 03F1M MIXTURES (ORAL) | [40-50]% by value / [30-40]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | sterile liquid pharmaceu icals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | sterile liquid pharmaceu icals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | sterile liquid pharmaceu icals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | sterile liquid pharmaceu icals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | sterile liquid pharmaceu icals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | sterile liquid pharmaceu icals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | medicated confectionary pharmaceuticals |

| | | |
|---|---|---|
| SPAIN | G4E9 ERECTILE DYSFUNC PRD OTH | [40-50]% by value / [50-60]% by volume |
| SWEDEN | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |
| BELGIUM | S1X2 OTH OPHTHALM TOPICAL | [80-90]% by value / [10-20]% by volume |
| FRANCE | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |
| ITALY | S1G1 OCUL.A-ALLERG ANTIHIST. | [30-40]% by value / [30-40]% by volume |
| ITALY | S1X2 OTH OPHTHALM TOPICAL | [40-50]% by value / [0-5]% by volume |
| NETHERLANDS | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |
| NORWAY | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [30-40]% by volume |
| PORTUGAL | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [70-80]% by volume |
| SWEDEN | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |
| LATVIA | 10A1O OINTMENTS/CREAMS | [40-50]% by value / [30-40]% by volume |
| LATVIA | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| LATVIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| LITHUANIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| PORTUGAL | 02E1K NON HEAT/COLD PATCHES | [60-70]% by value / [70-80]% by volume |
| ROMANIA | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce he FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce he FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce he FDP |

| | | |
|---|---|---|
| ROMANIA | C5A2 A-HAEMORRHOID W/O CORTIC | [60-70]% by value / [50-60]% by volume |
| SLOVAKIA | 10A1S SUPPOSITORIES | [30-40]% by value / [30-40]% by volume |
| SLOVAKIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| BELGIUM | S1X2 OTH OPHTHALM TOPICAL | [80-90]% by value / [10-20]% by volume |
| FRANCE | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |
| ITALY | S1G1 OCUL.A-ALLERG ANTIHIST. | [30-40]% by value / [30-40]% by volume |
| ITALY | S1X2 OTH OPHTHALM TOPICAL | [40-50]% by value / [0-5]% by volume |
| NETHERLANDS | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |
| NORWAY | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [30-40]% by volume |
| PORTUGAL | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [70-80]% by volume |
| SWEDEN | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |
| BELGIUM | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [90-100]% by volume |
| BELGIUM | S1X2 OTH OPHTHALM TOPICAL | [80-90]% by value / [10-20]% by volume |
| FINLAND | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [90-100]% by volume |
| FRANCE | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [80-90]% by volume |
| FRANCE | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |

| | | |
|---|---|---|
| GREECE | C8B2 CALC ANTAG/B BLOCKR COMB | [70-80]% by value / [70-80]% by volume |
| HUNGARY | C8B2 CALC ANTAG/B BLOCKR COMB | [50-60]% by value / [40-50]% by volume |
| ITALY | S1X2 OTH OPHTHALM TOPICAL | [40-50]% by value / [0-5]% by volume |
| NETHERLANDS | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |
| NORWAY | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [30-40]% by volume |
| POLAND | 12D2S SUPPOSITORIES | [90-100]% by value / [70-80]% by volume |
| PORTUGAL | 02E1K NON HEAT/COLD PATCHES | [60-70]% by value / [70-80]% by volume |
| PORTUGAL | G4E9 ERECTILE DYSFUNC PRD OTH | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [70-80]% by volume |
| SPAIN | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [90-100]% by volume |
| SPAIN | G4E9 ERECTILE DYSFUNC PRD OTH | [40-50]% by value / [50-60]% by volume |
| SWEDEN | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | A11X3 VITAMIN E PLAIN | [70-80]% by value / [0-5]% by volume |
| BELGIUM | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [90-100]% by volume |
| BELGIUM | S1X2 OTH OPHTHALM TOPICAL | [80-90]% by value / [10-20]% by volume |
| FINLAND | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |

| | | |
|---|---|---|
| FRANCE | 01A4E EFFERVESCENT | [20-30]% by value / [30-40]% by volume |
| FRANCE | 01A4P POWDERS | [30-40]% by value / [40-50]% by volume |
| FRANCE | 01A9Z OTHER FORMS | [90-100]% by value / [90-100]% by volume |
| FRANCE | A11X3 VITAMIN E PLAIN | [30-40]% by value / <[0-5]% by volume |
| FRANCE | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [80-90]% by volume |
| FRANCE | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |
| GREECE | C8B2 CALC ANTAG/B BLOCKR COMB | [70-80]% by value / [70-80]% by volume |
| HUNGARY | C8B2 CALC ANTAG/B BLOCKR COMB | [50-60]% by value / [40-50]% by volume |
| ITALY | 02D1O OINTMENTS/CREAMS | [50-60]% by value / [40-50]% by volume |
| ITALY | 02D1Z OTHER FORMS | [40-50]% by value / [40-50]% by volume |
| ITALY | 02E1L LIQUIDS (TOPICAL) | [60-70]% by value / [10-20]% by volume |
| ITALY | 09C1G RINSES/GARGLES | [10-20]% by value / [40-50]% by volume |
| ITALY | 10A1O OINTMENTS/CREAMS | [20-30]% by value / [40-50]% by volume |
| ITALY | 30C1Z OTHER MODULES | [40-50]% by value / [20-30]% by volume |
| ITALY | A7E9 INFLAM BOWEL DIS PRD OTH | <[0-5]% by value / [90-100]% by volume |
| ITALY | C5A1 A-HAEMORRHOIDL+CORTICOID | [50-60]% by value / [60-70]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |

| | | |
|---|---|---|
| ITALY | S1G1 OCUL.A-ALLERG ANTIHIST. | [30-40]% by value / [30-40]% by volume |
| ITALY | S1X2 OTH OPHTHALM TOPICAL | [40-50]% by value / [0-5]% by volume |
| LATVIA | 10A1O OINTMENTS/CREAMS | [40-50]% by value / [30-40]% by volume |
| LATVIA | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| LATVIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| LITHUANIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| NETHERLANDS | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |
| NORWAY | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [30-40]% by volume |
| POLAND | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |
| POLAND | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| POLAND | 12D2S SUPPOSITORIES | [90-100]% by value / [70-80]% by volume |
| POLAND | C5A2 A-HAEMORRHOID W/O CORTIC | [40-50]% by value / [30-40]% by volume |
| PORTUGAL | 02D1O OINTMENTS/CREAMS | [30-40]% by value / [10-20]% by volume |
| PORTUGAL | 02E1K NON HEAT/COLD PATCHES | [60-70]% by value / [70-80]% by volume |
| PORTUGAL | 03C4Q ENEMAS | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 05A1Z OTHER FORMS | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-syn hesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |

| | | |
|---|---|---|
| PORTUGAL | A2B9 ALL OTHER ANTIULCERANTS | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | A6A4 LAXATIVE ENEMAS | [70-80]% by value / [60-70]% by volume |
| PORTUGAL | G4E9 ERECTILE DYSFUNC PRD OTH | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [70-80]% by volume |
| ROMANIA | 03C1Z OTHER FORMS | [30-40]% by value / [20-30]% by volume |
| ROMANIA | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |
| ROMANIA | C5A2 A-HAEMORRHOID W/O CORTIC | [60-70]% by value / [50-60]% by volume |
| SLOVAKIA | 10A1S SUPPOSITORIES | [30-40]% by value / [30-40]% by volume |
| SLOVAKIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| SPAIN | 03C1Z OTHER FORMS | [60-70]% by value / [40-50]% by volume |
| SPAIN | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [90-100]% by volume |
| SPAIN | G4E9 ERECTILE DYSFUNC PRD OTH | [40-50]% by value / [50-60]% by volume |
| SWEDEN | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |
| FRANCE | 83E1 LEG CARE PRODUCTS | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | 03F1M MIXTURES (ORAL) | [50-60]% by value / [40-50]% by volume |
| SPAIN | 03F1M MIXTURES (ORAL) | [40-50]% by value / [30-40]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| AUSTRIA | A11X3 VITAMIN E PLAIN | [70-80]% by value / [0-5]% by volume |
| BELGIUM | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [90-100]% by volume |
| FINLAND | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [90-100]% by volume |
| FRANCE | 01A4E EFFERVESCENT | [20-30]% by value / [30-40]% by volume |
| FRANCE | 01A4P POWDERS | [30-40]% by value / [40-50]% by volume |
| FRANCE | 01A9Z OTHER FORMS | [90-100]% by value / [90-100]% by volume |
| FRANCE | 83E1 LEG CARE PRODUCTS | [50-60]% by value / [50-60]% by volume |
| FRANCE | A11X3 VITAMIN E PLAIN | [30-40]% by value / <[0-5]% by volume |
| FRANCE | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [80-90]% by volume |
| GREECE | C8B2 CALC ANTAG/B BLOCKR COMB | [70-80]% by value / [70-80]% by volume |
| HUNGARY | C8B2 CALC ANTAG/B BLOCKR COMB | [50-60]% by value / [40-50]% by volume |
| ITALY | 09C1G RINSES/GARGLES | [10-20]% by value / [40-50]% by volume |
| ITALY | 30C1Z OTHER MODULES | [40-50]% by value / [20-30]% by volume |
| ITALY | A7E9 INFLAM BOWEL DIS PRD OTH | <[0-5]% by value / [90-100]% by volume |
| PORTUGAL | 03C4Q ENEMAS | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1M MIXTURES (ORAL) | [50-60]% by value / [40-50]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |

| | | |
|---|---|---|
| PORTUGAL | 05A1Z OTHER FORMS | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A2B9 ALL OTHER ANTIULCERANTS | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | A6A4 LAXATIVE ENEMAS | [70-80]% by value / [60-70]% by volume |
| ROMANIA | 03C1Z OTHER FORMS | [30-40]% by value / [20-30]% by volume |
| SPAIN | 03C1Z OTHER FORMS | [60-70]% by value / [40-50]% by volume |
| SPAIN | 03F1M MIXTURES (ORAL) | [40-50]% by value / [30-40]% by volume |
| SPAIN | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [90-100]% by volume |
| FRANCE | 83E1 LEG CARE PRODUCTS | [50-60]% by value / [50-60]% by volume |
| ITALY | 02D1O OINTMENTS/CREAMS | [50-60]% by value / [40-50]% by volume |
| ITALY | 02D1Z OTHER FORMS | [40-50]% by value / [40-50]% by volume |
| ITALY | 02E1L LIQUIDS (TOPICAL) | [60-70]% by value / [10-20]% by volume |
| LATVIA | 10A1O OINTMENTS/CREAMS | [40-50]% by value / [30-40]% by volume |
| LATVIA | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| LATVIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| LITHUANIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| POLAND | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| POLAND | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| POLAND | C5A2 A-HAEMORRHOID W/O CORTIC | [40-50]% by value / [30-40]% by volume |
| PORTUGAL | 02D1O OINTMENTS/CREAMS | [30-40]% by value / [10-20]% by volume |
| ROMANIA | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |
| ROMANIA | C5A2 A-HAEMORRHOID W/O CORTIC | [60-70]% by value / [50-60]% by volume |
| SLOVAKIA | 10A1S SUPPOSITORIES | [30-40]% by value / [30-40]% by volume |
| SLOVAKIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| BELGIUM | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [90-100]% by volume |
| BELGIUM | S1X2 OTH OPHTHALM TOPICAL | [80-90]% by value / [10-20]% by volume |
| FINLAND | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [90-100]% by volume |
| FRANCE | 01A4E EFFERVESCENT | [20-30]% by value / [30-40]% by volume |
| FRANCE | 01A4P POWDERS | [30-40]% by value / [40-50]% by volume |
| FRANCE | 01A9Z OTHER FORMS | [90-100]% by value / [90-100]% by volume |
| FRANCE | 83E1 LEG CARE PRODUCTS | [50-60]% by value / [50-60]% by volume |
| FRANCE | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [80-90]% by volume |
| FRANCE | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| GREECE | C8B2 CALC ANTAG/B BLOCKR COMB | [70-80]% by value / [70-80]% by volume |
| HUNGARY | C8B2 CALC ANTAG/B BLOCKR COMB | [50-60]% by value / [40-50]% by volume |
| ITALY | 02D1O OINTMENTS/CREAMS | [50-60]% by value / [40-50]% by volume |
| ITALY | 02D1Z OTHER FORMS | [40-50]% by value / [40-50]% by volume |
| ITALY | 02E1L LIQUIDS (TOPICAL) | [60-70]% by value / [10-20]% by volume |
| ITALY | 09C1G RINSES/GARGLES | [10-20]% by value / [40-50]% by volume |
| ITALY | 10A1O OINTMENTS/CREAMS | [20-30]% by value / [40-50]% by volume |
| ITALY | A7E9 INFLAM BOWEL DIS PRD OTH | <[0-5]% by value / [90-100]% by volume |
| ITALY | C5A1 A-HAEMORRHOIDL+CORTICOID | [50-60]% by value / [60-70]% by volume |
| ITALY | S1G1 OCUL.A-ALLERG ANTIHIST. | [30-40]% by value / [30-40]% by volume |
| ITALY | S1X2 OTH OPHTHALM TOPICAL | [40-50]% by value / [0-5]% by volume |
| LATVIA | 10A1O OINTMENTS/CREAMS | [40-50]% by value / [30-40]% by volume |
| LATVIA | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| LATVIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| LITHUANIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| NETHERLANDS | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| NORWAY | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [30-40]% by volume |
| POLAND | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |
| POLAND | 10A1S SUPPOSITORIES | [30-40]% by value / [20-30]% by volume |
| POLAND | 12D2S SUPPOSITORIES | [90-100]% by value / [70-80]% by volume |
| POLAND | C5A2 A-HAEMORRHOID W/O CORTIC | [40-50]% by value / [30-40]% by volume |
| PORTUGAL | 02D1O OINTMENTS/CREAMS | [30-40]% by value / [10-20]% by volume |
| PORTUGAL | 02E1K NON HEAT/COLD PATCHES | [60-70]% by value / [70-80]% by volume |
| PORTUGAL | 03C4Q ENEMAS | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1M MIXTURES (ORAL) | [50-60]% by value / [40-50]% by volume |
| PORTUGAL | 05A1Z OTHER FORMS | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A2B9 ALL OTHER ANTIULCERANTS | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | A6A4 LAXATIVE ENEMAS | [70-80]% by value / [60-70]% by volume |
| PORTUGAL | G4E9 ERECTILE DYSFUNC PRD OTH | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [70-80]% by volume |
| ROMANIA | 03C1Z OTHER FORMS | [30-40]% by value / [20-30]% by volume |
| ROMANIA | 10A1O OINTMENTS/CREAMS | [30-40]% by value / [30-40]% by volume |

| | | | | | | |
|---|---|---|---|---|---|---|
| CMO services (excluding CDO services) | - | | | ROMANIA | C5A2 A-HAEMORRHOID W/O CORTIC | [60-70]% by value / [50-60]% by volume |
| CMO services (excluding CDO services) | - | | | SLOVAKIA | 10A1S SUPPOSITORIES | [30-40]% by value / [30-40]% by volume |
| CMO services (excluding CDO services) | - | | | SLOVAKIA | C5A2 A-HAEMORRHOID W/O CORTIC | [30-40]% by value / [30-40]% by volume |
| CMO services (excluding CDO services) | - | | | SPAIN | 03C1Z OTHER FORMS | [60-70]% by value / [40-50]% by volume |
| CMO services (excluding CDO services) | - | | | SPAIN | 03F1M MIXTURES (ORAL) | [40-50]% by value / [30-40]% by volume |
| CMO services (excluding CDO services) | - | | | SPAIN | C8B2 CALC ANTAG/B BLOCKR COMB | [90-100]% by value / [90-100]% by volume |
| CMO services (excluding CDO services) | - | | | SPAIN | G4E9 ERECTILE DYSFUNC PRD OTH | [40-50]% by value / [50-60]% by volume |
| CMO services (excluding CDO services) | - | | | SWEDEN | S1X2 OTH OPHTHALM TOPICAL | [90-100]% by value / [90-100]% by volume |

**Appendix 7.1**

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream) | | | | | | |
|---|---|---|---|---|---|---|
| Upstream Market (Target) | | | | Downstream FDP Market (Recordati) | | |
| Upstream Hypothetical Market Segment (CDMO) | Upstream Hypothetical Market Sub-Segment (CDMO) | Geographic Market | are (2020, EE | Geographic Market | Molecule-level Category | Share (2020) |
| CDMO services for FDPs | - | | | AUSTRIA | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs | - | | | AUSTRIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs | - | | | AUSTRIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs | - | | | AUSTRIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs | - | | | AUSTRIA | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs | - | | | AUSTRIA | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs | - | | | BELGIUM | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs | - | | | BELGIUM | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |

| | | |
|---|---|---|
| BELGIUM | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [10-20]% by value / [60-70]% by volume |
| BELGIUM | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| FRANCE | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [50-60]% by value / [50-60]% by volume |
| FRANCE | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |
| FRANCE | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| FRANCE | H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & SIMILAR --> OSILODROSTAT | [90-100]% by value / [90-100]% by volume |
| FRANCE | L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> CHLORMETHINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |

| | | |
|---|---|---|
| FRANCE | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC | [90-100]% by value / [90-100]% by volume |
| GERMANY | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| GERMANY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| GERMANY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [5-10]% by value / [30-40]% by volume |
| GERMANY | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |
| GERMANY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| GERMANY | H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & SIMILAR --> OSILODROSTAT | [90-100]% by value / [90-100]% by volume |
| GERMANY | K4D OTH INF SOLS/INF ADDITS --> K4D0 OTH INF SOLS/INF ADDITS --> HEMIN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |

| | | |
|---|---|---|
| GERMANY | L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> CHLORMETHINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. ANTIBIOTICS --> DACTINOMYCIN | [90-100]% by value / [90-100]% by volume |
| GERMANY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC | [60-70]% by value / [90-100]% by volume |
| HUNGARY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| ITALY | 30C1 MODULES --> 30C1Z OTHER MODULES --> GENERAL NUTRIENTS | [50-60]% by value / [50-60]% by volume |
| ITALY | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| ITALY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| ITALY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [80-90]% by volume |
| ITALY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |

| | | |
|---|---|---|
| ITALY | B1E DIRECT THROMBIN INHIBIT. --> B1E0 DIRECT THROMBIN INHIBIT. --> ARGATROBAN | [90-100]% by value / [90-100]% by volume |
| ITALY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| ITALY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> CHLORMETHINE | [90-100]% by value / [90-100]% by volume |
| ITALY | L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. ANTIBIOTICS --> DACTINOMYCIN | [90-100]% by value / [90-100]% by volume |
| ITALY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [70-80]% by value / [70-80]% by volume |
| NETHERLANDS | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |

| | | |
|---|---|---|
| NETHERLANDS | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| NORWAY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| NORWAY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| NORWAY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| NORWAY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| NORWAY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| POLAND | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| POLAND | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |

| | | |
|---|---|---|
| POLAND | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| SPAIN | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| SPAIN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |
| CDMO services for FDPs | - |

| | | |
|---|---|---|
| SPAIN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [70-80]% by value / [60-70]% by volume |
| SPAIN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [30-40]% by value / [80-90]% by volume |
| SPAIN | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| SPAIN | V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC | [90-100]% by value / [90-100]% by volume |
| SWEDEN | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| SWEDEN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| SWEDEN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [70-80]% by value / [70-80]% by volume |
| SWEDEN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [10-20]% by value / [70-80]% by volume |
| SWEDEN | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| SWEDEN | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs | - |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| SWEDEN | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| BELGIUM | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| BELGIUM | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| BELGIUM | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [10-20]% by value / [60-70]% by volume |
| BELGIUM | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |
| BELGIUM | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| BULGARIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| BULGARIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> ACETYLSALICYLIC ACID | [60-70]% by value / [60-70]% by volume |
| CZECH REPUBLIC | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL | [70-80]% by value / [80-90]% by volume |
| CZECH REPUBLIC | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> ACETYLSALICYLIC ACID | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL!IRON METAL | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!CYANOCOBALAMIN!DEXPANTHENOL!INOSITOL!METHIONINE!NICOTINAMIDE!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!THIAMINE!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTHENOL!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> ASCORBIC ACID!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ASCORBIC ACID!COPPER!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [70-80]% by value / [60-70]% by volume |
| CZECH REPUBLIC | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> PROPIVERINE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> ACETYLSALICYLIC ACID | [60-70]% by value / [60-70]% by volume |
| CZECH REPUBLIC | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| ESTONIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| FINLAND | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [10-20]% by volume |
| FINLAND | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | 01A4 CHESTY COUGH PRODUCTS --> 01A4E EFFERVESCENT --> ACETYLCYSTEINE | [20-30]% by value / [30-40]% by volume |
| FRANCE | 01A4 CHESTY COUGH PRODUCTS --> 01A4P POWDERS --> ACETYLCYSTEINE | [30-40]% by value / [40-50]% by volume |
| FRANCE | 05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS --> COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO BILOBA!PYRIDOXINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | 10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> AESCULUS HIPPOCASTANUM!ASCORBIC ACID!DRACAENA LOUREIRI!VITAMIN E!VITIS VINIFERA | [90-100]% by value / [90-100]% by volume |
| FRANCE | 10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | 83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS --> COMPOSITION UNKNOWN | [50-60]% by value / [50-60]% by volume |
| FRANCE | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [50-60]% by value / [50-60]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| FRANCE | A6A DRUGS FOR CONSTIPATION --> A6A7 OSMOTIC LAXATS W ELECTRO --> MACROGOL(S) | [90-100]% by value / [90-100]% by volume |
| FRANCE | A6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> MACROGOL(S)!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| FRANCE | C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [40-50]% by value / [20-30]% by volume |
| FRANCE | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | G1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL --> METRONIDAZOLE!NEOMYCIN!NYSTATIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| FRANCE | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| FRANCE | H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & SIMILAR --> OSILODROSTAT | [90-100]% by value / [90-100]% by volume |
| FRANCE | J1F MACROLIDES & SIMILR TYPE --> J1F0 MACROLIDES & SIMILR TYPE --> ERYTHROMYCIN | [10-20]% by value / [80-90]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| FRANCE | R5C EXPECTORANTS --> R5C0 EXPECTORANTS --> ACETYLCYSTEINE | [30-40]% by value / [30-40]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BENZOIC ACID!BROMINE!CODEINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BROMOFORM!CODEINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC | [90-100]% by value / [90-100]% by volume |
| GERMANY | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> INULIN!PLANTAGO OVATA | [90-100]% by value / [90-100]% by volume |
| GERMANY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS | [90-100]% by value / [90-100]% by volume |
| GERMANY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR JUGURTI POLYSACCHARIDE | [90-100]% by value / [90-100]% by volume |
| GERMANY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS HELVETICUS | [90-100]% by value / [90-100]% by volume |
| GERMANY | 04F9 OTHER MINERAL SUPPLEMENTS --> 04F9M MIXTURES (ORAL) --> CALCIUM!MAGNESIUM!POTASSIUM | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| GERMANY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| GERMANY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [5-10]% by value / [30-40]% by volume |
| GERMANY | A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS | [90-100]% by value / [90-100]% by volume |
| GERMANY | A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR JUGURTI POLYSACCHARIDE | [90-100]% by value / [90-100]% by volume |
| GERMANY | A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-ORGANISM --> LACTOBACILLUS HELVETICUS | [90-100]% by value / [90-100]% by volume |
| GERMANY | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [60-70]% by value / [50-60]% by volume |
| GERMANY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| GERMANY | H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & SIMILAR --> OSILODROSTAT | [90-100]% by value / [90-100]% by volume |
| GERMANY | L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. ANTIBIOTICS --> DACTINOMYCIN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| GERMANY | M3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE RELAXANTS,CENTRAL --> METHOCARBAMOL | [70-80]% by value / [60-70]% by volume |
| GERMANY | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [60-70]% by value / [60-70]% by volume |
| GERMANY | V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC | [60-70]% by value / [90-100]% by volume |
| GREECE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| GREECE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| GREECE | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| GREECE | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| GREECE | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| HUNGARY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [50-60]% by value / [30-40]% by volume |
| HUNGARY | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| IRELAND | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| ITALY | 02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS --> ASCORBIC ACID!CHONDROITINSULFURIC ACID!COLLAGEN!DIMETHYL SULFONE!GLUCOSAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS --> ASCORBIC ACID!CHONDROITINSULFURIC ACID!DIMETHYL SULFONE!GLUCOSAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03A9 OTH DIGEST TRACT&STOM PRD --> 03A9C CAPS/TABS --> TILACTASE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03D9 OTHER ANTIDIARRHOEALS --> 03D9C CAPS/TABS --> DIMETICONE!LOPERAMIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> BACILLUS COAGULANS!PYRIDOXINE!THIAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> COLECALCIFEROL!LACTOBACILLUS REUTERI | [70-80]% by value / [70-80]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS REUTERI | [80-90]% by value / [80-90]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> BACILLUS COAGULANS!PYRIDOXINE!THIAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> COLECALCIFEROL!LACTOBACILLUS REUTERI | [50-60]% by value / [50-60]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> HELIANTHUS ANNUUS!LACTOBACILLUS REUTERI!MEDIUM CHAIN TRIGLYCERIDES (UNSPECIFIED) | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS REUTERI | [60-70]% by value / [60-70]% by volume |
| ITALY | 04F9 OTHER MINERAL SUPPLEMENTS --> 04F9C CAPS/TABS --> DIMETHYL SULFONE | [50-60]% by value / [70-80]% by volume |
| ITALY | 04F9 OTHER MINERAL SUPPLEMENTS --> 04F9P POWDERS --> DIMETHYL SULFONE | [90-100]% by value / [90-100]% by volume |
| ITALY | 04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO OFFICINALIS!COLECALCIFEROL!EUPHAUSIA SUPERBA!FISH!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| ITALY | 04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO OFFICINALIS!EUPHAUSIA SUPERBA!FISH!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| ITALY | 04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> ARGININE | [50-60]% by value / [50-60]% by volume |
| ITALY | 04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> ASCORBIC ACID!DIMETHYL SULFONE!UBIDECARENONE | [90-100]% by value / [90-100]% by volume |
| ITALY | 04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> LYSINE | [50-60]% by value / [60-70]% by volume |
| ITALY | 04H1 OTHER DIETARY SUPPLEMENTS --> 04H1P POWDERS --> INOSITOL | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [80-90]% by value / [80-90]% by volume |
| ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | 11A1 ANTINAUSEANTS --> 11A1C CAPS/TABS --> PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE | [90-100]% by value / [90-100]% by volume |
| ITALY | 11A1 ANTINAUSEANTS --> 11A1M MIXTURES (ORAL) --> CITRIC ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE | [90-100]% by value / [90-100]% by volume |
| ITALY | 11A1 ANTINAUSEANTS --> 11A1Z OTHER FORMS --> CITRIC ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE | [90-100]% by value / [90-100]% by volume |
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> FENTICONAZOLE | [50-60]% by value / [60-70]% by volume |
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | 12D9 OTHER GYNAECOLOGICAL PREP --> 12D9C CAPS/TABS --> DIOSCOREA VILLOSA | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| ITALY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| ITALY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [80-90]% by volume |
| ITALY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> DOMPERIDONE | [60-70]% by value / [60-70]% by volume |
| ITALY | A7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E2 INTEST CORTICOSTER PROD --> BUDESONIDE | [20-30]% by value / [30-40]% by volume |
| ITALY | A7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E9 INFLAM BOWEL DIS PRD OTH --> CROMOGLICIC ACID | [90-100]% by value / [90-100]% by volume |
| ITALY | A7H MOTILITY INHIBITORS --> A7H0 MOTILITY INHIBITORS --> DIMETICONE!LOPERAMIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | A9A DIGESTIVES INC.ENZYMES --> A9A0 DIGESTIVES INCL ENZYMES --> TILACTASE | [90-100]% by value / [90-100]% by volume |
| ITALY | C10A CHOLEST&TRIGLY.REGULATOR --> C10A1 STATINS (HMG-COA RED) --> LOVASTATIN | [70-80]% by value / [70-80]% by volume |
| ITALY | C1X ALL OTHER CARDIAC PREPS --> C1X0 ALL OTHER CARDIAC PREPS --> ALPROSTADIL ALFADEX | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| ITALY | C4A CEREBR/PERIPH VASOTHERAP --> C4A2 CA ANTAG W CEREB ACTIV --> CINNARIZINE | [40-50]% by value / [50-60]% by volume |
| ITALY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> BISOPROLOL | [30-40]% by value / [20-30]% by volume |
| ITALY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [20-30]% by volume |
| ITALY | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [60-70]% by value / [90-100]% by volume |
| ITALY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | J1D CEPHALOSPORINS & COMBS --> J1D1 CEPHALOSPORINS,ORAL --> CEFTIBUTEN | [90-100]% by value / [90-100]% by volume |
| ITALY | J1D CEPHALOSPORINS & COMBS --> J1D2 CEPHALOSPORINS,PARENT. --> CEFODIZIME | [90-100]% by value / [90-100]% by volume |
| ITALY | L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. ANTIBIOTICS --> DACTINOMYCIN | [90-100]% by value / [90-100]% by volume |
| ITALY | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| ITALY | R6A ANTIHISTAMINES SYSTEMIC --> R6A0 ANTIHISTAMINES SYSTEMIC --> RUPATADINE | [30-40]% by value / [30-40]% by volume |
| ITALY | V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC | [90-100]% by value / [90-100]% by volume |
| LATVIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [40-50]% by value / [20-30]% by volume |
| LITHUANIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [70-80]% by value / [70-80]% by volume |
| LITHUANIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| LUXEMBOURG | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [70-80]% by value / [70-80]% by volume |
| NETHERLANDS | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| NETHERLANDS | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [80-90]% by value / [80-90]% by volume |
| NORWAY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| NORWAY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| NORWAY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [10-20]% by volume |
| NORWAY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| POLAND | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC ACID!LACTOFERRIN | [90-100]% by value / [90-100]% by volume |
| POLAND | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC ACID!LACTOFERRIN!MENTHOL | [90-100]% by value / [90-100]% by volume |
| POLAND | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| POLAND | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| POLAND | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| POLAND | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [20-30]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> SISYMBRIUM OFFICINALE | [70-80]% by value / [80-90]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1G GARGLES --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> CITRIC ACID!DODECYL SULFOACETIC ACID | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS LACTIS | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS LACTIS | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 05A1 TONICS --> 05A1Z OTHER FORMS --> ASCORBIC ACID!CAFFEINE!GLUCURONAMIDE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> COLECALCIFEROL | [30-40]% by value / [10-20]% by volume |
| PORTUGAL | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A2B ANTIULCERANTS --> A2B9 ALL OTHER ANTIULCERANTS --> SUCRALFATE | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | A5B HEPATIC PROCT LIPOTROPIC --> A5B0 HEPATIC PROCT LIPOTROPIC --> ASCORBIC ACID!CAFFEINE!GLUCURONAMIDE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A6A DRUGS FOR CONSTIPATION --> A6A4 LAXATIVE ENEMAS --> CITRIC ACID!DODECYL SULFOACETIC ACID | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | C9D ANGIOTEN-II ANTAG, COMB --> C9D3 AT2 ANTG COMB CALC ANTAG --> AMLODIPINE!CANDESARTAN CILEXETIL | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| PORTUGAL | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> DEXIBUPROFEN | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | M4A ANTI-GOUT PREPARATIONS --> M4A0 ANTI-GOUT PREPARATIONS --> COLCHICINE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | N5C TRANQUILLISERS --> N5C0 TRANQUILLISERS --> CLOXAZOLAM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> SISYMBRIUM OFFICINALE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> FRUCTOOLIGSACCHARIDES!MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> INULIN!MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM!COLECALCIFEROL | [30-40]% by value / [20-30]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| ROMANIA | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE THERAPY,SYSTEM. --> DIOSMIN | [80-90]% by value / [90-100]% by volume |
| ROMANIA | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | G1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL --> METRONIDAZOLE!NEOMYCIN!NYSTATIN | [90-100]% by value / [90-100]% by volume |
| ROMANIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> ACETYLSALICYLIC ACID | [80-90]% by value / [80-90]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> ACETYLSALICYLIC ACID | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> ACETYLSALICYLIC ACID!ASCORBIC ACID | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| SLOVAKIA | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL + IRON METAL | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> SILYMARIN | [70-80]% by value / [80-90]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!XANTOFYL!ZINC | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> CHROMIUM!COLECALCIFEROL!FOLIC ACID!THIOCTIC ACID!XANTOFYL | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| SLOVAKIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [30-40]% by volume |
| SLOVAKIA | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> PROPIVERINE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> ACETYLSALICYLIC ACID | [80-90]% by value / [80-90]% by volume |
| SLOVAKIA | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | S1K DRY EYE PRODUCTS --> S1K1 ARTIFIC TEAR&OCUL LUBRIC --> HYALURONIC ACID!MALVA SYLVESTRIS | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> VEGETABLE FIBRE | [70-80]% by value / [0-5]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS LACTIS | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1Z OTHER FORMS --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| SPAIN | 08A1 EAR CARE --> 08A1Z OTHER FORMS --> LACTOBACILLUS SALIVARIUS | [90-100]% by value / [90-100]% by volume |
| SPAIN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| SPAIN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [70-80]% by value / [60-70]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals |

| | | |
|---|---|---|
| SPAIN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [30-40]% by value / [80-90]% by volume |
| SPAIN | A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> CINITAPRIDE | [70-80]% by value / [70-80]% by volume |
| SPAIN | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [80-90]% by value / [80-90]% by volume |
| SPAIN | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| SPAIN | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [90-100]% by value / [90-100]% by volume |
| SPAIN | V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC | [90-100]% by value / [90-100]% by volume |
| SWEDEN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| SWEDEN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [70-80]% by value / [70-80]% by volume |
| SWEDEN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [10-20]% by value / [70-80]% by volume |
| SWEDEN | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| AUSTRIA | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |
| BELGIUM | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |
| BELGIUM | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| BULGARIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> ASCORBIC ACID!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ASCORBIC ACID!COPPER!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES NAPPY RASH --> COD LIVER OIL!PANTHENOL!PRUNUS AMYGDALUS (DULCIS)!VITAMIN E!ZINC | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES NAPPY RASH --> COD LIVER OIL!PARAFFIN OIL!WHITE BEESWAX!ZINC | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| FINLAND | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [10-20]% by volume |
| FRANCE | 01A9 OTHER COUGH PRODUCTS --> 01A9Z OTHER FORMS --> CALENDULA OFFICINALIS!EUCALYPTUS GLOBULUS!LINUM USITATISSIMUM!PROPOLIS | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| FRANCE | 01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS --> SODIUM | [80-90]% by value / [80-90]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE BARBADENSIS!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALGINIC ACID!ALOE BARBADENSIS!GLYCEROL!GLYCYRRHIZA GLABRA!HYALURONIC ACID!MENTHOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |
| FRANCE | 05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS --> COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO BILOBA!PYRIDOXINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE | [90-100]% by value / [90-100]% by volume |
| FRANCE | 10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | 83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS --> COMPOSITION UNKNOWN | [50-60]% by value / [50-60]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| FRANCE | 87B3 ADULT MOUTHWASHES --> 87B3D MOUTHWASH FOR BLEED GUM&G --> COMPOSITION UNKNOWN | [50-60]% by value / [70-80]% by volume |
| FRANCE | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| FRANCE | A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE | [90-100]% by value / [90-100]% by volume |
| FRANCE | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |
| FRANCE | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [40-50]% by value / [20-30]% by volume |
| FRANCE | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| FRANCE | L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> CHLORMETHINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| FRANCE | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | S2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> RIFAMYCIN | [90-100]% by value / [90-100]% by volume |
| GERMANY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> 2-PROPANOL | [60-70]% by value / [50-60]% by volume |
| GERMANY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1Z OTHER FORMS --> 2-PROPANOL | [40-50]% by value / [40-50]% by volume |
| GERMANY | 06F3 WOUND HEALING PROD --> 06F3A AEROSOLS/SPRAYS --> ZINC | [90-100]% by value / [90-100]% by volume |
| GERMANY | 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> ZINC | [50-60]% by value / [20-30]% by volume |
| GERMANY | 06L1 WART/CORN REMOV EXC PLAST --> 06L1L LIQUIDS (TOPICAL) --> SALICYLIC ACID | [90-100]% by value / [90-100]% by volume |
| GERMANY | 12F9 PR FR OT UROLOG MALE COND --> 12F9Z OTHER FORMS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | 18A2 NON-CLASSIFIABLE HERBAL P --> 18A2Z OTHER FORMS --> MENTHA ARVENSIS | [70-80]% by value / [20-30]% by volume |
| GERMANY | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| GERMANY | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |
| GERMANY | D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING AGENTS --> COD LIVER OIL!LEVOMENOL!ZINC | [90-100]% by value / [90-100]% by volume |
| GERMANY | D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING AGENTS --> ZINC | [70-80]% by value / [60-70]% by volume |
| GERMANY | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> OXYBUTYNIN | [30-40]% by value / [0-5]% by volume |
| GERMANY | G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL PRODS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| GERMANY | H2A PLAIN CORTICOSTEROIDS --> H2A1 INJ CORTICOSTEROIDS PLN --> DEXAMETHASONE | [40-50]% by value / [10-20]% by volume |
| GERMANY | L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> CHLORMETHINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> 2-PROPANOL | [50-60]% by value / [50-60]% by volume |
| GERMANY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| GERMANY | V3X ALL OTH.THERAPEUTIC PRDS --> V3X4 CURE-ALL PREPARATIONS --> MENTHA ARVENSIS | [90-100]% by value / [90-100]% by volume |
| GREECE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| GREECE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| GREECE | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| GREECE | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| HUNGARY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| HUNGARY | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| IRELAND | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> OXYBUTYNIN | [30-40]% by value / [5-10]% by volume |
| ITALY | 01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS --> ALOE BARBADENSIS!MATRICARIA CHAMOMILLA!SEA WATER | [90-100]% by value / [90-100]% by volume |
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!ENOXOLONE!HYALURONIC ACID!RICINUS COMMUNIS | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS COMMUNIS | [90-100]% by value / [90-100]% by volume |
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!BENZETHONIUM CHLORIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!ENOXOLONE!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS COMMUNIS | [90-100]% by value / [90-100]% by volume |
| ITALY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1L LIQUIDS (TOPICAL) --> DICLOFENAC | [90-100]% by value / [90-100]% by volume |
| ITALY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> NAPROXEN | [40-50]% by value / [40-50]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> BACILLUS COAGULANS!PYRIDOXINE!THIAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> COLECALCIFEROL!LACTOBACILLUS REUTERI | [70-80]% by value / [70-80]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS REUTERI | [80-90]% by value / [80-90]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> ASCORBIC ACID!BIFIDOBACTERIUM BIFIDUS!LACTOBACILLUS ACIDOPHILUS | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> BACILLUS COAGULANS!PYRIDOXINE!THIAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> COLECALCIFEROL!LACTOBACILLUS REUTERI | [50-60]% by value / [50-60]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> HELIANTHUS ANNUUS!LACTOBACILLUS REUTERI!MEDIUM CHAIN TRIGLYCERIDES (UNSPECIFIED) | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS REUTERI | [60-70]% by value / [60-70]% by volume |
| ITALY | 03G1 ANTACIDS --> 03G1M MIXTURES (ORAL) --> HOMOEOPATHIC MEDICINES | [90-100]% by value / [90-100]% by volume |
| ITALY | 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> HYALURONIC ACID!JOJOBA OIL!PANTHENOL!SILVER | [90-100]% by value / [90-100]% by volume |
| ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [80-90]% by value / [80-90]% by volume |
| ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | 07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> HYALURONIC ACID!MALVA SYLVESTRIS | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| ITALY | 07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> HYALURONIC ACID!SODIUM!TROMETAMOL | [90-100]% by value / [90-100]% by volume |
| ITALY | 07A5 EYE DECONG & ANTI-INFLAM --> 07A5N EYE DROPS --> EUPHRASIA OFFICINALIS!HAMAMELIS VIRGINIANA!MATRICARIA CHAMOMILLA!PHOSPHORIC ACID!SODIUM | [90-100]% by value / [90-100]% by volume |
| ITALY | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> CHLORHEXIDINE!FLUORINE!MELISSA OFFICINALIS!MENTHA PIPERITA!MENTHA VIRIDIS!SYZYGIUM AROMATICUM!XYLITOL | [90-100]% by value / [90-100]% by volume |
| ITALY | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> COMPOSITION UNKNOWN | [60-70]% by value / [80-90]% by volume |
| ITALY | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 11A1 ANTINAUSEANTS --> 11A1C CAPS/TABS --> PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE | [90-100]% by value / [90-100]% by volume |
| ITALY | 11A1 ANTINAUSEANTS --> 11A1M MIXTURES (ORAL) --> CITRIC ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE | [90-100]% by value / [90-100]% by volume |
| ITALY | 11A1 ANTINAUSEANTS --> 11A1Z OTHER FORMS --> CITRIC ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE | [90-100]% by value / [90-100]% by volume |
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> FENTICONAZOLE | [50-60]% by value / [60-70]% by volume |
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | 18A2 NON-CLASSIFIABLE HERBAL P --> 18A2C CAPS/TABS --> BORAGO OFFICINALIS | [20-30]% by value / [30-40]% by volume |
| ITALY | 30C1 MODULES --> 30C1Z OTHER MODULES --> GENERAL NUTRIENTS | [50-60]% by value / [50-60]% by volume |
| ITALY | 87A3 ADULT TOOTHPASTES --> 87A3C TOOTHPAST.SENSITIVE TEETH --> CHLORHEXIDINE!MELISSA OFFICINALIS!MENTHA PIPERITA!XYLITOL | [90-100]% by value / [90-100]% by volume |
| ITALY | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| ITALY | A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> DOMPERIDONE | [60-70]% by value / [60-70]% by volume |
| ITALY | B1E DIRECT THROMBIN INHIBIT. --> B1E0 DIRECT THROMBIN INHIBIT. --> ARGATROBAN | [90-100]% by value / [90-100]% by volume |
| ITALY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| ITALY | C4A CEREBR/PERIPH VASOTHERAP --> C4A2 CA ANTAG W CEREB ACTIV --> CINNARIZINE | [40-50]% by value / [50-60]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| ITALY | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A1 A-HAEMORRHOIDL+CORTICOID --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| ITALY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [20-30]% by volume |
| ITALY | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [60-70]% by value / [90-100]% by volume |
| ITALY | G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL PRODS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| ITALY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> CHLORMETHINE | [90-100]% by value / [90-100]% by volume |
| ITALY | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> NAPROXEN | [50-60]% by value / [40-50]% by volume |
| ITALY | R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> BUDESONIDE | [60-70]% by value / [60-70]% by volume (CVC share [70-80]% by value / [70-80]% by volume) |
| ITALY | R3D CORTICOIDS --> R3D1 CORTICOIDS INHALANTS --> BUDESONIDE | [60-70]% by value / [50-60]% by volume (CVC share [60-70]% by value / [60-70]% by volume) |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| ITALY | R6A ANTIHISTAMINES SYSTEMIC --> R6A0 ANTIHISTAMINES SYSTEMIC --> RUPATADINE | [30-40]% by value / [30-40]% by volume |
| ITALY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | S2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> CIPROFLOXACIN | [90-100]% by value / [90-100]% by volume |
| ITALY | S2C STEROID/ANTI-INFECT-EAR --> S2C0 STEROID/ANTI-INFECT-EAR --> CIPROFLOXACIN!FLUOCINOLONE ACETONIDE | [90-100]% by value / [90-100]% by volume |
| LATVIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LATVIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LATVIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LITHUANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LITHUANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LITHUANIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| LITHUANIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| LUXEMBOURG | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| NORWAY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| NORWAY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [10-20]% by volume |
| NORWAY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| NORWAY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| POLAND | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [50-60]% by value / [60-70]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| POLAND | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| POLAND | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| POLAND | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| POLAND | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [70-80]% by value / [60-70]% by volume |
| POLAND | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!CAPSICUM OLEORESIN!CETYLPYRIDINIUM!CROCUS SATIVUS!ENOXOLONE!HYALURONIC ACID!MALTODEXTRIN!SORBIC ACID!XANTHAN GUM!XYLITOL | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS LACTIS | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS LACTIS | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 06G2 ANTIFUNGALS FOR NAILS --> 06G2L LIQUIDS (TOPICAL) --> COPPER + DL-LACTIC ACID + SODIUM + THYMUS VULGARE + UREA | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A2B ANTIULCERANTS --> A2B9 ALL OTHER ANTIULCERANTS --> SUCRALFATE | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | G4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD OTH --> ALPROSTADIL | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| ROMANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!XANTOFYL!ZINC | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> CHROMIUM!COLECALCIFEROL!FOLIC ACID!THIOCTIC ACID!XANTOFYL | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | S1K DRY EYE PRODUCTS --> S1K1 ARTIFIC TEAR&OCUL LUBRIC --> HYALURONIC ACID!MALVA SYLVESTRIS | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS LACTIS | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1Z OTHER FORMS --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| SPAIN | 86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-AERO+SPRAY --> COMPOSITION UNKNOWN | [40-50]% by value / [10-20]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | liquid and semi-solid pharmaceuticals |

| | | |
|---|---|---|
| SPAIN | 86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-AERO+SPRAY --> DIMETICONE!JOJOBA OIL | [90-100]% by value / [90-100]% by volume |
| SPAIN | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| SPAIN | A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> CINITAPRIDE | [70-80]% by value / [70-80]% by volume |
| SPAIN | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| SPAIN | G4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD OTH --> ALPROSTADIL | [40-50]% by value / [50-60]% by volume |
| SPAIN | G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL PRODS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| SWEDEN | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| SWEDEN | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| SWEDEN | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| SWEDEN | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |

| | | |
|---|---|---|
| AUSTRIA | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |
| BELGIUM | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |
| BELGIUM | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL!IRON METAL | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [70-80]% by value / [60-70]% by volume |
| ESTONIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |
| FINLAND | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [10-20]% by volume |
| FRANCE | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |

| | | |
|---|---|---|
| FRANCE | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [40-50]% by value / [20-30]% by volume |
| FRANCE | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| FRANCE | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |
| GERMANY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| GERMANY | H2A PLAIN CORTICOSTEROIDS --> H2A1 INJ CORTICOSTEROIDS PLN --> DEXAMETHASONE | [40-50]% by value / [10-20]% by volume |
| GERMANY | K4D OTH INF SOLS/INF ADDITS --> K4D0 OTH INF SOLS/INF ADDITS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| GERMANY | M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> LIDOCAINE!PHENYLBUTAZONE!PROPYLENE GLYCOL | [90-100]% by value / [90-100]% by volume |
| GERMANY | M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> PHENYLBUTAZONE | [90-100]% by value / [90-100]% by volume |
| GERMANY | M3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE RELAXANTS,CENTRAL --> METHOCARBAMOL | [70-80]% by value / [60-70]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |

| | | |
|---|---|---|
| GERMANY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| HUNGARY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| HUNGARY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [50-60]% by value / [30-40]% by volume |
| ITALY | 07A2 EYE ANTIALLERGICS --> 07A2N EYE DROPS --> NAPHAZOLINE!THONZYLAMINE | [70-80]% by value / [60-70]% by volume |
| ITALY | 07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> HYALURONIC ACID!MALVA SYLVESTRIS | [90-100]% by value / [90-100]% by volume |
| ITALY | 07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> HYALURONIC ACID!SODIUM!TROMETAMOL | [90-100]% by value / [90-100]% by volume |
| ITALY | 07A5 EYE DECONG & ANTI-INFLAM --> 07A5N EYE DROPS --> EUPHRASIA OFFICINALIS!HAMAMELIS VIRGINIANA!MATRICARIA CHAMOMILLA!PHOSPHORIC ACID!SODIUM | [90-100]% by value / [90-100]% by volume |
| ITALY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| ITALY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [20-30]% by volume |
| ITALY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |

| | | |
|---|---|---|
| ITALY | S1G OCUL.A-ALLER.DECON.A-SEP --> S1G1 OCUL.A-ALLERG.ANTIHIST. --> NAPHAZOLINE!THONZYLAMINE | [70-80]% by value / [60-70]% by volume |
| ITALY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| LITHUANIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [70-80]% by value / [70-80]% by volume |
| LUXEMBOURG | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| NORWAY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| NORWAY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [10-20]% by volume |
| NORWAY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | sterile liquid pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |

| | | |
|---|---|---|
| NORWAY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| POLAND | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [20-30]% by volume |
| PORTUGAL | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL + IRON METAL | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [30-40]% by volume |
| SPAIN | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| SWEDEN | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| SWEDEN | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| SWEDEN | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |

| | | |
|---|---|---|
| CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE BARBADENSIS!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALGINIC ACID!ALOE BARBADENSIS!GLYCEROL!GLYCYRRHIZA GLABRA!HYALURONIC ACID!MENTHOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |
| FRANCE | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE | [90-100]% by value / [90-100]% by volume |
| FRANCE | 87B3 ADULT MOUTHWASHES --> 87B3D MOUTHWASH FOR BLEED GUM&G --> COMPOSITION UNKNOWN | [50-60]% by value / [70-80]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |

| | | |
|---|---|---|
| FRANCE | A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE | [90-100]% by value / [90-100]% by volume |
| GERMANY | 06F3 WOUND HEALING PROD --> 06F3A AEROSOLS/SPRAYS --> ZINC | [90-100]% by value / [90-100]% by volume |
| GERMANY | 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> ZINC | [50-60]% by value / [20-30]% by volume |
| GERMANY | D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING AGENTS --> COD LIVER OIL!LEVOMENOL!ZINC | [90-100]% by value / [90-100]% by volume |
| GERMANY | D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING AGENTS --> ZINC | [70-80]% by value / [60-70]% by volume |
| ITALY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES --> FLURBIPROFEN | [90-100]% by value / [90-100]% by volume |
| ITALY | 03G1 ANTACIDS --> 03G1M MIXTURES (ORAL) --> HOMOEOPATHIC MEDICINES | [90-100]% by value / [90-100]% by volume |
| ITALY | 87A3 ADULT TOOTHPASTES --> 87A3C TOOTHPAST.SENSITIVE TEETH --> CHLORHEXIDINE!MELISSA OFFICINALIS!MENTHA PIPERITA!XYLITOL | [90-100]% by value / [90-100]% by volume |
| ITALY | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> FLURBIPROFEN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |

| | | |
|---|---|---|
| LATVIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LATVIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LATVIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LITHUANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LITHUANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LITHUANIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1G GARGLES --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES --> FLURBIPROFEN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | medicated confectionary pharmaceuticals |

| | | |
|---|---|---|
| PORTUGAL | A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> COLECALCIFEROL | [30-40]% by value / [10-20]% by volume |
| PORTUGAL | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> FLURBIPROFEN | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | toxicity |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | toxicity |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | toxicity |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | toxicity |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | toxicity |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | toxicity |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | toxicity |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | toxicity |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | toxicity |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | toxicity |

| | | |
|---|---|---|
| FRANCE | H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & SIMILAR --> OSILODROSTAT | [90-100]% by value / [90-100]% by volume |
| FRANCE | J1F MACROLIDES & SIMILR TYPE --> J1F0 MACROLIDES & SIMILR TYPE --> ERYTHROMYCIN | [10-20]% by value / [80-90]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BENZOIC ACID!BROMINE!CODEINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BROMOFORM!CODEINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | S2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> RIFAMYCIN | [90-100]% by value / [90-100]% by volume |
| GERMANY | H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & SIMILAR --> OSILODROSTAT | [90-100]% by value / [90-100]% by volume |
| GERMANY | L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. ANTIBIOTICS --> DACTINOMYCIN | [90-100]% by value / [90-100]% by volume |
| ITALY | J1D CEPHALOSPORINS & COMBS --> J1D1 CEPHALOSPORINS,ORAL --> CEFTIBUTEN | [90-100]% by value / [90-100]% by volume |
| ITALY | J1D CEPHALOSPORINS & COMBS --> J1D2 CEPHALOSPORINS,PARENT. --> CEFODIZIME | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | toxicity |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |

| | | |
|---|---|---|
| ITALY | L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. ANTIBIOTICS --> DACTINOMYCIN | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |
| BELGIUM | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [70-80]% by value / [60-70]% by volume |
| ESTONIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |
| FRANCE | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |
| FRANCE | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| FRANCE | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |

| | | |
|---|---|---|
| GERMANY | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |
| GERMANY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| GERMANY | H2A PLAIN CORTICOSTEROIDS --> H2A1 INJ CORTICOSTEROIDS PLN --> DEXAMETHASONE | [40-50]% by value / [10-20]% by volume |
| GERMANY | K4D OTH INF SOLS/INF ADDITS --> K4D0 OTH INF SOLS/INF ADDITS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| GERMANY | M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> LIDOCAINE!PHENYLBUTAZONE!PROPYLENE GLYCOL | [90-100]% by value / [90-100]% by volume |
| GERMANY | M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> PHENYLBUTAZONE | [90-100]% by value / [90-100]% by volume |
| GERMANY | M3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE RELAXANTS,CENTRAL --> METHOCARBAMOL | [70-80]% by value / [60-70]% by volume |
| GERMANY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| HUNGARY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| HUNGARY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [50-60]% by value / [30-40]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |

| | | |
|---|---|---|
| ITALY | 07A2 EYE ANTIALLERGICS --> 07A2N EYE DROPS --> NAPHAZOLINE!THONZYLAMINE | [70-80]% by value / [60-70]% by volume |
| ITALY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| ITALY | C1X ALL OTHER CARDIAC PREPS --> C1X0 ALL OTHER CARDIAC PREPS --> ALPROSTADIL ALFADEX | [90-100]% by value / [90-100]% by volume |
| ITALY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | J1D CEPHALOSPORINS & COMBS --> J1D2 CEPHALOSPORINS,PARENT. --> CEFODIZIME | [90-100]% by value / [90-100]% by volume |
| ITALY | S1G OCUL.A-ALLER.DECON.A-SEP --> S1G1 OCUL.A-ALLERG.ANTIHIST. --> NAPHAZOLINE!THONZYLAMINE | [70-80]% by value / [60-70]% by volume |
| ITALY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| LITHUANIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [70-80]% by value / [70-80]% by volume |
| NETHERLANDS | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |

| | | |
|---|---|---|
| NETHERLANDS | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| NORWAY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| NORWAY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| NORWAY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| POLAND | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [20-30]% by volume |
| PORTUGAL | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [30-40]% by volume |
| SPAIN | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| SWEDEN | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| SWEDEN | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |

| | | |
|---|---|---|
| SWEDEN | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| BELGIUM | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |
| BELGIUM | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| BELGIUM | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| BULGARIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |
| BULGARIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [70-80]% by value / [60-70]% by volume |
| CZECH REPUBLIC | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ESTONIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |

| | | |
|---|---|---|
| FINLAND | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [10-20]% by volume |
| FINLAND | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [40-50]% by value / [20-30]% by volume |
| FRANCE | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | 12F9 PR FR OT UROLOG MALE COND --> 12F9Z OTHER FORMS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [60-70]% by value / [50-60]% by volume |
| GERMANY | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> OXYBUTYNIN | [30-40]% by value / [0-5]% by volume |
| GERMANY | G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL PRODS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |

| | | |
|---|---|---|
| GERMANY | L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. ANTIBIOTICS --> DACTINOMYCIN | [90-100]% by value / [90-100]% by volume |
| GERMANY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| GREECE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| GREECE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| GREECE | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| GREECE | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| GREECE | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| HUNGARY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| HUNGARY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [50-60]% by value / [30-40]% by volume |
| HUNGARY | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |

| | | |
|---|---|---|
| HUNGARY | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| IRELAND | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> OXYBUTYNIN | [30-40]% by value / [5-10]% by volume |
| ITALY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES --> FLURBIPROFEN | [90-100]% by value / [90-100]% by volume |
| ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [80-90]% by value / [80-90]% by volume |
| ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> FENTICONAZOLE | [50-60]% by value / [60-70]% by volume |
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |

| | | |
|---|---|---|
| ITALY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [20-30]% by volume |
| ITALY | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [60-70]% by value / [90-100]% by volume |
| ITALY | G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL PRODS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| ITALY | L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. ANTIBIOTICS --> DACTINOMYCIN | [90-100]% by value / [90-100]% by volume |
| ITALY | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> FLURBIPROFEN | [90-100]% by value / [90-100]% by volume |
| ITALY | R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> BUDESONIDE | [60-70]% by value / [60-70]% by volume (CVC share [70-80]% by value / [70-80]% by volume) |
| ITALY | R3D CORTICOIDS --> R3D1 CORTICOIDS INHALANTS --> BUDESONIDE | [60-70]% by value / [50-60]% by volume (CVC share [60-70]% by value / [60-70]% by volume) |
| ITALY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| LATVIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [40-50]% by value / [20-30]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |

| | | |
|---|---|---|
| LITHUANIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [70-80]% by value / [70-80]% by volume |
| LITHUANIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| LUXEMBOURG | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| NORWAY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| NORWAY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [10-20]% by volume |
| NORWAY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| POLAND | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| POLAND | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |

| | | |
|---|---|---|
| POLAND | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [20-30]% by volume |
| POLAND | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES --> FLURBIPROFEN | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | G4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD OTH --> ALPROSTADIL | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> FLURBIPROFEN | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [30-40]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | nature of the technology/know-how needed to produce the FDP |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| SPAIN | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| SPAIN | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [80-90]% by value / [80-90]% by volume |
| SPAIN | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| SPAIN | G4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD OTH --> ALPROSTADIL | [40-50]% by value / [50-60]% by volume |
| SPAIN | G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL PRODS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| SWEDEN | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| SWEDEN | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| AUSTRIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |
| BELGIUM | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| BELGIUM | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| BELGIUM | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [10-20]% by value / [60-70]% by volume |
| BELGIUM | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |
| BELGIUM | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| BELGIUM | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| BULGARIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |
| BULGARIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| CZECH REPUBLIC | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> ACETYLSALICYLIC ACID | [60-70]% by value / [60-70]% by volume |
| CZECH REPUBLIC | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL | [70-80]% by value / [80-90]% by volume |
| CZECH REPUBLIC | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> ACETYLSALICYLIC ACID | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL!IRON METAL | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!CYANOCOBALAMIN!DEXPANTHENOL!INOSITOL!METHIONINE!NICOTINAMIDE!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!THIAMINE!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTHENOL!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> ASCORBIC ACID!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ASCORBIC ACID!COPPER!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [70-80]% by value / [60-70]% by volume |
| CZECH REPUBLIC | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> PROPIVERINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| CZECH REPUBLIC | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> ACETYLSALICYLIC ACID | [60-70]% by value / [60-70]% by volume |
| CZECH REPUBLIC | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| ESTONIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |
| FINLAND | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [10-20]% by volume |
| FINLAND | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | 01A4 CHESTY COUGH PRODUCTS --> 01A4E EFFERVESCENT --> ACETYLCYSTEINE | [20-30]% by value / [30-40]% by volume |
| FRANCE | 01A4 CHESTY COUGH PRODUCTS --> 01A4P POWDERS --> ACETYLCYSTEINE | [30-40]% by value / [40-50]% by volume |
| FRANCE | 01A9 OTHER COUGH PRODUCTS --> 01A9Z OTHER FORMS --> CALENDULA OFFICINALIS!EUCALYPTUS GLOBULUS!LINUM USITATISSIMUM!PROPOLIS | [90-100]% by value / [90-100]% by volume |
| FRANCE | 01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS --> SODIUM | [80-90]% by value / [80-90]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE BARBADENSIS!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALGINIC ACID!ALOE BARBADENSIS!GLYCEROL!GLYCYRRHIZA GLABRA!HYALURONIC ACID!MENTHOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |
| FRANCE | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE | [90-100]% by value / [90-100]% by volume |
| FRANCE | 87B3 ADULT MOUTHWASHES --> 87B3D MOUTHWASH FOR BLEED GUM&G --> COMPOSITION UNKNOWN | [50-60]% by value / [70-80]% by volume |
| FRANCE | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| FRANCE | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [50-60]% by value / [50-60]% by volume |
| FRANCE | A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| FRANCE | A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE | [90-100]% by value / [90-100]% by volume |
| FRANCE | A6A DRUGS FOR CONSTIPATION --> A6A7 OSMOTIC LAXATS W ELECTRO --> MACROGOL(S) | [90-100]% by value / [90-100]% by volume |
| FRANCE | A6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> MACROGOL(S)!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| FRANCE | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |
| FRANCE | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [40-50]% by value / [20-30]% by volume |
| FRANCE | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | G1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL --> METRONIDAZOLE!NEOMYCIN!NYSTATIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| FRANCE | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| FRANCE | H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & SIMILAR --> OSILODROSTAT | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| FRANCE | J1F MACROLIDES & SIMILR TYPE --> J1F0 MACROLIDES & SIMILR TYPE --> ERYTHROMYCIN | [10-20]% by value / [80-90]% by volume |
| FRANCE | L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> CHLORMETHINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | R5C EXPECTORANTS --> R5C0 EXPECTORANTS --> ACETYLCYSTEINE | [30-40]% by value / [30-40]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BENZOIC ACID!BROMINE!CODEINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BROMOFORM!CODEINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | S2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> RIFAMYCIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC | [90-100]% by value / [90-100]% by volume |
| GERMANY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> 2-PROPANOL | [60-70]% by value / [50-60]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| GERMANY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1Z OTHER FORMS --> 2-PROPANOL | [40-50]% by value / [40-50]% by volume |
| GERMANY | 04F9 OTHER MINERAL SUPPLEMENTS --> 04F9M MIXTURES (ORAL) --> CALCIUM!MAGNESIUM!POTASSIUM | [90-100]% by value / [90-100]% by volume |
| GERMANY | 06F3 WOUND HEALING PROD --> 06F3A AEROSOLS/SPRAYS --> ZINC | [90-100]% by value / [90-100]% by volume |
| GERMANY | 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> ZINC | [50-60]% by value / [20-30]% by volume |
| GERMANY | 06L1 WART/CORN REMOV EXC PLAST --> 06L1L LIQUIDS (TOPICAL) --> SALICYLIC ACID | [90-100]% by value / [90-100]% by volume |
| GERMANY | 12F9 PR FR OT UROLOG MALE COND --> 12F9Z OTHER FORMS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | 18A2 NON-CLASSIFIABLE HERBAL P --> 18A2Z OTHER FORMS --> MENTHA ARVENSIS | [70-80]% by value / [20-30]% by volume |
| GERMANY | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| GERMANY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| GERMANY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [5-10]% by value / [30-40]% by volume |
| GERMANY | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |
| GERMANY | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [60-70]% by value / [50-60]% by volume |
| GERMANY | D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING AGENTS --> COD LIVER OIL!LEVOMENOL!ZINC | [90-100]% by value / [90-100]% by volume |
| GERMANY | D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING AGENTS --> ZINC | [70-80]% by value / [60-70]% by volume |
| GERMANY | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> OXYBUTYNIN | [30-40]% by value / [0-5]% by volume |
| GERMANY | G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL PRODS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| GERMANY | H2A PLAIN CORTICOSTEROIDS --> H2A1 INJ CORTICOSTEROIDS PLN --> DEXAMETHASONE | [40-50]% by value / [10-20]% by volume |
| GERMANY | H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & SIMILAR --> OSILODROSTAT | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| GERMANY | L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> CHLORMETHINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> LIDOCAINE!PHENYLBUTAZONE!PROPYLENE GLYCOL | [90-100]% by value / [90-100]% by volume |
| GERMANY | M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> PHENYLBUTAZONE | [90-100]% by value / [90-100]% by volume |
| GERMANY | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> 2-PROPANOL | [50-60]% by value / [50-60]% by volume |
| GERMANY | M3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE RELAXANTS,CENTRAL --> METHOCARBAMOL | [70-80]% by value / [60-70]% by volume |
| GERMANY | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [60-70]% by value / [60-70]% by volume |
| GERMANY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC | [60-70]% by value / [90-100]% by volume |
| GERMANY | V3X ALL OTH.THERAPEUTIC PRDS --> V3X4 CURE-ALL PREPARATIONS --> MENTHA ARVENSIS | [90-100]% by value / [90-100]% by volume |
| GREECE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| GREECE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| GREECE | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| GREECE | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| GREECE | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| HUNGARY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [50-60]% by value / [30-40]% by volume |
| HUNGARY | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| HUNGARY | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| IRELAND | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| IRELAND | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> OXYBUTYNIN | [30-40]% by value / [5-10]% by volume |
| ITALY | 01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS --> ALOE BARBADENSIS!MATRICARIA CHAMOMILLA!SEA WATER | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!ENOXOLONE!HYALURONIC ACID!RICINUS COMMUNIS | [90-100]% by value / [90-100]% by volume |
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS COMMUNIS | [90-100]% by value / [90-100]% by volume |
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!BENZETHONIUM CHLORIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!ENOXOLONE!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS COMMUNIS | [90-100]% by value / [90-100]% by volume |
| ITALY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES --> FLURBIPROFEN | [90-100]% by value / [90-100]% by volume |
| ITALY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1L LIQUIDS (TOPICAL) --> DICLOFENAC | [90-100]% by value / [90-100]% by volume |
| ITALY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> NAPROXEN | [40-50]% by value / [40-50]% by volume |
| ITALY | 02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS --> ASCORBIC ACID!CHONDROITINSULFURIC ACID!COLLAGEN!DIMETHYL SULFONE!GLUCOSAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS --> ASCORBIC ACID!CHONDROITINSULFURIC ACID!DIMETHYL SULFONE!GLUCOSAMINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| ITALY | 03D9 OTHER ANTIDIARRHOEALS --> 03D9C CAPS/TABS --> DIMETICONE!LOPERAMIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03G1 ANTACIDS --> 03G1M MIXTURES (ORAL) --> HOMOEOPATHIC MEDICINES | [90-100]% by value / [90-100]% by volume |
| ITALY | 04F9 OTHER MINERAL SUPPLEMENTS --> 04F9C CAPS/TABS --> DIMETHYL SULFONE | [50-60]% by value / [70-80]% by volume |
| ITALY | 04F9 OTHER MINERAL SUPPLEMENTS --> 04F9P POWDERS --> DIMETHYL SULFONE | [90-100]% by value / [90-100]% by volume |
| ITALY | 04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO OFFICINALIS!COLECALCIFEROL!EUPHAUSIA SUPERBA!FISH!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| ITALY | 04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO OFFICINALIS!EUPHAUSIA SUPERBA!FISH!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| ITALY | 04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> ARGININE | [50-60]% by value / [50-60]% by volume |
| ITALY | 04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> ASCORBIC ACID!DIMETHYL SULFONE!UBIDECARENONE | [90-100]% by value / [90-100]% by volume |
| ITALY | 04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> LYSINE | [50-60]% by value / [60-70]% by volume |
| ITALY | 04H1 OTHER DIETARY SUPPLEMENTS --> 04H1P POWDERS --> INOSITOL | [90-100]% by value / [90-100]% by volume |

| | | | | | | |
|---|---|---|---|---|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs | | | ITALY | 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> HYALURONIC ACID!JOJOBA OIL!PANTHENOL!SILVER | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs | At least EEA wide | <[10-20]% | ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs | | | ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [80-90]% by value / [80-90]% by volume |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs | | | ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs | | | ITALY | 07A2 EYE ANTIALLERGICS --> 07A2N EYE DROPS --> NAPHAZOLINE!THONZYLAMINE | [70-80]% by value / [60-70]% by volume |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs | | | ITALY | 07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> HYALURONIC ACID!MALVA SYLVESTRIS | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs | | | ITALY | 07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> HYALURONIC ACID!SODIUM!TROMETAMOL | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs | | | ITALY | 07A5 EYE DECONG & ANTI-INFLAM --> 07A5N EYE DROPS --> EUPHRASIA OFFICINALIS!HAMAMELIS VIRGINIANA!MATRICARIA CHAMOMILLA!PHOSPHORIC ACID!SODIUM | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs | | | ITALY | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> CHLORHEXIDINE!FLUORINE!MELISSA OFFICINALIS!MENTHA PIPERITA!MENTHA VIRIDIS!SYZYGIUM AROMATICUM!XYLITOL | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs | | | ITALY | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> COMPOSITION UNKNOWN | [60-70]% by value / [80-90]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| ITALY | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> FENTICONAZOLE | [50-60]% by value / [60-70]% by volume |
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | 30C1 MODULES --> 30C1Z OTHER MODULES --> GENERAL NUTRIENTS | [50-60]% by value / [50-60]% by volume |
| ITALY | 87A3 ADULT TOOTHPASTES --> 87A3C TOOTHPAST.SENSITIVE TEETH --> CHLORHEXIDINE!MELISSA OFFICINALIS!MENTHA PIPERITA!XYLITOL | [90-100]% by value / [90-100]% by volume |
| ITALY | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| ITALY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| ITALY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [80-90]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| ITALY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> DOMPERIDONE | [60-70]% by value / [60-70]% by volume |
| ITALY | A7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E2 INTEST CORTICOSTER PROD --> BUDESONIDE | [20-30]% by value / [30-40]% by volume |
| ITALY | A7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E9 INFLAM BOWEL DIS PRD OTH --> CROMOGLICIC ACID | [90-100]% by value / [90-100]% by volume |
| ITALY | A7H MOTILITY INHIBITORS --> A7H0 MOTILITY INHIBITORS --> DIMETICONE!LOPERAMIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | B1E DIRECT THROMBIN INHIBIT. --> B1E0 DIRECT THROMBIN INHIBIT. --> ARGATROBAN | [90-100]% by value / [90-100]% by volume |
| ITALY | C10A CHOLEST&TRIGLY.REGULATOR --> C10A1 STATINS (HMG-COA RED) --> LOVASTATIN | [70-80]% by value / [70-80]% by volume |
| ITALY | C1X ALL OTHER CARDIAC PREPS --> C1X0 ALL OTHER CARDIAC PREPS --> ALPROSTADIL ALFADEX | [90-100]% by value / [90-100]% by volume |
| ITALY | C4A CEREBR/PERIPH VASOTHERAP --> C4A2 CA ANTAG W CEREB ACTIV --> CINNARIZINE | [40-50]% by value / [50-60]% by volume |
| ITALY | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A1 A-HAEMORRHOIDL+CORTICOID --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| ITALY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> BISOPROLOL | [30-40]% by value / [20-30]% by volume |
| ITALY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [20-30]% by volume |
| ITALY | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [60-70]% by value / [90-100]% by volume |
| ITALY | G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL PRODS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| ITALY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | J1D CEPHALOSPORINS & COMBS --> J1D1 CEPHALOSPORINS,ORAL --> CEFTIBUTEN | [90-100]% by value / [90-100]% by volume |
| ITALY | J1D CEPHALOSPORINS & COMBS --> J1D2 CEPHALOSPORINS,PARENT. --> CEFODIZIME | [90-100]% by value / [90-100]% by volume |
| ITALY | L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> CHLORMETHINE | [90-100]% by value / [90-100]% by volume |
| ITALY | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> FLURBIPROFEN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| ITALY | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> NAPROXEN | [50-60]% by value / [40-50]% by volume |
| ITALY | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [90-100]% by value / [90-100]% by volume |
| ITALY | R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> BUDESONIDE | [60-70]% by value / [60-70]% by volume (CVC share [70-80]% by value / [70-80]% by volume) |
| ITALY | R3D CORTICOIDS --> R3D1 CORTICOIDS INHALANTS --> BUDESONIDE | [60-70]% by value / [50-60]% by volume (CVC share [60-70]% by value / [60-70]% by volume) |
| ITALY | R6A ANTIHISTAMINES SYSTEMIC --> R6A0 ANTIHISTAMINES SYSTEMIC --> RUPATADINE | [30-40]% by value / [30-40]% by volume |
| ITALY | S1G OCUL.A-ALLER.DECON.A-SEP --> S1G1 OCUL.A-ALLERG.ANTIHIST. --> NAPHAZOLINE!THONZYLAMINE | [70-80]% by value / [60-70]% by volume |
| ITALY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | S2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> CIPROFLOXACIN | [90-100]% by value / [90-100]% by volume |
| ITALY | S2C STEROID/ANTI-INFECT-EAR --> S2C0 STEROID/ANTI-INFECT-EAR --> CIPROFLOXACIN!FLUOCINOLONE ACETONIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| LATVIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LATVIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LATVIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LATVIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [40-50]% by value / [20-30]% by volume |
| LITHUANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LITHUANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LITHUANIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LITHUANIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [70-80]% by value / [70-80]% by volume |
| LITHUANIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| LUXEMBOURG | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| NETHERLANDS | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [70-80]% by value / [70-80]% by volume |
| NETHERLANDS | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [80-90]% by value / [80-90]% by volume |
| NETHERLANDS | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| NORWAY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| NORWAY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| NORWAY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [10-20]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| NORWAY | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| NORWAY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| POLAND | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC ACID!LACTOFERRIN | [90-100]% by value / [90-100]% by volume |
| POLAND | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC ACID!LACTOFERRIN!MENTHOL | [90-100]% by value / [90-100]% by volume |
| POLAND | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [50-60]% by value / [60-70]% by volume |
| POLAND | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| POLAND | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| POLAND | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| POLAND | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| POLAND | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| POLAND | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| POLAND | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [70-80]% by value / [60-70]% by volume |
| POLAND | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [20-30]% by volume |
| POLAND | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1G GARGLES --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!CAPSICUM OLEORESIN!CETYLPYRIDINIUM!CROCUS SATIVUS!ENOXOLONE!HYALURONIC ACID!MALTODEXTRIN!SORBIC ACID!XANTHAN GUM!XYLITOL | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| PORTUGAL | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES --> FLURBIPROFEN | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> CITRIC ACID!DODECYL SULFOACETIC ACID | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 05A1 TONICS --> 05A1Z OTHER FORMS --> ASCORBIC ACID!CAFFEINE!GLUCURONAMIDE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 06G2 ANTIFUNGALS FOR NAILS --> 06G2L LIQUIDS (TOPICAL) --> COPPER + DL-LACTIC ACID + SODIUM + THYMUS VULGARE + UREA | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> COLECALCIFEROL | [30-40]% by value / [10-20]% by volume |
| PORTUGAL | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| PORTUGAL | A2B ANTIULCERANTS --> A2B9 ALL OTHER ANTIULCERANTS --> SUCRALFATE | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | A5B HEPATIC PROCT LIPOTROPIC --> A5B0 HEPATIC PROCT LIPOTROPIC --> ASCORBIC ACID!CAFFEINE!GLUCURONAMIDE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A6A DRUGS FOR CONSTIPATION --> A6A4 LAXATIVE ENEMAS --> CITRIC ACID!DODECYL SULFOACETIC ACID | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | C9D ANGIOTEN-II ANTAG, COMB --> C9D3 AT2 ANTG COMB CALC ANTAG --> AMLODIPINE!CANDESARTAN CILEXETIL | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | G4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD OTH --> ALPROSTADIL | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> DEXIBUPROFEN | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> FLURBIPROFEN | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | M4A ANTI-GOUT PREPARATIONS --> M4A0 ANTI-GOUT PREPARATIONS --> COLCHICINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| PORTUGAL | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | N5C TRANQUILLISERS --> N5C0 TRANQUILLISERS --> CLOXAZOLAM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> FRUCTOOLIGSACCHARIDES!MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> INULIN!MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM!COLECALCIFEROL | [30-40]% by value / [20-30]% by volume |
| ROMANIA | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| ROMANIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE THERAPY,SYSTEM. --> DIOSMIN | [80-90]% by value / [90-100]% by volume |
| ROMANIA | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | G1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL --> METRONIDAZOLE!NEOMYCIN!NYSTATIN | [90-100]% by value / [90-100]% by volume |
| ROMANIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> ACETYLSALICYLIC ACID | [80-90]% by value / [80-90]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> ACETYLSALICYLIC ACID | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> ACETYLSALICYLIC ACID!ASCORBIC ACID | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| SLOVAKIA | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL + IRON METAL | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> SILYMARIN | [70-80]% by value / [80-90]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!XANTOFYL!ZINC | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> CHROMIUM!COLECALCIFEROL!FOLIC ACID!THIOCTIC ACID!XANTOFYL | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [30-40]% by volume |
| SLOVAKIA | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> PROPIVERINE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> ACETYLSALICYLIC ACID | [80-90]% by value / [80-90]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| SLOVAKIA | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | S1K DRY EYE PRODUCTS --> S1K1 ARTIFIC TEAR&OCUL LUBRIC --> HYALURONIC ACID!MALVA SYLVESTRIS | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> VEGETABLE FIBRE | [70-80]% by value / [0-5]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| SPAIN | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| SPAIN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| SPAIN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [70-80]% by value / [60-70]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |

| | | |
|---|---|---|
| SPAIN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [30-40]% by value / [80-90]% by volume |
| SPAIN | A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> CINITAPRIDE | [70-80]% by value / [70-80]% by volume |
| SPAIN | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [80-90]% by value / [80-90]% by volume |
| SPAIN | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| SPAIN | G4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD OTH --> ALPROSTADIL | [40-50]% by value / [50-60]% by volume |
| SPAIN | G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL PRODS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| SPAIN | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [90-100]% by value / [90-100]% by volume |
| SPAIN | V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC | [90-100]% by value / [90-100]% by volume |
| SWEDEN | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| SWEDEN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |

| | | |
|---|---|---|
| SWEDEN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [70-80]% by value / [70-80]% by volume |
| SWEDEN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [10-20]% by value / [70-80]% by volume |
| SWEDEN | H1C HYPOTHALAMIC HORMONES --> H1C2 ANTIGROWTH HORMONES --> PASIREOTIDE | [90-100]% by value / [90-100]% by volume |
| SWEDEN | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES NAPPY RASH --> COD LIVER OIL!PANTHENOL!PRUNUS AMYGDALUS (DULCIS)!VITAMIN E!ZINC | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES NAPPY RASH --> COD LIVER OIL!PARAFFIN OIL!WHITE BEESWAX!ZINC | [90-100]% by value / [90-100]% by volume |
| FRANCE | 05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS --> COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO BILOBA!PYRIDOXINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | 10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> AESCULUS HIPPOCASTANUM!ASCORBIC ACID!DRACAENA LOUREIRI!VITAMIN E!VITIS VINIFERA | [90-100]% by value / [90-100]% by volume |
| FRANCE | 10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |

| | | |
|---|---|---|
| FRANCE | 83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS --> COMPOSITION UNKNOWN | [50-60]% by value / [50-60]% by volume |
| FRANCE | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN | [90-100]% by value / [90-100]% by volume |
| GERMANY | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> INULIN!PLANTAGO OVATA | [90-100]% by value / [90-100]% by volume |
| GERMANY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS | [90-100]% by value / [90-100]% by volume |
| GERMANY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR JUGURTI POLYSACCHARIDE | [90-100]% by value / [90-100]% by volume |
| GERMANY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS HELVETICUS | [90-100]% by value / [90-100]% by volume |
| GERMANY | A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS | [90-100]% by value / [90-100]% by volume |
| GERMANY | A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR JUGURTI POLYSACCHARIDE | [90-100]% by value / [90-100]% by volume |
| GERMANY | A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-ORGANISM --> LACTOBACILLUS HELVETICUS | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |

| | | |
|---|---|---|
| GERMANY | K4D OTH INF SOLS/INF ADDITS --> K4D0 OTH INF SOLS/INF ADDITS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| GERMANY | L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. ANTIBIOTICS --> DACTINOMYCIN | [90-100]% by value / [90-100]% by volume |
| HUNGARY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| ITALY | 03A9 OTH DIGEST TRACT&STOM PRD --> 03A9C CAPS/TABS --> TILACTASE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> BACILLUS COAGULANS!PYRIDOXINE!THIAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> COLECALCIFEROL!LACTOBACILLUS REUTERI | [70-80]% by value / [70-80]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS REUTERI | [80-90]% by value / [80-90]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> ASCORBIC ACID!BIFIDOBACTERIUM BIFIDUS!LACTOBACILLUS ACIDOPHILUS | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> BACILLUS COAGULANS!PYRIDOXINE!THIAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> COLECALCIFEROL!LACTOBACILLUS REUTERI | [50-60]% by value / [50-60]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |

| | | |
|---|---|---|
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> HELIANTHUS ANNUUS!LACTOBACILLUS REUTERI!MEDIUM CHAIN TRIGLYCERIDES (UNSPECIFIED) | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS REUTERI | [60-70]% by value / [60-70]% by volume |
| ITALY | 11A1 ANTINAUSEANTS --> 11A1C CAPS/TABS --> PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE | [90-100]% by value / [90-100]% by volume |
| ITALY | 11A1 ANTINAUSEANTS --> 11A1M MIXTURES (ORAL) --> CITRIC ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE | [90-100]% by value / [90-100]% by volume |
| ITALY | 11A1 ANTINAUSEANTS --> 11A1Z OTHER FORMS --> CITRIC ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE | [90-100]% by value / [90-100]% by volume |
| ITALY | 12D9 OTHER GYNAECOLOGICAL PREP --> 12D9C CAPS/TABS --> DIOSCOREA VILLOSA | [90-100]% by value / [90-100]% by volume |
| ITALY | 18A2 NON-CLASSIFIABLE HERBAL P --> 18A2C CAPS/TABS --> BORAGO OFFICINALIS | [20-30]% by value / [30-40]% by volume |
| ITALY | A9A DIGESTIVES INC.ENZYMES --> A9A0 DIGESTIVES INCL ENZYMES --> TILACTASE | [90-100]% by value / [90-100]% by volume |
| ITALY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| ITALY | L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. ANTIBIOTICS --> DACTINOMYCIN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |

| | | |
|---|---|---|
| NETHERLANDS | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| NORWAY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> SISYMBRIUM OFFICINALE | [70-80]% by value / [80-90]% by volume |
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS LACTIS | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS LACTIS | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> SISYMBRIUM OFFICINALE | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS LACTIS | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the type of API used, i.e. | biopharmaceutical APIs |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1Z OTHER FORMS --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| SPAIN | 08A1 EAR CARE --> 08A1Z OTHER FORMS --> LACTOBACILLUS SALIVARIUS | [90-100]% by value / [90-100]% by volume |
| SPAIN | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| SWEDEN | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| BELGIUM | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| BELGIUM | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| BELGIUM | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [10-20]% by value / [60-70]% by volume |
| BELGIUM | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |
| BELGIUM | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| BULGARIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |
| CZECH REPUBLIC | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> ACETYLSALICYLIC ACID | [60-70]% by value / [60-70]% by volume |
| CZECH REPUBLIC | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL | [70-80]% by value / [80-90]% by volume |
| CZECH REPUBLIC | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> ACETYLSALICYLIC ACID | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| CZECH REPUBLIC | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL!IRON METAL | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!CYANOCOBALAMIN!DEXPANTHENOL!INOSITOL!METHIONINE!NICOTINAMIDE!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!THIAMINE!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTHENOL!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> ASCORBIC ACID!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ASCORBIC ACID!COPPER!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES NAPPY RASH --> COD LIVER OIL!PANTHENOL!PRUNUS AMYGDALUS (DULCIS)!VITAMIN E!ZINC | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| CZECH REPUBLIC | 88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES NAPPY RASH --> COD LIVER OIL!PARAFFIN OIL!WHITE BEESWAX!ZINC | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [70-80]% by value / [60-70]% by volume |
| CZECH REPUBLIC | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> PROPIVERINE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> ACETYLSALICYLIC ACID | [60-70]% by value / [60-70]% by volume |
| CZECH REPUBLIC | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| ESTONIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |
| FINLAND | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [10-20]% by volume |
| FINLAND | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | 01A4 CHESTY COUGH PRODUCTS --> 01A4E EFFERVESCENT --> ACETYLCYSTEINE | [20-30]% by value / [30-40]% by volume |
| FRANCE | 01A4 CHESTY COUGH PRODUCTS --> 01A4P POWDERS --> ACETYLCYSTEINE | [30-40]% by value / [40-50]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| FRANCE | 01A9 OTHER COUGH PRODUCTS --> 01A9Z OTHER FORMS --> CALENDULA OFFICINALIS!EUCALYPTUS GLOBULUS!LINUM USITATISSIMUM!PROPOLIS | [90-100]% by value / [90-100]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE BARBADENSIS!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALGINIC ACID!ALOE BARBADENSIS!GLYCEROL!GLYCYRRHIZA GLABRA!HYALURONIC ACID!MENTHOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |
| FRANCE | 05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS --> COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO BILOBA!PYRIDOXINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE | [90-100]% by value / [90-100]% by volume |
| FRANCE | 10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> AESCULUS HIPPOCASTANUM!ASCORBIC ACID!DRACAENA LOUREIRI!VITAMIN E!VITIS VINIFERA | [90-100]% by value / [90-100]% by volume |
| FRANCE | 10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| FRANCE | 83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS --> COMPOSITION UNKNOWN | [50-60]% by value / [50-60]% by volume |
| FRANCE | 87B3 ADULT MOUTHWASHES --> 87B3D MOUTHWASH FOR BLEED GUM&G --> COMPOSITION UNKNOWN | [50-60]% by value / [70-80]% by volume |
| FRANCE | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| FRANCE | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [50-60]% by value / [50-60]% by volume |
| FRANCE | A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE | [90-100]% by value / [90-100]% by volume |
| FRANCE | A6A DRUGS FOR CONSTIPATION --> A6A7 OSMOTIC LAXATS W ELECTRO --> MACROGOL(S) | [90-100]% by value / [90-100]% by volume |
| FRANCE | A6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> MACROGOL(S)!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| FRANCE | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| FRANCE | C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [40-50]% by value / [20-30]% by volume |
| FRANCE | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| FRANCE | H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & SIMILAR --> OSILODROSTAT | [90-100]% by value / [90-100]% by volume |
| FRANCE | J1F MACROLIDES & SIMILR TYPE --> J1F0 MACROLIDES & SIMILR TYPE --> ERYTHROMYCIN | [10-20]% by value / [80-90]% by volume |
| FRANCE | R5C EXPECTORANTS --> R5C0 EXPECTORANTS --> ACETYLCYSTEINE | [30-40]% by value / [30-40]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BENZOIC ACID!BROMINE!CODEINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BROMOFORM!CODEINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| FRANCE | S2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> RIFAMYCIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC | [90-100]% by value / [90-100]% by volume |
| GERMANY | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> INULIN!PLANTAGO OVATA | [90-100]% by value / [90-100]% by volume |
| GERMANY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS | [90-100]% by value / [90-100]% by volume |
| GERMANY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR JUGURTI POLYSACCHARIDE | [90-100]% by value / [90-100]% by volume |
| GERMANY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS HELVETICUS | [90-100]% by value / [90-100]% by volume |
| GERMANY | 04F9 OTHER MINERAL SUPPLEMENTS --> 04F9M MIXTURES (ORAL) --> CALCIUM!MAGNESIUM!POTASSIUM | [90-100]% by value / [90-100]% by volume |
| GERMANY | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| GERMANY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| GERMANY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [5-10]% by value / [30-40]% by volume |
| GERMANY | A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS | [90-100]% by value / [90-100]% by volume |
| GERMANY | A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR JUGURTI POLYSACCHARIDE | [90-100]% by value / [90-100]% by volume |
| GERMANY | A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-ORGANISM --> LACTOBACILLUS HELVETICUS | [90-100]% by value / [90-100]% by volume |
| GERMANY | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [60-70]% by value / [50-60]% by volume |
| GERMANY | H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & SIMILAR --> OSILODROSTAT | [90-100]% by value / [90-100]% by volume |
| GERMANY | L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. ANTIBIOTICS --> DACTINOMYCIN | [90-100]% by value / [90-100]% by volume |
| GERMANY | M3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE RELAXANTS,CENTRAL --> METHOCARBAMOL | [70-80]% by value / [60-70]% by volume |
| GERMANY | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [60-70]% by value / [60-70]% by volume |
| GERMANY | V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC | [60-70]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| GREECE | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| HUNGARY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| HUNGARY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [50-60]% by value / [30-40]% by volume |
| HUNGARY | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| IRELAND | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| ITALY | 02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS --> ASCORBIC ACID!CHONDROITINSULFURIC ACID!COLLAGEN!DIMETHYL SULFONE!GLUCOSAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS --> ASCORBIC ACID!CHONDROITINSULFURIC ACID!DIMETHYL SULFONE!GLUCOSAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03A9 OTH DIGEST TRACT&STOM PRD --> 03A9C CAPS/TABS --> TILACTASE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03D9 OTHER ANTIDIARRHOEALS --> 03D9C CAPS/TABS --> DIMETICONE!LOPERAMIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> BACILLUS COAGULANS!PYRIDOXINE!THIAMINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> COLECALCIFEROL!LACTOBACILLUS REUTERI | [70-80]% by value / [70-80]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS REUTERI | [80-90]% by value / [80-90]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> ASCORBIC ACID!BIFIDOBACTERIUM BIFIDUS!LACTOBACILLUS ACIDOPHILUS | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> BACILLUS COAGULANS!PYRIDOXINE!THIAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> COLECALCIFEROL!LACTOBACILLUS REUTERI | [50-60]% by value / [50-60]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> HELIANTHUS ANNUUS!LACTOBACILLUS REUTERI!MEDIUM CHAIN TRIGLYCERIDES (UNSPECIFIED) | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS REUTERI | [60-70]% by value / [60-70]% by volume |
| ITALY | 03G1 ANTACIDS --> 03G1M MIXTURES (ORAL) --> HOMOEOPATHIC MEDICINES | [90-100]% by value / [90-100]% by volume |
| ITALY | 04F9 OTHER MINERAL SUPPLEMENTS --> 04F9C CAPS/TABS --> DIMETHYL SULFONE | [50-60]% by value / [70-80]% by volume |
| ITALY | 04F9 OTHER MINERAL SUPPLEMENTS --> 04F9P POWDERS --> DIMETHYL SULFONE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| ITALY | 04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO OFFICINALIS!COLECALCIFEROL!EUPHAUSIA SUPERBA!FISH!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| ITALY | 04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO OFFICINALIS!EUPHAUSIA SUPERBA!FISH!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| ITALY | 04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> ARGININE | [50-60]% by value / [50-60]% by volume |
| ITALY | 04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> ASCORBIC ACID!DIMETHYL SULFONE!UBIDECARENONE | [90-100]% by value / [90-100]% by volume |
| ITALY | 04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> LYSINE | [50-60]% by value / [60-70]% by volume |
| ITALY | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> CHLORHEXIDINE!FLUORINE!MELISSA OFFICINALIS!MENTHA PIPERITA!MENTHA VIRIDIS!SYZYGIUM AROMATICUM!XYLITOL | [90-100]% by value / [90-100]% by volume |
| ITALY | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> COMPOSITION UNKNOWN | [60-70]% by value / [80-90]% by volume |
| ITALY | 11A1 ANTINAUSEANTS --> 11A1C CAPS/TABS --> PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE | [90-100]% by value / [90-100]% by volume |
| ITALY | 11A1 ANTINAUSEANTS --> 11A1M MIXTURES (ORAL) --> CITRIC ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE | [90-100]% by value / [90-100]% by volume |
| ITALY | 11A1 ANTINAUSEANTS --> 11A1Z OTHER FORMS --> CITRIC ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| ITALY | 12D9 OTHER GYNAECOLOGICAL PREP --> 12D9C CAPS/TABS --> DIOSCOREA VILLOSA | [90-100]% by value / [90-100]% by volume |
| ITALY | 18A2 NON-CLASSIFIABLE HERBAL P --> 18A2C CAPS/TABS --> BORAGO OFFICINALIS | [20-30]% by value / [30-40]% by volume |
| ITALY | 30C1 MODULES --> 30C1Z OTHER MODULES --> GENERAL NUTRIENTS | [50-60]% by value / [50-60]% by volume |
| ITALY | 87A3 ADULT TOOTHPASTES --> 87A3C TOOTHPAST.SENSITIVE TEETH --> CHLORHEXIDINE!MELISSA OFFICINALIS!MENTHA PIPERITA!XYLITOL | [90-100]% by value / [90-100]% by volume |
| ITALY | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| ITALY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| ITALY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [80-90]% by volume |
| ITALY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> DOMPERIDONE | [60-70]% by value / [60-70]% by volume |
| ITALY | A7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E2 INTEST CORTICOSTER PROD --> BUDESONIDE | [20-30]% by value / [30-40]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| ITALY | A7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E9 INFLAM BOWEL DIS PRD OTH --> CROMOGLICIC ACID | [90-100]% by value / [90-100]% by volume |
| ITALY | A7H MOTILITY INHIBITORS --> A7H0 MOTILITY INHIBITORS --> DIMETICONE!LOPERAMIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | A9A DIGESTIVES INC.ENZYMES --> A9A0 DIGESTIVES INCL ENZYMES --> TILACTASE | [90-100]% by value / [90-100]% by volume |
| ITALY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| ITALY | C10A CHOLEST&TRIGLY.REGULATOR --> C10A1 STATINS (HMG-COA RED) --> LOVASTATIN | [70-80]% by value / [70-80]% by volume |
| ITALY | C4A CEREBR/PERIPH VASOTHERAP --> C4A2 CA ANTAG W CEREB ACTIV --> CINNARIZINE | [40-50]% by value / [50-60]% by volume |
| ITALY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> BISOPROLOL | [30-40]% by value / [20-30]% by volume |
| ITALY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [20-30]% by volume |
| ITALY | J1D CEPHALOSPORINS & COMBS --> J1D1 CEPHALOSPORINS,ORAL --> CEFTIBUTEN | [90-100]% by value / [90-100]% by volume |
| ITALY | L1D ANTINEOPLAS. ANTIBIOTICS --> L1D0 ANTINEOPLAS. ANTIBIOTICS --> DACTINOMYCIN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| ITALY | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [90-100]% by value / [90-100]% by volume |
| ITALY | R6A ANTIHISTAMINES SYSTEMIC --> R6A0 ANTIHISTAMINES SYSTEMIC --> RUPATADINE | [30-40]% by value / [30-40]% by volume |
| ITALY | V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC | [90-100]% by value / [90-100]% by volume |
| LATVIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [40-50]% by value / [20-30]% by volume |
| LITHUANIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [70-80]% by value / [70-80]% by volume |
| LUXEMBOURG | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [70-80]% by value / [70-80]% by volume |
| NETHERLANDS | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| NETHERLANDS | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [80-90]% by value / [80-90]% by volume |
| NORWAY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| NORWAY | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| NORWAY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| NORWAY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [10-20]% by volume |
| POLAND | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC ACID!LACTOFERRIN | [90-100]% by value / [90-100]% by volume |
| POLAND | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC ACID!LACTOFERRIN!MENTHOL | [90-100]% by value / [90-100]% by volume |
| POLAND | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| POLAND | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| POLAND | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| POLAND | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [20-30]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> SISYMBRIUM OFFICINALE | [70-80]% by value / [80-90]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1G GARGLES --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> CITRIC ACID!DODECYL SULFOACETIC ACID | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS LACTIS | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS LACTIS | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 05A1 TONICS --> 05A1Z OTHER FORMS --> ASCORBIC ACID!CAFFEINE!GLUCURONAMIDE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> COLECALCIFEROL | [30-40]% by value / [10-20]% by volume |
| PORTUGAL | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A2B ANTIULCERANTS --> A2B9 ALL OTHER ANTIULCERANTS --> SUCRALFATE | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | A5B HEPATIC PROCT LIPOTROPIC --> A5B0 HEPATIC PROCT LIPOTROPIC --> ASCORBIC ACID!CAFFEINE!GLUCURONAMIDE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A6A DRUGS FOR CONSTIPATION --> A6A4 LAXATIVE ENEMAS --> CITRIC ACID!DODECYL SULFOACETIC ACID | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | C9D ANGIOTEN-II ANTAG, COMB --> C9D3 AT2 ANTG COMB CALC ANTAG --> AMLODIPINE!CANDESARTAN CILEXETIL | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| PORTUGAL | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> DEXIBUPROFEN | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | M4A ANTI-GOUT PREPARATIONS --> M4A0 ANTI-GOUT PREPARATIONS --> COLCHICINE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | N5C TRANQUILLISERS --> N5C0 TRANQUILLISERS --> CLOXAZOLAM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> SISYMBRIUM OFFICINALE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> FRUCTOOLIGSACCHARIDES!MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> INULIN!MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM!COLECALCIFEROL | [30-40]% by value / [20-30]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| ROMANIA | C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE THERAPY,SYSTEM. --> DIOSMIN | [80-90]% by value / [90-100]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> ACETYLSALICYLIC ACID | [80-90]% by value / [80-90]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> ACETYLSALICYLIC ACID | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> ACETYLSALICYLIC ACID!ASCORBIC ACID | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL + IRON METAL | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> SILYMARIN | [70-80]% by value / [80-90]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!XANTOFYL!ZINC | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> CHROMIUM!COLECALCIFEROL!FOLIC ACID!THIOCTIC ACID!XANTOFYL | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [30-40]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| SLOVAKIA | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> PROPIVERINE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> ACETYLSALICYLIC ACID | [80-90]% by value / [80-90]% by volume |
| SLOVAKIA | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | S1K DRY EYE PRODUCTS --> S1K1 ARTIFIC TEAR&OCUL LUBRIC --> HYALURONIC ACID!MALVA SYLVESTRIS | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> VEGETABLE FIBRE | [70-80]% by value / [0-5]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS LACTIS | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |

| | | |
|---|---|---|
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1Z OTHER FORMS --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| SPAIN | 08A1 EAR CARE --> 08A1Z OTHER FORMS --> LACTOBACILLUS SALIVARIUS | [90-100]% by value / [90-100]% by volume |
| SPAIN | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| SPAIN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| SPAIN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [70-80]% by value / [60-70]% by volume |
| SPAIN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [30-40]% by value / [80-90]% by volume |
| SPAIN | A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> CINITAPRIDE | [70-80]% by value / [70-80]% by volume |
| SPAIN | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | inhalation |

| | | |
|---|---|---|
| SPAIN | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [80-90]% by value / [80-90]% by volume |
| SPAIN | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| SPAIN | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [90-100]% by value / [90-100]% by volume |
| SPAIN | V3E ANTIDOTES --> V3E0 ANTIDOTES --> ZINC | [90-100]% by value / [90-100]% by volume |
| SWEDEN | A11X OTHER VITAMINS --> A11X3 VITAMIN E PLAIN --> TOCOFERSOLAN | [90-100]% by value / [90-100]% by volume |
| SWEDEN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> BETAINE | [90-100]% by value / [90-100]% by volume |
| SWEDEN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> CARGLUMIC ACID | [70-80]% by value / [70-80]% by volume |
| SWEDEN | A16A OTHER METABOLIC PRODUCTS --> A16A0 OTHER METABOLIC PRODUCTS --> MERCAPTAMINE | [10-20]% by value / [70-80]% by volume |
| SWEDEN | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | 01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS --> SODIUM | [80-90]% by value / [80-90]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | inhalation |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | inhalation |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | inhalation |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |

| | | |
|---|---|---|
| ITALY | 01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS --> ALOE BARBADENSIS!MATRICARIA CHAMOMILLA!SEA WATER | [90-100]% by value / [90-100]% by volume |
| ITALY | R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> BUDESONIDE | [60-70]% by value / [60-70]% by volume (CVC share [70-80]% by value / [70-80]% by volume) |
| ITALY | R3D CORTICOIDS --> R3D1 CORTICOIDS INHALANTS --> BUDESONIDE | [60-70]% by value / [50-60]% by volume (CVC share [60-70]% by value / [60-70]% by volume) |
| BULGARIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL!IRON METAL | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |

| | | |
|---|---|---|
| FRANCE | 05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS --> COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO BILOBA!PYRIDOXINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE | [90-100]% by value / [90-100]% by volume |
| FRANCE | 10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | 83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS --> COMPOSITION UNKNOWN | [50-60]% by value / [50-60]% by volume |
| FRANCE | A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE | [90-100]% by value / [90-100]% by volume |
| FRANCE | C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> CHLORMETHINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> 2-PROPANOL | [60-70]% by value / [50-60]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |

| | | |
|---|---|---|
| GERMANY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1Z OTHER FORMS --> 2-PROPANOL | [40-50]% by value / [40-50]% by volume |
| GERMANY | 06F3 WOUND HEALING PROD --> 06F3A AEROSOLS/SPRAYS --> ZINC | [90-100]% by value / [90-100]% by volume |
| GERMANY | 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> ZINC | [50-60]% by value / [20-30]% by volume |
| GERMANY | 06L1 WART/CORN REMOV EXC PLAST --> 06L1L LIQUIDS (TOPICAL) --> SALICYLIC ACID | [90-100]% by value / [90-100]% by volume |
| GERMANY | 12F9 PR FR OT UROLOG MALE COND --> 12F9Z OTHER FORMS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | 18A2 NON-CLASSIFIABLE HERBAL P --> 18A2Z OTHER FORMS --> MENTHA ARVENSIS | [70-80]% by value / [20-30]% by volume |
| GERMANY | D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING AGENTS --> COD LIVER OIL!LEVOMENOL!ZINC | [90-100]% by value / [90-100]% by volume |
| GERMANY | D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING AGENTS --> ZINC | [70-80]% by value / [60-70]% by volume |
| GERMANY | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> OXYBUTYNIN | [30-40]% by value / [0-5]% by volume |
| GERMANY | G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL PRODS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |

| | | |
|---|---|---|
| GERMANY | L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> CHLORMETHINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> 2-PROPANOL | [50-60]% by value / [50-60]% by volume |
| GERMANY | V3X ALL OTH.THERAPEUTIC PRDS --> V3X4 CURE-ALL PREPARATIONS --> MENTHA ARVENSIS | [90-100]% by value / [90-100]% by volume |
| GREECE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| GREECE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| GREECE | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| GREECE | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| IRELAND | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> OXYBUTYNIN | [30-40]% by value / [5-10]% by volume |
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!ENOXOLONE!HYALURONIC ACID!RICINUS COMMUNIS | [90-100]% by value / [90-100]% by volume |
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS COMMUNIS | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |

| | | |
|---|---|---|
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!BENZETHONIUM CHLORIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!ENOXOLONE!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS COMMUNIS | [90-100]% by value / [90-100]% by volume |
| ITALY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1L LIQUIDS (TOPICAL) --> DICLOFENAC | [90-100]% by value / [90-100]% by volume |
| ITALY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> NAPROXEN | [40-50]% by value / [40-50]% by volume |
| ITALY | 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> HYALURONIC ACID!JOJOBA OIL!PANTHENOL!SILVER | [90-100]% by value / [90-100]% by volume |
| ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [80-90]% by value / [80-90]% by volume |
| ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |

| | | |
|---|---|---|
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> FENTICONAZOLE | [50-60]% by value / [60-70]% by volume |
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [60-70]% by value / [90-100]% by volume |
| ITALY | G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL PRODS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| ITALY | L1A ALKYLATING AGENTS --> L1A0 ALKYLATING AGENTS --> CHLORMETHINE | [90-100]% by value / [90-100]% by volume |
| ITALY | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> NAPROXEN | [50-60]% by value / [40-50]% by volume |
| LATVIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LATVIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LATVIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |

| | | |
|---|---|---|
| LITHUANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LITHUANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LITHUANIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LITHUANIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| POLAND | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [50-60]% by value / [60-70]% by volume |
| POLAND | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| POLAND | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [70-80]% by value / [60-70]% by volume |
| PORTUGAL | 02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!CAPSICUM OLEORESIN!CETYLPYRIDINIUM!CROCUS SATIVUS!ENOXOLONE!HYALURONIC ACID!MALTODEXTRIN!SORBIC ACID!XANTHAN GUM!XYLITOL | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |

| | | |
|---|---|---|
| PORTUGAL | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 06G2 ANTIFUNGALS FOR NAILS --> 06G2L LIQUIDS (TOPICAL) --> COPPER + DL-LACTIC ACID + SODIUM + THYMUS VULGARE + UREA | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | absorption through the skin |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | intravenous injection |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | intravenous injection |

| | | |
|---|---|---|
| SLOVAKIA | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL + IRON METAL | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| SPAIN | 86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-AERO+SPRAY --> COMPOSITION UNKNOWN | [40-50]% by value / [10-20]% by volume |
| SPAIN | 86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-AERO+SPRAY --> DIMETICONE!JOJOBA OIL | [90-100]% by value / [90-100]% by volume |
| SPAIN | G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL PRODS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |
| FRANCE | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | intravenous injection |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| GERMANY | C6X OTHER CARDIOVASCULAR PRODUCTS --> C6X0 OTHER CARDIOVASCULAR PRD --> IBUPROFEN | [90-100]% by value / [90-100]% by volume |
| AUSTRIA | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| BELGIUM | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |
| BELGIUM | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| BELGIUM | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| BULGARIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |
| BULGARIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> ACETYLSALICYLIC ACID | [60-70]% by value / [60-70]% by volume |
| CZECH REPUBLIC | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL | [70-80]% by value / [80-90]% by volume |
| CZECH REPUBLIC | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| CZECH REPUBLIC | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> ACETYLSALICYLIC ACID | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL!IRON METAL | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!CYANOCOBALAMIN!DEXPANTHENOL!INOSITOL!METHIONINE!NICOTINAMIDE!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!THIAMINE!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTHENOL!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> ASCORBIC ACID!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ASCORBIC ACID!COPPER!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES NAPPY RASH --> COD LIVER OIL!PANTHENOL!PRUNUS AMYGDALUS (DULCIS)!VITAMIN E!ZINC | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | 88B2 BABY CREAMS AND PASTES --> 88B2B OTH CRM+PASTES NAPPY RASH --> COD LIVER OIL!PARAFFIN OIL!WHITE BEESWAX!ZINC | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [70-80]% by value / [60-70]% by volume |
| CZECH REPUBLIC | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> PROPIVERINE | [90-100]% by value / [90-100]% by volume |
| CZECH REPUBLIC | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> ACETYLSALICYLIC ACID | [60-70]% by value / [60-70]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| CZECH REPUBLIC | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| ESTONIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [50-60]% by volume |
| FINLAND | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [10-20]% by volume |
| FINLAND | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | 01A4 CHESTY COUGH PRODUCTS --> 01A4E EFFERVESCENT --> ACETYLCYSTEINE | [20-30]% by value / [30-40]% by volume |
| FRANCE | 01A4 CHESTY COUGH PRODUCTS --> 01A4P POWDERS --> ACETYLCYSTEINE | [30-40]% by value / [40-50]% by volume |
| FRANCE | 01A9 OTHER COUGH PRODUCTS --> 01A9Z OTHER FORMS --> CALENDULA OFFICINALIS!EUCALYPTUS GLOBULUS!LINUM USITATISSIMUM!PROPOLIS | [90-100]% by value / [90-100]% by volume |
| FRANCE | 01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS --> SODIUM | [80-90]% by value / [80-90]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE BARBADENSIS!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALGINIC ACID!ALOE BARBADENSIS!GLYCEROL!GLYCYRRHIZA GLABRA!HYALURONIC ACID!MENTHOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |
| FRANCE | 05G1 COGNITIVE STIMULANTS --> 05G1C CAPS/TABS --> COLECALCIFEROL!CYANOCOBALAMIN!FISH!FOLIC ACID!GINKGO BILOBA!PYRIDOXINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE | [90-100]% by value / [90-100]% by volume |
| FRANCE | 10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> AESCULUS HIPPOCASTANUM!ASCORBIC ACID!DRACAENA LOUREIRI!VITAMIN E!VITIS VINIFERA | [90-100]% by value / [90-100]% by volume |
| FRANCE | 10B1 SYSTEMIC ANTIVARICOSE --> 10B1C CAPS/TABS --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | 83E1 LEG CARE PRODUCTS --> 83E1 LEG CARE PRODUCTS --> COMPOSITION UNKNOWN | [50-60]% by value / [50-60]% by volume |
| FRANCE | 87B3 ADULT MOUTHWASHES --> 87B3D MOUTHWASH FOR BLEED GUM&G --> COMPOSITION UNKNOWN | [50-60]% by value / [70-80]% by volume |
| FRANCE | A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| FRANCE | A1A STOMATOLOGICALS --> A1A2 MOUTH A-SEPTICS+A-INFECT --> CETYLPYRIDINIUM!CHLOROBUTANOL!EUGENOL!VERATROLE | [90-100]% by value / [90-100]% by volume |
| FRANCE | A6A DRUGS FOR CONSTIPATION --> A6A7 OSMOTIC LAXATS W ELECTRO --> MACROGOL(S) | [90-100]% by value / [90-100]% by volume |
| FRANCE | A6B BOWEL CLEANSERS --> A6B2 OSMOT BWL CLEAN W ELECTR --> MACROGOL(S)!POTASSIUM!SODIUM | [90-100]% by value / [90-100]% by volume |
| FRANCE | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE THERAPY,SYSTEM. --> GINKGO BILOBA!HEPTAMINOL!TROXERUTIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [40-50]% by value / [20-30]% by volume |
| FRANCE | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | G1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL --> METRONIDAZOLE!NEOMYCIN!NYSTATIN | [90-100]% by value / [90-100]% by volume |
| FRANCE | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| FRANCE | H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & SIMILAR --> OSILODROSTAT | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| FRANCE | J1F MACROLIDES & SIMILR TYPE --> J1F0 MACROLIDES & SIMILR TYPE --> ERYTHROMYCIN | [10-20]% by value / [80-90]% by volume |
| FRANCE | R5C EXPECTORANTS --> R5C0 EXPECTORANTS --> ACETYLCYSTEINE | [30-40]% by value / [30-40]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BENZOIC ACID!BROMINE!CODEINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> ASCORBIC ACID!BROMOFORM!CODEINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | R5D ANTITUSSIVES --> R5D2 ANTITUSSIVES COMB --> CODEINE!GRINDELIA ROBUSTA!SULFOGAIACOL | [90-100]% by value / [90-100]% by volume |
| FRANCE | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| FRANCE | S2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> RIFAMYCIN | [90-100]% by value / [90-100]% by volume |
| GERMANY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> 2-PROPANOL | [60-70]% by value / [50-60]% by volume |
| GERMANY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1Z OTHER FORMS --> 2-PROPANOL | [40-50]% by value / [40-50]% by volume |
| GERMANY | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> INULIN!PLANTAGO OVATA | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| GERMANY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS | [90-100]% by value / [90-100]% by volume |
| GERMANY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR JUGURTI POLYSACCHARIDE | [90-100]% by value / [90-100]% by volume |
| GERMANY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS HELVETICUS | [90-100]% by value / [90-100]% by volume |
| GERMANY | 04F9 OTHER MINERAL SUPPLEMENTS --> 04F9M MIXTURES (ORAL) --> CALCIUM!MAGNESIUM!POTASSIUM | [90-100]% by value / [90-100]% by volume |
| GERMANY | 06F3 WOUND HEALING PROD --> 06F3A AEROSOLS/SPRAYS --> ZINC | [90-100]% by value / [90-100]% by volume |
| GERMANY | 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> ZINC | [50-60]% by value / [20-30]% by volume |
| GERMANY | 06L1 WART/CORN REMOV EXC PLAST --> 06L1L LIQUIDS (TOPICAL) --> SALICYLIC ACID | [90-100]% by value / [90-100]% by volume |
| GERMANY | 12F9 PR FR OT UROLOG MALE COND --> 12F9Z OTHER FORMS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | 18A2 NON-CLASSIFIABLE HERBAL P --> 18A2Z OTHER FORMS --> MENTHA ARVENSIS | [70-80]% by value / [20-30]% by volume |
| GERMANY | A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| GERMANY | A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-ORGANISM --> LACTOBACILLUS ACIDOPHILUS!LACTOBACILLUS HELVETICUS VAR JUGURTI POLYSACCHARIDE | [90-100]% by value / [90-100]% by volume |
| GERMANY | A7F ANTIDIARR MICRO-ORGANISM --> A7F0 ANTIDIARR MICRO-ORGANISM --> LACTOBACILLUS HELVETICUS | [90-100]% by value / [90-100]% by volume |
| GERMANY | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [60-70]% by value / [50-60]% by volume |
| GERMANY | D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING AGENTS --> COD LIVER OIL!LEVOMENOL!ZINC | [90-100]% by value / [90-100]% by volume |
| GERMANY | D3A WOUNDHEALING AGENTS --> D3A9 OTH WOUND HEALING AGENTS --> ZINC | [70-80]% by value / [60-70]% by volume |
| GERMANY | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> OXYBUTYNIN | [30-40]% by value / [0-5]% by volume |
| GERMANY | G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL PRODS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | H2A PLAIN CORTICOSTEROIDS --> H2A1 INJ CORTICOSTEROIDS PLN --> DEXAMETHASONE | [40-50]% by value / [10-20]% by volume |
| GERMANY | H4X OTHER HORMONES & SIMILAR --> H4X0 OTHER HORMONES & SIMILAR --> OSILODROSTAT | [90-100]% by value / [90-100]% by volume |
| GERMANY | K4D OTH INF SOLS/INF ADDITS --> K4D0 OTH INF SOLS/INF ADDITS --> HEMIN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| GERMANY | M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> LIDOCAINE!PHENYLBUTAZONE!PROPYLENE GLYCOL | [90-100]% by value / [90-100]% by volume |
| GERMANY | M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> PHENYLBUTAZONE | [90-100]% by value / [90-100]% by volume |
| GERMANY | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> 2-PROPANOL | [50-60]% by value / [50-60]% by volume |
| GERMANY | M3B MUSCLE RELAXANTS,CENTRAL --> M3B0 MUSCLE RELAXANTS,CENTRAL --> METHOCARBAMOL | [70-80]% by value / [60-70]% by volume |
| GERMANY | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [60-70]% by value / [60-70]% by volume |
| GERMANY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| GERMANY | V3X ALL OTH.THERAPEUTIC PRDS --> V3X4 CURE-ALL PREPARATIONS --> MENTHA ARVENSIS | [90-100]% by value / [90-100]% by volume |
| GREECE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| GREECE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| GREECE | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| GREECE | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| GREECE | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| HUNGARY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| HUNGARY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [50-60]% by value / [30-40]% by volume |
| HUNGARY | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| HUNGARY | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| IRELAND | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| IRELAND | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> OXYBUTYNIN | [30-40]% by value / [5-10]% by volume |
| ITALY | 01F1 NASAL SALINE SOLUTIONS --> 01F1A AEROSOLS/SPRAYS --> ALOE BARBADENSIS!MATRICARIA CHAMOMILLA!SEA WATER | [90-100]% by value / [90-100]% by volume |
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!ENOXOLONE!HYALURONIC ACID!RICINUS COMMUNIS | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS COMMUNIS | [90-100]% by value / [90-100]% by volume |
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!BENZETHONIUM CHLORIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!ENOXOLONE!HYALURONIC ACID | [90-100]% by value / [90-100]% by volume |
| ITALY | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!GLYCYRRHIZIC ACID!HYALURONIC ACID!RICINUS COMMUNIS | [90-100]% by value / [90-100]% by volume |
| ITALY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES --> FLURBIPROFEN | [90-100]% by value / [90-100]% by volume |
| ITALY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1L LIQUIDS (TOPICAL) --> DICLOFENAC | [90-100]% by value / [90-100]% by volume |
| ITALY | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1O OINTMENTS/CREAMS --> NAPROXEN | [40-50]% by value / [40-50]% by volume |
| ITALY | 02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS --> ASCORBIC ACID!CHONDROITINSULFURIC ACID!COLLAGEN!DIMETHYL SULFONE!GLUCOSAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 02G2 JOINT CARE PRDS(SYSTEMIC) --> 02G2Z OTHER FORMS --> ASCORBIC ACID!CHONDROITINSULFURIC ACID!DIMETHYL SULFONE!GLUCOSAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03A9 OTH DIGEST TRACT&STOM PRD --> 03A9C CAPS/TABS --> TILACTASE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| ITALY | 03D9 OTHER ANTIDIARRHOEALS --> 03D9C CAPS/TABS --> DIMETICONE!LOPERAMIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> BACILLUS COAGULANS!PYRIDOXINE!THIAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> COLECALCIFEROL!LACTOBACILLUS REUTERI | [70-80]% by value / [70-80]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS REUTERI | [80-90]% by value / [80-90]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> ASCORBIC ACID!BIFIDOBACTERIUM BIFIDUS!LACTOBACILLUS ACIDOPHILUS | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> BACILLUS COAGULANS!PYRIDOXINE!THIAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> COLECALCIFEROL!LACTOBACILLUS REUTERI | [50-60]% by value / [50-60]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> HELIANTHUS ANNUUS!LACTOBACILLUS REUTERI!MEDIUM CHAIN TRIGLYCERIDES (UNSPECIFIED) | [90-100]% by value / [90-100]% by volume |
| ITALY | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS REUTERI | [60-70]% by value / [60-70]% by volume |
| ITALY | 03G1 ANTACIDS --> 03G1M MIXTURES (ORAL) --> HOMOEOPATHIC MEDICINES | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| ITALY | 04F9 OTHER MINERAL SUPPLEMENTS --> 04F9C CAPS/TABS --> DIMETHYL SULFONE | [50-60]% by value / [70-80]% by volume |
| ITALY | 04F9 OTHER MINERAL SUPPLEMENTS --> 04F9P POWDERS --> DIMETHYL SULFONE | [90-100]% by value / [90-100]% by volume |
| ITALY | 04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO OFFICINALIS!COLECALCIFEROL!EUPHAUSIA SUPERBA!FISH!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| ITALY | 04G1 OMEGA-3 FATTY ACIDS --> 04G1C CAPS/TABS --> BORAGO OFFICINALIS!EUPHAUSIA SUPERBA!FISH!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| ITALY | 04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> ARGININE | [50-60]% by value / [50-60]% by volume |
| ITALY | 04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> ASCORBIC ACID!DIMETHYL SULFONE!UBIDECARENONE | [90-100]% by value / [90-100]% by volume |
| ITALY | 04H1 OTHER DIETARY SUPPLEMENTS --> 04H1C CAPS/TABS --> LYSINE | [50-60]% by value / [60-70]% by volume |
| ITALY | 04H1 OTHER DIETARY SUPPLEMENTS --> 04H1P POWDERS --> INOSITOL | [90-100]% by value / [90-100]% by volume |
| ITALY | 06F3 WOUND HEALING PROD --> 06F3O OINTMENTS/CREAMS --> HYALURONIC ACID!JOJOBA OIL!PANTHENOL!SILVER | [90-100]% by value / [90-100]% by volume |
| ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3A AEROSOLS/SPRAYS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [80-90]% by value / [80-90]% by volume |
| ITALY | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3P POWDERS/TALC --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | 07A2 EYE ANTIALLERGICS --> 07A2N EYE DROPS --> NAPHAZOLINE!THONZYLAMINE | [70-80]% by value / [60-70]% by volume |
| ITALY | 07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> HYALURONIC ACID!MALVA SYLVESTRIS | [90-100]% by value / [90-100]% by volume |
| ITALY | 07A3 ARTIFICIAL TEARS & LUBRIC --> 07A3N EYE DROPS --> HYALURONIC ACID!SODIUM!TROMETAMOL | [90-100]% by value / [90-100]% by volume |
| ITALY | 07A5 EYE DECONG & ANTI-INFLAM --> 07A5N EYE DROPS --> EUPHRASIA OFFICINALIS!HAMAMELIS VIRGINIANA!MATRICARIA CHAMOMILLA!PHOSPHORIC ACID!SODIUM | [90-100]% by value / [90-100]% by volume |
| ITALY | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> CHLORHEXIDINE!FLUORINE!MELISSA OFFICINALIS!MENTHA PIPERITA!MENTHA VIRIDIS!SYZYGIUM AROMATICUM!XYLITOL | [90-100]% by value / [90-100]% by volume |
| ITALY | 09C1 MOUTH INFECTION TREATMENT --> 09C1G RINSES/GARGLES --> COMPOSITION UNKNOWN | [60-70]% by value / [80-90]% by volume |
| ITALY | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| ITALY | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| ITALY | 11A1 ANTINAUSEANTS --> 11A1C CAPS/TABS --> PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE | [90-100]% by value / [90-100]% by volume |
| ITALY | 11A1 ANTINAUSEANTS --> 11A1M MIXTURES (ORAL) --> CITRIC ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE | [90-100]% by value / [90-100]% by volume |
| ITALY | 11A1 ANTINAUSEANTS --> 11A1Z OTHER FORMS --> CITRIC ACID!MATRICARIA CHAMOMILLA!POTASSIUM!PYRIDOXINE!RIBOFLAVIN!THIAMINE!ZINGIBER OFFICINALE | [90-100]% by value / [90-100]% by volume |
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> FENTICONAZOLE | [50-60]% by value / [60-70]% by volume |
| ITALY | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2Z OTHER FORMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | 12D9 OTHER GYNAECOLOGICAL PREP --> 12D9C CAPS/TABS --> DIOSCOREA VILLOSA | [90-100]% by value / [90-100]% by volume |
| ITALY | 18A2 NON-CLASSIFIABLE HERBAL P --> 18A2C CAPS/TABS --> BORAGO OFFICINALIS | [20-30]% by value / [30-40]% by volume |
| ITALY | 87A3 ADULT TOOTHPASTES --> 87A3C TOOTHPAST.SENSITIVE TEETH --> CHLORHEXIDINE!MELISSA OFFICINALIS!MENTHA PIPERITA!XYLITOL | [90-100]% by value / [90-100]% by volume |
| ITALY | A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> DOMPERIDONE | [60-70]% by value / [60-70]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| ITALY | A7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E2 INTEST CORTICOSTER PROD --> BUDESONIDE | [20-30]% by value / [30-40]% by volume |
| ITALY | A7E INFLAMMATORY BOWEL DISORDER PRODUCTS --> A7E9 INFLAM BOWEL DIS PRD OTH --> CROMOGLICIC ACID | [90-100]% by value / [90-100]% by volume |
| ITALY | A7H MOTILITY INHIBITORS --> A7H0 MOTILITY INHIBITORS --> DIMETICONE!LOPERAMIDE | [90-100]% by value / [90-100]% by volume |
| ITALY | A9A DIGESTIVES INC.ENZYMES --> A9A0 DIGESTIVES INCL ENZYMES --> TILACTASE | [90-100]% by value / [90-100]% by volume |
| ITALY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| ITALY | C10A CHOLEST&TRIGLY.REGULATOR --> C10A1 STATINS (HMG-COA RED) --> LOVASTATIN | [70-80]% by value / [70-80]% by volume |
| ITALY | C1X ALL OTHER CARDIAC PREPS --> C1X0 ALL OTHER CARDIAC PREPS --> ALPROSTADIL ALFADEX | [90-100]% by value / [90-100]% by volume |
| ITALY | C4A CEREBR/PERIPH VASOTHERAP --> C4A2 CA ANTAG W CEREB ACTIV --> CINNARIZINE | [40-50]% by value / [50-60]% by volume |
| ITALY | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A1 A-HAEMORRHOIDL+CORTICOID --> FLUOCINOLONE ACETONIDE!KETOCAINE | [90-100]% by value / [90-100]% by volume |
| ITALY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> BISOPROLOL | [30-40]% by value / [20-30]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| ITALY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [20-30]% by volume |
| ITALY | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ITALY | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [60-70]% by value / [90-100]% by volume |
| ITALY | G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL PRODS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| ITALY | J1D CEPHALOSPORINS & COMBS --> J1D1 CEPHALOSPORINS,ORAL --> CEFTIBUTEN | [90-100]% by value / [90-100]% by volume |
| ITALY | J1D CEPHALOSPORINS & COMBS --> J1D2 CEPHALOSPORINS,PARENT. --> CEFODIZIME | [90-100]% by value / [90-100]% by volume |
| ITALY | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> FLURBIPROFEN | [90-100]% by value / [90-100]% by volume |
| ITALY | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> NAPROXEN | [50-60]% by value / [40-50]% by volume |
| ITALY | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [90-100]% by value / [90-100]% by volume |
| ITALY | R1A TOPICAL NASAL PREPS --> R1A1 NASAL CORTIC W/O ANTIINF --> BUDESONIDE | [60-70]% by value / [60-70]% by volume (CVC share [70-80]% by value / [70-80]% by volume) |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| ITALY | R3D CORTICOIDS --> R3D1 CORTICOIDS INHALANTS --> BUDESONIDE | [60-70]% by value / [50-60]% by volume (CVC share [60-70]% by value / [60-70]% by volume) |
| ITALY | R6A ANTIHISTAMINES SYSTEMIC --> R6A0 ANTIHISTAMINES SYSTEMIC --> RUPATADINE | [30-40]% by value / [30-40]% by volume |
| ITALY | S1G OCUL.A-ALLER.DECON.A-SEP --> S1G1 OCUL.A-ALLERG.ANTIHIST. --> NAPHAZOLINE!THONZYLAMINE | [70-80]% by value / [60-70]% by volume |
| ITALY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| ITALY | S2A ANTI-INFECTIVES - EAR --> S2A0 ANTI-INFECTIVES - EAR --> CIPROFLOXACIN | [90-100]% by value / [90-100]% by volume |
| ITALY | S2C STEROID/ANTI-INFECT-EAR --> S2C0 STEROID/ANTI-INFECT-EAR --> CIPROFLOXACIN!FLUOCINOLONE ACETONIDE | [90-100]% by value / [90-100]% by volume |
| LATVIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LATVIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LATVIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LATVIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [40-50]% by value / [20-30]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| LITHUANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LITHUANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LITHUANIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| LITHUANIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [70-80]% by value / [70-80]% by volume |
| LITHUANIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| LUXEMBOURG | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| NETHERLANDS | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [80-90]% by value / [80-90]% by volume |
| NETHERLANDS | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| NORWAY | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| NORWAY | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [10-20]% by volume |
| NORWAY | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| POLAND | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC ACID!LACTOFERRIN | [90-100]% by value / [90-100]% by volume |
| POLAND | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> ASCORBIC ACID!LACTOFERRIN!MENTHOL | [90-100]% by value / [90-100]% by volume |
| POLAND | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [50-60]% by value / [60-70]% by volume |
| POLAND | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| POLAND | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| POLAND | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| POLAND | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [70-80]% by value / [60-70]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| POLAND | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [30-40]% by value / [20-30]% by volume |
| POLAND | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1A AEROSOLS/SPRAYS --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> SISYMBRIUM OFFICINALE | [70-80]% by value / [80-90]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1C LOZENGES --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 01C1 SORE THROAT REMS. --> 01C1G GARGLES --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 02D1 MOUTH PAIN RELIEF --> 02D1L LIQUIDS (TOPICAL) --> ALOE BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 02D1 MOUTH PAIN RELIEF --> 02D1O OINTMENTS/CREAMS --> ALOE BARBADENSIS!CAPSICUM OLEORESIN!CETYLPYRIDINIUM!CROCUS SATIVUS!ENOXOLONE!HYALURONIC ACID!MALTODEXTRIN!SORBIC ACID!XANTHAN GUM!XYLITOL | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 02D1 MOUTH PAIN RELIEF --> 02D1Z OTHER FORMS --> ALOE BARBADENSIS!BENZALKONIUM CHLORIDE!BENZOIC ACID!ENOXOLONE!HYALURONIC ACID!POVIDONE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| PORTUGAL | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1K NON HEAT/COLD PATCHES --> FLURBIPROFEN | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03C4 SALINE LAXATIVES --> 03C4Q ENEMAS --> CITRIC ACID!DODECYL SULFOACETIC ACID | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS LACTIS | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS LACTIS | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 05A1 TONICS --> 05A1Z OTHER FORMS --> ASCORBIC ACID!CAFFEINE!GLUCURONAMIDE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 06G2 ANTIFUNGALS FOR NAILS --> 06G2L LIQUIDS (TOPICAL) --> COPPER + DL-LACTIC ACID + SODIUM + THYMUS VULGARE + UREA | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> COLECALCIFEROL | [30-40]% by value / [10-20]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| PORTUGAL | A2B ANTIULCERANTS --> A2B9 ALL OTHER ANTIULCERANTS --> SUCRALFATE | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | A5B HEPATIC PROCT LIPOTROPIC --> A5B0 HEPATIC PROCT LIPOTROPIC --> ASCORBIC ACID!CAFFEINE!GLUCURONAMIDE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | A6A DRUGS FOR CONSTIPATION --> A6A4 LAXATIVE ENEMAS --> CITRIC ACID!DODECYL SULFOACETIC ACID | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | C9D ANGIOTEN-II ANTAG, COMB --> C9D3 AT2 ANTG COMB CALC ANTAG --> AMLODIPINE!CANDESARTAN CILEXETIL | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> FLAVOXATE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | G4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD OTH --> ALPROSTADIL | [50-60]% by value / [50-60]% by volume |
| PORTUGAL | M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> DEXIBUPROFEN | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | M2A TOP A-RHEUMATICS & ANALG --> M2A0 TOP A-RHEUMATICS & ANALG --> FLURBIPROFEN | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | M4A ANTI-GOUT PREPARATIONS --> M4A0 ANTI-GOUT PREPARATIONS --> COLCHICINE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| PORTUGAL | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | N5C TRANQUILLISERS --> N5C0 TRANQUILLISERS --> CLOXAZOLAM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> SISYMBRIUM OFFICINALE | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | R2A THROAT PREPARATIONS --> R2A0 THROAT PREPARATIONS --> TIBEZONIUM | [90-100]% by value / [90-100]% by volume |
| PORTUGAL | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> FRUCTOOLIGSACCHARIDES!MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> INULIN!MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM!COLECALCIFEROL | [30-40]% by value / [20-30]% by volume |
| ROMANIA | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| ROMANIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE + TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | C5C VARICOSE THERAPY,SYSTEM. --> C5C0 VARICOSE THERAPY,SYSTEM. --> DIOSMIN | [80-90]% by value / [90-100]% by volume |
| ROMANIA | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| ROMANIA | G1A TRICHOMONACIDES --> G1A2 TRICHOMONACIDES,TOPICAL --> METRONIDAZOLE!NEOMYCIN!NYSTATIN | [90-100]% by value / [90-100]% by volume |
| ROMANIA | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> FENTICONAZOLE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> ACETYLSALICYLIC ACID | [80-90]% by value / [80-90]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> ACETYLSALICYLIC ACID!CAFFEINE!PARACETAMOL | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1C CAPS/TABS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> ACETYLSALICYLIC ACID | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| SLOVAKIA | 02A1 GENER.PAIN RELIEF ADULTS --> 02A1E EFFERVESCENT --> ACETYLSALICYLIC ACID!ASCORBIC ACID | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 02E1 MUSC. PAIN RELIEF (TOP) --> 02E1H HEAT/COLD PATCHES --> CHARCOAL + IRON METAL | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!CYANOCOBALAMIN!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!THIAMINE!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> CHOLINE!INOSITOL!METHIONINE!NICOTINAMIDE!PANTOTHENIC ACID!PYRIDOXINE!RIBOFLAVIN!SILYMARIN!VITAMIN E | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 03B1 LIVER REMEDIES --> 03B1C CAPS/TABS --> SILYMARIN | [70-80]% by value / [80-90]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ASCORBIC ACID!COLECALCIFEROL!FOLIC ACID!TAURINE!XANTOFYL!ZINC | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> CHROMIUM!COLECALCIFEROL!FOLIC ACID!THIOCTIC ACID!XANTOFYL | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!FISH!SOYA LECITHIN!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!GINKGO BILOBA!RUTOSIDE!VITAMIN E!XANTOFYL!ZEAXANTHIN | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| SLOVAKIA | 07A6 EYE VITAMIN & SUPPLEMENTS --> 07A6C CAPS/TABS --> ESCIN!VITAMIN E!XANTOFYL!ZEAXANTHIN!ZINC | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1O OINTMENTS/CREAMS --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1S SUPPOSITORIES --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | 10A1 ANTIHAEMORRHOIDS --> 10A1Z OTHER FORMS --> RUSCUS ACULEATUS!SODIUM | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | C5A TOPICAL ANTIHAEMORRHOIDL --> C5A2 A-HAEMORRHOID W/O CORTIC --> LIDOCAINE!TRIBENOSIDE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [60-70]% by value / [30-40]% by volume |
| SLOVAKIA | G4D URINARY INCONTINENCE PRD --> G4D4 URINARY INCONTINENCE PRD --> PROPIVERINE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> ACETYLSALICYLIC ACID | [80-90]% by value / [80-90]% by volume |
| SLOVAKIA | N2B NON-NARCOTIC ANALGESICS --> N2B0 NON-NARCOTIC ANALGESICS --> CAFFEINE!PARACETAMOL!PROPYPHENAZONE | [90-100]% by value / [90-100]% by volume |
| SLOVAKIA | S1K DRY EYE PRODUCTS --> S1K1 ARTIFIC TEAR&OCUL LUBRIC --> HYALURONIC ACID!MALVA SYLVESTRIS | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1C CAPS/TABS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN + VEGETABLE FIBRE | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1P POWDERS --> VEGETABLE FIBRE | [70-80]% by value / [0-5]% by volume |
| SPAIN | 03C1 FIBRE LAXATIVES --> 03C1Z OTHER FORMS --> FRUCTOOLIGSACCHARIDES + MALTODEXTRIN | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS LACTIS | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1C CAPS/TABS --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1M MIXTURES (ORAL) --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| SPAIN | 03F1 PROBIOTICS DIGEST HEALTH --> 03F1Z OTHER FORMS --> LACTOBACILLUS REUTERI | [90-100]% by value / [90-100]% by volume |
| SPAIN | 08A1 EAR CARE --> 08A1Z OTHER FORMS --> LACTOBACILLUS SALIVARIUS | [90-100]% by value / [90-100]% by volume |

| | |
|---|---|
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |
| CMO services (excluding CDO services) | - |

| | | |
|---|---|---|
| SPAIN | 86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-AERO+SPRAY --> COMPOSITION UNKNOWN | [40-50]% by value / [10-20]% by volume |
| SPAIN | 86H1 ANTIPARASITIC PROD HAIR --> 86H1A A/PARASITIC-AERO+SPRAY --> DIMETICONE!JOJOBA OIL | [90-100]% by value / [90-100]% by volume |
| SPAIN | A3F GASTROPROKINETICS --> A3F0 GASTROPROKINETICS --> CINITAPRIDE | [70-80]% by value / [70-80]% by volume |
| SPAIN | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |
| SPAIN | C7A B-BLOCKING AGENTS,PLAIN --> C7A0 B-BLOCKING AGENTS,PLAIN --> METOPROLOL | [80-90]% by value / [80-90]% by volume |
| SPAIN | C8B CALCIUM ANTAGONIST COMBS --> C8B2 CALC ANTAG/B BLOCKR COMB --> FELODIPINE!METOPROLOL | [90-100]% by value / [90-100]% by volume |
| SPAIN | G4E ERECTILE DYSFUNCTION PRD --> G4E9 ERECTILE DYSFUNC PRD OTH --> ALPROSTADIL | [40-50]% by value / [50-60]% by volume |
| SPAIN | G4X ALL OTH UROLOGICAL PRODS --> G4X0 ALL OTH UROLOGICAL PRODS --> LIDOCAINE!PRILOCAINE | [90-100]% by value / [90-100]% by volume |
| SPAIN | N5A ANTIPSYCHOTICS --> N5A1 ATYPICAL ANTIPSYCHOTICS --> CARIPRAZINE | [90-100]% by value / [90-100]% by volume |
| SWEDEN | B6X OTHER HAEMATOLOGICAL AGENTS --> B6X0 OTH HAEMATOLOGIC AGENTS --> HEMIN | [90-100]% by value / [90-100]% by volume |

| | | | | | | |
|---|---|---|---|---|---|---|
| CMO services (excluding CDO services) | - | | | SWEDEN | S1X OTHER OPHTHALMOLOGICALS --> S1X2 OTH OPHTHALM TOPICAL --> MERCAPTAMINE | [90-100]% by value / [90-100]% by volume |

**Appendix 7.2**

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream) | | | | | | |
|---|---|---|---|---|---|---|
| Upstream Market (Target) | | | | Downstream FDP Market (Theramex) | | |
| Upstream Hypothetical Market Segment (CDMO) | Upstream Hypothetical Market Sub-Segment (CDMO) | Geographic Market | Share (2020, EEA) | Geographic Market | Product Market (ATC3/CHC3) | Share (2020) |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals | At least EEA-wide | <10% | BULGARIA | A11C VIT A & D INC. COMBS | [30-40]% by value / [30-40]% by volume |
| | | | | ITALY | 04F1 CALCIUM SUPPLEMENTS | [30-40]% by value / [30-40]% by volume |
| | | | | ROMANIA | A11C VIT A & D INC. COMBS | [40-50]% by value / [40-50]% by volume |
| | | | | SLOVAKIA | A11C VIT A & D INC. COMBS | [50-60]% by value / [50-60]% by volume |
| | | | | SPAIN | 04F1 CALCIUM SUPPLEMENTS | [80-90]% by value / [80-90]% by volume |
| | liquid and semi-solid pharmaceuticals | | | FRANCE | G2F TOPICAL SEX HORMONES | [30-40]% by value / [20-30]% by volume |
| | | | | | G3C OESTROG EX G3A,G3E,G3F | [20-30]% by value / [50-60]% by volume |
| | | | | SPAIN | G2F TOPICAL SEX HORMONES | [30-40]% by value / [50-60]% by volume |
| | sterile liquid pharmaceuticals | | | LITHUANIA | G3G GONADOTROPHINS | [50-60]% by value / [50-60]% by volume |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment | | | LITHUANIA | G3G GONADOTROPHINS | [50-60]% by value / [50-60]% by volume |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs | | | BULGARIA | A11C VIT A & D INC. COMBS | [30-40]% by value / [30-40]% by volume |
| | | | | FRANCE | G2F TOPICAL SEX HORMONES | [30-40]% by value / [20-30]% by volume |
| | | | | | G3C OESTROG EX G3A,G3E,G3F | [20-30]% by value / [50-60]% by volume |
| | | | | ITALY | 04F1 CALCIUM SUPPLEMENTS | [30-40]% by value / [30-40]% by volume |
| | | | | POLAND | G3F OESTROGEN + PROGESTOGEN | [30-40]% by value / [30-40]% by volume |
| | | | | ROMANIA | A11C VIT A & D INC. COMBS | [40-50]% by value / [40-50]% by volume |
| | | | | SLOVAKIA | A11C VIT A & D INC. COMBS | [50-60]% by value / [50-60]% by volume |
| | | | | SPAIN | 04F1 CALCIUM SUPPLEMENTS | [80-90]% by value / [80-90]% by volume |
| | | | | | G2F TOPICAL SEX HORMONES | [30-40]% by value / [50-60]% by volume |
| | biopharmaceutical APIs | | | LITHUANIA | G3G GONADOTROPHINS | [50-60]% by value / [50-60]% by volume |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing | | | BULGARIA | A11C VIT A & D INC. COMBS | [30-40]% by value / [30-40]% by volume |
| | | | | ITALY | 04F1 CALCIUM SUPPLEMENTS | [30-40]% by value / [30-40]% by volume |
| | | | | ROMANIA | A11C VIT A & D INC. COMBS | [40-50]% by value / [40-50]% by volume |
| | | | | SLOVAKIA | A11C VIT A & D INC. COMBS | [50-60]% by value / [50-60]% by volume |
| | | | | SPAIN | 04F1 CALCIUM SUPPLEMENTS | [80-90]% by value / [80-90]% by volume |
| | absorption through the skin | | | FRANCE | G2F TOPICAL SEX HORMONES | [30-40]% by value / [20-30]% by volume |
| | | | | | G3C OESTROG EX G3A,G3E,G3F | [20-30]% by value / [50-60]% by volume |
| | | | | POLAND | G3F OESTROGEN + PROGESTOGEN | [30-40]% by value / [30-40]% by volume |
| | | | | SPAIN | G2F TOPICAL SEX HORMONES | [30-40]% by value / [50-60]% by volume |

**Appendix 7.2**

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream) | | | | | | |
|---|---|---|---|---|---|---|
| Upstream Market (Target) | | | | Downstream FDP Market (Theramex) | | |
| Upstream Hypothetical Market Segment (CDMO) | Upstream Hypothetical Market Sub-Segment (CDMO) | Geographic Market | Share (2020, EEA) | Geographic Market | Product Market (ATC4/CHC4) | Share (2020) |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals | At least EEA-wide | <10% | BELGIUM | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | FINLAND | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | FRANCE | 04F1E EFFERVESCENT | [90-100]% by value / [90-100]% by volume |
| | | | | | G3A1 MONOPHAS PREP<50MCG OEST | [20-30]% by value / [30-40]% by volume |
| | | | | | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | GERMANY | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | ITALY | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | LITHUANIA | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | LUXEMBOURG | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | PORTUGAL | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | SPAIN | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | SWEDEN | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs | | | BELGIUM | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | FINLAND | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | FRANCE | 04F1E EFFERVESCENT | [90-100]% by value / [90-100]% by volume |
| | | | | | G3A1 MONOPHAS PREP<50MCG OEST | [20-30]% by value / [30-40]% by volume |
| | | | | | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | GERMANY | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | ITALY | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | LITHUANIA | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | LUXEMBOURG | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | PORTUGAL | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | SPAIN | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | SWEDEN | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs segmented by the | swallowing | | | BELGIUM | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | FINLAND | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | FRANCE | 04F1E EFFERVESCENT | [90-100]% by value / [90-100]% by volume |
| | | | | | G3A1 MONOPHAS PREP<50MCG OEST | [20-30]% by value / [30-40]% by volume |
| | | | | | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | GERMANY | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |

| | | | | | | |
|---|---|---|---|---|---|---|
| delivery mechanism used, i.e. | swallowing | | | ITALY | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | LITHUANIA | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | LUXEMBOURG | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | PORTUGAL | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | SPAIN | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |
| | | | | SWEDEN | G3A2 MONOPHAS PREP>=50MCG OES | [90-100]% by value / [90-100]% by volume |

**Appendix 7.2**

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in CDMO Services (Upstream) | | | | | | |
|---|---|---|---|---|---|---|
| Upstream Market (Target) | | | | Downstream FDP Market (Theramex) | | |
| Upstream Hypothetical Market Segment (CDMO) | Upstream Hypothetical Market Sub Segmen (CDMO) | Geographic Market | Share (2020, EEA) | Geographic Market | Product Market (Molecule) | Share (2020) |
| CDMO services for FDPs segmented by its pharmaceutical form, i.e. | solid and powder pharmaceuticals | | | BELGIUM | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | | G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE | [60-70]% by value / [60-70]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [50-60]% by value / [40-50]% by volume |
| | | | | FINLAND | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | FRANCE | 04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM!CITRIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | | | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> SERTACONAZOLE | [90-100]% by value / [90-100]% by volume |
| | | | | | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> SERTACONAZOLE | [90-100]% by value / [90-100]% by volume |
| | | | | | A12A CALCIUM --> A12A0 CALCIUM --> CITRIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | | | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> SERTACONAZOLE | [90-100]% by value / [90-100]% by volume |
| | | | | | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> SERTACONAZOLE | [90-100]% by value / [90-100]% by volume |
| | | | | | G3A HORMONAL CONTRACEPT SYST --> G3A1 MONOPHAS PREP<50MCG OEST --> ETHINYLESTRADIOL!LEVONORGESTREL | [40-50]% by value / [30-40]% by volume |
| | | | | | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | | M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> FLURBIPROFEN | [80-90]% by value / [80-90]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [30-40]% by value / [20-30]% by volume |
| | | | | GERMANY | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID | [10-20]% by value / [90-100]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!RISEDRONIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | | ITALY | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | | G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE | [80-90]% by value / [80-90]% by volume |
| | | | | | G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [40-50]% by value / [20-30]% by volume (CVC share [40-50]% by value / [20-30]% |
| | | | | LITHUANIA | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | LUXEMBOURG | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | | G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE | [80-90]% by value / [80-90]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | | NETHERLANDS | 04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM + CITRIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | | | A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> ALFACALCIDOL | [40-50]% by value / [40-50]% by volume |
| | | | | | A12A CALCIUM --> A12A0 CALCIUM --> CALCIUM!CITRIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | | | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | POLAND | G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | PORTUGAL | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL | [90-100]% by value / [90-100]% by volume |
| | | | | | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | | G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [30-40]% by value / [10-20]% by volume |
| | | | | SPAIN | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [70-80]% by value / [70-80]% by volume |
| | | | | SWEDEN | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | liquid and semi-solid pharmaceuticals | | | FRANCE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> SERTACONAZOLE | [90-100]% by value / [90-100]% by volume |
| | | | | | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> SERTACONAZOLE | [90-100]% by value / [90-100]% by volume |
| | | | | | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> SERTACONAZOLE | [90-100]% by value / [90-100]% by volume |
| | | | | | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> SERTACONAZOLE | [90-100]% by value / [90-100]% by volume |
| | | | | | G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE | [90-100]% by value / [90-100]% by volume |
| | | | | | G3C OESTROG EX G3A,G3E,G3F --> G3C0 OESTROG EX G3A,G3E,G3F --> ESTRADIOL | [20-30]% by value / [50-60]% by volume |

| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | ITALY | G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE | [90-100]% by value / [90-100]% by volume |
| | | | | LATVIA | G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE | [90-100]% by value / [90-100]% by volume |
| | | | | PORTUGAL | G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE | [90-100]% by value / [90-100]% by volume |
| | | | | SPAIN | G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE | [90-100]% by value / [90-100]% by volume |
| | sterile liquid pharmaceuticals | | | GERMANY | 55B3 AUTO-INJECTORS --> 55B3 AUTO-INJECTORS --> COMPOSITION UNKNOWN | [0-5]% by value / [40-50]% by volume |
| | | | | HUNGARY | G3G GONADOTROPHINS --> G3G0 GONADOTROPHINS --> FOLLITROPIN ALFA | [40-50]% by value / [20-30]% by volume |
| CDMO services for FDPs segmented by the conditions of manufacture, i.e. | sterile environment | | | GERMANY | 55B3 AUTO-INJECTORS --> 55B3 AUTO-INJECTORS --> COMPOSITION UNKNOWN | [0-5]% by value / [40-50]% by volume |
| | | | | HUNGARY | G3G GONADOTROPHINS --> G3G0 GONADOTROPHINS --> FOLLITROPIN ALFA | [40-50]% by value / [20-30]% by volume |
| | | | | BELGIUM | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | | G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE | [60-70]% by value / [60-70]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [50-60]% by value / [40-50]% by volume |
| | | | | FINLAND | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | FRANCE | 04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM!CITRIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | | | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> SERTACONAZOLE | [90-100]% by value / [90-100]% by volume |
| | | | | | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> SERTACONAZOLE | [90-100]% by value / [90-100]% by volume |
| | | | | | A12A CALCIUM --> A12A0 CALCIUM --> CITRIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | | | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> SERTACONAZOLE | [90-100]% by value / [90-100]% by volume |
| | | | | | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> SERTACONAZOLE | [90-100]% by value / [90-100]% by volume |
| | | | | | G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE | [90-100]% by value / [90-100]% by volume |
| | | | | | G3A HORMONAL CONTRACEPT SYST --> G3A1 MONOPHAS PREP<50MCG OEST --> ETHINYLESTRADIOL!LEVONORGESTREL | [40-50]% by value / [30-40]% by volume |
| | | | | | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | | G3C OESTROG EX G3A,G3E,G3F --> G3C0 OESTROG EX G3A,G3E,G3F --> ESTRADIOL | [20-30]% by value / [50-60]% by volume |
| | | | | | G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!LEVONORGESTREL | [90-100]% by value / [90-100]% by volume |
| | | | | | M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> FLURBIPROFEN | [80-90]% by value / [80-90]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [30-40]% by value / [20-30]% by volume |
| | | | | GERMANY | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID | [10-20]% by value / [90-100]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!RISEDRONIC ACID | [90-100]% by value / [90-100]% by volume |
| | | At least EEA-wide | <[10-20]% | ITALY | G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE | [90-100]% by value / [90-100]% by volume |
| | | | | | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | | G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE | [80-90]% by value / [80-90]% by volume |
| | | | | | G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!LEVONORGESTREL | [90-100]% by value / [90-100]% by volume |
| | | | | | G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [40-50]% by value / [20-30]% by volume (CVC share [40-50]% by value / [20-30]% |
| | | | | LATVIA | G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE | [90-100]% by value / [90-100]% by volume |
| | | | | LITHUANIA | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | LUXEMBOURG | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | | G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE | [80-90]% by value / [80-90]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | | NETHERLANDS | 04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM + CITRIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | | | A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> ALFACALCIDOL | [40-50]% by value / [40-50]% by volume |
| | | | | | A12A CALCIUM --> A12A0 CALCIUM --> CALCIUM!CITRIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | | | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | POLAND | G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | | | G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE | [90-100]% by value / [90-100]% by volume |
| | | | | | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL | [90-100]% by value / [90-100]% by volume |
| CDMO services for FDPs segmented by the type of API used, i.e. | chemically-synthesized APIs | | | | | |

| | | | | |
|---|---|---|---|---|
| | | PORTUGAL | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [30-40]% by value / [10-20]% by volume |
| | | SPAIN | G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE | [90-100]% by value / [90-100]% by volume |
| | | | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [70-80]% by value / [70-80]% by volume |
| | | SWEDEN | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | biopharmaceutical APIs | GERMANY | 55B3 AUTO-INJECTORS --> 55B3 AUTO-INJECTORS --> COMPOSITION UNKNOWN | [0-5]% by value / [40-50]% by volume |
| | | HUNGARY | G3G GONADOTROPHINS --> G3G0 GONADOTROPHINS --> FOLLITROPIN ALFA | [40-50]% by value / [20-30]% by volume |
| CDMO services for FDPs segmented by the delivery mechanism used, i.e. | swallowing | BELGIUM | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE | [60-70]% by value / [60-70]% by volume |
| | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [50-60]% by value / [40-50]% by volume |
| | | FINLAND | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | FRANCE | 04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM!CITRIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | A12A CALCIUM --> A12A0 CALCIUM --> CITRIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | G3A HORMONAL CONTRACEPT SYST --> G3A1 MONOPHAS PREP<50MCG OEST --> ETHINYLESTRADIOL!LEVONORGESTREL | [40-50]% by value / [30-40]% by volume |
| | | | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | M1A ANTIRHEUMATIC N-STEROID --> M1A1 ANTIRHEUMATICS NON-S PLN --> FLURBIPROFEN | [80-90]% by value / [80-90]% by volume |
| | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [30-40]% by value / [20-30]% by volume |
| | | GERMANY | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID | [10-20]% by value / [90-100]% by volume |
| | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!RISEDRONIC ACID | [90-100]% by value / [90-100]% by volume |
| | | ITALY | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE | [80-90]% by value / [80-90]% by volume |
| | | | G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [40-50]% by value / [20-30]% by volume (CVC share [40-50]% by value / [20-30]% |
| | | LITHUANIA | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | LUXEMBOURG | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE | [80-90]% by value / [80-90]% by volume |
| | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> CALCIUM!COLECALCIFEROL!RISEDRONIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [90-100]% by value / [90-100]% by volume |
| | | NETHERLANDS | 04F1 CALCIUM SUPPLEMENTS --> 04F1E EFFERVESCENT --> CALCIUM + CITRIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | A11C VIT A & D INC. COMBS --> A11C2 VITAMIN D PLAIN --> ALFACALCIDOL | [40-50]% by value / [40-50]% by volume |
| | | | A12A CALCIUM --> A12A0 CALCIUM --> CALCIUM!CITRIC ACID | [90-100]% by value / [90-100]% by volume |
| | | | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | POLAND | G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | PORTUGAL | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL | [90-100]% by value / [90-100]% by volume |
| | | | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | G3D PROGESTOG, EXCL G3A,G3F --> G3D0 PROGESTOG, EXCL G3A,G3F --> NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [30-40]% by value / [10-20]% by volume |
| | | SPAIN | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | | M5B BONE CALCIUM REGULATORS --> M5B3 BISPHOSPH OSTEOPOROSIS --> RISEDRONIC ACID | [70-80]% by value / [70-80]% by volume |
| | | SWEDEN | G3A HORMONAL CONTRACEPT SYST --> G3A2 MONOPHAS PREP> 50MCG OES --> ESTRADIOL!NOMEGESTROL ACETATE | [90-100]% by value / [90-100]% by volume |
| | | FRANCE | 06G3 ANTIFUNGALS SKIN/OTHER --> 06G3O OINTMENTS/CREAMS --> SERTACONAZOLE | [90-100]% by value / [90-100]% by volume |
| | | | 12D2 GYNAECOLOGICAL ANTIFUNGAL --> 12D2S SUPPOSITORIES --> SERTACONAZOLE | [90-100]% by value / [90-100]% by volume |
| | | | D1A ANTIFUNGALS DERMATOLOGCL --> D1A1 TOPICAL DERMAT ANTIFUNG --> SERTACONAZOLE | [90-100]% by value / [90-100]% by volume |
| | | | G1B GYNAECOLOG ANTIFUNGALS --> G1B0 GYNAECOLOG ANTIFUNGALS --> SERTACONAZOLE | [90-100]% by value / [90-100]% by volume |

| | | | | | | |
|---|---|---|---|---|---|---|
| | absorption through the skin | | | | G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE | [90-100]% by value / [90-100]% by volume |
| | | | | | G3C OESTROG EX G3A,G3E,G3F --> G3C0 OESTROG EX G3A,G3E,G3F --> ESTRADIOL | [20-30]% by value / [50-60]% by volume |
| | | | | | G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL/LEVONORGESTREL | [90-100]% by value / [90-100]% by volume |
| | | | | ITALY | G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE | [90-100]% by value / [90-100]% by volume |
| | | | | | G3F OESTROGEN + PROGESTOGEN --> G3F0 OESTROGEN + PROGESTOGEN --> ESTRADIOL/LEVONORGESTREL | [90-100]% by value / [90-100]% by volume |
| | | | | LATVIA | G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE | [90-100]% by value / [90-100]% by volume |
| | | | | PORTUGAL | G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE | [90-100]% by value / [90-100]% by volume |
| | | | | SPAIN | G2F TOPICAL SEX HORMONES --> G2F0 TOPICAL SEX HORMONES --> PROMESTRIENE | [90-100]% by value / [90-100]% by volume |

## Appendix 8

| (Potential) Vertical Links Giving Rise to Affected Markets Involving the Target's Activities in FDPs (Upstream) | | | | | |
|---|---|---|---|---|---|
| **Upstream Market (Target)** | | | **Downstream Market (CVC)** | | |
| **Product Market (ATC3/CHC3)** | **Geographic Market** | **Share (2020)[1]** | **Geographic Market** | **Product Market** | **Share (2020, Greece)** |
| N5B HYPNOTICS & SEDATIVES<br>13A2 CALMING PRODUCTS | Greece | <30% in value and volume | Greece (or narrower) | Private Hospital Services | [30-40]% |

[1] Also at ATC4/CHC4 and at molecule level.